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INTRODUCTION 
Progress in nuclear medicine has been always tightly linked to the development of new radiopharmaceuticals 
and efficient production of relevant radioisotopes. The use of radiopharmaceuticals is an important tool for 
better understanding of human diseases and developing effective treatments. The availability of new 
radioisotopes and radiopharmaceuticals may generate unprecedented solutions to clinical problems by 
providing better diagnosis and more efficient therapies. 
Impressive progress has been made recently in the radioisotope production technologies owing to the 
introduction of high-energy and high-current cyclotrons and the growing interest in the use of linear 
accelerators for radioisotope production. This has allowed broader access to several new radionuclides, 
including gallium-68, copper-64 and zirconium-89. Development of high-power electron linacs resulted in 
availability of theranostic beta emitters such as scandium-47 and copper-67.  Alternative, accelerator-based 
production methods of technetium-99m, which remains the most widely used diagnostic radionuclide, are 
also being developed using both electron and proton accelerators. 
Special attention has been recently given to α-emitting radionuclides for in-vivo therapy. A few years ago, the 
first α-emitting radiopharmaceutical, Xofigo, (pharmaceutical-grade radium-223 dichloride solution) has been 
approved by the US FDA for cancer treatment. Many other α-emitting radiopharmaceuticals based on 
astatine-211, bismuth-212, bismuth-213, actinium-225, radium-223, lead-212, thorium-227 and terbium-149, 
are currently being developed. However, numerous research groups worldwide are working on efficient 
production of these much sought after α-emitters as demand for these α-emitting radionuclides significantly 
exceed their supply 
The field of radiopharmaceuticals has witnessed continuous evolution thanks to the immense contributions 
of scientists from diverse disciplines such as radiochemistry, inorganic chemistry, organic chemistry, 
organometallic chemistry, biochemistry, molecular biology, physiology and pharmacology. Several milestones 
can be cited in the trajectory of this growth, which include continuing development of technetium-99m 
radiopharmaceuticals, automated synthesis of fluorine-18 labelled compounds, radiopharmaceuticals labelled 
with generator eluted gallium-68, labelled peptides and monoclonal antibodies for accurate diagnosis and 
treatment of tumours. The concept of theranostic radioisotopes, that combines the diagnosis and therapy 
properties of one radioisotope or a pair of similar radioisotopes, may provide an attractive paradigm for future 
development of medical applications of radionuclides. Biomolecules developed for specific molecular target 
and labelled with theranostic radionuclides provide clinically significant information for diagnosis, suitability 
of radionuclide therapy, dosimetry and post therapy planning, making personalised medicine a reality. 
Purpose and Objectives  
The International Symposium on Trends in Radiopharmaceuticals, ISTR-2019, will provide scientists and 
professionals working in the fields of radioisotope production and radiopharmaceuticals an international 
forum for discussing the most recent developments in the field. Various topics will be covered during the 
Symposium including development, production, and uses of diagnostic, therapeutic, and theranostic 
radioisotopes and radiopharmaceuticals, as well as regulatory and licensing issues related to their production.  
Education, certification and training methodologies will also be addressed. 
The ISTR-2019 will provide a great opportunity for chemists, biologists, pharmacists, physicists, medical 
researchers, and other experts in the international community to meet and discuss their most recent work. 
This meeting will help maintain existing and establish new collaborations to address common problems and 
expand the worldwide use of radiopharmaceuticals. 
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Structure, Themes and Topics  
The symposium programme will consist of an opening session, plenary sessions, technical sessions, poster 
sessions, exhibitions, side events and a closing session. The opening session will include welcoming addresses 
by representatives of the IAEA, cooperating organizations and other relevant organizations. The plenary 
sessions will continue with a combination of invited keynote presentations and submitted papers addressing 
the main themes and topics of the symposium. Each topical session will include presentations and/or panel 
discussions delivered by participants which will have been selected based on the abstracts submitted. The 
symposium will also include poster sessions, and enough time will be provided for discussion and interaction 
with colleagues. The final plenary session on the last day of the symposium will be dedicated to conclusions 
and recommendations on the way forward. 
The scope of the symposium is meant to cover, but is not limited to, the following topical areas: 
• Production of PET- and SPECT-based diagnostic, therapeutic and theranostic medical radioisotopes 
• Production of radionuclide generators 
• Production of PET- and SPECT-based diagnostic, therapeutic and theranostic radiopharmaceuticals 
• Research and Development related to the production of medical radioisotopes and 
radiopharmaceuticals 
• Quality control and quality assurance of medical radioisotopes and radiopharmaceuticals 
• Pre-clinical evaluation of radiopharmaceuticals 
• Good Manufacturing Practices for production of medical radioisotopes and radiopharmaceuticals 
• Design of radiopharmacy (industrial, hospital and centralized) facilities 
• Health regulatory aspects related to the production of radiopharmaceuticals 
• Radiopharmacy Chapter in Pharmacopoeias 
• Education, including e-learning, certification and training methodologies for professionals involved in 
radiopharmacy. 
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SCIENTIFIC COMMITTEE  
Name  Country/International Organization  
Adriano Duatti Italy 
Alfred Morgenstern Germany 
Ana Rey Ríos Uruguay 
Antero Abrunhosa Portugal  
Boris Zhuikov Russian Federation  
Brigitte Guérin Canada 
Cathy Cutler United States of America  
Charles Smith United States of America  
Clemens Decristoforo Austria 
Guillermina Ferro-Flores  Mexico 
Ibrahim Aljammaz Saudi Arabia 
Jason Lewis United States of America  
Jeong Hoon Park Republic of Korea 
Jim Ballinger United Kingdom 
Li Hongyu People's Republic of China 
Meera Venkatesh India 
Miguel Ávila Rodríguez Mexico 
M.R. A. Pillai India 
Mohammad Haji Saeed United States of America 
Mouldi Saidi  Tunisia 
Oscar Pozzi Argentina  
Philip Elsinga The Netherlands 
Raisa Krasikova Russian Federation  
Renata Mikolajczak Poland 
Rene Leyva Montana Cuba 
Sabine Kopp World Health Organization 
Salah Eddine Bouyoucef Algeria 
Serge Lyashchenko United States of America 
Sietske Rubow South Africa 
Suzanne Lapi United States of America 
Syed M. Qaim Germany 
Tamer Sakr Egypt 
Uday Bhonsle United Arab Emirates 
Valery Radchenko Canada 
Vijay Kumar Australia 
  
Internal Members:  
Amirreza Jalilian  IAEA 
Aruna Korde IAEA 
Valeriia Starovoitova IAEA 
Names are listed alphabetically   
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IAEA Symposium Secretariat: 
Radioisotope Products and Radiation Technology Section 
International Atomic Energy Agency 
Vienna International Centre, PO Box 100 
1400 Vienna, Austria 
ISTR2019@iaea.org  
 
Scientific Secretary: 
Mr João Alberto Osso Júnior 
tel: +43 1 2600 21748 
ISTR2019@iaea.org ; J.A.Osso-junior@iaea.org 
Local Administration Support: 
Team Assistants  Yasser Al Ghraoui 
 Corinna L. Herden  
 Olha Bilous  
Administrative Assistant  Kristina Pleskach 
Consultants Julia S. Vera Araujo  
 Vojna Ngjeqari 
Communications Officer Aleksandra Peeva 
Voluntary Contribution Co-ordination  Veronika Komaromi 
 Larysa Tanchuk  
Symposium Clerks  Ayham Aldhairi 
 Gil Levanon 
 Leo Chavanne 
 Minja Jovanovic 
 Sarah Balah 
 
Conference Services: 
Division of Conference and Document Services (MTCD) 
International Atomic Energy Agency 
Vienna International Centre, PO Box 100 
1400 Vienna, Austria 
 
Conference Coordination: 
Ms. Julie Zellinger 
tel: +43 1 2600 21321 
J.Zellinger@iaea.org  
Exhibition Coordination: 
Mr. Sanjai Padmanabhan 
tel: +43 1 2600 24838 
S.Padmanabhan@iaea.org  
 
  
ISTR–2019 
 
5 
 
Exhibits 
Exhibits will be located in M–Building, on floors M0E and M01, and on the corridors between B and M Building 
and between M and A Buildings. Participants are encouraged to view the exhibits during the hosted coffee 
breaks. The following organizations and companies will have information stands during the symposium: 
⎯ Berthold Technologies GmbH 
⎯ Best ABT Molecular Imaging Best Cyclotron Systems 
⎯ Bioemission Technology Solutions P.C. Bioemtech 
⎯ Bruker BioSpin GmbH 
⎯ Baltic Scientific Instruments 
⎯ Cardinal Health Nuclear & Precision Health Solutions 
⎯ China Isotopes & Radiation Corporation, CNNC-  
⎯ COMECER S.p.A. 
⎯ DSD Pharma GmbH   
⎯ Eckert & Ziegler Radiopharma GmbH 
⎯ Elysia Raytest  
⎯ ENVINET GmbH 
⎯ GEMS PET Systems AB 
⎯ Department of Nuclear Sciences and Applications, IAEA 
⎯ Permanent Mission of India Vienna  
⎯ Institute of Isotopes CO. LTD. 
⎯ ITG Isotope Technologies Garching Gmbh 
⎯ LabLogic Systems Limited  
⎯ Mediso 
⎯ MILabs B.V. 
⎯ Eczacibaşi-Monrol Nuclear Products CO. 
⎯ Nanolife  
⎯ piCHEM Forschungs- und Entwicklungs GmbH 
⎯ National Centre for Nuclear Research Radioisotope Centre POLATOM 
⎯ Publishing Section, IAEA  
⎯ Ridgeview Instruments AB 
⎯ Rotem GmbH  
⎯ Scintomics GmbH  
⎯ SHIMADZU HandelsgesmbH 
⎯ Tema Sinergie S.p.A. 
⎯ Trasis SA 
⎯ TrisKem International 
⎯ Von Gahlen Nederland B.V.  
⎯ World Council of Isotopes 
⎯ World Nuclear University  
⎯ Zag Zyklotron AG 
Names are listed alphabetically  
The fact that the IAEA has provided facilities for exhibiting equipment and products at the symposium does 
not imply that it endorses the equipment and products.   
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Working Language & Resolutions 
Working Language: English. No simultaneous interpretation will be provided. 
Resolutions: No resolutions may be submitted for consideration on any subject; no votes will be taken. 
Symposium Location 
International Atomic Energy Agency (IAEA)  
Wagramer Str. 5, 1220 Vienna, Austria 
 
 
 
Wireless Internet 
Public access WiFi is available throughout the IAEA buildings. Select access point wlan-guest and the 
connection will be automatic: there is no password. 
Hosted Coffee Breaks 
There will be complimentary mid-morning and afternoon refreshments which have been funded using the 
voluntary contributions from those exhibitors acknowledged in the last few pages. Participants are 
encouraged during these breaks to not only enjoy the refreshments but to profit from the posters and 
exhibition stands displayed on M–Building floors M0E, M01, M02, and A building. 
Refreshments, snacks and lunch can be purchased either from the VIC Cafeteria and Restaurant on the ground 
floor of the F–building, or from the coffee corners located on the M–Building ground floor. 
ISTR  
 
Building   
Sunday Oct. 27 
(15:00-18:30) 
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Posters 
Posters will be displayed on their respective time and day on M–Building in MO2. Authors are asked to be 
available at their posters for discussions with interested participants according to their assigned poster session 
(Tuesday or Thursday, 14:00–15:30). Participants are also encouraged to view the posters during the hosted 
coffee breaks. 
Book of Abstracts and Symposium Proceedings 
This book contains all contributions and abstracts to be presented at the symposium. Abstracts have been 
edited for IAEA style uniformity. The views expressed remain the responsibility of the named authors. No 
responsibility is held by the organizers for any material reproduced, or linked, in this book.  
The Proceedings of the symposium will be published by IAEA and made available for free download by 
participants and interest persons at IAEA’s website. The Proceedings will contain the contents of the 
Programme & Abstracts, together with a review of each session and highlights of the symposium. The guest 
editor of the Proceedings is Mr Natesan Ramamoorthy. 
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CN-276 International Symposium on Trends in Radiopharmaceuticals (ISTR-2019) 
M BLDG – M0E EXHIBITION AREA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF EXHIBITORS 
M1 – Baltic Scientific Instruments 
M2 – LabLogic Systems Limited 
M3 – Von Gahlen Nederland B.V. 
M4 – National Centre for 
Nuclear Research Radioisotope 
Centre POLATOM  
M5 – Trasis SA 
M6 –Eczacibaşi-Monrol Nuclear Products Co. 
 
 
M6 
 
M5 
 
M4 
 
M3 
 
M2 
 
M1 
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N-276 International Symposium on Trends in Radiopharmaceuticals (ISTR-2019) 
 M BLDG – M01 EXHIBITION AREA 1 
LIST OF EXHIBITORS 
M1 – Bruker BioSpin GmbH 
M2 – Bioemission Technology Solutions P.C. Bioemtech  
M3 – Shimadzu HandelsgesmbH 
M4 – Rotem GmbH 
M5 – ITG Isotope Technologies Garching Gmbh 
M6 – Comecer S.P.A 
M7– Institute of Isotopes CO. LTD  
M8 – Triskem International 
M9 – Zag Zyklotron AG 
M10 – GEMS PET Systems AB 
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Emergency Exit 
 
CN-276 International Symposium on Trends in Radiopharmaceuticals (ISTR-2019) 
M BLDG – M01 EXHIBITION AREA 2 
 
 
 
  
 
 
 
 
 
LIST OF EXHIBITORS 
 
M1 – Best ABT Molecular Imaging Best Cyclotron Systems 
M2 – Cardinal Health Nuclear & Precision Health Solutions 
M3 – Eckert & Ziegler Radiopharma GmbH 
M4 – Ridgeview Instruments AB 
M5 – MILabs B.V.  
M6 – Berthold Technologies GmbH 
M7 – Scintomics GmbH 
M8 – Nanolife   
   
 M8 M7 M6 M5 M4 M3 M2 M1  
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CN-276 International Symposium on Trends in Radiopharmaceuticals (ISTR-2019) A-building 
 
 
 
 
 
 
 
 
 
A1 – China Isotopes & Radiation 
Corporation CNNC 
A2 – Tema Sinergie S.p.A. 
A3 – World Council of Isotopes  
A4 – Mediso 
A5 – World Nuclear University  
A6 – Elysia Raytest 
A7 – Pichem Forschungs und Entwicklungs 
GmbH 
A8 – Department of Nuclear Sciences and 
Applications, IAEA 
A9 – Envinet GmbH 
A10 – DSD Pharma GmbH 
A11 – Indian Permanent Mission of Vienna
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CN-276 International Symposium on Trends in Radiopharmaceuticals (ISTR-2019) 
M BLDG – M02 EXHIBITION AREA 
 
 
 
 
 
 
 
 
 
 
 
 
Posterboard area 
40 Poster boards 
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TIMETABLE 
 
 
Registration                                      
(8:00 -9:30)
10:30-
11:00
M2 MO2
16:00-
17:30 
15:30-
16:00
Coffee Break 
S3. Production of 
Medical Radioisotopes: 
Generators (Focus on 
Mo-99)
S6. Production of 
Radiopharmaceuticals: 
Therapy
S10. New Trends in Radiopharmaceuticals: 
Chemistry
S13. Radiopharmacy Installations
18:00-
20:00 Welcome Reception Side Event: India 
Side Event: Women in Radiopharmaceutical 
Sciences: Challenges and Opportunities 
S14. Databases and Apps                               
(17:30-18:30)
12:30-
14:00
14:00-
15:30 
S2. Production of 
Medical Radioisotopes: 
Accelerators
Poster Session I
S9. Health Regulations: Production of 
Radiopharmaceuticals
Working Lunch: MILabs 
(12:45-13:45)
Lunch (12:30-14:00)Lunch
S5. Production of 
Radiopharmaceuticals: 
SPECT
S12. Emerging Radioisotopes for 
Radiopharmacy
 WNU Olympiad FinalsS8. QA/QC/Pre-clinical
09:00
– 
10:30 
S4. Production of 
Radiopharmaceuticals: 
Theranostic 
S7-A. Production of 
Radiopharmaceuticals: 
PET   
S7-B. Parallel 
Session: Clinical 
Advances in 
Nuclear Medicine
S11-A. Production of 
Alpha Emitters and 
Radiopharmaceuticals
 
Boardroom B/M1
Poster Session II
Closing Session/Awards 
Ceremony
ISTR 2019 - DRAFT PROGRAMME AT A GLANCE
Monday 28-10-2019 Tuesday 29-10-2019 Wednesday 30-10-2019 Thursday 31-10-2019 Friday 1-11-2019
S11-B. Parallel 
Session: Technical 
Cooperation 
Success Stories  
S15. Education in 
RadiopharmacyOpening Session                             
(9:30-10:30)
Morning Coffee Break
11:00-
12:30 
S1. Production of 
medical radioisotopes: 
Research Reactor
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Monday 28 October 2019 
REG 08:00-9:30 Symposium Registration 
Venue Entrance M–Building  
   
OS 09:30-10:30 Opening Session 
Venue Board Room B/M1  
T.Sec J. Osso Junior  
Time ID Presenter Country/Org Title 
09:30 OS-01 C. Feruta  IAEA Opening Remarks by Acting Director General 
09:40 OS-02 N. Mokhtar IAEA Welcome by Deputy Director General, Head of 
Department of Nuclear Sciences and Applications  
09:50 OS-03 M. Abdel-Wahab  IAEA Welcome by Director, Division of Human Health  
09:55 OS-04 M. Denecke IAEA Welcome by Director, Division of Physical and 
Chemical Sciences  
10:00 OS-05 S. Lapi United States 
of America 
From isotopes to images: radioactive materials as 
tools in medicine  
 
S1 11:00-12:30 Production of medical radioisotopes: Research Reactor 
Venue Board Room B/M1  
Chair: S. Lapi  
T.Sec: A. Jalilian  
Time  ID  Presenter  Country/Org Title  
11:00 S1-01 M. Venkatesh India  Production of reactor-based radioisotopes: an 
international scenario 
11:25 S1-02 R. Mikolajczak Poland Production and supply of medical radioisotopes: a 
Polish experience 
11:45 S1-03 J.L. Crudo Argentina Laboratory scale production of medium specific 
activity 177Lu (carrier added) through the [176Lu (n,γ) 
177Lu]  nuclear reaction under standardized conditions 
12:00 S1-04 B. Ocampo-
García 
Mexico Synthesis and neutron activation of Lu2O3 
nanoparticles functionalized with target specific 
peptides 
12:15 S1-05 T. Tielens The 
Netherlands 
Towards a robust supply chain for medical 
radioisotopes  
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S2 14:00-15:30 Production of medical radioisotopes: Accelerators 
Venue Board Room B/M1  
Chair: M. Venkatesh  
T.Sec: A. Korde  
Time  ID  Presenter  Country/Org Title  
14:00 S2-01 S.M. Qaim Germany Accelerator based production of non-standard positron 
emitters and therapeutic radionuclides  
14:25 S2-02 S. Lapi United States 
of America 
Production of radiometals using a medical 24MeV 
cyclotron 
14:45 S2-03 A. Abrunhosa Portugal Production of radiometals using liquid targets: status and 
perspectives   
15:00 S2-04 J. H. Park Republic of 
Korea 
Radioisotope production and development with 30MeV 
cyclotron  
15:15 S2-05 V. Radchenko Canada Production and application of 225Ac/213Bi: TRIUMF 
experience and perspectives  
S3 16:00-17:30 Production of medical radioisotopes: Generators 
Venue Board Room B/M1  
Chair: R. Mikolajczak  
T.Sec: V. Starovoitova  
Time  ID  Presenter  Country/Org Title  
16:00 S3-01 J. Osso Junior IAEA The role of the IAEA on the supply of 99Mo 
16:15 S3-02 B. Grimshaw IAEA Nuclear safeguards in radiopharmaceutical facilities 
16:30 S3-03 C. Cutler United States 
of America 
Supply of 99Mo: focus on US 
16:55 S3-04 B. Zhuikov Russian 
Federation  
Radionuclide production at high energy accelerators: 
the new possibilities for radioisotope generators 
17:15 S3-05 R. Walczak Poland Cyclotron production of 47Ca for 47Ca/47Sc generator  
  18:00-20:00 Welcome Reception 
Venue MOE  
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Tuesday 29 October 2019 
S4 09:00-10:30 Production of radiopharmaceuticals: Theranostic  
Venue Board Room B/M1  
Chair: A. Duatti  
T.Sec: J. Osso Junior  
Time  ID  Presenter  Country/Org Title  
09:00 S4-01 J. Lewis United States 
of America 
Development and application of monoclonal antibody-
based radiopharmaceuticals  
09:25 S4-02 C. Decristoforo Austria Theranostic radiopharmacy  
09:45 S4-03 V. Gadelshin Germany Innovative medical radioisotopes for theranostic 
application, and how they are produced   
10:00 S4-04 B. Alirezapour Islamic 
Republic of 
Iran 
Preparation and preclinical evaluation of 64Cu-NOTA-
anti MUC1 as a radioimmunoconjugate for diagnosis 
of MUC1+ breast cancer by PET  
10:15 S4-05 L. Melendez-
Alafort 
Italy  Development of a new prostate cancer theranostic 
radiopharmaceutical  
 
S5 11:00-12:30 Production of radiopharmaceuticals: SPECT 
Venue Board Room B/M1  
Chair: J. Lewis  
T.Sec: A. Korde  
Time  ID  Presenter  Country/Org Title  
11:00 S5-01 A. Duatti Italy Revisiting 99mTc radiopharmaceuticals with recent advances 
in chemistry & imaging tools  
11:25 S5-02 G. Ferro-Flores Mexico Production of radiolabelled peptides for SPECT-based 
theranostics  
11:45 S5-03 S. Bouyoucef Algeria Radiopharmacy and growth of nuclear medicine in 
developing countries  
12:00 S5-04 C. Bolzati Italy Selective αvβ3 integrin detection using [99mTc(N)PNP43]-
tagged RGDechi peptides: synthesis and pharmacological 
studies 
12:15 S5-05 E. Araujo 
Perini 
Brazil The past, present and future trends in radiopharmaceuticals 
production in Brazil  
 12:45:13:45 Working Lunch: MILabs 
Venue Board Room M2 
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PS1 14:00-15:30 Poster Session 1 
Venue MO2 
 
ID Name  Country  Title 
Track 
Production of PET- and SPECT-based diagnostic, therapeutic, and theranostic 
radiopharmaceuticals 
PS1-01 M. Agolti Argentina Tc-99m octreotide in Neuroendocrine tumours: a different 
radiotracer from traditional 111In: our experience 
PS1-02 B. Alirezapour  Islamic 
Republic of 
Iran 
Preparation and biological assessment of 64Cu-NOTA-anti 
ROR1 as a radioimmunoconjugate for diagnosis of ROR1+ 
breast cancer by PET 
PS1-03 T. Assaad Syrian Arab 
Republic 
In house preparation and biodistribution of 64Cu-ATSM, 64Cu-
PTSM and 64Cu-DOTATATE for theranostic application 
PS1-04 M. Avila 
Rodriguez  
Mexico Trends and perspectives in prostate-specific membrane 
antigen based radiopharmaceuticals in Mexico: the 
experience of the National University 
PS1-05 J. Bhatt Mitra India Membrane interacting peptides as positron emission 
tomography (PET) based infection imaging probes 
PS1-06 C. Bolzati  Italy [99mTc(N)(DASD)(PNPn)]+ (DASD=1,4-dioxa-8-
azaspiro[4,5]decandithiocarbamate, 
PNPn=bisphosphinoamine) for myocardial imaging 
PS1-07 S. Bouyoucef Algeria Clinical indications and labelling procedures influencing in 
vitro stability and early myocardial uptake of 99mTc-
tetrofosmin 
PS1-08 M. Cardoso 
Moreno 
Uruguay Development, characterisation and in vivo evaluation of two 
68Ga-labelled NPY analogues as potential tracers for breast 
cancer imaging 
PS1-09 E. Cazzola  Italy [89Zr]ZrOx/Cl preparation  based on commercial cassette base, 
synthesis module. 
PS1-10 E. Cazzola  Italy [18F]-FPSMA1007 synthesis HPLC free on fastlab platform qc 
evolution 
PS1-11 A. Chakrabotry India Preparation of single patient dose of Lu-177-DOTA-Rituximab 
– using low specific activity Lu-177-Chloride 
PS1-12 A. Charef  Algeria  Synthesis of m-Iodobenzylguanidine (m-IBG) by solid phase 
method and its evaluation 
PS1-13 P. Charoenphun Thailand  In-house radiocolloid development for sentinel lymph node 
detection 
PS1-14 E. Chilug  Romania  Comparative preclinical evaluation of 68Ga-labelled 
Neuromedin N and B for targeting glioblastoma malignant 
tissues 
PS1-15 V. 
Chouthkanthiwa 
India Development of ready-to-use 177Lu-PSMA-617 formulation for 
treatment of inoperable metastatic prostate cancer 
PS1-16 J. Costes Switzerland Impact of hospital production vs commercial kits purchase of 
68Ga-DOTA peptides 
PS1-17 I. Daruwati  Indonesia Optimization of labeling α,γ-mangosteen isolated from 
mangosteen cortex fructus (garcinia mangostana l) with 
radionuclide technetium-99m for cancer detection 
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PS1-18 N. Delgado 
Lopez 
Colombia  Radiopharmaceutical production of 68Ga-PSMA at the National 
Cancer Institute, Bogotá, Colombia 
PS1-19 B. Egorova Russian 
Federation  
Complexes of copper and bismuth cations with acyclic and 
macrocyclic polyamines bearing picolinic pendant arms 
PS1-20 G. Ferro-Flores Mexico Synthesis and preclinical evaluation of 64Cu-NOTA-HYNIC-
iPSMA 
PS1-21 W. Gawęda  Poland Bioconjugates of barium ferrite as a Ra-223 carriers in alpha-
radioimmunotherapy 
PS1-22 R. George India Comparison of 68Ga-NOTA-Bisphophonate with 99mTc-MDP in 
34 patients with skeletal metastases in various type of cancers 
PS1-23 S. George  India Methods of integration of radio Cu-64 label in luminescent 
copper nanoclusters for pre and intra operative imaging and 
therapy of pancreatic cancer 
PS1-24 N. Gomzina  Russian 
Federation  
Potential radiotracers based on the 4’-O-methylhonokiol 
structure for PET visualization of neuroinflammation 
PS1-25 B. Guérin Canada Direct production of 68Ga using 68Zn-pressed target 
PS1-26 M. Guleria India Preparation of 177Lu-DOTA-Trastuzumab: an insight into the in-
house optimized radiochemistry procedures employed for 
patient dose preparation 
PS1-27 P. Halik  Poland In vitro NK1R affinity evaluation of novel radioconjugates 
based on peptide antagonist SPANTIDE I and Ga-68/Lu-177 
theranostic-like isotopes for glioma cancer 
PS1-28 W. Hamouda Egypt Synthesis, characterization and radiolabeling of iminodiacetic 
acid derivative with technetium-99m 
PS1-29 S. Kar India Radiosynthesis of 1-{4-[4-(2-[18F] Fluoroethoxy)-phenyl] 
Piperazine-1-yl} ethenone and its evaluation in animal models 
bearing C57BL6 melanoma xenograft 
PS1-30 K. Kolevska  North 
Macedonia 
Correlation between the yield of produced [18F]FDG and the 
activity retained during synthesis 
PS1-31 R. Krasikova Russian 
Federation  
Nucleophilic synthesis of 6-[18F]fluoro-L-DOPA via copper 
mediated radiofluorination 
PS1-32 A. M. K India Evaluation of oxygen-18 water enriched for the production of 
fluorine-18 in a medical cyclotron 
PS1-33 D. Kumar India Radiolabeled TATE functionalized gold nanoparticles for 
potential use in imaging and therapy of neuroendocrine 
tumours 
PS1-34 V. Kumar Australia Recent advances in Ga-68 radiopharmaceuticals and Ga-68 
bisphosphonates for the theranostic management of 
neuroendocrine tumours. 
PS1-35 J. Le Roux  South Africa An automated synthesis method for Ga-68 labelled 
ubiquicidin 29-41 
PS1-36 W. Lestari Indonesia Formulation and radiolabelling of ethambutol with 
technetium-99m for detection of extrapulmonary tuberculosis 
PS1-37 R. Leyva 
Montaña  
Cuba  Radioconjugates based on the monoclonal antibody 
Nimotuzumab® for use in radioimmunotherapy. 
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PS1-38 M. Luna-
Gutiérrez 
Mexico Preclinical evaluation of the theranostic 68Ga/177Lu-[DOTA-
CXCR4-L] pair 
PS1-39 A. Majoul Tunisia Study of the physicochemical stability of HMPAO-Technetium 
(99mTc) 
PS1-40 N. Malek Tunisia Synthesis and biodistribution of 1-((2-methoxyphenyl) 
piperazine)ferrocenecarboxamide labeled with technetium-
99m as a potential brain receptor imaging ag 
PS1-41 J. Manrique-
Arias 
Mexico A practical method for the preparation of 18F[TFB] labeled 
with sodium fluoride, using a ITG IQS fluidic labelling module 
PS1-42 J. Manrique-
Arias 
Mexico Radiation dosimetry in healthy subjects of 68Ga-DOTA-BBN, a 
potential theranostic tracer in oncology 
PS1-43 A.A. Marie Ethiopia Tc-99m labeled human immunoglobulin G polyclonal antibody 
– different approach for better results 
PS1-44 K. Masłowska Poland Radiolabeled peptidomimetic inhibitor of the VEGF/NRP-1 
complex for the imaging of malignant tumours - preliminary 
research 
PS1-45 M. Maurin  Poland The critical parameters of Ga-68 labelling of POLATOM’s 
PSMA-11 kit 
PS1-46 G. Mercanoglu  Turkey Development of synthesis method for the automated 
production of 177Lu-EDTMP with ml-eazy and pharmtracer 
modules 
PS1-47 Z. Mohd Ashhar  Malaysia Preparation, characterization and in-vitro studies of 
[68Ga]NODAGA-Pamidronic acid for PET bone imaging 
PS1-48 R. Nanabala India Nucleophilic synthesis of [18F]FDOPA by using an automated 
module : a summary of the results of 18 batches 
PS1-49 R. Nanabala  India Synthesis of [18F]PSMA-1007 for imaging prostate cancer by 
using an automated module and clinical studies 
PS1-50 S. Nandy India Fully automated radiosynthesis of 18F-16-α-Fluoroestradiol 
([18F]FES) with solid phase extraction cartridge purification by 
sep pak® plus alox n 
PS1-51 S. Nandy  India Development and evaluation of 18F-radiolabeled 
acetaminophen (paracetamol) for tumour imaging based on 
COX-2 overexpression 
PS1-52 N.  Naseer 
Ahmed  
Pakistan  Comparative evaluation of Tc-99m octreotide, synthesized by 
different labeling methods: for diagnostic accuracy 
assessment in neuro-endocrine tumours 
PS1-53 N.  Naseer 
Ahmed  
Pakistan  Utility of gamma camera as an effective non-invasive imaging 
modality for docetaxel loaded liposomal chitosan 
nanoparticles: synthesis and the in-vivo trafficking in animal 
model 
PS1-54 Y. Ng Malaysia Radiolabelling and preliminary biodistribution study of 
Samarium-153-Zoledronic Acid as a novel bone pain palliative 
agent 
PS1-55 S. Okarvi Saudi Arabia  Development and evaluation of a 68Ga-labeled angiotensin 
peptide coupled to rhodamine for diagnostic imaging of heart  
PS1-56 S. Okarvi   Saudi Arabia  Total solid-phase synthesis of DOTA-Functionalized tumour 
targeting peptides for PET imaging and therapy  
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PS1-57 V. Orlovskaya Russian 
Federation  
Use of tetrabutylammonium tosylate in conjunction with 
chiral NiII complex precursor for automated synthesis of 
[18F]FET 
PS1-58 M. Pereira  Uruguay Optimization of the automatic synthesis of 16α-
[18F]fluoroestradiol in  the  SYNTHRA RNplus Research Module 
PS1-59 M. Pino Peraza  Cuba Labelling of anti-cd20 monoclonal antibody cimabior with 90Y 
PS1-60 S. Rubow  South Africa Influence of the source of Lu-177 on radiopharmacy waste 
management – an estimate 
PS1-61 M. Saidi Tunisia Synthesis and biodistribution study by rats of two new 99mTc-
Tricarbonyl complexes as potential brain imaging agents 
PS1-62 M. Sterjova Arev North 
Macedonia  
Freeze-dried kit formulation of 177Lu- and 90Y-labeled 
immunoconjugates of Trastuzumab – formulation and 
characterization  
PS1-63 H. Shamseldin Egypt A novel therapeutic phthalimide derivative for cancer: 
Synthesis, radioiodination and biological evaluation 
PS1-64 S. Shiratori Thailand  The first proof-of-concept theranostic radiopharmaceutical in 
Thailand 
PS1-65 J. Shukla India Exploring Ga-68 Trastuzumab Fab for noninvasive PET imaging 
to detect HER2 expressing lesions. 
PS1-66 T. Siriprapa Thailand  Improvement of synthesizing material and method for an in-
house production of [18F]-florbetapir PET tracer for imaging 
beta amyloid deposition in the brain 
PS1-67 N. Tag  Oman  Evaluating quality control 18F-FDG: experience in Sultan 
Qaboos University Hospital, Oman 
PS1-68 M. Tejeria Uruguay Design, synthesis and evaluation of a family of 99mTc estradiol 
derivatives for breast cancer imaging 
PS1-69 K. Urbanová  Czech 
Republic 
Labeling of PSMA-11 with 68Ga in NaHCO3 
PS1-70 K. Vats India Influence of 99mTc-chelation at N-terminal and/or C-terminal 
on receptor binding affinity of NGR peptides 
PS1-71 A. Vukadinovic Serbia  Development of automatic system for production of small 
batches of radioiodine capsules 
PS1-72 F. Vultos  Portugal 111In-labelled bifunctional agents for dual targeting of breast 
cancer cells 
PS1-73 T. Wibawa  Indonesia Cancer drugs and 99mTc-glutation radiopharmaceutical 
interaction to achieve optimal result of cancer diagnostics in 
nuclear medicine 
PS1-74 E. Widyasari  Indonesia In vivo study of radiolabeled flavonoid 99mTc-quercetin as 
cancer radiotracer on normal balb/c mice 
PS1-75 B. Guerin Canada  The synthesis and cytotoxicity of 64Cu/NOTA-terpyridine 
platinum conjugate, as a novel theranostic agent 
PS2-06 H. Elkhatib  Egypt Studying and assessment of clean area for Tc-99m production 
in radioisotope production facility 
PS2-33 H. Honarvar  Sweden In vitro kinetics property evaluation of 11C-acetate in real time 
PS2-72 A. Kellerbauer EU Production of actinium-225 at JRC Karlsruhe 
 
Surnames are listed alphabetically (exceptions for modifications made after the Programme was created).   
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S6 16:00-17:30 Production of radiopharmaceuticals: Therapy 
Venue Board Room B/M1  
Chair: C. Cutler  
T.Sec: A. Jalilian  
Time  ID  Presenter  Country/Org Title  
16:00 S6-01 M.R.A. Pillai India Production and quality control of beta emitters bone pain 
palliation agents using -emitters 
16:25 S6-02 J. Rijn 
Zeevaart 
South Africa Comparison of promising new short-range therapeutic 
radiopharmaceuticals using 225Ac, 213Bi and 161Tb 
16:45 S6-03 V. Chirayil India  Freeze-dried kit for quick and efficient preparation of 
188Re-DEDC/lipiodol in hospital radiopharmacy 
17:00 S6-04 C. H. Yeong Malaysia Production of theranostic 153Sm labelled polystyrene 
microspheres for hepatic radioembolization  
17:15 S6-05 A. 
Chakrabotry 
India Radiolabelling and pre-clinical evaluation of 90Y-
DOTATATE formulated using 90Y-acetate from high level 
liquid waste  
 18:00-20:00 Side Event: India  
Venue Board Room M2  
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Wednesday 30 October 2019 
S7-A 09:00-10:30 Production of radiopharmaceuticals: PET 
Venue Board Room B/M1  
Chair: J. Smith   
T.Sec: J. Osso Junior  
Time  ID  Presenter  Country/Org Title  
09:00 S7-A1 P. Elsinga The 
Netherlands 
Recent advances in the development of 18F and 11C 
radiopharmaceuticals 
09:25 S7-A2 C. Decristoforo Austria Recent advances in the development of 68Ga 
radiopharmaceuticals  
09:45 S7-A3 I. Aljammaz Saudi Arabia Synthesis and in vitro and in vivo evaluation of 124I 
labelled PSMA peptides: potential theranostic 
radiopharmaceuticals for prostate cancer  
10:00 S7-A4 V. Kumar Australia A radiocopper somatostatin anolog (Cu-Sartate) for 
NET theranostics  
10:15 S7-A5 W. Chintawan Thailand  Comparative study of [18F]PSMA-1007 and 
[68Ga]PSMA-11 for prostate cancer PET imaging in 
Thailand  
S7-B 09:00-10:30 Clinical advances in nuclear medicine 
Venue Board Room M2  
Chair: 
T.Sec: 
E. Bombardieri  
A. Jalilian  
Time  ID  Presenter  Country/Org Title   
09:00 S7-B1 D. Paez  IAEA IAEA activities related to nuclear medicine 
09:30 S7-B2 H. Macapinlac United States 
of America 
Recent advances in nuclear medicine: diagnostic and 
therapy 
10:00 S7-B3 D. Le United States 
of America 
Production and use of cyclotron-produced 
radiopharmaceuticals at MD Anderson Cancer Center 
S8 11:00-12:30 QA/QC/Pre-clinical 
Venue Board Room B/M1  
Chair: C. Decristoforo  
T.Sec: A. Korde  
Time  ID  Presenter  Country/Org Title  
11:00 S8-01 S. Rubow South Africa Quality control of hospital-based 
radiopharmaceuticals  
11:20 S8-02 J. Smith United States 
of America  
Development and preclinical evaluation of 64Cu 
radiolabelled compounds  
11:40 S8-03 B. Guérin Canada Preclinical evaluation of 68Ga-PET tracers using 68Ga 
produced by cyclotron, a Canadian experience 
12:00 S8-04 E. 
Bombardieri 
EANM Ethics in animal experiments in nuclear medicine and 
the application of the directive 2010/63 EU  
12:15 S8-05 R. Teodoro Germany PET for the imaging of cerebral α7 acetylcholine 
receptors: from tracer development to clinical 
application 
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S9 14:00-15:30 Health regulations: Production of radiopharmaceuticals 
Venue Board Room B/M1  
Chair P. Elsinga  
T.Sec: J. Osso Junior  
Time  ID  Presenter  Country/Org Title  
14:00 S9-01 S. Kopp WHO A move towards harmonization of GMP regulations in 
radiopharmacy  
14:20 S9-02 C. Decristoforo Austria The status of radiopharmaceutical regulations in 
Europe  
14:40 S9-03 S. Lyashchenko United States 
of America 
The status of radiopharmaceutical regulations in the 
US  
15:00 S9-04 Y. Chakrova Kazakhstan GMP certification of a radiopharmaceutical 
production facility in Kazakhstan 
15:15 S9-05 S. Nazarenko Estonia  Compounding radiopharmaceuticals: any regulatory 
difference with extemporaneous preparation?  
S10 16:00-17:30 New trends in radiopharmaceuticals: chemistry 
Venue Board Room B/M1  
Chair: M.R.A. Pillai  
T.Sec:  A. Jalilian  
Time  ID  Presenter  Country/Org Title  
16:00 S10-01 B. Guérin Canada Development and evaluation of chelators for 
specific radiometals  
16:20 S10-02 S. Lyashchenko United States 
of America 
Novel radiopharmaceuticals for clinical translation  
16:40 S10-03 J. Smith United States 
of America 
Translation of new chelators for old pairs: Tc/Re 
NODAGA 
17:00 S10-04 K. Katti United States 
of America 
Radioactive 198Au nanoparticles in nanomedicine  
17:15 S10-05 P. Brust Germany  New strategies for imaging of brain cancer with 
radiopharmaceuticals 
 
18:00-20:00 Side Event: Women in Radiopharmaceutical Sciences: 
Challenges and Opportunities  
Venue Board Room M2  
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Thursday 31 October 2019 
S11-A 09:00-10:30 Production of alpha emitters and radiopharmaceuticals  
Venue Board Room B/M1  
Chair: M. Betti   
T.Sec: V. Starovoitova  
Time  ID  Presenter  Country/Org Title  
09:00 S11-A1 A. 
Morgenstern 
Germany Production and quality control of 
radiopharmaceuticals labelled with 225Ac and 213Bi 
09:30 S11-A2 C. Cutler United States of 
America 
U.S. DOE Tri lab production effort to provide 
accelerator produced 225Ac 
10:00 S11-A3 M. Lesinki Canada Recent results of the joint CNL and TRIUMF project on 
the production of 225Ac 
10:15 S11-A4 O. Pozzi Argentina Argentinian project for developing production of 225Ac 
and 213Bi in cyclotrons for targeted therapy  
S11-B 09:00-10:30 Technical cooperation success stories 
Venue Board Room M2  
Chair: U. Bhonsle  
T.Sec: A. Elrefaei  
Time  ID  Presenter  Country/Org Title  
09:00 S11-B0 D. Yang IAEA-TC Opening Remarks by Deputy Director General, Head 
of Department of Technical Cooperation 
09:10 S11-B1 S. Abdulrazak IAEA-TC Technical cooperation programme: enhancing 
capacities in radiopharmacy in Africa 
09:30 S11-B2 R. Montaña Cuba Sustainable production of 99mTc generators and 
radiopharmaceuticals an IAEA/Cuban experience  
10:00 S11-B3 Y. Chakrova Kazakhstan  Gel generator production project in Kazakhstan: 
IAEA support       
10:15 S11-B4 A. Duran Argentina Strengthening capacities for the development of 
radiotracers labelled with 18F, different from 
fluordesoxyglucose in the FCDN  
S12 11:00-12:30 Emerging radioisotopes for radiopharmacy 
Venue Board Room B/M1  
Chair: A. Duatti   
T.Sec: A. Jalilian  
Time  ID  Presenter  Country/Org Title  
11:00 S12-01 V. Radchenko Canada Development of production strategies for new 
emerging research radionuclides using cyclotrons  
11:25 S12-02 M. Avila 
Rodríguez 
Mexico Emerging clinical applications of [64Cu]CuCl2 
radiopharmaceutical  
11:45 S12-03 P. Martini Italy Towards large-scale 67Cu cyclotron production  
12:00 S12-04 I. Cieszykowska Poland Production of 47Sc from 47Ca: comparison of four 
separation methods  
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12:15 S12-05 G. Pupillo Italy   Accelerator-based production of 47Sc: results of the 
PASTA project  
PS2 14:00-15:30 Poster Session 2 
Venue MO2  
ID Name  Country  Title 
Track Design of industrial, hospital and centralized radiopharmacy facilities 
PS2-01 N. Ayachi Tunisia Creation of the first public PET unit at Sahloul hospital in 
Sousse, Tunisia 
PS2-02 S. Bertrand Belgium A new compact high-power e-beam accelerator for 
radiotherapeutic production: a first evaluation 
PS2-03 S. Bertrand Belgium Optimized non-conventional radioisotopes production with 
industrial mid-energy cyclotron 
PS2-04 A. Bulos Philippines Research and development initiatives on radiopharmaceutical 
production in the Philippines 
PS2-05 F. Ekoume Cameroon A comparative study of passive air sampling in different 
radiopharmacies 
PS2-06 H. Elkhatib  Egypt Studying and assessment of clean area for Tc-99m production in 
radioisotope production facility. (Presenting on Tuesday 29 
October) 
PS2-07 Y. Lagebo  Ethiopia Survey on arduous challenges and possible tracks of 
heightening the radiopharmacy and nuclear medicine services 
in Africa 
PS2-08 M. Maneiro Argentina Parametrical study for iodine plate out theoretical model in 
fission radioisotope production plant ventilation pipes 
PS2-09 J. Norenberg United 
States of 
America 
An overview of commercial nuclear pharmacy in the US safely 
delivering 35,000 patient-ready radiopharmaceuticals doses 
each day  
PS2-10 D. Schick-Martin Canada Saskatchewan centre for cyclotron sciences: a new multi-user 
research and production facility 
PS2-11 M. Waheed  Bangladesh  Development of radiopharmaceutical production in Bangladesh 
Track 
Education, including e-learning, certification and training methodologies for professionals 
involved in radiopharmacy 
PS2-12 B. Darju Liberia Education/Awareness-2 
PS2-13 E. Huanca 
Sardinas 
Bolivia Relevance of the study of radiopharmacy at San Francisco 
Xavier university 
PS2-14 N. Mat Ail  Malaysia Development of nuclear pharmacy training module in Malaysia 
PS2-15 A. Rey Ríos Uruguay Diploma of radiopharmacy specialist in Uruguay: a flexible tool 
to achieve a certificated postgraduate education in 
radiopharmacy 
PS2-16 O. Riabukhin Russian 
Federation  
Accelerators of Ural Federal University as a base for student 
education and stuff training 
PS2-17 M. Siddig Sudan  Status of radiopharmacy practices in Sudan 
PS2-18 D. Wata Kenya Assessment of training needs for radiopharmacists in Africa 
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Track Health regulatory aspects related to the production of radiopharmaceuticals 
PS2-19 M. Baracaldo 
Cortes 
Colombia  Regulatory aspects related to good practices of preparation of 
radiopharmaceuticals in Colombia 
PS2-20 J. Giglio  Uruguay Optimization of 18F-radiopharmaceutical production with a new 
platform, in accordance with GMP 
PS2-21 S. Marques de 
Carvalho  
Brazil Current status of radiopharmaceuticals production in Brazil: 
Licensing and radioprotection aspects 
PS2-22 L. Pozzo  Brazil [68Ga]PSMA PET/CT: which HTA tools can be used in local or 
regional reimbursement decision? 
PS2-23 R. Ssekajjugo Uganda  Regulation of radiopharmaceuticals in Uganda: current situation 
Track Nanosized radiopharmaceuticals 
PS2-24 F. Bin Madin  Malaysia Synthesis of radioactive gold nanoparticles and bimetallic gold 
nanoparticles for cancer therapeutic application 
PS2-25 A. Heitor 
Ferreira 
Brazil Radiation crosslinked protein-based nanoparticles as delivery 
system for radiopharmaceuticals 
PS2-26 A. Majkowska-
Pilip 
Poland Multimodal radiobioconjugate Octreotide-PEG-198AuNPs-PEG-
DOX for targeted cancer therapy 
PS2-27 M. Żuk Poland Gold-198 coated Superparamagnetic iron oxide nanoparticles 
(SPION) for cancer radiotherapy and magnetic hyperthermia 
Track Pre-clinical evaluation of radiopharmaceuticals 
PS2-28 E. Azorin-Vega Mexico Dosimetric model based on the distribution of PSMA targeted 
radiopharmaceuticals to bone metastasis 
PS2-29 A. Chakraborty India In-vitro and in vivo pre-clinical evaluation for Lu-177, Y-90 and 
Ga-68-DOTATATE in SSTRII positive AR42J cell line and negative 
HCT116 and MCF7 cell line 
PS2-30 T. Dallagi  Tunisia Evaluation of Rhenium and 99mTechnetium of tamoxifen 
derivatives as potential breast cancer radiopharmaceuticals 
PS2-31 A. Escudero-
Castellanos  
Mexico Biological evaluation of 177Lu-DOTA-PSMA(inhibitor)-RGD in 
LNCaP and PC3 prostate cancer cells 
PS2-32 L. Fernández Uruguay [99mTc]Tc labelled levonorgestrel derivative as potential 
ER+/PR+ imaging agent 
PS2-33 H. Honarvar  Sweden In vitro kinetics property evaluation of 11C-acetate in real time 
(Presenting on Tuesday 29 October) 
PS2-34 N. Jiménez-
Mancilla 
Mexico Application of the Cerenkov radiation produced by 177Lu-
radiopharmaceuticals in preclinical studies 
PS2-35 M. Maurin Poland Evaluation of biological properties of radiolabelled nanogel-
bombesin conjugates 
PS2-36 D. Niculae  Romania  Comparative radiobiological evaluation of intracellular effects 
induced by 64CuCl2 in different tumour cells 
PS2-37 L. Ondrák Czech 
Republic 
In-vitro study of therapeutic radionuclides’ impact on selected 
tissue and tumour cell lines 
PS2-38 G. Rabiller Argentina Factors and drug interactions that cause altered biodistribution 
of radiopharmaceuticals 
PS2-39 C. Santos-
Cuevas 
Mexico 99mTc-CXCR4-L: Biokinetics and radiation dosimetry in humans 
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PS2-40 M. Silindir 
Gunay 
Turkey In vitro cell binding detection of novel radiopharmaceuticals: a 
radionuclidic evaluation 
PS2-41 S. Treiger 
Borborema 
Brazil The advantage of using radiotracers for pre-clinical assays with 
conventional drugs: the case of meglumine antimoniate 
Track Quality control and quality assurance of medical radioisotopes and radiopharmaceuticals 
PS2-42 A. Ahmad 
Zikrileh 
Malaysia An experimental study on radiochemical purity (RCP) of 99mTc-
Tetrofosmin compounded outside manufacturer’s guideline 
using TEC-Control™ chromatography system 
PS2-43 A. Aiboud  Morocco Development of a new method for the microbiological analysis 
of Iodine-131 
PS2-44 C. Arjun India User-friendly sterility testing method for injectable 
radiopharmaceuticals – feasibility study and validation 
PS2-45 C. Arjun India Feasibility of a green analytical method for radiochemical purity 
determination of sodium [99mTc] pertechnetate 
PS2-46 C. Arjun India Bacterial endotoxin testing of injectable radiopharmaceuticals: 
BRIT experience 
PS2-47 M. Bricha Morocco “99Mo/99mTc radionuclide generators” optimization: new quality 
control standards of alumina columns and kinetic study of 
Molybdenum adsorption on α alumina 
PS2-48 A. Duran Argentina Effect of autoclaving, activity concentration and ethanol on the 
stability of [18F] -FDG 
PS2-49 O. Fedorova Russian 
Federation  
Enantiomeric purity of radiolabelled amino acids is influenced 
by the type of chiral column 
PS2-50 A. Larenkov Russian 
Federation  
Quality control of 68Ga radiopharmaceuticals: pitfalls and 
solutions 
PS2-51 L. Piola Argentina 89Sr and 90Sr/90Y activity by cherenkov counting in medical 99Mo 
quality control 
PS2-52 K. Skovorodko  Lithuania  Implementation of a quality assurance program and quality 
control results of radiopharmaceuticals 
Track Production of radionuclide generators 
PS2-53 A. Alberti 
Ramírez  
Cuba Production of radionuclide generators: Cuban experience 
PS2-54 E. Aliaga Peru Design and development of an automated mini-plant for 99mTc 
production 
PS2-55 S. 
Chattopadhyay 
India Recovery of highly pure 99mTc from low specific activity 
(n,g)99Mo using activated charcoal column 
PS2-56 K. Fialová Czech 
Republic 
Development of Ge-68/Ga-68 radionuclide generator for 
nuclear medicine 
PS2-57 M. El-Gizawy Egypt Selective separation of no carrier added Sc-47 from reactor 
irradiated Ca using zirconium vanadate gel for nuclear medical 
applications 
PS2-58 M. V. Gonzalez Argentina Evaluation of alternatives for the removal of heat within the 
Mo-99 production cell by fission from the estimation of the 
radionuclidic composition and power of filters with uranium 
precipitate 
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PS2-59 D. 
Kottuparamban 
India Fluorine-18 Production Yield in an 11 MeV Medical Cyclotron: 
Comparison of Theoretical and Practical Yields 
PS2-60 K. Kushwaha India Production, Separation and Purification of In-111 from 
Irradiated Natural Cd:  Produced In-111 Quality Evaluated after 
Radiolabeling with Pentetreotide 
PS2-61 P. Martini  Italy Worldwide ten-year trend analysis of the scientific literature on 
therapeutic radiometals (2008-2018) 
PS2-62 O. Odintsov Ukraine Preparation of zirconium molybdate gel as material for 
99Mo/99mTc chromatographic column generator 
PS2-63 A. Tsechanski  Israel Photonuclear production of 67Cu radionuclide using “one-stage” 
setup 
Track 
Production of PET- and SPECT-based diagnostic, therapeutic and theranostic medical 
radioisotopes 
PS2-64 A. Abrunhosa Portugal  Fully automated liquid target production of [68Ga]GaCl3 in line 
with GMP requirements 
PS2-65 N. Bentaleb Morocco Study of the optimization of the use of the reducing agent in 
the formulation and production of sodium iodide-131 oral 
solution 
PS2-66 S. Brinkevich Belarus Long-lived radionuclidiс impurities in the production of 18F 
labeled radiopharmaceuticals 
PS2-67 S. Campos  Argentina Analysis and model of radioactive noble gases and iodine 
emissions from a fission Mo-99 production process 
PS2-68 L. Canton Italy Nuclear reaction calculations applied to cyclotron production of 
emerging radiopharmaceuticals 
PS2-69 J. Červenák Czech 
Republic 
Measurement of excitation functions of proton-induced nuclear 
reactions on gold 
PS2-70 I. Cieszykowska  Poland Separation of 99mTc from low specific activity 99Mo 
PS2-71 S. Cisternino Italy Yttrium cyclotron solid target preparation for zirconium-89 
production 
PS2-72 A. Kellerbauer EU Production of actinium-225 at JRC Karlsruhe 
(Presenting on Tuesday 29 October) 
PS2-73 A. Boschi Italy Technetium-99m production by medical cyclotron 
PS2-74 L. Melendez-
Alafort  
Italy Assessment of dose increase after administration of 
radiopharmaceuticals prepared with cyclotron-produced 99mTc 
PS2-75 J. Merino  Argentina Development of a copper oxide reactor to convert hydrogen to 
water in the dissolution of radioisotopes production targets 
PS2-76 L. Mou  Italy The LARAMED project at INFN-LNL: Laboratory of Radionuclides 
for Medicine 
PS2-77 F.L. Navarro 
Marques 
Brazil Production of 89Zr and radiolabeling of phosphatidylserine 
liposome 
PS2-78 M. Pasquali  Italy Towards multimodal PET/MRI imaging with cyclotron-produced 
52/51 min 
PS2-79 O. Pozzi Argentina Effect of the radiolysis produced by the high levels of radiation 
dose (Gy) delivered by alpha particles on the production and 
supply of Ac-225, and the labeling of radiopharmaceutical for 
therapy 
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PS2-80 H. Skliarova Italy High energy vibrational powder plating for cyclotron solid 
target preparation for radiopharmaceuticals production 
PS2-81 V. Uvarov  Ukraine The yield of 47Sc at photonuclear production 
PS2-82 W. Wojdowska  Poland Cyclotron production of scandium-44 
PS2-83 B. Zhang China Biodistribution of nanoradiopharmaceuticals in internal organs 
Surnames are listed alphabetically (exceptions for modifications made after the Programme was created). 
S13 16:00-17:30 Radiopharmacy installations  
Venue Board Room B/M1  
Chair: B. Guerin  
T.Sec: A. Jalilian  
Time  ID  Presenter  Country/Org Title  
16:00 S13-01 A. Duatti Italy How to set up a medium size 99mTc generator facility: 
IAEA experience        
16:25 S13-02 V. Kumar Australia Design and successful operation of a SPECT hospital 
radiopharmacy  
16:45 S13-03 M.R.A Pillai India Cyclotron and PET radiopharmacy installation: 
experience in setting up in a commercial centre  
17:00 S13-04 U. Bhonsle United Arab 
Emirates 
How to set up a PET radiopharmaceutical facility: IAEA 
experiences 
17:15 S13-05 K. Washiyama Japan An effort to diagnostic and therapeutic nuclear medicine 
at Fukushima Medical University using two medical 
cyclotrons 
S14 17:30-18:30 IAEA Databases and Apps  
Venue: 
Chair: 
T.Sec: 
Board Room B/M1 
M. Haji-Saeed 
J. Osso Junior   
Time  ID  Presenter  Country/Org Title  
17:30 S14-01 A. Koning IAEA The medical isotope browser 
18:00 S14-02 N. Pessoa  IAEA The IAEA's research reactor database (RRDB) 
18:15 S14-03 A. Jalilian  IAEA Introduction to the new IAEA database “Cyclotrons 
used for Radionuclide Production” 
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Friday 1 November 2019 
S15 09:00-10:30 Education in radiopharmacy 
Venue Board Room B/M1  
Chair: S. Rubow  
T.Sec: A. Korde  
Time  ID  Presenter  Country/Org Title  
09:00 S15-01 P. Elsinga The Netherlands Development and performance of a radiopharmacy 
platform certification, EANM experience  
09:20 S15-02 A. Rey Ríos Uruguay Education and qualification of radiopharmacists in 
Latin America  
09:40 S15-03 N. Bentaleb Morocco Master’s degree in radiopharmaceutical sciences: step 
forward to enhance regional capacities in nuclear 
medicine in Africa  
10:00 S15-04 E. Janevik-
Ivanovska 
North Macedonia Developing, testing and installing e-learning system 
for radiopharmacy as a tool to harmonize education in 
developing country  
10:15 S15-05 P. Wieland WNA The World Nuclear University’s 7 approaches to 
enhance professional performance  
S16 11:00-12:30 WNU OLYMPIAD: FINALS 
Venue Board Room B/M1  
Chair: A. Rey Ríos  
Time  ID Presenter  Country/Org Title  
11:00                                                                              Introduction Remarks  
11:15 S16-01 T. Almeida WNA Public opinion about nuclear science and technology 
in Brazil 
11:30 S16-02 Z. Deziel WNA Public opinion on radiopharmaceuticals and the 
nuclear industry in USA 
11:45 S16-03 S. Tian  WNA Public opinion on nuclear science and technology in 
China 
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12:15                                                  Closing Remarks and Awards Ceremony 
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J. Osso    
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14:00 CS-01 N. Ramamoorthy India Highlights of ISTR2019 
14:30 CS-02   Awards Ceremony 
14:45 CS-03 M. Denecke IAEA Closing Remarks 
15:00 CS-04 J. Osso IAEA Closing of the Symposium 
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Production of reactor based radioisotopes: An international Scenario 
Author: Meera Venkatesh 
Corresponding author: Venkatesh.meera@gmail.com 
Radioisotopes have been used for applications since almost eight decades in varied fields, healthcare being 
the most vital and widely known. Nuclear research reactors, through production of radioisotopes, have played 
a key role in enabling and sustenance of such applications, including in nuclear medicine.  
A quick overview of the reactor produced isotopes used in radiopharmaceuticals over the past several decades 
shows the trend from the initial predominant use for  therapeutic purposes (Iodine-131 and Phosphorus-32) 
with limited non-ideal diagnostic uses, to a dramatic shift and steep growth in diagnostic nuclear medicine 
with the advent of technetium-99m (the most widely used medical radioisotope), to be followed by a surge in 
therapeutic applications using particulate (especially β- emitting radionuclides among which Lutetium-177, 
Samarium-153, Rhenium-188/186 and Yttrium-90 are noteworthy) in the past 2 decades.  
While the advances in closely associated fields such as cancer molecular biology influence radioisotopes used 
in nuclear medicine, the feasibility of production is dictated by the capacity of the nuclear reactor facilities and 
the regulations to be followed. The reactors worldwide have continuously adapted to the needs, improvised 
to meet the requirements and gear up for future demands, albeit often with severe constraints, owing to the 
ageing and the stringent regulations. The last decade witnessed acute short supply of important medical 
isotopes, especially Tc-99m, owing to the unavoidable long shut downs of the aged long serving reactors. 
Although radioisotope production in accelerators has seen a huge growth, it is beyond doubts that research 
reactors are essential for production of a huge range of important radioisotopes in large quantities and at 
affordable cost, recognizing which, efforts to build a few new research reactors have been initiated to cater to 
the global needs. 
An overview of the above aspects and a general status of the production of radioisotopes in the world will be 
provided, keeping the focus on the use in radiopharmaceuticals, aligning with the theme of the Symposium. 
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Production and supply of medical radioisotopes: A polish experience 
Author: Renata Mikolajczak 
Radioisotope Centre POLATOM, National Centre for Nuclear Research, 05-400 Otwock, Poland 
Corresponding author: Renata.Mikolajczak@polatom.pl 
Nuclear reactors are the main source of neutrons of various energies (thermal, epithermal and fast) which can 
be utilized for irradiation of various target materials to produce radionuclides for therapy.  The characteristics 
of neutron flux, a parameter specific for each individual reactor, and the composition of the target material 
will determine the final specific activity of the desired radionuclide. Maria Research Reactor at the National 
Centre for Nuclear Research in Poland is one of the worldwide leading suppliers of iodine-131 and plays an 
important role as a source of other radionuclides for therapeutic use. The availability of beta emitters, 90Y and 
reactor produced 177Lu, allowed to initiate the peptide receptor radionuclide therapy of neuroendocrine 
tumours in Poland already in 2004. Special attention is given to radiometals which can be obtained in carrier-
free form from (n,p) and (n,γ)→β-reactions giving a parent radionuclide decaying in short time to required 
daughter radioisotope, an example of the latter being n.c.a. scandium-47. The processing of such targets 
requires separation chemistry and further pharmaceutical formulation. The ultimate goal is to obtain the 
radiometal with high specific activity, radionuclide and chemical purity, in the solution suitable for 
radiolabeling of various molecules for medicinal use.   
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Laboratory scale production of medium specific activity lutetium-177 (carrier added) through the 
[176Lu (n,γ) 177Lu] nuclear reaction under standardized conditions 
Author: José Luis Crudo  
Co-author(s):  Sofía Aguilar; Diego Martin; Marisa Trotta; Noemí Nevares; Ana Lopez Bularte; Alfredo Zapata; 
Dino Isolani; Jorge Quintana 
CNEA, Argentina  
Corresponding author: joseluiscrudo@cnea.gov.ar 
The goals were:  
1) To calculate 176Lu target enrichment percentage, 177Lu specific activity (S.A.) and its uncertainties and 
chemical impurities; 
2) To calculate 177Lu S.A. normalized error between four batches; 
3) To compare methods of target volume recovery from quartz ampoule. 
The product was obtained by irradiation in the RA-3 research reactor neutron trap of the Centro Atómico 
Ezeiza using an 86.5% 176Lu enriched target provided by IAEA. 176Lu target enrichment determination was 
carried out by Inductively Coupled Plasma–Mass Spectrometry (ICP-MS). Calculation of Lu mass in the ampoule 
was done by gravimetry. Geometry factor was used to correct the measured 177Lu activity of the quartz 
ampoule. 177Lu S.A. and its uncertainty were calculated for every single batch (n = 4). Metal impurities 
determination was performed by total reflection X-ray fluorescence spectroscopy (TXRF). 177Lu S.A. normalized 
error were obtained according standard ISO 13528:2015. Manual pipetting and reverse centrifugation of 20 
µL volume recovery from quartz ampoule were compared. 
Results showed that 176Lu/ (175Lu + 176Lu) ratio was 86.8 ± 0.9 %. 177Lu S.A. and its uncertainties at EOB for 
batches 1, 2, 3 and 4 were 26.7 ± 2.0, 18.5 ± 2.4, 16.6 ± 2.4 and 16.2 ± 2.3 mCi/µg of Lu respectively.  Fe, Mn, 
Sr, Cr, Ni, Cu and Zn concentration referred to 177Lu activity in batch 2 were 0.03, 0.0005, 0.0002 µg of metal / 
GBq of 177Lu and less than 0.0001 µg / GBq for the last ones respectively. Average and standard deviations for 
Lu mass, irradiation time and 177Lu S.A. at EOB (n =4) were 2.4 ± 0.1 μg, 151.7 ± 0.4 h and 19.5 ± 4.9 mCi/ μg of 
Lu respectively. Percentage (%) error of irradiation time, Lu mass and 177Lu S.A. were 0.2, 2.6 and 25.2 % 
respectively. 177Lu S.A. normalized error calculation showed that result of batch 1 was inconsistent. 
Comparison between manual pipetting and reverse centrifugation showed that 0.6 ± 0.8 mg and 1.7 ± 2.0 mg 
of target solution was not recovered from the quartz ampolle (n = 10). This was equivalent to 97.0 and 91.3% 
of total target volume recovery respectively. Metal impurities level complied with quality control specifications 
referred in table II-6 of IAEA-TECDOC 1856. Then, if the radionuclides were delivered in a short time since EOB, 
the product can be used for preparing moderate S.A. therapeutic radiopharmaceuticals. 
In conclusion, 177Lu (c.a.) can be efficiently produced under standardized conditions in the RA-3 with a medium 
S.A. and low level of chemical impurities using a commercially available enriched target. This fact is of big 
relevance because there are not industrial producers of high S.A. 177Lu in Latin America and 177Lu (c.a.) S.A. 
decrease 50 % with the time consumed for delivery from Europe or North America. 
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Synthesis and neutron activation of Lu2O3 nanoparticles functionalized with target specific 
peptides 
Author: Alejandra Ancira-Cortés1  
Co-author(s): Blanca Ocampo-García2; Enrique Morales-Avila3; Myrna Luna-Gutiérrez2; Nallely Jiménez-
Mancilla2 
1Instituto Nacional de Investigaciones Nucleares, Universidad Autónoma del Estado de México 
2Instituto Nacional de Investigaciones Nucleares 
3Universidad Autónoma del Estado de México 
Corresponding author: aancira2@gmail.com 
The preparation of 177Lu-peptides for targeted radionuclide therapy requires the use of lutetium-177 from 
medium to high specific activity (from 400 to 3000 GBq/mg), which cannot be obtained in low flux research 
nuclear reactors. However, the synthesis of 176Lu in the form of injectable nanoparticles functionalized with 
target-specific peptides, would allow to irradiate in the TRIGA (Training, Research, Isotopes, General Atomics) 
Mark III reactor, a mass of lutetium enough to obtain radiopharmaceuticals with activities suitable for direct 
medical use. 
The objective was to synthesize and characterize Lu2O3 nanoparticles functionalized with the RGD peptide, as 
well as to study the effect on their structural properties after neutron irradiation in the Triga Mark III reactor. 
Lu2O3 tablets were prepared and immersed in an injectable solution containing the DOTA-RGD peptide. The 
sample was irradiated in a Nd:YAG laser equipment (Q-Smart-100, quantel laser)(50 mJ) with a repetition rate 
of 10 Hz (irradiance of 16 Watts/cm2), producing instantaneously a turbid solution containing the lanthanide 
oxide nanoparticles with the peptide (Lu2O3-NPs-peptide) attached on their surface. The solution was purified 
and concentrated by ultracentrifugation and filtered through a 0.22 µm membrane (Millipore). The 
nanosystem was analysed by TEM, DLS, UV- Vis and IR techniques. The Lu2O3-NPs-peptide solution (1 mg/mL), 
contained in a sealed vial of pharmaceutical grade plastic, was irradiated in the Triga Mark III reactor (3x1013 
n.cm-2.s-1) for 20h. After decay, the sample was reanalysed by TEM, DLS, UV-Vis and IR techniques. 
The TEM, DLS, UV-Vis and IR analyses of the Lu2O3-NPs-peptide sample, showed that the method of synthesis 
by laser irradiation (thermo-reduction) is suitable for the preparation of nanosystems based   on lutetium 
oxide functionalized with target-specific peptides (size from 2 to 100 nm), which were not significantly affected 
when subjected to neutron irradiation in the Triga Mark III reactor. The irradiation of the Lu2O3-NPs-peptide 
(sterile solution) for 20h, yielded 9.2 GBq useful for direct clinical use. The Lu2O3-NPs-RGD system could 
potentially be applied in targeted radiotherapy of intrahepatic carcinomas. In order to produce significant 
amounts of Lu2O3-NPs, other methods of synthesis can be applied, such as thermo-reduction by calcination. 
In conclusion, laser irradiation is suitable for the synthesis of lutetium oxide nanoparticles functionalized with 
target-specific peptides, which are not significantly affected after neutron irradiation. The Lu2O3-NPs-RGD 
nanosystem is potentially useful for targeted radiotherapy purposes. 
Acknowledgment: this study was supported by the Mexican National Council of Science and Technology 
(“Laboratorios Nacionales” and CONACyT-SEP-CB-2018, A1-S-36841). 
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Towards a robust supply chain for medical radioisotopes 
Author: Titus Tielens 
Co-author(s): Hermen Van der Lugt; Alex Rood; Anneloes Geldermans 
PALLAS, the Netherlands  
Corresponding author: titus.tielens@pallasreactor.com 
Demand for nuclear medicines for diagnostic, therapeutic and theranostic use is growing fast, driven by the 
development of highly effective novel drugs against cancer and life-threatening diseases. Whereas 
molybdenum-99 is the most commonly used isotope for diagnostic SPECT scans, it is expected that lutetium-
177 will be the main workhorse in the coming decades for therapeutic applications. However, security of 
supply is at risk, especially for therapeutic isotopes, as radioisotopes are irradiated by only a handful of aging 
reactors, some of which will stop production in the coming decade. The objective of this paper is to assess if 
any shortage of production may emerge and to identify options for creating a robust supply chain. 
PALLAS has built a bottom-up model to estimate potential global demand for medical isotopes, based on an 
analysis of medicines under development, their indications and potential adoption among patient populations. 
PALLAS has also made a forecast model of available reactor capacity for both diagnostics and therapeutics. 
Finally, PALLAS has developed scenarios to assess any gap in production capacity. 
The resulting demand and supply scenarios indicate that while the number of diagnostic scans will grow 
moderately, the number of therapies could grow steeply to several hundred thousand by 2030. 
PALLAS research shows that the available capacity for a key isotope such as lutetium-177 will not be able to 
meet demand as of 2025. As no effective alternative production methods exist for most therapeutic isotopes, 
it is clear that new reactor capacity will be required. 
The PALLAS foundation was initiated with a loan from the Dutch government with the objective of constructing 
a new nuclear reactor, to replace the current High Flux Reactor in Petten, the Netherlands, for the production 
of medical isotopes and research, but under the explicit condition that the reactor be privately financed. 
Driven by the need for private investment, the PALLAS team has developed a market-oriented approach and 
value proposition that will help transform the nuclear isotope sector. 
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Accelerator-based production of non-standard positron emitters and therapeutic radionuclides 
Author: Syed M. Qaim 
Institut für Neurowissenschaften und Medizin, Nuklearchemie, Forschungszentrum Jülich, Germany 
Corresponding author: s.m.qaim@fz-juelich.de 
The radionuclide production technology with regard to patient care studies is well developed, both at reactors 
and accelerators. For some newer emerging medical applications, however, there are increasing demands for 
two types of novel radionuclides: (a) longer lived positron emitters to study slow metabolic processes and to 
quantity radiation dose, (b) low-energy, highly ionising radiation emitting radionuclides for efficient internal 
radiotherapy of deep-lying tumours (targeted therapy). The development of a novel radionuclide demands 
interdisciplinary studies involving nuclear data measurements, target construction for high-current 
irradiations, devising chemical separation schemes to obtain high purity products and finally elaborating 
quality assurance tests for human use. The chain of work involved in the development of an accelerator-based 
radionuclide will be illustrated through a few examples. 
Over the last three decades about 25 non-standard positron emitters have been developed, the most 
important ones being 64Cu (T½ = 12.7 h); 86Y (T½ = 14.7 h); 89Zr (T½ = 3.3 d) and 124I (T½ = 4.2 d). Many of the non-
standard PET radionuclides are produced at a cyclotron via the low-energy (p,n) reaction on a highly-enriched 
target isotope. In general, small-sized solid targets are used, provided an extracted beam is available. At a few 
medical cyclotrons, however, attempts to use solution targets have also been fairly successful. On the other 
hand, a few positron emitters, like 52Fe (T½ = 8.3 h), 73Se (T½ = 7.1 h), 152Tb (T½ = 17.5 h), etc. can be produced 
only using accelerators delivering protons of energies up to 120 MeV.  Exceptionally the spallation process is 
also utilized. All those possibilities will be elucidated. 
With regard to novel therapeutic radionuclides, the present emphasis is on low-energy β- emitters, e.g. 47Sc 
(T½ = 3.35 d) and 67Cu (T½ = 2.58 d), low-energy conversion and Auger electron emitters, e.g. 117mSn (T½ = 13.6 
d) and 193mPt (T½ = 4.33 d), and α-emitters, e.g. 225Ac (T½ = 10.0 d). The on-going work on those radionuclides 
at intermediate energy accelerators will be briefly described, including the role of the α-particle beam in the 
production of the high-spin isomers like 117mSn and 193mPt. The most recent attempts to produce a few 
therapeutic radionuclides like 47Sc and 67Cu via the (n,xp) process induced by d/Be breakup neutrons at a 
cyclotron or via the (γ,p) reaction at a powerful electron linear accelerator (LINAC) will be outlined. Finally, the 
significance of the non-standard positron emitters and novel therapeutic radionuclides in theranostic 
applications will be briefly considered. 
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Production of radiometals using a 24 MeV cyclotron 
Author: Suzanne E. Lapi 
University of Alabama at Birmingham, United States 
Corresponding author: lapi@uab.edu 
With the expansion of approved 18F based agents for medical imaging using positron emission tomography 
(PET), low energy (11-24 MeV) cyclotrons are now used at many commercial and academic centers to produce 
isotopes for medical imaging.   The energy of these machines is ideal for isotope production via (p,n), (p,α) and 
in some cases (p,2n) reactions.  Using the UAB TR24 cyclotron, our group has focused on the development of 
reaction routes, target materials and the separation chemistry of isotopes to expand the toolbox of nuclear 
imaging agents. These have included transition metals such as 52Mn, 55Co, 89Zr, 43,47Sc and 45Ti.  Additional 
research has developed chemistry to incorporate these isotopes into new imaging radiopharmaceuticals for 
preclinical or clinical research.   
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Production of radiometals using liquid targets: Status and perspectives 
Author: Antero Abrunhosa 
ICNAS/University of Coimbra  
Corresponding author: antero@pet.uc.pt 
The ever-increasing demand of radiometal isotopes for PET imaging is not being met by the currently available 
sources that rely mainly on radioisotope generators (when available, e.g. for Ga-68) and cyclotrons equipped 
with solid targets. 
Our group has been actively involved in developing processes for the production of commonly used PET 
radiometals using liquid (solution) targets. This approach presents considerable advantages over the 
conventional solid targets as it much simpler, faster, amenable to automation and easier to comply with GMP 
production requirements. Moreover, these processes can be adapted, with minimal adaptation, to virtually all 
existing cyclotron facilities, most of them devoted F-18 production during the night and idle during the rest of 
the day. 
This technology enables easy on-demand access to isotopes such as Ga-68, Zr-89, Cu-64 and Cu-61 among 
others that are essential to supply the ever-increasing requests of research and clinical theranostic 
applications. Ga-68 production is especially critical as current GMP generator production is far from being able 
to meet the fast-expanding market needs of this important isotope.  
In this presentation we will discuss important issues regarding the production of radiometals using liquid 
targets including purity of target materials, irradiation conditions, purification processes, automation, GMP 
and regulatory considerations.  
We believe that the widespread use of this technology could provide a stable supply of radiometals to fulfil 
current and future market needs for research and clinical applications with minimal adaptation of currently 
existing infrastructures. 
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Radioisotope production and development with a 30 MeV cyclotron 
Author: Jeong Hoon Park  
Korea Atomic Energy Research Institute, Jeongeup, Republic of Korea (South) 
Corresponding author: parkjh@kaeri.re.kr 
RFT-30 is a 30 MeV cyclotron research facility at Korea Atomic Energy Research Institute in Jeongeup city 
located to the south east of Seoul. Radionuclide based pharmaceuticals are playing major role in several 
medical procedures. Medical community has experienced a rapid growth for radionuclide applications in the 
field of therapy, diagnosis and/ or therapeutic purposes due to the technological development in cyclotron-
based radionuclide production. We have been successful in irradiating targets for producing bulk quantities of 
Zr-89 and Ge-68. Complete process optimization has been finished for Zr-89 targetry, production, separation 
and purification. We have started regular supply of high purity Zr-89 (oxalate/ chloride) to hospitals such as 
Seoul national hospital, Samsung Seoul hospital etc. based research groups in Korea. Process optimization for 
Ge-68 production has been achieved and we are working on purification of Ge-68. And furthermore, the 
electroplating associated with nickel target was optimized for Cu-64 and Co-57. Simultaneous efforts are made 
towards electrodeposition of Zn-70 for the production of Cu-67 respectively. One of the major activities at the 
Cyclotron Application and Research Facility (CARF) is research and development in the field of production of 
cyclotron-based radionuclides and its applications. We at CARF are routinely involved in performing 
preliminary studies and process development required for the bulk production of high purity radionuclides for 
medical applications. As a part of this activity the major R& D efforts are dedicated towards targetry, 
production, separation/ purification, applications and achieving the efficient technologies for cyclotron based 
emerging radiometals (viz. Zr-89, Ge-68, Cu-64/67, Sc-44/47, Co-55/57, etc.) production, ensuring its 
sustainable supply for research and medical purposes. An overview of the efforts made by the researchers at 
CARF towards developing and optimizing production of radiometals using RFT-30 cyclotron is the sole 
purposes of this presentation. Methods from target production, irradiation conditions, target processing, 
separation and purification of radionuclides of interest, recovery of enriched target material would be 
discussed in brief. 
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Production and application of Ac-225/Bi-213: TRIUMF experience and perspectives 
Author: Valery Radchenko1  
Co-author(s):  Paul Schaffer1; Caterina Ramogida2; Cornelia Hoehr1; Patrick Causey3; Randy Perron3; Andrew 
Robertson1; Peter Kunz1 
1TRIUMF 
2SFU/TRIUMF 
3Canadian Nuclear Laboratories 
Corresponding author: vradchenko@triumf.ca 
Targeted Alpha Therapy (TAT) showed recently very promising clinical results and it is a superior therapeutic 
tool compared to chemotherapy and beta radionuclide therapy. Due to the high Linear Energy Transfer (LET) 
and higher energy than beta particles, alpha particles are ideally suitable for localized therapy with selective 
delivery systems (e.g. peptides, antibodies etc.). Ac-225 (t1/2 9.92 days) and daughter Bi-213 (t1/2 45.6 
minutes) are two very potent candidates for TAT, but their wide clinical application is limited due to the limited 
supply. TRIUMF (Canada’s Particle Accelerator Centre) has unique capabilities to produce Ac-225/Bi-213 via 
several production routes and significantly increase world supply of these emerging isotopes for TAT. 
Several production routes are currently utilized to make available Ac-225 at TRIUMF. The first one is based on 
production of beam of mass number 225 with TRIUMF ISAC (Isotope Separator and Accelerator) facility, which 
enables to produce isotopically pure beam of actinium-225 and its parent radium-225. Produced research 
quantities (KBq- MBq’s) enabled us to establish handling procedures for radiochemical purification and 
radiolabelling of actinium and bismuth isotopes and conducting unique research in chelation for preference 
of both elements. 
Further, we have active collaboration with the Canadian Nuclear Laboratories (CNL), Ontario, Canada where 
the limited source of Th-229 is available and we are working together on testing the quality of this material 
and establishing sufficient radiochemical purity for radiolabelling. We are also working on a comparison study 
of Ac-225 sources derived from ISAC and CNL and establishing quality control tests and highest specific activity. 
In addition to the above mentioned sources, TRIUMF has the world largest (520 MeV, 100 µA) cyclotron, which 
has capabilities at the target station at the end of the beam line 1A to produce a clinically (GBq) amount of Ac-
225 and other promising alpha emitters suitable for TAT, via spallation reaction of thorium target. The main 
challenge in this production route is the radiochemical separation to purify actinium from the bulk mass of 
thorium target and several hundreds of co-produced fission products. Life sciences are currently working on 
developing several radiochemical separation methods for extraction of actinium isotopes from irradiated 
thorium as well as coextraction of other useful medical isotopes. 
With the upcoming ARIEL facility, TRIUMF will enable two additional routes for production of actinium-225. 
First, by using ARIEL proton beam line in the same fashion how we utilize beamline 1A, to irradiate bulk mass 
of thorium for production of actinium isotopes. Appropriate infrastructure including irradiation station, 
transfer system and processing hot cells are currently under design. Additional promising production 
capability, which is still under consideration, for TAT isotopes will be electron beamline of ARIEL which will 
enable photonuclear reaction on radium (Ra-226(γ, n)Ra- 225→Ac-225) and will enable to produce clinical 
quantity of Ac-225 and other promising medical isotopes. 
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Role of IAEA on the supply of 99Mo 
Author: Joao Osso Junior 
IAEA, Vienna, Austria 
Corresponding Author: J.A.Osso-Junior@iaea.org 
Technetium-99m (99mTc), the daughter product of molybdenum-99 (99Mo), is the most utilized medical 
radioisotope, amounting to about 30 million studies per year and more than 80% of all procedures in 
diagnostic nuclear medicine. The IAEA supports its Member States in various areas related to the production 
of 99Mo and 99mTc, without using high enriched uranium (HEU), through activities such as coordinated research 
projects (CRP), thematic technical meetings, technical cooperation projects and publications. Some recent 
activities are: CRPs on (i) Direct cyclotron production of 99mTc (ii) Guidelines on how to reduce radioactive 
gaseous releases during radioisotope production (iii) New Ways of Producing 99mTc/99mTc Generators. 
Additionally, the HEU minimization project and the Peaceful Uses Initiative project on supporting the global 
99Mo production without using HEU are being implemented. A Symposium on the supply of 99Mo, organized 
by the National Academies of Sciences of United States of America and Russian Federation, was supported in 
2017. All activities will be discussed along with future planning. 
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Nuclear safeguards in radiopharmaceutical facilities 
Author: Bret Grimshaw 
IAEA, Vienna, Austria  
Corresponding author: b.grimshaw@iaea.org 
One of the many functions of the International Atomic Energy Agency (IAEA) is to undertake verification of 
nuclear materials (uranium, plutonium and thorium) in peaceful use, including within radiopharmaceutical 
facilities, to verify states’ undertakings under their respective safeguards agreements with the IAEA. This 
function includes the specific verification of nuclear materials associated with the production of 
radiopharmaceuticals used in shielding, and for both pre-irradiated and post-irradiated nuclear material as 
seen in Mo-99 production.  The verification of nuclear material employs a variety of IAEA verification 
techniques including, gamma ray spectroscopy and neutron coincidence counting. This presentation will cover 
definitions of nuclear material and nuclear material verification using analytical techniques deployed. 
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 Supply of Mo-99:  Focus on US supply 
Author: Cathy S. Cutler  
Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY USA 
Corresponding author: ccutler@bnl.gov 
There has been no large-scale production of Mo-99 in the United States since Cintichem shut down in 1989.  
The US the largest user of Mo-99 for the supply of Mo-99/Tc-99m generators has relied on outside production 
of Mo-99 traditionally produced by neutron irradiation of highly enriched uranium targets (HEU).  The world 
supply was largely provided by four irradiation sources NRU, HFIR, BR2 and NTP reactors.  The NRU reactor 
was able to supply roughly 80% of the world’s supply and was able to cover the production if the other reactors 
unexpectedly went down.  This all came to a head when these aging facilities started having unexpected 
shutdowns that resulted in worldwide shortages in supply.  Further around the same time the US government 
became concerned about the shipment of HEU targets around the world and the possibility that they could 
fall into the wrong hands and be used for nefarious purposes and thus wanted to see production switched to 
the use of low enriched uranium (LEU)targets and LEU fuel.  In 2010 the NNSA began funding cooperative 
agreements with partners that were able to come up with 50% of the funding to create a redundant reliable 
supply of Mo-99.  The initial goal was for the partners to produce 50% of the needed Mo-99 supply in five 
years.  In 2018 with only one US supplier approved by the FDA and producing at levels that were relatively 
minor the NNSA issued a new funding opportunity announcement to produce Mo-99 without the use of HEU.  
Earlier this year the DOE announced that four US companies were under negotiation for potential new 
cooperative agreement awards.  The NNSA has also made available technical expertise from the Department 
of Energy national laboratories on a non-proprietary basis.  The current state of Mo-99 supply will be 
presented with a focus on US supply. 
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Radionuclide production at high energy accelerators: New possibilities for radioisotope 
generators 
Author: Boris L. Zhuikov 
Institute for nuclear Research of Russian Academy of Sciences, Moscow 
Corresponding author: bz@inr.ru  
Radionuclide production on high energy protons is considered as a prospective approach for creating medical 
generators providing diagnostic or therapy, in particular: 82Sr/82Rb, 68Ge/68Ga, 72Se/72As, 44Ti/44Sc (PET 
diagnostics), 225Ac/213Bi, 223Ra/211Pb, 230Pa/230U/226Th (radioimmunotherapy). Besides the old accelerators in 
BNL (200 MeV), LANL (100 MeV), TRIUMF (120 MeV), iThemba (66 MeV) and INR RAS (160 MeV), two 70 MeV 
cyclotrons and processing facilities in Nantes, France (ARRONAX) and in Indianapolis, USA (ZEVACOR) have 
been installed recently and are successfully operated now. Several more facilities are proposed to be installed 
soon in different countries. 
Several new generators are under development basing on the above radionuclides.   In particular, INR RAS has 
created a new design of 82Sr/82Rb-generator of activity up to 160 mCi providing PET diagnostics for cardiology 
and neuro-oncology of about 600 patients with each generator (30 L of eluent before breakthrough). Clinical 
trials successfully passed in Russia for the both medical applications.   
At the old high energy (more than 100 MeV) proton irradiation facilities in INR RAS, LANL, BNL and TRIUMF 
one can produce in future via irradiating metallic 232Th a big amount of a prospective alpha-emitter 225Ac (tens 
of Ci per year) with a small admixture of 227Ac (0.2%). INR RAS has successfully solved targetry problems using 
specially constructed diffusion high temperature welding facility. New 225Ac/213Bi-generators for high activity 
basing on cycling scheme and/or inorganic sorbents are under development. The new generator has been 
already tested for labeling, providing pure 213Bi with breakthrough of 225Ac less than 10-6 %. 
A new commercial accelerator facility with proton energy more than 100 MeV is necessary to develop in future 
to provide routinely a high level production 225Ac and 213Bi-generators along with other important 
radionuclides. 
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Cyclotron production of 47Ca for 47Ca/47Sc generator 
Author: Rafał Walczak1   
Co-author(s):  Mateusz Sitarz2/4; Ryszard Misiak3; Marek Pruszyński1; Agnieszka Majkowska-Pilip1; Jerzy 
Jastrzębski2; Ferid Haddad4 Aleksander Bilewicz1 
1Institute of Nuclear Chemistry and Technology, Warsaw, Poland 
2University of Warsaw, Warsaw, Poland  
3Institute of Nuclear Physics Polish Academy of Sciences, Cracow, Poland 
4GIP ARRONAX, Saint-Herblain, France and Subatech, Nantes, France 
Corresponding author: r.walczak.ichtj@gmail.com 
Scandium-47 is a low energy β- emitter which together with β+ emitters 43Sc and 44Sc, creates very attractive 
theranostic pairs for nuclear medicine. As far, obtaining 43Sc and 44Sc are well developed, whereas 47Sc 
production is still difficult. In our work, we propose a new cyclotron method for producing 47Ca in 48Ca(p,x)47Ca 
nuclear reaction and design and construction of 47Ca/47Sc generator. 48Ca target in CaCO3 form (enriched with 
69.2% 48Ca) and mixed with graphite was irradiated at the ARRONAX cyclotron in Saint-Herblain, France in the 
energy range 60 → 13 MeV. Results show that recalculated TTY production for 47Ca on commercially available 
97.1% enrichment 48Ca is 140(11) MBq/μAh. This result is consistent with our previous measurements at the 
AIC-144 cyclotron in Cracow, Poland and with the predictions based on TENDL-2017. Therefore, after 24 hours 
of irradiation, with a current of 30 μA, it is possible to generate 94 GBq of 47Ca. During this process also 46Sc, 
47Sc, 48Sc are generated, and as impurities, they must be separated from 47Ca. 
For separation of scandium radioisotopes, we applied a precipitation method using microfilters with PTFE 
membrane (0.22 μm). After the irradiation, CaCO3 target was dissolved in 1 M HCl and then alkalized with 25% 
ammonia. In this environment scandium forms insoluble compounds and can be separated from calcium by 
using microfilters. After separation of impurities the Ca solution was left 5.6 days for the maximum growth of 
47Sc. Our results indicate that with 100% effective dissolution, about 60 MBq/μAh of pure 47Sc without other 
contaminating scandium activity could be separated on the filter for the highly enriched 48CaCO3 target.  
Therefore, by irradiation of 48Ca target for 24 hours with 30 μA protons is possible to produce 39 GBq of 47Sc, 
which is enough for about 10 therapeutic doses. After next 5.6 days another 17 GBq of 47Sc is generated, which 
is about 4 doses.  
Scandium-47, separated by our developed method, has sufficient quality for labelling biologically active 
molecule, which has been confirmed by labelling bioconjugates of Trastuzumab, anti HER2 nanobody and 
Substance-P with DTPA and DOTA chelators. For DTPA-Trastuzumab, DTPA- nanobody and DOTA-Substance-
P efficiency of labelling was 99% (T=95℃) and for DOTA-nanobody 60% (T=50oC). 
Acknowledgement: this study was financed by the Ministry of Science and Higher Education of Poland from 
funding for science in the years 2016–2019 (co-financed international program) and by IAEA Research Contract 
No: 20488 and NCN grant “Nanobodies labelled with alpha emitters as potential radiopharmaceuticals in 
targeted radioimmunotherapy” no: 2013/09/D/ST4/03791. This work has been, in part, supported by a grant 
from the French National Agency for Research called “Investissements d’Avenir”, Equipex ArronaxPlus noANR-
11-EQPX-0004 and Labex IRON noANR-11-LABX-18-01.
ISTR–2019 
 
52 
 
S4. Production of radiopharmaceuticals: Theranostic
ISTR–2019 
 
53 
 
Development and application of monoclonal antibody-based radiopharmaceuticals 
Author: Jason lewis  
Memorial Sloan Kettering Cancer Centre, New York, United States of America  
Corresponding author: mailto:lewisj2@mskcc.org 
The use of Positron Emission Tomography (PET) for cancer imaging is a well-established and widely used 
molecular imaging modality both in clinical and research settings. PET offers the ability to quantitatively 
measure biological and receptor-based processes using a wide spectrum of specifically designed 
radiopharmaceuticals. The use of PET is expanding and the inclusion of longer-lived radiometal positron-
emitters is broadening the application and appeal of this imaging modality.  
The remarkable specificity and selectivity of antibodies for cancer biomarkers have made immunoglobulins 
some of the most flexible and adaptable tools in modern medicine. For therapeutic purposes, a wide range of 
non-labeled antibodies has now entered the clinic. Antibody-based PET and SPECT imaging agents are not far 
behind. For example, an array of 89Zr-labeled radioimmunoconjugates has shown significant promise in both 
preclinical and clinical studies.  
Zirconium-89 has a number of distinct advantages which make it ideal for immunoPET: (i) the radioactive half-
life of 78.41 h matches closely the extend times required for optimum biodistribution of intact mAbs, (ii) the 
positron yield of 22.7% is comparable to that of Cu-64, Y-86 and I-124 which improves counting statistics in 
PET imaging, (iii) zirconium and its ions are generally inert to biological systems and have no known biological 
role or function, (iv) cyclotron production of Zr-89 via the (p,n) transmutation reaction using a 100% naturally 
abundant Y-89 solid target is highly efficient and cost effective, and (v) high purity and high specific-activity Zr-
89 is now available in various chemical forms which are suitable for radiolabeling mAbs.  
This presentation will review the current state-of-the-art in non-standard PET nuclide application with an 
emphasis on the use of radiometals with antibody constructs. In addition, since the effective use of a 
radiometal nuclide often relies on their attachment to the targeting probe via a bifunctional chelator, this talk 
will focus on novel strategies for using “click” chemistry methodology for attachment of the radiometals to 
active antibodies. 
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Theranostic radiopharmacy 
Author: C. Decristoforo 
Medizinische Universität Innsbruck, Austria 
Corresponding author: Clemens.Decristoforo@tirol-kliniken.at 
The concept of theranostics has found increasing interest in the Nuclear Medicine community. Even though 
applied for decades in the context of radioiodine therapy recent interest is driven mainly by combining the 
use of 68Ga-radiopharmaceuticals in PET with Lu-177 for therapeutic applications. The two major 
radiopharmaceuticals are Somatostatin analogs and PSMA ligands. In this talk the requirements for the small 
scale preparation of these radiopharmaceuticals in a combined theranostic settings are discussed. 
Preparations cane be performed manually, but today are usually made using automated modules allowing to 
use similar and well documented processes for preparation of both the diagnostic as well as the therapeutic 
radiopharmaceuticals. Technological differences are discussed and strategies to comply with Good 
Manufacturing Practices. Recent trends towards kit based preparation for 68Ga-radiopharmaceuticals and 
centralized production of therapeutic analogs provide new opportunities for wider application of the 
theranostic concept in Nuclear Medicine. 
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Co-author(s): Roberto Formento-Cavaier2; Férid Haddad3; Ulli Köster4; Frank Rösch5; Thierry Stora6; Dominik 
Studer1; Klaus Wendt1 
1AG LARISSA, Institute of Physics, Johannes Gutenberg University Mainz (Germany) 
2Advanced Accelerator Application, Novartis Group (Ivrea, Italy) 
3GIP ARRONAX (Nantes, France) 
4Institut Laue-Langevin (Grenoble, France) 
5Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz (Germany) 
6Engineering Department, CERN (Geneva, Switzerland) 
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Nowadays, there are several developments focused on the expanding of the availability of innovative medical 
radioisotopes. One of them is the use of mass separators, which can extract a desired isotope from a mixture 
of others of the same element, a task nearly impossible just by means of chemical methods. An 
electromagnetic mass separator, dedicated for medical isotope production, has been launched in the frame 
of CERN-MEDICIS facility. This R&D project is intended: to study and to establish production routes for 
radionuclides, having a potential for the theranostic approach, like terbium isotopes (Tb-149, Tb-152, Tb-155, 
Tb-161); to test a purification method for carrier-added Lu-177; and to demonstrate the availability for other 
innovative isotopes, like Er-169, a nearly pure short-range beta-emitter with similar chemistry to Lu-177. 
To identify the optimal requirements for extraction of isotopes of interest, different types of ion sources were 
studied. It was done by a direct comparison of the performance of surface ion source with laser ion source in 
a separation of a quantified sample of elements of interest. The ratio between a number of atoms collected 
after separation and known number of atoms in the sample initially gives an ionization efficiency value, which 
can serve as a direct measure of the performance. The experiments were performed at the MEDICIS facility 
in-situ (surface ion source), and at the Mainz University mass separator setup RISIKO (laser ion source). 
During the in-situ measurements with the surface ion source, the production of Tb-155 and Er-169 with a high 
specific activity was demonstrated. On the other side, the collected quantity was only enough for pre-clinical 
tests. Thereby, the obtained ionization efficiency was around 5 % for Tb-155 and 0.3 % for Er-169. The 
experiments with laser ion source gave exceptionally high ionization efficiency results above 50%, what should 
increase the production performance of terbium and erbium at least by one or two orders of magnitude 
respectively. 
The highly efficient laser ionization process of considered elements has a clear potential to be applied to 
radioactive ion beam facilities. It will allow the production of radionuclides in a quantity being sufficient for a 
regular supply of nuclear medicine institutions. In 2019, the MEDICIS Laser Ion Source Setup MELISSA is going 
to be launched. The combination of the laser resonance ionization and electromagnetic separation will 
become a starting point for production of many other nuclides, not accessible before because of a strong 
isotopic contamination. Several experiments are foreseen, to test additionally the performance for scandium 
and actinium isotopes. 
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Preparation and preclinical evaluation of 64Cu-NOTA-anti MUC1 as a radioimmunoconjugate for 
diagnosis of MUC1+ breast cancer by PET 
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Radioimmunoscintigraphy (RIS) has attracted considerable clinical applications in tumour detection. 
Underglycosylated MUC1 antigen is one of the early hallmarks of tumour genesis and is overexpressed in more 
than 80% of breast cancers. PR81 is a new murine anti-MUC1 monoclonal antibody (mAb). In this study, as the 
first step, we have developed an efficient indirect labelling method of PR81 with 64Cu (T1/2 = 12.8 h, β+ = 17%, 
β− = 39%, EC = 43%) through using NOTA (p- SCN-Bn-NOTA) bi-functional chelator and performed preliminary 
biodistribution studies in mouse bearing breast adenocarcinoma. 
PR81 was conjugated with NOTA (Macrocyclics B-605), the average number of the chelator conjugated per 
mAb was calculated and total concentration was determined by spectrophotometrically. NOTA–antiMUC1 was 
labelled with 64Cu then Radiochemical purity and immunoreactivity, internalization study by MCF7 cell line and 
serum stability of 64Cu–NOTA– anti MUC1 were determined. The biodistribution studies and 
radioimmunoscintigraphy were performed in female BALB/c mouse bearing breast carcinoma tumour (64Cu–
NOTA–antiMUC1 i.v., 100 μl, 20±5 μg mAb , 6, 12, 24 and 48 h). 
64Cu–NOTA–anti MUC1 was prepared (RCP >98% ± 0.4, Specific activity 5.2 ± 1.2 μCi/μg). Conjugation reaction 
of chelator (50 molar excess ratio) to antibody resulted in a product with the average number of chelators 
attached to a mAb (c/a) of 4.1 ± 0.5. Labelling yield with 64Cu in 400µg concentration of bioconjugate was 
96.5% ± 2.1. Immunoreaction of 64Cu–NOTA– anti MUC1 complex towards MUC1 antigen was determined by 
RIA and the complex showed high immunoreactivity towards MUC1. In vitro and in vivo stability of 
radioimmunoconjugate was investigated respectively in PBS and blood serum by RTLC method. In vitro 
stability showed more than 94% ± 1.26 in the PBS and 81% ± 2.62 in the serum over 24 hours. The 
Immunoreactivity of the radiolabelled PR81 towards MCF7 cell line was done by using Lindmo assay protocol. 
Under these conditions, the immunoreactivity of the radioimmunoconjugate was found to be 0.82. The 
biodistribution of 64Cu–NOTA– anti MUC1 complex in the mice with normal and breast tumour at 6, 12, 24 and 
48 h after intravenous administration, expressed as percentage of injected dose per gram of tissue (%ID/g). 
Biodistribution and imaging studies at 24 and 48 h post-injection revealed the specific localization of 
complexity at the site of tumours. 
In conclusion, 64Cu–NOTA– anti MUC1 is a potential compound for molecular imaging of PET for diagnosis and 
follow up of MUC1 expression in oncology. 
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Prostate cancer (PCa) is the second leading cause of cancer deaths for adult men in the Western world. 
Although radical prostatectomy and local radiotherapy are largely successful for patients with localized cancer, 
available treatments for metastatic PCa have demonstrated weak curative efficacy. Consequently, new tools 
to improve the detection of recurrent PCa, and to identify and treat metastases, are imperatively needed. 
Antibody-based constructs represent a good strategy to develop theranostic agents. Currently, the murine 
mAb 111In-capromab pendetide (ProstaScint®) is the only product that has been approved by the Food and 
Drug Administration (FDA) as a diagnostic radiopharmaceutical for PCa. ProstaScint® showed promising results 
in clinical diagnosis, but as a whole antibody exhibits low tumour targeting with a maximum uptake at 6-7 days 
post-injection and delayed clearance from non-target tissues. These issues limit its use as theranostic agent. 
Recently, preclinical studies of an anti-PSMA single-chain variable fragment of IgGD2B mAb (scFvD2B) la- 
belled with 123I, showed high tumour affinity, improved antigen-positive tumour uptake, with shorter 
circulatory half-life, and decreased uptake in non-target tissues. The aim of this work was to develop a new 
PCa theranostic radiopharmaceutical based on the scFvD2B radiolabel with 177Lu. 
The scFvD2B was conjugated to the chelating agent DOTA by using different stoichiometric molar ratios. The 
number of DOTA per scFvD2B and the affinity constant (Kd) for each construct was determined to choose the 
conjugated with higher specific targeting activity against PSMA receptors. The select DOTA-scFvD2B conjugate 
was labelled with 177LuCl3. Stability of 177Lu-DOTA-scFvD2B was studied using HPLC analysis after incubation at 
37 ℃ with fresh hu- man serum, cysteine, glutathione or EDTA solutions (300-fold excess), at time points 
ranging from 0.5 to 192 h. In vitro cell studies were performed to determine the binding specificity and cellular 
internalization of 177Lu-DOTA-scFvD2B. Biodistribution studies were performed in both healthy and PCa-
bearing mice to evaluate 177Lu-DOTA-scFvD2B pharmacokinetics and assess its tumour detection potential 
using SPECT imaging. 
DOTA-scFvD2B Kd values showed that the construct characterized by 1:5 (scFvD2B:DOTA) molar ratio is the 
one with the greatest number of DOTA per scFvD2B which maintains the high specificity for the PSMA 
receptor. 177Lu-DOTA-scFvD2B possessed high in vitro stability, the radiochemical purity of the radioconjugate 
accomplished at 192 hours after dilution was higher than 98%. Biodistribution studies performed in healthy 
mice after intravenous administration of the radioconjugate demonstrated that DOTA did not significantly 
change the scFvD2B pharmacokinetic properties. Indeed, 177Lu-DOTA-scFvD2B showed a favourable biokinetic 
profile with a rapid blood clearance. Moreover, SPECT/CT imaging studies carried out in mice bearing PCa 
tumours in lungs proved good and specific tumour detection properties of 177Lu-DOTA-scFvD2B from 6 to 192 
hours post-injection. 
In conclusion, 177Lu-DOTA-scFvD2B high stability and specific affinity for the PSMA receptors in vitro and in 
vivo make this radioconjugate a promising PCa theranostic radiopharmaceutical. However, further dosimetric 
studies have to be performed to establish its therapeutic potential.
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Revising Tc-99m radiopharmaceuticals with recent advances in chemistry & imaging tools 
Author: Adriano Duatti 
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Technetium-99m radiopharmaceuticals still remain the most extensively used radiodiagnostic agents covering 
approximately 70% of all nuclear medicine procedures carried out each year worldwide. Reasons for this 
success are well-known and can be traced back to the easy handling of the radionuclide in an hospital setting 
through the 99Mo/99mTc generator, the almost ideal nuclear properties of the radionuclide 99mTc when applied 
in combination with the imaging modality of single photon emission tomography (SPECT) and the simplicity of 
the preparation of 99mTc radiopharmaceuticals carried out through the use of freeze-dried kit formulations. 
However, despite its relevance, in the last decades interest in the development of new imaging agents has 
mostly switched from 99mTc to radionuclides for positron emission tomography (PET). This change in the 
nuclear medicine scenario was mainly justified by the far higher sensitivity and spatial resolution of PET as 
compared to SPECT. Yet, this scenario is going to take a turn again mostly driven by unprecedented 
advancements in SPECT technology. A new generation of high-resolution, ultrafast SPECT cameras are being 
introduced into the field, and these new devices are expected to bring SPECT approaching almost the same 
performances of PET. To mention just a few of these recent technological advancements, the new SPECT 
cameras allow collecting a SPECT brain or cardiac scan in only 1-3 minutes, with a spatial resolution below 2 
millimetres, by administering less than half of the activity currently injected in a conventional SPECT study. 
Evidently, given this outstanding progress, single photon emitting radionuclides might receive a renewed 
attention and impetus. In particular, 99mTc radiopharmaceuticals may recover again a crucial role in nuclear 
imaging. Actually, it is curious to note that there exist already 99mTc analogues of some of the most celebrated 
PET tracers. For instance, the radiopharmaceutical 99mTc-HYNIC-TOC is a SPECT agent for the diagnosis of 
neuroendocrine tumours analogous to the PET tracer 68Ga-DOTATATE. Similarly, the radiopharmaceutical 
99mTc-Trofolastat is an analogous of 68Ga-PSMA agents for the diagnosis of prostate cancer. Remarkably, a 
number of different derivatives of these radiopharmaceuticals are under investigation at the preclinical and 
clinical level. It turns out, therefore, that the arsenal of 99mTc radiopharmaceuticals is already equipped to 
address relevant clinical problems currently considered of exclusive domain of PET, possibly with the same, or 
even higher, level of diagnostic accuracy, taking advantage of the fundamental developments underway in 
SPECT technology. 
Interestingly, it may also happen that old 99mTc radiopharmaceuticals, previously abandoned because of the 
difficult in handling them with current SPECT imaging devices, could be resurrected and their considerable 
diagnostic properties fully exploited with the novel ultrafast SPECT cameras. A typical example might be 
pinpointed with one of the very first cardiac tracer 99mTc-Teboroxime, which possesses almost ideal properties 
for myocardial perfusion, but that was given up because of its fast washout from myocardium within 5 
minutes. Since a cardiac SPECT study can be completed in one-two minutes with the new ultrafast SPECT 
detectors, it turns out that the rapid cardiac elimination of 99mTc-Teboroxime may become an advantage rather 
than a disadvantage. 
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Author: Guillermina Ferro-Flores 
 Instituto Nacional de Investigaciones Nucleares, Estado de México, Mexico 
Corresponding author: guillermina.ferro@inin.gob.mx 
Single-photon emission computed tomography (SPECT) cameras equipped with CT are still the systems most 
used in many nuclear medicine centers worldwide. The main advantage of the preparation of SPECT-based 
radiopharmaceuticals is the use of radiometals, which allows the development of simple, efficient, and 
reproducible radiolabeling procedures by using lyophilized kit formulations, without the need of further 
purification processes. 
In this lecture, recent achievements on the design, freeze-dried kit formulations, and theranostic applications 
of SPECT-based radiopeptides with high affinity to cancer-associated target proteins are presented.  
99mTc-HYNIC-iPSMA, 177Lu-DOTA-HYNIC-iPSMA, and 225Ac-DOTA-HYNIC-iPSMA. Considering that the 
heterocyclic ring of HYNIC interacts with the hydrophobic active sites of some enzymes and proteins, different 
prostate-specific membrane antigen inhibitor radiotracers (iPSMA) were prepared based on the HYNIC-iPSMA 
and DOTA-HYNIC-iPSMA ligands formulated as freeze-dried kits for the labeling with 99mTc, 177Lu or 225Ac. All 
radiopharmaceuticals were obtained with high radiochemical purities, which allows the availability of 
theranostic pairs. 99mTc-iPSMA was useful as a SPECT molecular imaging option to assist in the initial diagnosis 
of prostate cancer and the monitoring of disease progression. Prostate tumours are clearly visualized at three 
hours because of the high radiopharmaceutical affinity and low bladder activity. 177Lu-iPSMA obtained from 
kit formulations showed high tumour uptake with good response (70%) rates in patients, including pain relief. 
225Ac-iPSMA prepared from lyophilized formulations also showed high in vitro and in vivo stability.  
99mTc-HYNIC-CXCR-4-L, 177Lu-DOTA-HYNIC-CXCR-4-L, and 225Ac-DOTA-HYNIC-CXCR-4-L. As in the above case, 
99mTc-,177Lu- and 225Ac-CXCR4-L were also prepared from lyophilized formulations with high radiochemical 
purity and high in vitro and in vivo stability. 99mTc-CXCR4-L was used for imaging of the chemokine-4 receptor-
associated with brain tumour invasiveness. A direct relationship between the grade of differentiation and the 
expression of CXCR4 was found in patients. 
99mTc-HYNIC-FAP-inhibitor, 177Lu-DOTA-HYNIC-FAP-inhibitor, and 225Ac-DOTA-HYNIC-FAP-inhibitor. 
Derivative ligands of the (N-(pyridine-4-carbonyl)-D-Alanyl)-L-Proline-boronic acid, a fibroblast activation 
protein (FAP) inhibitor, have also been obtained with high radiochemical purity and stability.  
99mTc-HYNIC-TOC, 177Lu-DOTA-TOC, and 225Ac-DOTA-TOC. Lyophilized formulations have also been used for 
the preparation of 177Lu- and 225Ac-octreotide in high radiochemical yields and with excellent stability to works 
as theranostic pairs of 99mTc-HYNIC-TOC. 
In conclusion, the use of quantitative SPECT/CT and the easy preparation of SPECT-based target-specific 
radiopharmaceuticals promotes the routine application of theranostics in oncological nuclear medicine, even 
in places where PET is not available. 
Acknowledgment: this study was supported by the Mexican National Council of Science and Technology 
(“Laboratorios Nacionales” and CONACyT-SEP-CB-2018, A1-S-36841). 
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Clinical Nuclear medicine applications are growing very fast in the world. The great impact of nuclear medicine 
in the management of major health problems is becoming evident and visible. Many hospitals in developing 
countries, public and private, are interested more than before by installing a department of nuclear medicine. 
The approach in developing countries for supporting the expansion of nuclear medicine should be adapted to 
the new contest taking in consideration the development of radiopharmacy and the availability of new 
radiopharmaceuticals. Classically radiopharmacy in developing was limited to “hot lab” where basics 
preparations of technetium 99m radiolabelled cold kits are done sometimes in hot cells when available. Today 
those infrastructures are no longer appropriate and do not fit with the increase of clinical needs expressed 
daily in hospitals. This situation requires to educate train and recruit a radiopharmacist. The main 
responsibility of the radiopharmacist or “radiopharmaceutical scientist” in nuclear medicine is the preparation 
of radiopharmaceuticals to ensure their safety and efficacy. They are also responsible for the quality of the 
product which is essential to increase the impact on patient management through a correct interpretation of 
the results of the investigation, or the delivery of the correct therapeutic dose. There is a considerable scope 
for research and development in the field of radiopharmaceutical science. Also, the infrastructure should be 
adapted to the new requirements with appropriate drawing, air circulation, staff education and trackability of 
gross products and radiopharmaceuticals including clinical aspects. 
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The development of new integrin-selective molecules suitable for therapeutic or imaging purposes are 
currently of interest in development of effective personalized medical platforms. Recently, a bifunctional 
chimeric echistatin-RGD-peptide, RGDechi, has been reported as a potent and selective antagonist of αvβ3, in 
which the echistatin portion is essential for such selectivity 1. 
Herein, RGDechi and three truncated derivatives functionalized with a cysteine (1-4), were synthetized and 
labelled with the [99mTc][Tc(N)PNP43]-synthon ([PNP43=(CH3)2P(CH2)2N(C2H4OCH3)(CH2)2P(CH3)2]) 
(99mTc1-4) as basis for selective integrin recognition. 
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RGDechi and derivatives were synthetized and conjugated to cysteine to allow the labelling with the 
[99mTc][Tc(N)PNP]-synthon, and characterised by HPLC. The chemical identity of 99mTc-RGDechi complexes was 
determined by carrier-added experiments supported by radio/UV- HPLC and LC-MS analyses. Dilution and 
transchelation stability studies of 99mTc-RGDechi complexes were carried out. Biological properties and binding 
specificity studies to the receptors were assessed on a panel of cancer cells expressing different levels of αvβ3 
and αvβ5. Finally, the pharmacokinetic profiles of the more promising candidates 99mTc1 and 99mTc2 were 
evaluated both on healthy and melanoma-bearing mice. Their metabolism and metabolite identification were 
also performed. 
Peptides were efficiently labelled with the [99mTc][Tc(N)(PNP)]-synthon. The compounds were stable at least 
for 18 hours in the reaction mixture. Dilution and transchelation studies demonstrated a high stability. In vitro 
binding data evidenced that the [99mTc][Tc(N)(PNP)]-synthon does not affect the biological properties of the 
peptides. The truncate 99mTc4, which lacks the last five C-terminal amino acid, lost the selectivity to αvβ3. 
Biodistribution studies conducted on 99mTc1 and 99mTc2 showed that the compounds selectively localize in 
tumour models expressing αvβ3 and fails to accumulate in those expressing αvβ5 receptors. 
99mTc1-2 are able to discriminate between endogenously expressed integrins αvβ3 and αvβ5 and possess 
favourable pharmacokinetics characterized by low liver uptake and rapid elimination from non-target tissues 
resulting in positive target-to-non-target ratios. Results are promising; the presented construct can be 
considered the starting point for the development of agents for the selective detection of αvβ3 expression by 
SPECT. 
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The origins of the Nuclear and Energy Research Institute (IPEN), formerly known as the Institute of Atomic 
Energy (IEA), date back to the 30’s with the coming of European teachers to the University of São Paulo (USP) 
that generated the Physics section of the Faculty of Philosophy, Sciences and Letters. The confluence of 
interests between the National Council for Scientific and Technological Development (CNPq) and USP, 
together with the donation of a nuclear research reactor by the Atoms for Peace Program, made possible the 
creation of the IEA of the Faculty of Physics of USP in 1956. In 1959, IPEN, through its former Department of 
Radioactive Material Processing, pioneered the experimental production of 131I radioisotope for medical 
application in Brazil. With the growing interest in the nuclear medical community, in 1961, IPEN started to 
produce 42K and 51Cr radioisotopes. Over the years the demand for radioisotopes grew and in 1976 the 
Radiopharmacy Center (CR) was inaugurated to exclusively house the production and quality control of 
radioisotopes and labelled molecules. By the end of 1980, IPEN embraced the technological advancement and 
began the distribution of technetium generators in parallel with a growing number of freeze-dried kits for the 
diagnosis of several diseases. The acquisition of the Cyclone 30-IBA (1998) and CV-18-IBA (2008) and cyclotrons 
allowed the production of 123I and 18F radioisotopes and the preparation of the 18F-FDG radiotracer (the gold 
standard radiotracer for cancer diagnosis). 
Currently, IPEN stands out in the Latin America and the Caribbean for providing the highest number of 
radiopharmaceuticals that account for more than 1.7 million procedures per year in the nuclear medicine 
clinics. The CR supplies 13 lyophilized kits for labelling with 99mTc, the technetium generator and 18 ready-to-
use radiopharmaceuticals for diagnostic and therapeutic purposes all over Brazil. 
IPEN is presently enrolled in the creation of conditions to face up what society needs for new 
radiopharmaceuticals by implementing a number of initiatives in order to boost innovation. Among them, CR 
is pursuing active research and development aiming for radiopharmaceuticals to reach market deployment 
and, has settled the goal to attract and involve young people in the field, ensuring the transfer of knowledge 
associated with decades of radiopharmaceuticals development. Moreover, the Brazilian Multipurpose Reactor 
(RMB) Project, will certainly impact the radiopharmacy allowing Brazil to be self-sufficient in the production 
of radioisotopes, such as molybdenum-99, which are nowadays imported and depended on the foreign market 
and exchange rate fluctuation. 
Here we provide an overview of the past achievements, the present state of radiopharmacy and the future 
milestones we identified to encourage young generations and universities to engage in the 
radiopharmaceutical production activity. We expect IPEN to keep expanding the knowledge, use and access 
of nuclear medicine, providing a better quality of life, to the Brazilian population. 
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Production and quality control of bone pain palliation agents using -emitters  
Author: M.R.A. Pillai  
Molecular Cyclotrons, Puthuvype, Ernakulam, Kerala, India 
Corresponding author: pillai.m.r.a@gmail.com 
Palliative care is an important aspect of cancer management. Bone metastasis is a major problem in lung, 
breast and prostate cancers. The major pain for terminally ill cancer patients is due to bone metastasis. Doctors 
try to improve the quality of life through palliative care. Opioid drugs are used for this purpose and have severe 
side effects. The use of bone seeking radiopharmaceuticals labelled with - particles that irradiate and destroy 
the cancer cells is effective to reduce the pain due to bone metastasis.  
Phosphorus-32 as sodium phosphate and strontium-89 as chloride were the first radiopharmaceuticals to be 
used for metastatic bone pain palliation. Despite having differing nuclear characteristics both the 
radiopharmaceuticals were found effective to reduce pain. The mechanism of action of these 
radiopharmaceuticals is based on the inherent property of the two elements to accumulate in bone. The 
production as well as the quality control of these tracers is straight forward as they are used as inorganic salts 
and are highly stable.  
Beta particles emitting radiometals complexed with bone seeking chelating agents was a novel idea introduced 
by the scientists at the University of Missouri-Columbia. Over a dozen - emitting radionuclides are tried for 
this purpose. Table 1 gives a limited list of bone pain palliation agents reported of which some are clinically 
tested.  One important point to note is that the characteristics of these radionuclides vary significantly both in 
half life and in energy. 188Re with 17-hour half-life to 90Sr with half-life of 50 days is found effective. So is the 
case with energy of the - particles, 188Re emits high energy - particles whereas 90Sr is a medium energy - 
emitter.  Use of low energy - emitters are preferred to reduce the bone marrow dose which is a limiting factor 
in the amount of radioactivity that can be administered.  
153Sm-EDTMP is a FDA approved radiopharmaceutical which is widely used and effective.  153Sm can be 
prepared in medium flux reactors by irradiating enriched 152Sm targets. Despite the logistical disadvantage of 
the short half-life of 46 hours, 153Sm-EDTMP is available in many countries.   IAEA took the initiative for the 
clinical implementation of 177Lu-EDTMP through a coordinated research project and this product is successfully 
used in a few countries. The major advantage of this product is the 6.7 d half-life of 177Lu and the ease of its 
production in large quantities by irradiating enriched 176Lu targets in medium flux reactors.    
The production and quality control of the radiometal based bone pain palliating agents are straight forward. 
Relatively large excess of the chelating agent is used and hence the products formed are stable over extended 
periods of time. Simple chromatographic methods such as paper and thin layer chromatography are sufficient 
to establish the radiochemical purity of the products.  
Bone pain palliation therapy using radiopharmaceuticals has not realized its full potential despite the option 
of having several products.   
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Table 1. List of the radionuclides used for preparation bone pain palliation agents  
Radionuclide Half-life 
in days 
- Energy 
in keV (%) 
 energy 
in keV (%) 
Production 
 
Chemical form 
used 
Rhenium-188 0.7 
 
2120 (71.1) 
1965 (25.6) 
155 (14.9) 188W/188Re 
Generator 
188Re-HEDP 
Samarium-153 1.9  
 
808 (17.5) 
705 (49.6)    
635 (32.2) 
103 (28.3)           152Sm(n,)153Sm 
 
153Sm-EDTMP 
Lutetium-177 6.7  
 
498 (78.6)   
  176 (12.2)     
208 (11.0)  
113(6.4) 
176Lu(n,)177Lu   177Lu-EDTMP 
177Lu-DOTMP 
Phosphorus-32 14.3  1711 (100) nil 32S(n,p)32P Na332PO4 
Strontium-89 50.5   
 
1497 (100) Nil 88Sr(n,)89Sr 
89Y(n,p)89Sr 
90SrCl2 
Thulium-170 128.6  968 (81.6)    
883 (18.3) 
84(3.26) 169Tm(n,)170Tm 170Tm-EDTMP 
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Comparison of promising new short-range therapeutic radiopharmaceuticals using 225Ac, 213Bi and 
161Tb 
Author: Jan Rijn Zeevaart1 
Co-author(s): Mike Sathekge2; Thomas Ebenhan2; Nick Van der Meulen3; Cristina Mueller3 
 1Necsa, Radiochemistry 
2University of Pretoria and Steve Biko Academic Hospital, Nuclear Medicine, Pretoria, South Africa 
 3Center of Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen-PSI, Switzerland 
Corresponding author: zeevaart@necsa.co.za 
Prostate-specific membrane antigen is a prominent imaging biomarker in nuclear medicine. With Gallium-68 
(68Ga) opportunely available to hospital radiopharmacies we recently developed a PSMA11 single kit vial 
radiolabelling solution which is now routinely used in the Steve Biko Academic hospital in Pretoria, South 
Africa. The most widely used therapeutic pendant for 68Ga is 177Lu but recent advances in radionuclide 
production methods have made 225Ac, 213Bi and 161Tb available as alternatives to 177Lu. This created interesting 
opportunities to treat metastases with the short-range Alpha or Auger and conversion electron emissions. 
225Ac is a very promising radionuclide for targeted alpha therapy. With its relatively long half-life (9.9 d) it has 
enough time to target also less-easily accessible tumours, and the 4 emitted alphas in the decay chain ensure 
effective cell killing once at the targeted site. 225Ac is produced by radio-chemical extraction from 229Th at the 
Institute for Transuranium Elements, Karlsruhe, Germany.  In a recent study by the Sathekge group in Pretoria, 
[225Ac]Ac-PSMA-617 radioligand therapy of chemotherapy-naïve patients with advanced metastatic prostate 
carcinoma led to a ≥ 90% decline in serum PSA in 82% of patients including 41% of patients with undetectable 
serum PSA who remained in remission 12 months after therapy. 
In contrast the radioactive decay of 213Bi (T½= 46 min) results in the emission of two high-LET α-particles 
releasing around 100 keV/μm. Due to the relatively short half-life of 213Bi, it can deliver a high radiation dose 
to the target within a short period of time. 213Bi is eluted from 225Ac/213Bi Generator (ITG, Munich, Germany). 
In a recent study by the Sathekge group in Pretoria a first-in- human treatment with [213Bi]Bi-PSMA-617 in a 
patient with mCRPC that was progressive under conventional therapy, was undertaken. The patient was 
treated with two cycles of [213Bi]Bi-PSMA- 617 and restaging with [68Ga]Ga-PSMA PET/CT after 11 months 
showed a remarkable response w.r.t. soft tissue metastases. 
The use of these short-range emitters does not go without challenges that will have to be overcome. Upon 
emission of an alpha particle, the daughter nuclide experiences a recoil energy which is several orders of 
magnitude larger than the energy of the chemical bond of the nuclide resulting in the daughter to be released 
from the targeting vector. 
Terbium is a unique element, as it provides a quadruplet of radionuclides suited for diagnostics and therapy 
in nuclear medicine. 161Tb (Auger/conversion electron and β–emitter, T1/2 = 6.9 d) was produced by neutron 
irradiation of enriched 160Gd in the SAFARI-1 research reactor from which no-carrier-added 161Tb was 
produced. In a recent study by the Müller group in Villigen-PSI, [161Tb]Tb- PSMA-617 showed superior in vitro 
and preclinical in vivo results as compared to [177Lu]Lu-PSMA- 617 confirming theoretical dose calculations 
with regard to a positive effect of conversion and Auger electrons. 
The various options & pros and cons for these three radionuclides/radiopharmaceuticals will be discussed. 
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Freeze-dried kit for quick and efficient preparation of 188ReN-DEDC/lipiodol in hospital 
radiopharmacy 
Author: Viju Chirayil1   
Co-author(s):  Madhava B Mallia1; Ashutosh Dash1   
1Bhabha Atomic Research Centre, India 
Corresponding author: vijuc@barc.gov.in 
188ReN-DEDC/lipiodol (DEDC – diethyldithiocarbamate) is a clinically established agent for the therapy of 
unresectable hepatocellular carcinoma (HCC). The original two-vial method for the preparation of 188ReN-
DEDC/lipiodol involved compulsory addition of stipulated amount of glacial acetic acid (GAA), which was 
cumbersome in a busy radiopharmacy. Moreover, an error in glacial acetic acid volume had significant impact 
on overall yield of 188ReN-DEDC complex. Herein, we present a two-vial kit for quick, efficient and glacial acetic 
acid free preparation of 188ReN- DEDC/lipiodol. 
Sterile two-vial freeze-dried kits, vial 1 containing N-methyl-S-methyl dithiocarbazate (DTCz) (2 mg), 
SnCl2.2H2O (0.8 mg), oxalic acid (28 mg), sodium ascorbate (10 mg) and vial 2 containing DEDC (100 mg), were 
prepared in a clean room facility. In the first step, 188ReN-core was prepared by adding freshly eluted sodium 
perrhenate (1-5 mL, ~3700 MBq), obtained from a tungsten-188/rhenium-188 generator, into kit vial 1. Vial 1 
was gently shaken to dissolve the contents and incubated at room temperature for 5 min. In the second step, 
kit vial 2 was reconstituted with 2 mL of physiological saline.  About 1 mL of the reconstituted solution was 
transferred into kit vial 1.  Subsequently, vial 1 was sequentially incubated at room temperature for 15 min, at 
65C for 5 min and then cooled to room temperature. To extract 188ReN-DEDC complex, lipiodol (2-3 mL) was 
added into kit vial 1 and the contents are mixed for 10 min. Clear separation of two layers was achieved by 
centrifugation of vial 1 at 1600g for another 10 min. Subsequently, lipiodol layer containing 188ReN-DEDC was 
carefully separated for further use. The quality control of 188ReN-DEDC/lipiodol was carried out by TLC in 
dichloromethane. Developed strip was analysed on a TLC scanner and radiochemical purity (RCP) was 
determined from peak area measurements. 
The use of GAA reported in the original method of preparation of 188ReN-DEDC complex was avoided by 
including oxalic acid/sodium ascorbate combination to provide an acidic environment conducive for 188ReN 
formation. This modification also brought significant reduction in time required for patient dose preparation. 
Presence of ascorbate provided an additional protection from possible radiolytic damage to 188ReN core as 
well as 188ReN-DEDC complex. Using kit vial 1, 188ReN-core could be consistently prepared in quantitative yield 
within 5 minutes. Upon addition of the constituents from kit vial 2 following the recommended procedure, 
188ReN-DEDC complex could be prepared in >85% yield. It was observed that >99% of 188ReN-DEDC complex 
could be extracted into lipidol phase in the first attempt itself. Quality control of the lipiodol phase confirmed 
absence of perrhenate. 
In conclusion, the two-vial freeze-dried kit presented here offer a quick and efficient way for the preparation 
of 188ReN-DEDC/lipiodol in a hospital radiopharmacy setup and allows the use of up to five ml of radioactive 
solution, making a step forward from the original method in terms of ease of patient dose preparation as well 
as effective utilization of the 188W-188Re generator. 
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Production of theranostic 153Samarium-labelled polystyrene microparticles for hepatic 
radioembolization 
Author: Chai Hong Yeong1 
Co-author(s):  Yin How Wong1; Hun Yee Tan1,2; Azahari Kasbollah3; Basri Johan Jeet Abdullah4 
1School of Medicine, Taylor’s University, Selangor, Malaysia 
2Medical Radiation Surveillance Division, Ministry of Health, Malaysia 
3Malaysian Nuclear Agency, 43000 Bangi, Selangor, Malaysia 
4University of Malaya Medical Centre, Kuala Lumpur, Malaysia 
Corresponding author: chaihong.yeong@taylors.edu.my 
Hepatic radioembolization is a minimally invasive procedure involving intraarterial administration of 
radioembolic microparticles for the treatment of liver tumours. A biocompatible polystyrene (PS) 
microparticles containing Samarium-153 (153Sm) were developed for hepatic radioembolization therapy. The 
incorporation of 153Sm that possessed both diagnostic gamma energy and therapeutic beta radiation has made 
it a theranostic radioembolic agent for hepatic radioembolization.  
The 152Sm-labelled PS microparticles were prepared using solid-in-oil-in-water solvent evaporation method. 
The 152Sm-labelled PS microparticles were neutron activated to 153Sm (Eβmax = 807.6 keV, half-life= 46.3 hours) 
through 152Sm(n,γ)153Sm reaction in a nuclear reactor with a neutron flux of 2.0 × 1012 n.cm-2.s-1. 
Physicochemical characterization of the microparticles, gamma spectrometry and in vitro radiolabeling studies 
were performed to study the performance and stability of the microparticles before and after neutron 
activation. 
The 153Sm-labelled PS microparticles achieved a nominal activity of 4.0 Gbq.g-1 after 6 hours neutron activation. 
Scanning electron microscope and particle size analysis suggest the microparticles remained spherical with the 
diameter within 15–60 μm after neutron activation. No long half-life radionuclide impurities were found in the 
samples as indicated by gamma spectrum of the microparticles. The 153Sm-labelled PS microparticles was 
found to have a radiolabeling efficiency of more than 95% in saline and blood plasma over 480 hours.  
The favorable microparticles and radiation characteristics along with excellent radiolabeling efficiency have 
rendered the 153Sm-labelled PS microparticles as potentially theranostic agent for hepatic radioembolization. 
This study described a safer method to prepare the microparticles for hepatic radioembolization as the 
preparation does not involve any harmful ionizing radiation.  
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Radiolabelling and pre-clinical evaluation of Y-90-DOTATATE - formulated using Y-90-Acetate 
from high level liquid waste 
Author: Avik Chakrabotry1  
Co-author(s):  Arpit Mitra2; Sangita Lad1; Sujoy Gaikwad1; Megha Tawate1; Sudeep Sahu1; Trupti Upadhye1; 
Sreeja Menon1; Sharmila Banerjee2 
1Radiation Medicine Centre, BARC, Mumbai, India 
2Medical Cyclotron Facility, RMC, BRIT, Mumbai, India 
Corresponding author: avikbarc@gmail.com 
The effectiveness of Y-90-DOTATATE as a therapeutic radiopharmaceutical for Peptide Receptor Radionuclide 
Therapy (PRRT) in treatment of large volume neuroendocrine lesions is well established. The high energy of β- 
particle emission (Emax: 2.28MeV) is suitable for treatment of neuroendocrine lesion with diameter of 5cm 
and more. The challenges involved in the formulation of this radiopharmaceutical is the purity of the 
radiochemical(Y-90-Chloride/Y-90-Acetate) used, which in turn necessitates the cost-effective extraction in 
clinical grade, from high level liquid waste (HLLW). Towards this, Y-90-Acetate was sourced from HLLW based 
on supported liquid membrane (SLM) technology. Isolated Y-90-Acetate complies with the regulatory 
requirement with respect to its use as a clinical grade API. This Y-90-Acetate was used in radiolabelling 
DOTATATE and the radiopharmaceutical was evaluated on in-vitro cell-binding and in in-vivo biodistribution 
studies in a suitable animal model. The present work documents the effort towards developing indigenous 
cost- effective Y-90-based radiopharmaceutical for PRRT of neuroendocrine tumours. 
Clinical grade Y-90-Acetate sourced from two-stage Sr-90/Y-90 generator based on SLM technology. The 
formulation of Y-90-DOTATATE was carried out using Y-90-Acetate, 0.2N ammonium-acetate buffer(pH~5.5) 
and DOTATATE. The reaction mixture was incubated at 95degC for 35minutes at pH~4.0. On cooling, 60mg of 
gentisic acid/mL of saline was added. RCP assessed by TLC-SG {(0.1M sodium-citrate buffer(pH-5.0)} and HPLC 
using RP18 with gradient (0.1%TFA in water and acetonitrile). Gel-clot BET-assay and Sterility test were 
performed. In-vitro and serum-stability of the product on storage at -20degC was evaluated by TLC/HPLC at 
24h and 48h post radiolabelling. 
Pancreatic carcinoma cell-line AR42J was used for in-vitro evaluation, and it was grown in IMDM with 10%FBS 
at 37C. In-vitro cell-binding was performed by incubating AR42J cells in 1mL of internalization buffer 
containing radioligand (~5pmol peptide) for 15, 30, 60 and 120minutes and washed with PBS. For membrane 
receptor binding assay, AR42J cells homogenates were incubated for above time points.  Biodistribution 
studies carried out in AR42J cell-line xenograft tumour bearing nude mice at 6h, 24h, 48h & 72h intervals and 
quantified by β-spectrometer. 
Using pharmaceutical-grade Y-90, formulation of 50-55 mCi of Y-90-DOTATATE prepared. Y-90- DOTATATE was 
clear, pale-yellow color, pH between 5.0-5.5. RAC between 8-12 mCi/mL. RCP of Y- 90-DOTATATE estimated 
by TLC was >98% with retention-factor 0.0-0.1. RCP derived by HPLC was >98% with retention-time of 
radioactive-chromatogram between 10.4-11.4minutes. EL was <6EU/mL, radiopharmaceutical was sterile. In-
vitro and serum stability of the product indicated stability up to 48hrs upon storage at -20C with stabilizer. 
Y-90-DOTATATE showed rapid binding (30%) in AR42J cells, reaching a plateau after 15-30minutes. In a 
biodistribution study, radioactivity in the blood and most of the organs decreased after 24h post-injection. 
High-uptake and long-term retention of radioactivity were found in the kidney (8.01% ID/gm) and tumour 
(3.17% ID/gm) which corroborates scintigraphy studies. 
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In conclusion, the Y-90 isolated from HLLW has been approved as a clinical grade radiochemical. This has been 
utilized in the formulation of patient doses of Y-90-DOTATATE, and used in the treatment of large NET lesions. 
This development offers an affordable treatment option to many patients. 
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Recent advances in the development of 18F and 11C radiopharmaceuticals 
Author: Philip H. Elsinga 
University Medical Center Groningen, University of Groningen, The Netherlands 
Corresponding author: p.h.elsinga@umcg.nl 
PET-studies with short-lived 11C and 18F-radiopharmaceuticals offer advantages of low radiation burden for 
patients and option for repeated PET-studies. Moreover, using 11C, the (bio)chemical properties of the 
molecules often do not change, whereas with 18F steric effects of the radionuclide on pharmacological 
properties of radiopharmaceuticals is very small. A substantial number of 11C- and 18F radiopharmaceuticals 
have proven its clinical value with [18F]FDG being the real work horse tracer for PET. 
The number of radiopharmaceuticals used in humans is continuously growing with a tendency to shift from 
11C- to 18F-radiopharmaceuticals enabling transportation to PET-sites without a cyclotron and radiochemistry 
lab. 
Besides the increasing number of radiopharmaceuticals, also the production methods improve and expand. 
For production of 11C-radiopharmaceuticals, the 11C-methylation route is the most used method, but some 
other routes including use of [11C]CO become more easily available. For 18F-production, several late stage 18F-
fluorination procedures have progressed enormously. 
During the presentation, new emerging 11C and 18F radiopharmaceuticals and production methods are 
highlighted. 
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Recent advances in the development of Ga-68 radiopharmaceuticals 
Author: C. Decristoforo 
Medizinische Universität Innsbruck, Austria 
Corresponding author: Clemens.Decristoforo@tirol-kliniken.at 
The worldwide interest in 68Ga-radiopharmaceuticals was initiated by the clinical success of 68Ga-Somatostatin 
analogues in the context of theranostics and the availability of 68Ga from generators becoming commercially 
available. Automated synthesis procedures and modules were established enabling routine clinical 
production. An additional advancement was reached by the establishment of 68Ga-PSMA11 in clinical routine. 
A number of alternatives to PSMA 11 have been developed and will be presented, Somatostatin antagonists 
have the potential to improve established PET imaging with 68Ga. Besides that, a number of other targets have 
been investigated and in particular peptide based 68Ga-radiopharmaceuticals enter the clinical area. Among 
the most promising candidates are Bombesin antagonists targeting the GRP receptor, RGD containing peptides 
targeting integrins, peptides targeting CXCR4 and most recently FAPI-analogues binding to cancer associated 
fibroblasts. Preparation is shifting from automated procedures to kit-based preparation also with the 
availability of generators with marketing authorisation. 
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Synthesis and in vitro and in vivo evaluation of iodine-124-labelled PSMA peptides: Potential 
theranostic radiopharmaceuticals for prostate cancer 
Author: Ibrahim Aljammaz 
Co-Author(S): Abdulrahman Alrabiah; Basim Alotaibi; Faisal Alrumayan; Subhani Okarvi 
King Faisal specialist hospital & research centre 
Corresponding author: jammaz@kfshrc.edu.sa 
Receptor-targeted radiopharmaceuticals have shown promises in the improvement of the specificity and 
sensitivity of nuclear medicine imaging and therapy procedures. The prostate specific membrane antigen 
(PSMA) is a transmembrane protein with significantly elevated expression in prostate cancer (PCa) cells 
compared to benign prostatic tissue. Several radiotracers have been used for molecular imaging of PCa 
including choline as a marker of membrane cell proliferation. However, there have been numerous studies 
reporting a low sensitivity and specificity of these radiotracers. Therefore, different gallium-68 and fluorine-
18 PSMA-targeted PET tracers have been developed, utilized and demonstrated a high diagnostic efficacy. 
However, the short half-life of these radiotracers may limit distribution to distant imaging centres. 
Thus, as part of our on-going research effort to develop theranostic radiopharmaceuticals, we here report the 
synthesis and preclinical evaluation of new 123/124/131I-PSMA conjugates. The synthetic approaches for the 
preparation of [123/124/131I]iodobenzene and pyridine rhodamine conjugates entailed sequence of reactions. 
The key precursors N-hydroxysuccinimide 3-tri-n-butylstannyl- benzoate and 3-tri-n-butylstannyl-pyridine 
carboxylate were radioiodinated using classical method involving 0.1% acetic acid/methanol, iodogen and NaI 
(123/124/131I, 50 MBq) at room temperature. The N-succinimidyl-p-[I]-iodobenzoate ([123/124/131I]-SIB) and N-
succinimidyl-m-[I]-iodopyridine carboxylates ([123/124/131I]-SIP) were purified using Sep-pak silica cartridge. 
PSMA peptide was then reacted with [123/124/131I]-SIB and [123/124/131I]-SIP, then purified using C-18 Sep-pak 
cartridge to furnish [123/124/13I]-SIB- and [123/124/131I]-SIP-PSMA peptide conjugates. Radiochemical yields were 
>75% and synthesis times were ~45 min. Radiochemical purity was always >99% without HPLC purification. 
The metabolic stability of [123/124/131I]-SIB- and [123/124/131I]-SIP- PSMA peptide conjugates were determined in 
human plasma and revealed that these radioconjugates remained stable during incubation at 37oC for at least 
24 h. In vitro tests on LNCaP cell line has shown that the significant amount of the radioconjugate associated 
with cell fractions. In vivo characterization in normal Balb/c mice revealed rapid blood clearance of these 
radioconjugates with excretion predominantly by the renal system. Initial in vivo biological characterizations 
in nude mice bearing LNCaP cell line xenografts, demonstrated significant tumour uptake. The uptake in the 
tumours was blocked by excess injection of PSMA peptide, suggesting a receptor-mediated process. These 
results demonstrate that these radioconjugates may be useful as precise theranostic radiopharmaceuticals for 
PSMA receptor-positive cancers and their metastasis. However, further evaluation is warranted. 
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A radio-copper somatostatin analog (Cu-Sartate) for NET (neuroendocrine tumours) theranostics  
Author: Vijay Kumar  
Sydney Medical School, University of Sydney, Australia  
Corresponding authors:  vijay.kumar@health.nsw.gov.au 
Radiolabelled 68Ga-DOTAOctreotate or 68Ga-DOTATATE was very effective PET-imaging agent for NETs and 
have quickly became the gold standard for diagnosis and staging of NETs. However, due to the short half-life 
(68min) of 68Ga, there were several limitations. Therefore, 64Cu was sought for this project, as its half-life is 
sufficiently long enough (12.7 hours) to capture the clearance kinetics required for personalized dosimetry 
and therapy.  
Clarity Pharmaceuticals Pty Ltd (Clarity) developed 64Cu-SARTATE as a PET radio-diagnostic agent for the 
localization of SSTR-positive NETs and “dosimetry planning” for personalized Peptide Receptor Radionuclide 
Therapy (PRRNT). 64Cu-SARTATE was 64Cu-labeled MeCOSar-Tyr3-octreotate. 64Cu-SARTATE has 3 basic 
components; copper-64, a pure ß emitting radiometal linked via MeCOSar (a bifunctional copper chelator) to 
octreotate, a somatostatin analogue that targets SSTRs 2 & 5. Clarity also developed 67Cu-SARTATE as a PRRNT 
for treatment of NETs.  
64Cu-SARTATE was formulated as a liquid, sterile, apyrogenous preparation. The radiochemical purity 
estimated by HPLC is NLT (not less than) 90% and the Radiochemical Purity by TLC was NLT 95%. Radionuclidic 
Purity (Gamma spec, %) was reported as 99% 64Cu. Incubation of 64Cu-SARTATE (radiochemical purity >99%) 
with fresh human serum demonstrated high metabolic stability. HPLC analysis indicated that >90% 
radioactivity in the non-protein bound fraction at 30mins, 1hr, 2hrs, & 24hrs was still chelator-bound 
representing intact radio-peptide and indicating no loss of copper or appreciable metabolic decomposition. 
The biodistribution of 64Cu-SARTATE was investigated in tumour-bearing Balb/c nude mice. The biodistribution 
data was compared against 68Ga-DOTATATE (data not shown). Both 64Cu-SARTATE and 68Ga-DOTATATE 
demonstrated effective blood clearance at 2 hours (0.8 ± 0.2 %ID/g and 0.1 ± 0.03 %ID/g, respectively) with 
further clearance shown by 64Cu-SARTATE at 24 hours (0.4 ± 0.04 %ID/g, p < 0.05). Uptake in the liver and 
kidneys was higher for 64Cu-SARTATE at the 2 hour time point as compared to 68Ga-DOTATATE, 6.3 ± 1.5 %ID/g 
and 0.4 ± 0.05 %ID/g respectively. Uptake of 64Cu-SARTATE in the kidneys was moderate at 2 hours (70.9 ± 
5.78 %ID/g), and fell by 53% to 33.6 ± 6.8 %ID/g at 24 hours (p < 0.05) indicating effective clearance.  
Pre-clinical biodistribution and micro-PET imaging studies indicate 64Cu-SARTATE displays favourable kinetic 
and in-vivo stability properties of particular importance to diagnostic radiopharmaceuticals. Phase 1 first in 
human imaging study of 64CuSARTATE showed high safety profile, excellent clearance, biodistribution, and 
diagnostic efficacy. The half-life of 64Cu is also well suited to capture the clearance kinetics required for 
personalized than PRRNT dosimetry. In addition, the advantages of 64Cu extend to also include logistical 
advantages such as centralized manufacture, GMP processes and costings that can be sufficiently lowered to 
become competitive once industrialized. Cu-67 Sartate was used to study biodistribution and dosimetry in 
patients with Meningioma. The preliminary observation was very encouraging as it localised in the lesions 
which are consistent with the biodistibution of Cu-64 Sartate in these patients.   
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Corresponding author: chanisa.ja@gmail.com 
In Thailand, PET/CT is a new technology of nuclear medicine with high efficacy for cancer diagnosing, 
measuring response to treatment, and guiding radiation therapy. With the advantages of PET/CT, physicians 
are able to accurately make treatment planning for each cancer patient toward the improved quality of life 
and longer survival. National Cyclotron and PET Centre was established at Chulabhorn Hospital following the 
aspirations of Prof. Dr. HRH Princess Chulabhorn Mahidol to serve as the first national center to produce 
radiopharmaceuticals in cancer research and development of new treatment modalities. 
Currently, radiolabelled tracers targeting prostate-specific membrane antigen (PSMA) have become the 
important radiopharmaceuticals for PET-imaging of prostate cancer. The first PSMA-based radioligand in 
Thailand is [68Ga]PSMA-11 produced by 68Ge/68Ga generator and a manual synthesis module, supplied by 
Isotope Technologies Garching (ITG). During the period of a generator, about 200 batches of [68Ga]PSMA-11 
should be prepared with the product stability of only 4 hours. In addition, the maximum activity is sufficient 
for only 3 patients at the beginning and lower at the later batches. Whereas, there is limited production 
capacity given by 68Ga generator. In contrast, [18F]PSMA-1007 from cyclotron has a longer half-life and 
demonstrates higher yield of activity, with outstanding tumour uptake and better diagnostic efficacy when 
compared to [68Ga]PSMA-11. Hence, it is likely that [18F]PSMA-1007 can possibly be an alternative tracer to 
replace [68Ga]PSMA-11. 
The radiosynthesis of [68Ga]PSMA-11 was carried out by using ITG manual synthesis module and disposable 
cassettes. 68GaCl3 from generator in 0.05 M HCl and PSMA-11 precursor in 0.25 M sodium acetate buffer were 
labelled at 105℃ for 5 minutes, followed by the purification of a C18 cartridge and collection through a 0.22μm 
sterile filter. Whilst, the radiosynthesis of [18F]PSMA-1007 was done on ORA NEPTIS® performed using 
disposable cassettes. 18F from cyclotron was trapped on the QMA and eluted by 0.075 M TBAHCO3 to the 
reactor for radiolabelling with PSMA-1007 precursor in DMSO, followed by the purification through a series of 
PS-H+ and C18ec cartridges. Then, [18F]PSMA-1007 passed through 0.22μm sterile filter to final product vial. 
The radiosynthesis of [68Ga]PSMA-11 achieved in 15 minutes with radiochemical yield of 74.69% (n=32) and 
maximum activity of 32.9 mCi. The radiochemical purity (RCP) was >95% for only 4 hours. Whereas, [18F]PSMA-
1007 was achieved in 45 minutes with a radiochemical yield of 56.64% (n=10). The obtained activity was 
enough for at least 8 patients and the maximum depended on the cyclotron irradiation time. The 
radiochemical purity was >95% for 8 hours. Additionally, PET/CT imaging of [18F]PSMA-1007 showed higher 
uptake in liver and better lymph node pathology. Moreover, the non-urinary background overcame some 
limitations of [68Ga]PSMA-11. 
[18F]PSMA-1007 possesses longer half-life than [68Ga]PSMA-11 with high radiochemical yield and more 
accurate diagnostics, which can serve to other PET/CT centres. As a result, more patients have more chances 
to access effective diagnosis and better opportunity towards the improved quality of life and longer survival. 
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IAEA activities related to nuclear medicine 
Author: Diana Paez 
IAEA, Vienna, Austria  
Corresponding author: D.Paez@iaea.org 
The long-term objective of the subprogram in Nuclear Medicine focuses on enhancing Member States’ 
capability to address health needs by the use Nuclear Medicine techniques in both imaging and therapeutic 
applications, complementary to conventional techniques. 
Different activities are run under this subprogram: Coordinated Research Projects (CRPs); Expert Meetings to 
advise the Agency on specific topics; Publications and Manuals, including educational material, and creation 
of educational website and databases. Many projects run under Nuclear Medicine have been clearly oriented 
towards the clinical applications of standard and emerging technologies in Nuclear Medicine such as SPECT/CT, 
PET/CT for diseases related to two of the major causes of death: cancer and cardiovascular diseases. Focus is 
also given to therapeutic applications wherein the primary objective is to make available fundamental 
radiopharmaceuticals for routine clinical use in developing countries, and to develop, evaluate and standardize 
new diagnostic and therapeutic radiopharmaceuticals for the effective use in diagnostic and therapeutic 
nuclear medicine procedures. Finally, the section manages projects related to quality improvement in the 
clinical practice of nuclear medicine. 
The IAEA supports the dissemination of quality education and strives to produce pertinent literature to better 
the application of nuclear medicine techniques as part of the clinical management of many diseases. 
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Recent advances in nuclear medicine: Diagnosis and therapy  
Author: Homer A. Macapinlac  
Co-author: Dao Le  
Department of Nuclear Medicine, UT MD Anderson Cancer Center, Houston, TX USA  
Corresponding author: jwmaxwell@mdanderson.org 
The recent advances in the treatment of cancer patients have had imaging as a cornerstone of staging and 
response evaluation. Recent advances in nuclear medicine with hybrid imaging with FDG PET/CT and SPECT/CT 
has allowed more accurate staging and response evaluation. The multidisciplinary care of oncology patients is 
now supplemented by the availability and insurance coverage in the USA of theranostic agents. We will review 
the most frequently used diagnostic and therapeutic tracers, including applications for thyroid cancer, 
neuroendocrine tumours and prostate cancer. We will highlight the effect of these radio pharmaceuticals on 
improving disease free progression and overall survival. We will also focus on current ongoing theranostic 
trials to demonstrate the promising future of these diagnostic and therapeutic pairs. These advances depend 
of reliable clinical production of these radio pharmaceuticals which have become a valuable weapon in the 
effort to effectively select and treat cancer patients worldwide. 
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Production & use of cyclotron-produced radiopharmaceuticals UT MD Anderson Cancer Center 
Author: Dao Le  
Co-Author: Homer Macapinlac 
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Corresponding author: dble@mdanderson.org 
The University of Texas MD Anderson Cancer Center (UT MDACC) Cyclotron Radiochemistry Facility (CRF) is a 
unique facility dedicated to the production of radioistopes and radiopharmaceuticals for both research and 
standard patient care.  Located in the Texas Medical Center in Houston, Texas; this facility is equipped with a 
16 Mev Cyclotron, Nuclear Pharmacy, 34 Hot & Warm cells, 4 GMP Manufacturing Suites, 3 Development Hot 
Labs, a Microbiology Lab, Pk Lab, and a 2400 square foot development and analytical lab space.  The CRF is 
located across the hall from an imaging clinic which is equipped with PET/ CT, MRI, SPECT/CT, and Hyper-
Polarizer.  The short distance between the GMP manufacturing facility, the radiopharmacy and imaging facility 
enables the utilization of short lived isotopes such as C-11 and N-13 for both research and patient care.  The 
CRF team prepares and dispenses radiopharmaceuticals for standard of care such as Ga-68 DOTATATE, C-11 
Choline and F-18 FDG, but the mission is to provide investigational radiopharmaceuticals for research use.  The 
function of the CRF is to provide the full spectrum of development, analytical, and manufacturing services to 
take a radiopharmaceutical from a novel compound to an approved drug. We refer to this full process as Bench 
to Bedside:  radioisotope production, preclinical radiopharmaceutical development, investigational new drug 
(IND) development and radiopharmaceutical validation. 
The current focus of the MDACC CRF team is the project involving cyclotron produced 68Ga. The team has 
successfully produced more than 1 Curie of Ga-68-chloride in a single run. This development has led to multiple 
innovations at the facility, including the development of fully-automated Ga-68-PSMA-11 production method.  
In the accepted publication, we reported the Ga-68-PSMA-11 in curie quantities that can be routinely 
produced.  Additionally, in that publication, we demonstrated biological equivalence of PSMA-11 labelled by 
either generator- or cyclotron-produced 68Ga.  We have successfully filed a DMF for our cyclotron generated 
68Ga. 
The future focus for the MDACC CRF is on the production of theranostic radiopharmaceuticals therefore we 
are building a partnership with Texas A&M University, Cyclotron Institute.  Because Texas A&M Cyclotron 
Institute has a large cyclotron capacity, a strong nuclear physics program for target design and the CRF at 
MDACC has expertise in target processing and isotope purification, the joint effort is conducive for the 
investigation into cost-efficient procedures for producing “theranostic pairs”.  The spotlight is on the 
production of medically important isotopes such as 209At/211At, 149Tb/161Tb, and 44Sc/47Sc.
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Quality control of hospital based radiopharmaceuticals 
Author: S.M. Rubow 
Stellenbosch University, South Africa 
Corresponding author: smr@sun.ac.za 
Quality assurance plays an important role to ensure that medicines produced and dispensed in hospitals are 
safe, pure and effective. Radiopharmaceuticals pose special challenges due to their short shelf life and the 
radioactivity that is inherently part of these products. The facility, functioning and maintenance of equipment, 
and staff competence can all influence the quality of radiopharmaceuticals. A well-designed quality assurance 
programme is essential. This presentation focuses on essential quality control tests for diagnostic and 
therapeutic radiopharmaceuticals prepared in operational level 2 and 3 radiopharmacies. Regardless of the 
type of radiopharmaceutical, quality parameters include purity (radionuclidic, radiochemical and chemical), 
pH, particle size or absence of particles, stability, sterility and absence of endotoxins.  
Radiopharmaceuticals prepared from sterile, licenced generator eluates and kits carry lower risk than those 
involving complex multiple step synthesis. The hospital radiopharmacy should however still test radionuclidic 
and radiochemical purity. The latter can be done with fast and relatively low-cost thin layer chromatography 
methods, provided the methods are validated.  
Radiopharmaceuticals that are synthesised using more complex methods, inherently carry greater risk, 
especially of microbial contamination and the presence of impurities. These products require more complex 
analytical procedures and equipment, like HPLC (e.g. for radiochemical purity analysis) and GC (e.g. to test for 
residual solvents). Equipment is available that allows endotoxin testing within 20 minutes. Prior to routine 
production of unlicensed products, the method should be validated by proving that at least 3 production runs 
yield products that meet all quality criteria. This should include evaluation of the shelf-life of the product. 
Sterility tests can in many cases not be completed prior to release of radiopharmaceuticals for administration 
to patients. These tests should nevertheless be done to ensure that the methods used will always provide 
sterile products. Radioactivity in sterility samples can pose a challenge, which should be addressed through 
methods like testing the outcome of non-radioactive dummy runs.   
Radiopharmacy staff should be aware of the consequences of using poor quality radiopharmaceuticals, both 
from a patient safety perspective, and regarding good quality studies. It is important to have the necessary 
equipment, knowledge and competence to manage a quality programme that matches the level of 
radiopharmacy operations and nature of the radiopharmaceuticals produced at each hospital radiopharmacy.  
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Author: Jeff Smith 
University of Missouri School of Medicine, Columbia, United States  
Corresponding author: smithcj@health.missouri.edu 
In this presentation, we report investigations that describe advances and new targeting strategies using 64Cu-
radiolabeled peptides for molecular imaging of human cancers. Specifically, we attempt to highlight 
somatostatin, gastrin releasing peptide, melanocortin, and other receptor-targeting peptides and recent 
advances in radiolabelled, multivalent peptides for targeting and molecular imaging of cell-surface receptors 
via 64Cu-radionuclide. 
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Preclinical evaluation of 68Ga-PET tracers using 68Ga produced by cyclotron, a Canadian 
experience 
Author: B. Guerin 
Université de Sherbrooke, Montreal, Canada 
Corresponding author: brigitte.guerin2@usherbrooke.ca 
Gallium-68 (68Ga, T1/2 = 68 min) has attracted increasing interest in recent years due to the expanding clinical 
applications of 68Ga-based radiopharmaceuticals. With this increased-demand, there is a need for improving 
the 68Ga production capacity. The aims of this study are to enhance the production yield of 68Ga using pressed 
targets and the purification of 68Ga by using an automated cassette-based purification process. We also 
compare the chemical, radiochemical and biological properties of cyclotron- and generator-derived 68Ga for 
common nuclear imaging procedures. 
Using a digital hydraulic press, the pressed targets were prepared using enriched 68Zn powder. They were 
mounted on custom-made magnetic target supports. 68Ga was produced using 19 MeV and 24 MeV cyclotrons, 
recovered by chemical dissolution and purified by chromatography with two cation exchange resins. The 
radiotracers were then formulated the usual way as [68Ga]-DOTA-TATE and [68Ga]-PSMA-617. The PET images 
and distribution patterns of the cyclotron- and 68Ge/68Ga generator-produced 68Ga radiopharmaceuticals were 
compared in healthy rats and mice. 
Up to 140 GBq of 68Ga was produced following 90 min irradiation. The overall recovery yield of 68GaCl3 was 
89% with an EMA of 77 ± 5 GBq/mol at EOB. The outcome was a radiochemical yield >95% of [68Ga]-DOTA-
TATE and [68Ga]-PSMA-617. Cyclotron- and generator-produced 68Ga-radiopharmaceuticals were shown to be 
radioisotopically, chemically and biologically equivalent, giving matching images and identical kinetic and 
biodistribution patterns in animals. 
Overall, these results show that irradiation of 68Zn-pressed target is a very effective process. The cassette-
based purification-process developed is rapid, simple, efficient and leads to high radiochemical yield and EMA 
of 68GaCl3. Medical cyclotron can produce European Pharmacopeia-compliant 68Ga-radiopharmaceuticals that 
can be used as substitute of generator derived 68Ga. 
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Ethics in animal experiments in nuclear medicine and the application of the directive 2010/63/EU 
Author: Emilio Bombardieri 
EANM (Italy) 
Corresponding author: emilio.bombardieri@gavazzeni.it 
Researches on animals were carry out for a very long time. The question is: do we actually need to use animals 
for medical research or we simply guilty for speciesism? The general subject “Ethics in animal 
experimentations” has often been and still remains an area of intense debate. The final terminal of the 
discussions is whether the animals can or cannot be considered equal to human beings. This approach is a very 
complex matter, involving a lot of different matters as philosophy, religion, politics, bioethics, sociology, 
economy and biology. However today the big part of the scientific community and the public opinion is still in 
favour of animal testing due to the great benefits that humans obtain in terms of data essential for developing 
the scientific knowledge, treating the diseases and providing many benefits to society. The animal 
experimentation can be accepted if we save the concept that is morally acceptable to use animals for research 
only under certain conditions. These conditions drive why and how these animals should be treated. This 
approach in Europe has inspired the statement of a strict Legislation that transformed the meaning “Ethics in 
animal Experiments” in the Directive 2010/63/EU, written for the protection of animals used for scientific 
purposes.  Under the umbrella of this Directive all the pre-clinical studies of nuclear medicine that use 
radioactivity are covered. The three fundamental principles, called 3Rs, are: replacement, reduction and 
refinement. Animal experiments must be replaced wherever possible by other methods such in vitro biological 
systems, or mathematical modelling. There must be a reduction in the number of animals used, by limiting the 
number required to obtain reliable data. The refinement requests to minimize the overall impact in animals 
used. According to this directive each country should have a local animal care committee, which reviews the 
animal research protocols, the rationale of the study, determine if animals are enough to test the hypothesis, 
check the appropriate sample size and procedures, in order to prevent some inappropriate use and undue 
suffering. These committees should control that animals are housed in appropriate facilities, have access to 
veterinary care, and require that personnel who work with the animals should be trained. Our personal 
perception about the problem of the animal experiments in the area of nuclear medicine is that in those 
countries where the directive is applied there are enough guarantees that the animal welfare is respected and 
the requests coming from 3Rs are fulfilled. To further improve this system the use of imaging instruments 
could be increased, the dedicated labs could be centralized, and the researches could be organized in a 
multidisciplinary network of information about needs and goals of the single researchers. Besides this, as far 
as we know, any statistics on animal experiments in Europe are not available, therefore in my opinion a general 
picture could be welcome in order to have a complete overview on this activity and the eventual problems. 
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Changes in the expression of homomeric α7 nicotinic acetylcholine receptors (α7 nAChR) in the human brain 
are widely assumed to be associated with neuropsychiatric and neuro-oncological processes. Indeed, 
thoroughly performed studies have shown the ability of α7 nAChR modulators to minimise the extent of cell 
death as well as to promote synaptic plasticity in different diseases including depression, schizophrenia, stroke 
and Alzheimer´s disease. Nonetheless, up to date, the clinical meaningful findings obtained with these agents 
were not always supported by a complete understanding of the downstream effects initiated by α7 nAChR 
modulators. 
To help understanding these processes an extensive work has been done by our and other groups on the 
development of positron emission tomography (PET) α7 nAChR agents labelled with the radioisotopes 
fluorine-18 (18F) and carbon-11 (11C). So far two main classes of α7 nAChR PET tracers have been advanced to 
clinical trials: scaffolds composed of a three-side binding mode to the receptor (e.g., hydrogen bond acceptor, 
hydrophobic element and a rigid basic amine as the cationic centre), and the scaffolds containing fused 
functionalities belonging to the interferon inducer tilorone class of derivatives. 
Structure-activity relationship studies on these two classes have been the subject of continuous research 
aiming at the development of highly affine and selective α7 nAChR PET tracers with suitable pharmacokinetic 
properties for an accurate receptor occupancy quantification and distribution of α7 nAChR in the brain. As a 
result, [18F]NS10743, [18F]NS14490, [11C]NS14992, [18F]DBT10 and its ortho isomer [18F]ASEM emerged as the 
most promising α7 nAChR PET tracers developed so far. Studies in piglets were done for [18F]NS10743 and 
[11C]NS14992. Ongoing clinical trials have been reported using [18F]ASEM. Efforts to translate [18F]DBT10 into 
the clinics have been initiated with its transfer onto an automated synthesis in compliance to clinical 
production. The results of a successful pre-clinical imaging study, including dosimetry in piglets and evaluation 
in monkeys suggests the suitability of [18F]DBT10 for imaging α7 nAChR. Very recently a pilot study in a large 
animal model of ischemic stroke in sheep revealed a high inflammation-related specific uptake of [18F]DBT10 
in the stroke border 14 days after permanent middle cerebral artery occlusion. 
Among the receptor-specific α7 nAChR PET tracers developed so far, the dibenzothiophene isomers [18F]DBT10 
and [18F]ASEM are under continuous investigation due to their suitable pharmacokinetics and high target-
specific signal. More proof-of-concept studies are required to support the usefulness of these tracers for 
sensitive and specific α7 nAChR PET imaging.
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A move towards harmonization of GMP regulations in radiopharmacy  
Author: Sabine Kopp 
World Health Organization, Geneva, Switzerland 
Corresponding author: kopps@who.int 
The cooperative efforts between IAEA and WHO supporting the production of high quality, safe and effective 
radiopharmaceuticals will be highlighted. In recognition of the longstanding request by IAEA Member States 
(and recommendations emerging from three technical meetings) to strengthen good manufacturing practices 
(GMP) for radiopharmaceuticals, the IAEA began collaborating with WHO to update its guidelines on GMP for 
radiopharmaceutical production.  
In addition to the guidelines on GMP for radiopharmaceuticals, the IAEA has collaborated with WHO to 
identify, and develop, a set of specific monographs for priority radiopharmaceuticals to be included in The 
International Pharmacopoeia, as well as a general monograph.  
The outcome of these efforts and next steps will be presented.  
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 The status of radiopharmaceutical regulations in Europe 
Author: C. Decristoforo 
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Corresponding author: Clemens.Decristoforo@tirol-kliniken.at 
In this presentation the main rules, guidelines and guidance documents in the European Union (EU) in relation 
to the pharmaceutical regulatory framework are described. Radiopharmaceuticals, radionuclide generators, 
kits and radionuclide precursors are defined as medicinal products within the EU directive 2001/85/EC. These 
directives also implement the requirement for GMP and marketing authorisation for these products, unless 
they are exempted either as investigational medicinal products or products prepared extemporaneously.  
Extemporaneously prepared radiopharmaceuticals thereby are an important segment in Europe for 
preparation of SPECT, PET and therapeutic radiopharmaceuticals, which are regulated nationally, examples 
will be given. In this context, the European Pharmacopoeia with a legal status plays an important role in 
defining quality standards. For clinical trials the application system and regulatory framework in Europe is 
currently considerably changing. Whereas the current clinical trial directive requires a lengthy and complicated 
national application process, the new regulation 536/2014 will introduce a streamlined and unified European 
application process. This new regulation also takes into account the specific properties of radioactive 
investigational medicinal products and has introduced exceptions for good manufacturing practices (GMP) 
and labelling for radiopharmaceuticals. Besides the main regulatory texts, several guidelines have been 
published, e.g. by professional organization, in particular the EANM, in relation to GMP, documentation and 
toxicity studies, that support professionals in the process of radiopharmaceutical preparation. Important 
documents are summarized and discussed. 
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The status of radiopharmaceutical regulations in the United States 
Author: Serge Lyashchenko 
Department of Radiology, Memorial Sloan Kettering Cancer Center, United States  
Corresponding author: lyashchs@mskcc.org 
The manufacture of radiopharmaceuticals in the United States is subject to specific laws, also known as 
regulations, passed on by the United States Food and Drug Administration.  The FDA, as well as several other 
governmental agencies responsible for overseeing radioactive material handling, pharmaceutical production, 
and radiation safety, enforce compliance with the regulations through inspection. Additionally, these agencies 
periodically issue guidance documents that provide recommendations on how producers should comply with 
the relevant regulations. These guidance documents provide a more detailed description of the relevant 
requirements that should be followed by the radiopharmaceutical producers.  In situations where a specific 
issue, not addressed in the regulations and guidance arises, producers have the ability to communicate with 
the FDA directly through meetings.  
The regulatory oversite of the radiopharmaceutical manufacturing process by governmental agencies is 
further supplemented by manufacturing standards issued by the non-government entities such as United 
States Pharmacopeia or International Committee on Harmonization. The standards documents provide 
detailed descriptions on the requirements for particular processes related to pharmaceutical manufacture and 
quality control. The FDA often aligns their requirements with the requirements described in the standards 
documents.  
Under certain circumstances (e.g. when as cold kit is used to prepare the radiopharmaceutical or when the 
radiopharmaceutical needs to be compounded based on the physician order for a specific patient) the process 
of radiopharmaceutical preparation is considered to be practice of nuclear pharmacy and medicine. In such 
situations, the local state agencies such as Boards of Pharmacy or Boards of Medicine are tasked with 
implementation of local regulations, ensuring compliance with those regulations, and actively performing 
inspections.  However, the FDA still has the overall regulatory oversight of these activities and has the ability 
to become more involved in the regulation of these processes whenever required.  
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Author: Yelena Chakrova  
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Corresponding author: elchakrova@yandex.ru 
In the end of 2018, the Institute of Nuclear Physics (INP) in Almaty became the first producer of 
radiopharmaceuticals in Kazakhstan certified for compliance with the GMP standard. 
National Pharmaceutical Quality System, based on the recommendations of the International Conference on 
Harmonization of technical requirements for registration of pharmaceuticals for human use, ICH Q10, was 
introduced in Kazakhstan in 2015. One of the major elements of the system is Good Manufacturing Practice 
(GMP) harmonized with GMP of European Union. GMP became obligatory for all pharmaceutical producers in 
Kazakhstan since the beginning of 2018 and immediately affected the operation of new radiopharmaceutical 
production facility commissioned at INP in 2017. This more than 700m2 facility accommodates class A, B, C 
and D clean rooms and hot cells, and is intended for production of pharmaceuticals based on both cyclotron- 
and reactor-produced radioisotopes, including 99Mo/99mTc generators, sodium iodide 131I, 153Sm-EDTMP, 18F-
FDG and others. The main stages of the establishment of GMP system and preparation for GMP certification 
were: 
⎯ Development of the plan of certification; 
⎯ Development of the validation master plan; 
⎯ Development of draft documents; 
⎯ Risk assessment for each technology; 
⎯ Qualification of equipment and engineering systems; 
⎯ Validation of processes; 
⎯ Production and quality control of validation batches; and 
⎯ Finalization of documents. 
The developed four-level system of documents included the external documents, the documented 
procedures, the standard operating procedures and the records of results, altogether more than 500 
documents. 
Qualification of the equipment and systems required some technical modifications. It was not always possible 
to fully isolate the production of hot cells from the less biologically clean environment. In some cases, it was 
easier to provide the required cleanness outside underpressurized hot cells, to comply with both GMP and 
radiation safety requirements. 
The application package was reviewed, and the inspection of the facility was conducted by the Pharmacy 
Committee of the Ministry of Public Health. After elimination of the inconsistencies revealed by the 
Committee, the radiopharmaceutical production facility at INP was certified for compliance with GMP. 
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Author: Tiina Titma  
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Corresponding author: tjjna@gmail.com 
Regulation of preparation of radiopharmaceuticals, as a relatively new class of emerging medicines for human 
use, is carried out in different ways in the European Union member states. This may create a potential problem 
when the principles of free movement of services and free movement of patients are considered. Since 
applicable guidelines and directives consider preparing of such medicines similarly as manufacturing or 
compounding, different interpretation of ‘compounding’ could result in lower conformity with the good 
manufacture practice. 
Traditional ’compounding’ refers to the ‘pharmacy compounding’ or ‘extemporaneous compounding’, which 
is globally known as the practice of essential part of pharmacist’ competency. The World Health Organisation 
(WHO) Technical Report Series states that ‘Compounded preparations involve the preparation, mixing, 
assembling, altering, packaging and labelling of a medicine or drug-delivery device, in accordance with a 
licensed practitioner’s prescription, medication order or initiative based on the relationship between the 
practitioner, patient, pharmacist and compounder in the course of professional practice’. 
According to the EU Directive, radiopharmaceutical kit and radionuclides from the generator (both mother 
and daughter radionuclides) are considered as active substances and detailed instructions for 
extemporaneous preparation and quality control of radiopharmaceutical should be included in the summary 
of the product characteristics. Preparation of radiopharmaceuticals used as diagnostic investigational 
medicinal products is carried out in hospitals, health centres or clinics, by pharmacists or other persons legally 
authorised in the Member State concerned to carry out such process, and if the investigational medicinal 
products are intended to be used exclusively in hospitals. 
In Estonia, there is no specific regulation on radiopharmaceuticals. Estonian Medicinal Products Act say that 
the ‘Act applies to radiopharmaceuticals in so far as legislation concerning radioactive substances does not 
provide otherwise’.  In addition, it is provided that “Medicinal products prepared as magistral formulae are 
medicinal products prepared in a pharmacy in accordance with a medical prescription or order form.” On the 
other hand, Estonian Radiation Act and its derivative regulative documents, do not contain provisions about 
preparation of radiopharmaceuticals, except for radiation safety. 
In this paper, we provide an overview of the applicable regulations in case the radiopharmaceuticals are 
prepared in other departments of the hospital or facility.
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 Development and evaluation of chelators for specific radiometals 
Author: B. Guerin 
Université de Sherbrooke, Montreal, Canada 
Corresponding author: brigitte.guerin2@usherbrooke.ca 
There was continued interest in developing more efficient new chelating agents for metal radionuclides mostly 
used for positron emission tomography (PET) imaging. We focused on the development of convenient 
syntheses and conjugation of cyclic and acyclic chelators derivatized with N-hydroxy-N-methyl succinamide 
pendant arms for copper-64 (64Cu), gallium-68 (68Ga) and zirconium-89 (89Zr) complexation. The aim of this 
project was to assess the suitability of the new chelators for 64Cu-,68Ga- and 89Zr -PET. 
The chelators were prepared through multiple steps starting with a nonadecane, cyclen and spermine 
backbones to offer chelating agents with high overall yields. They exhibited strong selective coordination of 
64Cu, 68Ga and 89Zr and offered a very fast labelling kinetic at room temperature as compared to NOTA, DOTA 
and DFO analogs. Achievable effective molar activities for the resulting complexes are higher compared to the 
one prepared with commercially available chelators. The radio-complexes were stable in saline, serum, as well 
as against transchelation and transmetallation. They showed high stability in mouse plasma in vitro and in vivo. 
Biodistribution and imaging studies were performed in balb/C mice and the background activity in various 
tissues was low. Finally, the conjugation of unprotected chelators to peptides and antibodies of biological 
interest were complete with overall yields of 50-60%. 
In conclusion, our new class of cyclic and acyclic chelators show an outstanding promise as 64Cu, 68Ga and 89Zr 
chelators.  
 
 
  
ISTR–2019 
 
97 
 
Novel radiopharmaceuticals for clinical translation 
Author: Serge Lyashchenko 
Department of Radiology, Memorial Sloan Kettering Cancer Center, United States  
Corresponding author: lyashchs@mskcc.org 
Over the last several decades radiopharmaceuticals have emerged as a an extremely useful modality for both 
diagnosis and treatment of disease.  Much wider availability of novel radionuclides, more advanced image 
collection technologies, simplified radiopharmaceutical production technologies, and, most importantly, 
increased clinical community interest in application of radiopharmaceuticals in patients have created a 
significant demand for these agents.  
In the field of molecular imaging, increasingly more imaging agents are used for patient selection, therapy 
optimal dose finding, and patient response monitoring. Increased availability of PET radionuclides with 
relatively longer radioactive half-lives such as 124I, 64Cu, and 89Zr have resulted in a much wider clinical 
application of diagnostic radiolabeled antibodies, molecules that were impossible to PET image with 
historically due to the long biological circulation and target localization time. While the application of the 
majority of these agents remains limited to clinical research use, there are several agents in development that 
may someday be used as radiopharmaceuticals approved for standard clinical care.  
In parallel, the field of targeted radiotherapy with radiopharmaceuticals is undergoing a significant expansion, 
with 177Lu and 131I radiolabeled peptides and antibodies being the most common agents of interest undergoing 
clinical translation.  More recently, targeted alpha therapy radiopharmaceuticals, containing alpha emitting 
radionuclides such as 225Ac, 213Bi, 212Pb, and 211At have generated great interest in the medical community. 
More controlled clinical studies are needed to fully elucidate the safety and efficacy of this class of agents in 
patients, but the available preliminary clinical studies data looks highly promising.  
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 Translation of new chelators for old pairs: Tc/Re NODAGA 
Author: Jeff Smith 
University of Missouri School of Medicine, Columbia, United States  
Corresponding author: smithcj@health.missouri.edu 
In this presentation, we report diagnostic (99mTc) and therapeutic (186Re) agents for targeting somatostatin 
receptor (SSTR) and gastrin releasing peptide receptor (GRPR) positive tumours. We have evaluated in vitro 
complexes of the general formula [M(CO)3(L-sst2-ANT)]  and [M(CO3)(L-C6-BBN-ANT)] (M = 99mTc, 186Re), where 
L denotes NODAGA or NOTA and sst2-ANT denotes the potent SSTR2 antagonist 4-NO2-Phe-c(DCys-Tyr-DTrp-
Lys-Thr-Cys)-DTyr-NH2. For the GRPR targeting agent, C6 is an aminohexanoic linker conjugated to BBN-ANT, 
a powerful GRPR peptide antagonist (H-DPhe-GIn-Trp-Ala-VaI-Gly-His-Sta-Leu-NH2). Moreover, we have 
assessed the in vivo properties of the 99mTc-complexes in animal SSTR-positive or GRPR-positive tumour 
models. 
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Radioactive Gold-198 nanoparticles in nanomedicine: green nanotechnologies in digital and 
molecular agents for innovative cancer diagnosis and therapy approaches in oncology 
Author: Kattesh Katti1  
Co-author(s):  Kavita Katti1; Menka Khoobchandani1; Ademar Lugao2 
1University of Missouri 
2IPEN, Sao Paulo, Brazil 
Corresponding author: kattik@health.missouri.edu 
Cancer alone continues to kill more people than AIDS, malaria, and tuberculosis combined. According to the 
International Agency for Research on Cancer, there were 12.7 million new cancer cases in 2018. The World 
Health Organization projects that without major breakthroughs in cancer prevention, discovery of new and 
accurate diagnostic modalities and development of highly effective therapeutic approaches, the global 
number of deaths from cancer will increase by nearly 80% by 2030, with most occurring cases in low- and 
middle-income countries. There are over 100 pharmaceutical formulations approved by the US Food and Drug 
Administration (FDA) in order to combat this deadly pandemic. Although surgery and radiation treatments are 
the initial treatments for most cancers, a large number of oncological approaches are being used to control or 
cure cancer.  Today, cancer patients have more choices in which treatment or combination of treatments may 
be used, encompassing three areas of emphasis: (a) Chemotherapy, (b) Hormone therapy; (c) Biological 
treatment. Despite the currently available choice of established anticancer agents for first-line of activity 
against cancer, effective delivery of chemotherapeutic, hormonal and biological pharmaceuticals to the 
tumour tissue and cancer cells selectively continues to be the most vexing problem in cancer oncology. 
Problems associated with effective delivery of cancer drugs pose severe oncological challenges especially 
when treating solid tumours (sarcomas, carcinomas, and lymphomas) which account for over 85% of all human 
cancers. Circumventing these problems is not easy because molecular and cellular biology of neoplastic cells 
alone has failed to explain the non-uniform uptake of these agents in solid tumours. Repeated delivery of 
cancer drugs leads to systemic toxicity creating major collateral adverse effects where cancer cells mutate 
making them resistant to chemotherapeutic treatments. Therefore, the discovery of new drug delivery 
approaches that effectively penetrate extracellular compartments consisting of vascular and interstitial valves 
within solid tumours is of profound importance. 
Radioactive nanoparticles with diagnostic and therapeutic capabilities provide intelligent drug delivery 
systems to maximize therapeutic activity and to minimize undesirable side effects. For example, the 
radioisotope of gold metal, Au-198, provides a desirable beta energy emission and half-life that destroys 
tumour cells/tumour tissue (βmax = 0.96 MeV; half-life of 2.7 days). Its penetration range (up to 4 mm in tissue 
or up to 1100 cell diameters) is sufficiently long to provide cross-fire effects to destroy tumour cells/tissue, 
but short enough to minimize radiation exposure to adjacent tissues. One particularly attractive feature of 
radioactive gold nanoparticles is that it does not have to be incorporated into every tumour cell to have a 
therapeutic effect. The path length of the emitted radiation is sufficient to allow effective therapy following 
uptake into a subpopulation of tumour cells. It is this feature that has attracted recent attention to apply 
nanotechnology for the effective delivery of therapeutic doses of beta emitting nanoparticles selectively to 
tumour tissue and tumour cells. We have reported the synthesis of novel radioactive gold nanoparticles using 
the trimeric phosphine (referred to as ‘Katti Peptide’ discovered in our laboratory. 
In our continued efforts to apply green nanotechnology for the development of therapeutic radioactive gold 
nanoparticles, recently we have discovered that the high antioxidant capacity of Epigallocatechin gallate 
(EGCG), which is the most abundant catechin polyphenol in tea, can be used to convert radioactive Gold-198 
precursor to the corresponding biocompatible radioactive gold nanoparticles. Most recently, we have shown 
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that Mangiferin—a glucose functionalized xanthanoid, found in abundance in mango peels, serves dual roles 
of chemical reduction and in situ encapsulation, to produce gold nanoparticles with optimum in vivo stability 
and tumour specific characteristics. Interaction of mangiferin with Au-198 gold precursor affords MGF-
198AuNPs as the beta emissions of Au-198 provide unique advantages for tumour therapy while gamma rays 
are used for the quantitative estimation of gold within the tumours and various organs. Laminin receptor 
specificity of mangiferin affords specific accumulation of therapeutic payloads of this new therapeutic agent 
within prostate tumours (PC-3) of human prostate tumour origin induced in mice which overexpress this 
receptor subtype. Detailed in vivo therapeutic efficacy studies, through the intratumoural delivery of MGF-
198AuNPs, shows retention of over 80% of the injected dose (ID) in prostate tumours up to 24 h. In order to 
estimate the tumour and local tissue doses in MGF-198-AuNPs for prostate cancer radiotherapy, we have 
undertaken Monte-Carlo N-Particle code calculations. The overall objective of this investigation was to 
estimate the dose distribution delivered by radioactive gold nanoparticles (198AuNPs or 199AuNPs) to the 
tumour inside the human prostate as well as to the normal tissues surrounding the tumour using Monte-Carlo 
N-Particle code (MCNP-6.1.1 code). This lecture will provide: (a) scope and prospects of beta emitting 
radioisotopes in nanomedicine; (b) details in the intervention of nuclear activation analysis and various 
radioanalytical approaches for the production of tumour specific radioactive gold-198 nanoparticles; and (c) 
full in vivo investigations on therapeutic properties of MGF-198-AuNP agent in treating prostate tumours and 
(d) the overall implications of green nanotechnology of therapeutic beta emitting nanoparticles in oncology. 
According to the MCNP results, 198AuNPs are a promising modality to treat prostate cancer and other solid 
cancers and the gamma of 198AuNPs, as well as 199AuNPs could be used for imaging purposes. In summary, the 
preclinical therapeutic efficacy studies and the detailed toxicity studies of MGF-198-AuNPs provide compelling 
evidence for the clinical translation of this innovative nanotherapeutic agent for use in treating prostate and 
related solid tumours in human patients. Therefore, future studies will focus on clinical trials of MGF-198-
AuNPs, in prostate tumour bearing patients, in order to seek approval from regulatory agencies (FDA) for the 
utility of this new nanomedicine agent in oncology. 
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New strategies for imaging brain cancer with radiopharmaceuticals 
Author: Peter Brust 
Helmholtz-Zentrum Dresden-Rossendorf 
Corresponding author: p.brust@hzdr.de 
Brain cancer is a challenge for the health care system because of major problems for treatment. Radical 
surgery is not possible. Radiation treatment is restricted by missing borderlines, and drug treatment is limited 
by the blood-brain barrier. Therefore, glioblastoma multiforme, the most aggressive type of primary brain 
tumour, has a median overall survival of only ~12 months. Although new molecular pathways are being 
constantly discovered, translation of basic science into clinical practice is rather slow. Major obstacles in the 
resistance to therapy are heterogeneity of brain tumours, multiple genetic alterations, and their diffuse, 
infiltrative behaviour. Hence, monitoring of pathways related to tumour etiology and growth are highly 
important. 
Positron emission tomography (PET) offers the potential to identify key signalling and metabolic pathways in 
tumours and to discover drugs for targeted therapy.  An important prerequisite for PET is the development of 
radiolabelled molecules (radiotracer) to investigate impaired brain functions in living human subjects. 
Fluorine-18 is currently the most favourable radionuclide that is routinely used for radiolabelling because of 
its half-life of 109.8 min. The presentation will focus on the development of fluorine-18 labelled radiotracers 
bridging from basic science to biomedical application and focusing on four targets of major importance for 
brain cancer. 
Cannabinoids are known to induce apoptosis of glioma cells and the extent of cannabinoid CB2 receptor 
expression is related to tumour malignancy. The challenge in radiotracer development is the high expression 
of CB1 receptors. Therefore, our strategies will be presented to achieve highly selective PET radiotracers for 
CB2 receptors. 
The immunosuppressive effects of adenosine and the adenosine-triggered activation of catabolic energy 
production account for pro-cancer roles of extracellular adenosine. Accordingly, plasma-membrane-bound 
adenosine receptors were identified as new targets in the immunotherapy of brain tumours. Currently, we 
have PET radiotracers for A2A and A2B receptors under development, which are regarded as potential tools 
for therapy monitoring. 
Sigma receptors, previously regarded as opioid receptors, are comprised of the σ1 and σ2 subtypes and 
represent orphan receptors of different families. While the σ1 receptor is a molecular chapter one, which 
interacts with various ion channels and G-protein coupled receptors, the σ2 receptor (TMEM97) is an 
intracellular protein located at the endoplasmic reticulum that binds numerous drugs. There is evidence that 
both subtypes are important for glioblastoma growth thus facilitating the ongoing development of selective 
PET radiotracers for both subtypes in our department. 
Furthermore, as other cancers, glioblastoma is characterized by metabolic reprogramming to preferentially 
undergo aerobic glycolysis. The elevated production of lactate is accompanied by the increased expression of 
monocarboxylate transporters (MCTs). Accordingly, a therapeutic approach targeting MCTs is a promising 
strategy in brain cancer treatment. A PET radiotracer for peripheral MCT1/MCT4 imaging has already been 
developed by us and will be discussed concerning its suitability for glioblastoma imaging. 
Numerous attempts are ongoing for molecular characterization of brain cancer with PET 
radiopharmaceuticals. It is expected that they will support in the future patient stratification and hence 
individualized therapy.
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 Production and quality control of radiopharmaceuticals labelled with Actinium-225 and Bismuth-
213 
Author: Alfred Morgenstern 
European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, 
Germany 
Corresponding Author: Alfred.morgenstern@ec.europa.eu 
Alpha emitters are highly effective radionuclides for targeted alpha therapy of cancer. The remarkable clinical 
results obtained in the last years for treatment of advanced prostate cancer with 225Ac-PSMA617 have strongly 
stimulated the global interest in targeted alpha therapy. The supply of suitable alpha emitters in enough 
quantity and purity is a main pre-requisite for a widespread application. This presentation will give an overview 
of methods for the production of the alpha emitters Actinium-225 and Bismuth-213 and describe methods for 
the labelling of biomolecules. 
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US DOE Tri-Lab Effort to Produce Ac-225 
Author: Cathy S. Cutler  
Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY USA 
Corresponding author: ccutler@bnl.gov 
There is growing interest in using alpha emitters for targeted therapy particularly in cases where the disease 
has metastasized.  A major limitation to this approach has been the limited availability of the alpha emitters 
themselves.  The US DOE isotope program has made its top research priority developing production capability 
to meet the quantities and quality of Ac-225 needed to support clinical applications.  After evaluating multiple 
production pathways, the DOE chose to concentrate on the high energy accelerator route through the proton 
bombardment of Th-232.  This effort utilizes the high energy accelerators housed at BNL and LANL along with 
the Ac-225 chemistry separation and experience contained at ORNL.  Over the past two years over 22 thorium 
targets have been irradiated at BNL and LANL and then shipped to ORNL for processing and distribution.  The 
material has been thoroughly characterized and then sent out to external users for evaluation.  Actinium-225 
can either be directly used for targeted therapy applications or as generator feedstock for Bismuth-213.  Thus, 
the development of Ac-225 provides two alpha emitters with different nuclear properties expanding the 
library of radionuclides that can be utilize for targeted therapy.  The project has successfully completed the 
first stage of the effort demonstrating the feasibility of developing targetry which can be irradiated at high 
energies and developing the chemistry that enables the separation of the Ac-225 from over 100 other 
radionuclides that are produced from the irradiation.  Stage 2 is ongoing which involves scaling up production 
to 100 mCi quantities and developing facility plans to allow for curie level production at multiple sites.  
Submission of a drug master file for the accelerator material by the end of the 2019 calendar year.  Material 
is being produced with up to 30-50 mCi being routinely put into inventory for external stakeholders.  Details 
regarding the Tri-Lab production effort for Ac-225 will be provided. 
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Recent results of the joint CNL and TRIUMF project on the production of Ac-225 
Author: Mark Lesinki1  
C-author(s): Patrick Causey1, Kathryn Hayashi2, Keith Ladouceur2, Kevin McDuffie2, Andrew Robertson2, Paul 
Schaffer2 
1Canadian Nuclear Laboratories (CNL) 
2TRIUMF Innovations, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3 
Corresponding author: patrick.causey@cnl.ca 
CNL has a history spanning more than 70 years in the application of nuclear technology toward the betterment 
of human health. Pioneering accomplishments include megavoltage radiation therapy for the treatment of 
cancer, and the implementation of large-scale production of several critical isotopes, including the global 
supply of 99Mo (molybdenum-99) for 99Mo/99mTc (technetium-99m) generator manufacture and distribution. 
In total, an estimated one-billion medical treatments and scans were conducted using isotopes produced at 
CNL’s Chalk River Laboratories. Presently, CNL has expanded its research capabilities and continues to serve 
as a world-leader in the development and delivery of medical isotope technology andnuclear health sciences. 
Recently, CNL has developed a thorium-229 (229Th)/actinium-225 (225Ac) generator to enable both internal and 
collaborative research at TRIUMF, the University of Saskatchewan, the Fedoruk Center; to further develop 
known and novel radiopharmaceuticals for treatment of various cancers. 225Ac is an alpha-emitting 
radioisotope, and when radiolabeled to a targeting vector, it has attracted worldwide attention in the medical 
community for its potential to treat and cure cancers. Known as targeted alpha therapy (TAT), various drugs 
incorporating alpha emitting isotopes are in clinical trials and pre-clinical research for an array of cancers,as 
well as viral and bacterial infections, including infectious diseases. However, anticipated demand for225Ac far 
exceeds supply as producers work to overcome the many challenges associated with scaled-up production. 
TRIUMF houses a high energy (520 MeV) accelerator that allows for the production of both radium-225 (225Ra) 
and 225Ac via 232Th spallation. CNL and TRIUMF have partnered on a project thataims to produce isotopically 
pure 225Ac in quantities needed to support clinical studies, preclinical researchand multiple drugs once 
approved for human use. The joint project begins at TRIUMF’s Isotope Production Facility, with the high energy 
proton spallation of 232Th, producing a wide range of isotopes, including appreciable and scalable quantities 
of 225Ra. The irradiated targets are shipped to CNL for 225Ra separation using standard separation techniques, 
modified by proprietary improvements, to yield a 225Ra generator. Milking the 225Ra generator produces pure 
225Ac, free of long-lived impurities, including 227Ac and other spallation products. 
Multiple processing runs have been completed with processing yields for 225Ra and 225Ac of greater than 70% 
decay corrected to End-of-Bombardment (EOB). This material, devoid of 227Ac, performs identical to material 
produced via 229Th decay when subjected to radiolabeling, and has passed all internal quality control release 
tests. A key challenge to this work is the disposition of waste generated during processing, an area of expertise 
CNL is known for and developing further. With promising results to date, the CNL-TRIUMF partnership is part 
of a critical path to ultimately demonstrate a supply route for significant quantities of clinical-grade 225Ac. 
The results, significance and key challenges of the joint project will be discussed during the presentation.  
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Argentinian project for developing production of Ac-225 and Bi-213 in cyclotrons for targeted 
therapy 
Author: Oscar Pozzi  
Co-author(s):  Valentina Vercelli; Celeste Iljadica; Carmen Ali Santoro; Sandra Siri; Carmelo Rocco; Hector 
Cols 
Ezeiza Atomic Center, Argentina 
Corresponding author: pozzi@cae.cnea.gov.ar 
The Alpha Project of the National Atomic Energy Commission of Argentina is a local project for developing the 
production of Ac-225 and Bi-123 from Ra-226 targets via Ra-226(p,2n)Ac-225 reaction in medium-low energy 
cyclotrons. The main goal of the Alpha Project is to secure the regional supply of Ac-225 in order to provide 
future treatment of cancer patients and to support the R&D for new applications. To fulfil the goals of the 
project, a new dedicated nuclear facility is being built in Argentina and expected to become fully operational 
in 2020-2021. It will have several radiochemical labs containing one multipurpose hot cell, five hot cells 
dedicated to Ac-225 processing, and one GMP hot cell. This installation will also have a pilot plant for 
radiopharmaceutical production, initially under local GMP condition but capable to be upgraded to 
international GMP regulation. 
The irradiation of the Ra-226 target will be made in the cyclotron “Cyclotron Corporation CP42” (25- 42 MeV) 
located at the Ezeiza Atomic Center of CNEA, using the fully automated irradiation station for solid target with 
a new target holder specifically designed to work with sealed Ra-226 targets and 4 pi water for cooling. 
Theoretical models predict the cooling time to be at least 240 hours (one T1/2 of Ac-225) before processing 
the target. This will decrease the Ac-226 activity to < 0.3% of its initial value and provide Ac-226/Ac225 ration 
to be < 0.005. This cooling time will also result in a decay of the Ac-226 daughters. According to the yield 
calculations for the preliminary target designed to run at lower density current <100 microampere/cm2, with 
58 mg RaCl2 irradiated 4 hrs. x 50 microampere/cm2 at 24-10 MeV will be able to produce 335 mCi EOB per 
batch, and 167.5 mCi after cooling time of 240 hrs. A production target capable to withstand 200 
microamperes will require a bigger amount of RaCl2 (230mg for 2 cm2) with 24 hrs. x 50 microampere 
irradiation at 24-10 MeV will result in 1.34 Ci of Ac-225 EOB per batch, and 670 mCi after 240 hrs. of cooling. 
Assuming an average dose of 0.5 mCi/patient, this amount will be enough for 1340 patient (losses for 
purification are not considered). Based on this assumption, one cyclotron running once a week, 4 
weeks/month, 11 month/year will be able to produce 29.5 Ci/year of Ac-225, which is enough for almost 
59,000 patients per year. 
This production method based on the Ra-226(p,2n)Ac-225 based in cyclotrons have several advantages. It 
produces Ac-225 of high radionuclide purity; it is suitable for local and regional markets where Ac-225 
production can be adjusted depending on the needs; it can produce on demand up to ~30 Ci/year using only 
one non-dedicated cyclotron working once a week; and it fulfils the goals set for the Alpha Project to secure 
the Ac-225 supply for our country and the region. 
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Sustainable production of Tc-99m generators and radiopharmaceuticals an IAEA/Cuban 
experience 
Author: René Leyva Montaña 
Isotope Centre, Cuba 
Corresponding author: leyvamontanarene4@gmail.com 
Through collaboration with the IAEA, CENTIS has managed to establish a system for the sustainable production 
of generators and radiopharmaceuticals. Radionuclide generator systems continue to play a key role in 
providing both diagnostic and therapeutic radionuclides for various applications in nuclear medicine. The 
generators represent important in-house production systems that can provide daughter radioisotopes 
generated by parent decay on-demand without the need for local access to an accelerator or nuclear reactor. 
Cuba has not had accelerators or reactors for many years, so its radionuclide and radiopharmaceuticals 
production is based mainly on importation or local generators production. Our presentation resumes the 
Cuban experience in the production of radionuclide generators and radiopharmaceuticals. 
In CENTIS facilities, the production of 99Mo/99mTc generator began in 2003 using the column chromatography 
method as separation technology. More than 4 000 generators have been produced in different presentations 
(8 GBq, 20 GBq, 37GBq, 55,5 GBq and 74 GBq) during this years. However, long before in the 90s, CENTIS 
already manufactured cool kits to form radiopharmaceuticals from imported generators. Starting with 
generator production in 2003 allowed us to guarantee the sustainability of nuclear medicine services in the 
country. 
Among many other requirements one of the main challenges for our radionuclide generators production has 
been the need to manufacture and operate under the conditions of good manufacturing practices (GMP) 
guidelines since these products represent final product or active pharmaceutical ingredients (APIs) which will 
be incorporated into radiopharmaceutical products prepared for human use. In this presentation, we included 
the necessary modifications performed to our 99Mo/99mTc generators production and the conditions 
established to comply with the current GMP guidelines supported by a Technical Cooperation Project with the 
IAEA (CUB/6/023). 
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IAEA support of 99Mo/99mTc gel generator production project in Kazakhstan  
Author: Yelena Chakrova  
Co-author(s):  Denis Afanasyev; Vladimir Kutepov; Igor Fetssov; Zoya Medvedeva 
Institute of Nuclear Physics, Almaty, Kazakhstan 
Corresponding author: elchakrova@yandex.ru 
The Institute of Nuclear Physics (INP) in Almaty for more than 18 years produces and supplies all nuclear 
medicine organizations of the Republic of Kazakhstan with the most used radiopharmaceutical for radionuclide 
diagnostic 99mTc solution.  
For production of generators activation 99Mo is used, obtained by irradiation of natural molybdenum oxide at 
the WWR-K research reactor with a thermal neutron flax 2·1014 n·s-1·cm-2. The “gel” technology, the basis of 
which have been developed by scientists from Australia and the United States, applied on an industrial scale 
in India is used to produce 99Mo/99mTc gel generators at the Institute. Specialists of the Institute of Nuclear 
Physics have improved this technology by developing unique technological equipment for the production of 
generators in hot cells and creating a new generator design, as well as implementing GMP principles in 
production.  
The project of creation of 99Mo/99mTc gel generator production was implemented within the framework of 
budget programs aimed at the development of new technologies in the Republic of Kazakhstan and the success 
of the project is largely due to the significant support provided by IAEA through Technical Cooperation and 
Coordinated Research Projects.  
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Strengthening capacities for the development of radiotracers labelled with fluorine-18, different 
from Fluordesoxyglucose in the FCDN 
Author: Adrian Duran1  
Co-author(s):  Fabiana Rodriguez2; Jonathan Santiñan2; Erica Heringer3; Rebeca Vargas2; Sabrina Seidel3; 
Jaime Palatnik3; Alicia Coronel2 
1 Comision Nacional de Energia Atomica, Argentina 
2 FCDN, Argentina 
3 FCDN/CNEA, Argentina 
Corresponding author: aduran@fcdn.org.ar 
The “Fundación Centro Diagnóstico Nuclear (FCDN)” has a large experience in Argentina as a FDG producer 
with more than 3500 batches, distributing a large part of the production to other sites as well as to our own 
patients. Besides, the institution produces routinely 11C, 68Ga and 13N radiopharmaceuticals. Do to the 
expansion of applications related with PET and specially with 18F, the institution has decided to apply to an 
IAEA’s TC program in order to get the input to strengthen our capacities to produce 18F radiopharmaceuticals 
other than FDG. The program consists of fellowships, expert missions and procurement of equipment. In the 
first year we have installed an automatic synthesis module, two fellowships have been granted and one expert 
mission was completed. 
With the help of this program in the first year the radiopharmacy department was able to produce 18F-Cholina, 
18F-PSMA1007, 18F-FMISO and 18F-FAZA with all the required quality controls. 18F-Choline is in clinical use for 
internal patients and 18F-PSMA1007 documentation has been presented to the regulatory agencies in order to 
apply to a clinical trial. Regarding 18F-FMISO and 18F-FAZA, we are defining which of them is the best candidate 
for the clinical applications. 
In conclusion, the program has proven to be helpful to train staff and implement new technologies aimed to 
help Argentina´s community.
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Development of production strategies for new emerging research radionuclides using cyclotrons 
Author: Valery Radchenko  
TRIUMF/UBC, Canada 
Corresponding author: vradchenko@triumf.ca 
Targeted Radionuclide Therapy (TRT) with Auger emitters has great potential due to the low energy (eV-KeV) 
and high Linear Energy Transfer (LET) that is ideal for local damage on the cellular level. Auger emitters in 
combination with selective delivery systems may maximize damage of tumour cells with minimal effect on 
surrounding healthy tissues. However, dosimetry of Auger emitters for nuclear medicine application is still 
relatively unexplored and mostly performed with commercially available radionuclides which are not 
necessarily the most suitable for Auger therapy (e.g. 111In, 99mTc, 125I). Therefore, production and testing of 
alternative radionuclides is important to realize the full potential of Auger emitters for therapy. 
TRIUMF (Canada’s Particle Accelerator Centre) has unique infrastructure to produce a broad pallet of 
promising radionuclide candidates for TRT research. This includes a number of cyclotrons with operating 
energies between 13 and 520 MeV and radiochemical facilities to perform radiochemical separations and 
radiolabeling. In this work, production, radiochemical separation and radiolabeling of potent radionuclides for 
Auger therapy namely antimony (119Sb), erbium (165Er) and mercury (197m+gHg) will be presented.  
Sb and Hg isotopes were produced by irradiation of natural tin and gold targets respectively at TR-13 cyclotron. 
Liquid-liquid extraction was applied for Sn/Sb separation and previously published procedure based on Ln 
resin was applied for Hg purification. 
For production of 165Er, the ISAC facility at TRIUMF. Radiochemical purification from co-produced no-carrier 
added lanthanides was performed using solid phase extraction chromatography on a Ln resin.  
Irradiation of natural tin resulted in a variety of Sb isotopes including 119Sb, but due convenient for detection 
gamma lines, 120mSb was used as a tracer for antimony to establish radiochemical separation and chelation 
yields. Liquid-liquid extraction with dibutyl ether yielded over 95% of Sb recovery and >103 of Sn/Sb. Irradiation 
of monoisotopic gold provide mixture of 197m+gHg which was further purified with Ln resin with recovery yield 
over 90%. 
Detection of produced 165Er and 165Tm was performed with gamma spectroscopy. Radiochemical separation 
from co-produced 165Tm results in efficient separation and purified erbium was tested for chelation with DOTA 
and macropa. Results showed over 99% radiolabelling efficiency with DOTA for using in combination with 
selective delivery systems for microdosimetry studies.  
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Emerging clinical applications of [64Cu]CuCl2 radiopharmaceutical 
Author: Miguel A. Avila-Rodriguez 
Unidad Radiofarmacia-Ciclotrón, Universidad Nacional Autónoma de México, Ciudad de México, Mexico 
Corresponding author: avilarod@uwalumni.com 
Over the last two decades there has been a growing interest in Copper-64 (Cu-64) and important advances 
have been achieved in preclinical and clinical applications with this emerging radionuclide. Given its favorable 
physical properties (half-life and decay scheme), Cu-64 has the potential to be used for PET molecular imaging 
and targeted radionuclide therapy (TRT) in oncology. Among the positron emitters of copper, Cu-64 is by far 
the most commonly used for PET molecular imaging, in part given by the versatility of its half-life of 12.7 h that 
allows the imaging of peptides and small molecules with fast clearance, and macromolecules with slow 
pharmacokinetics. However, in recent years, Cu-64 in the chemical form of copper dichloride ([64Cu]CuCl2) has 
been identified as a potential agent for PET molecular imaging and TRT, using the copper transporter protein 
CTR1 as molecular target.  
CTR1, a 190-aminoacid protein of 28 kDa with three transmembrane domains, is expressed in many normal 
tissues but most interestingly it has been found that this copper transporter is overexpressed in a variety of 
cancer cells, converting it in a molecular target for tumours overexpressing CTR1, characteristic that has been 
employed for PET imaging with promising results in both, preclinical applications in animal models, and clinical 
applications in humans. The potential of [64Cu]CuCl2 as theranostic agent have also been evaluated in animal 
models, but to date, no clinical trials have been performed in humans, only case reports have been described. 
In this talk an overview on the emerging clinical applications of [64Cu]CuCl2 radiopharmaceutical will be 
presented. 
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Towards large-scale Cu-67 cyclotron production 
Author: Petra Martini1  
Co-author(s): Gaia Pupillo1; Liliana Mou1; Micòl Pasquali1; Alessandra Boschi2; Carlos Rossi Alvarez1; Férid 
Haddad3; Adriano Duatti2; Juan Esposito1 
1INFN-LNL 
2UNIFE 
3ARRONAX 
Corresponding author: psqmcl@unife.it 
Among the most promising radionuclides for cancer therapy, Cu-67 is worldwide under the spot- light thanks 
to its potential application in theranostics, by itself or in pair with Cu-64. The main advantage of Cu-67 and 
theranostic radionuclides in general, is their peculiar possibility to perform diagnosis and therapy with the 
same radiopharmaceutical, allowing the selection of patients with a significant chance of responding to the 
specific treatment by performing low‐dose imaging studies prior therapy. Currently, the use of Cu-67 in 
preclinical and clinical trials is curtailed by its short availability. The production of Cu-67 still presents 
considerable challenges because of some unfavourable parameters characterizing the nuclear reactions that 
have been investigated. In particular, the most intensively studied reaction has been the 68Zn(p,2p)67Cu nuclear 
process. The efforts of the international community are thus focused on technological improvements allowing 
larger and reliable productions. 
At the INFN Legnaro National Laboratories (LNL, Padua), a new high-performance particle accelerator (i.e. 
BEST 70p cyclotron) has been installed in 2015 and a dedicated research facility called LARAMED (laboratory 
of radionuclides for medicine) is currently under completion. Cu-67 has been a top priority of LARAMED project 
in the last years: in 2016 the project COME (Copper Measurement), funded by INFN (CSN3), was carried out 
and research activities were presented at the CRP No. F22053 by the IAEA. The aim of the COME project was 
to experimentally determine the cross-section of the Zn-70(p,x)Cu-67 reaction in the still unexplored proton 
energy region above 35 MeV. Irradiation runs were performed at the ARRONAX facility (Nantes, France), by 
using the 70 MeV proton beam and stacked-foils targets, composed by a set of thin metal foils. An added value 
of this project was the development of a high-yield chemical separation procedure of Cu from Zn and Ga 
elements, optimized for the cross-section measurement. 
We successfully measured the Zn-70(p,x)Cu-67 cross section in the energy range 45-70 MeV, applying a 
radiochemical process to irradiated targets and by using gamma-spectrometry. The optimal experimental 
conditions to maximize the Cu-67 yield were identified and compared to the well-known reaction on Zn-68 
targets. 
Results of this study brought us to the idea of a special target design that allows the maximization of Cu-67 
production while minimizing the Cu-64 contamination, by using 70 MeV proton beams. This result led in 2018 
to the INFN patent entitled “A method and a target for the production of Cu-67”. The experience gained on 
the technologies for target realization and processing so far is the starting point for developing and optimizing 
the large-scale Cu-67 cyclotron-production chain. 
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Production of 47Sc from 47Ca – comparison of four separation methods 
Author: Izabela Cieszykowska  
Co-author(s):  Dariusz Pawlak; Wioletta Wojdowska; Małgorzata Żółtowska; Józef Leon Parus; Piotr 
Garnuszek; Renata Mikołajczak 
National Centre for Nuclear Research, Radioisotope Centre POLATOM 
Corresponding author: izabela.cieszykowska@polatom.pl 
Scandium-47 with a half-life of 3.35 days is a promising low-energy β- emitter (Eβ- (max) = 600 keV) suitable 
for targeted radionuclide therapy. It also emits radiation (E = 159 keV, 68.3%), which could be utilized for 
imaging by using SPECT technique for tracing the radiopharmaceutical administered for therapy. Together 
with positron emitter 44Sc, it can create the pair of radionuclides proposed for theranostic application. 
Scandium-47 can be produced by irradiation of 46Ca with thermal neutrons in 46Ca(n,g)47Ca→47Sc nuclear 
reaction.  The aim of this work was to find the best procedure of 47Sc separation from 46Ca irradiated in a 
nuclear reactor enabling multiple separation of 47Sc from 47Ca/47Sc generator system and the production of 
47Sc of high radionuclidic and chemical purity suitable for radiolabelling of radiopharmaceuticals. 
Scandium-47 was produced by irradiation of 46Ca targets (48.5 mg of CaCO3, 5.2% enrichment in 46Ca) for 150 
h in thermal neutron flux of 1.2 1014 cm-2s-1 in Maria research reactor. Four different methods of 47Sc 
separation from Ca were investigated and compared: the precipitation of scandium hydroxide with ammonia, 
the solid phase extraction chromatography using UTEVA resin, extraction chromatography with TBP resin and 
extraction chromatography with DGA resin. In 47Sc solutions obtained from precipitation, UTEVA and TBP 
methods were necessary to decrease their acidity. It was done on the cation exchange columns in H+ form. 
The solutions after 47Sc separation were used for next recoveries of 47Sc after about 4 days. Four cycles of 
separation were carried out. Target material was recovered via precipitation of calcium carbonate. 
Irradiation of targets containing 48 mg of [46Ca]CaCO3 resulted in 47Sc activity up to 660 MBq at EOB. The 
separation yields of 47Sc obtained with the use of four methods for 4 consecutive separation runs were as 
follows: for hydroxide precipitation: 99%, 54%, 24%, 16 %, for extraction of UTEVA resin: 79%, 42%, 27%, 16%, 
for extraction of TBP resin: 80%, 55%, 83%, 62%, for extraction of DGA resin: 96%, 91%, 87%, 93%. The only 
radionuclidic contaminant in separated 47Sc was 47Ca with concentration below 0.1%. 
Out of the four evaluated separation methods the highest separation yield was achieved for DGA resin. Also, 
the radiolabelling yield of DOTATATE was the highest when using 47Sc obtained by this method. In addition, it 
was demonstrated that multiple separations of 47Sc from irradiated enriched 46Ca target material are efficient 
until 15 days after the end of irradiation in nuclear reactor. 
Acknowledgements: This project was supported with the funds awarded by the Ministry of Science and Higher 
Education in Poland within the agreement No. 3639/FAO/IAEA/16/2017/0, IAEA Research Contract No. 20496 
and CERAD project, financed under Smart Growth Operational Programme 2014-2020, Priority IV, Measure 
4.2. 
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Accelerator-based production of Sc-47: results of the PASTA project 
Author: Gaia Pupillo1 
Co-author(s): Hanna Skliarova1; Sara Cisternin1; Petra Martini2; Micòl Pasquali2; Alessandra Boschi3; Luciano 
Canton1; Andrea Fontana1; Férid Haddad4; Carlos Rossi Alvarez1; Adriano Duatti3; Juan Esposito1; Liliana Mou1  
1INFN 
 2INFN-LNL and University of Ferrara 
 3University of Ferrara 
 4Arronax-Subatech, University of Nantes 
Corresponding author: gaiapupillo@hotmail.com 
47Sc is an emerging theranostic radionuclide included in the CRP No. F22053 by the IAEA, together with 67Cu 
and 186Re. The long half-life of 47Sc (about 3.35 days) is suitable to follow the slow biodistribution of monoclonal 
antibodies and large molecules, while its β- and γ radiation are useful to deliver cytotoxic dose to small-
medium size tumours and to perform SPECT imaging studies to select patient prior therapy. In addition, 47Sc 
can be paired to β+ emitters such as 44Sc or 43Sc to perform low-dose PET with the same radiopharmaceutical, 
to tailor the dose to the specific patient before therapy. The critical issue in the use of 47Sc is the lack of 
availability in sufficient quantities and at a reasonable cost. In the framework of the LARAMED program, the 
PASTA project (acronym of Production with Accelerator of Sc-47 for Theranostic Applications) was funded at 
INFN-LNL. The goal of the PASTA project is to measure several nuclear cross sections, comparing them with 
previous experimental data and theoretical predictions, in order to find out the best irradiation conditions for 
47Sc production. 
Data in literature regarding nuclear reactions induced by proton beams were analysed in detailed, finding that 
the most interesting materials for 47Sc production are natV and the enriched 48Ti, 49Ti and 50Ti targets. Highly 
pure natV foils are easily available on the market, while the enriched titanium targets were obtained by using 
metal powder deposited on an aluminium substrate by using the high-energy Vibrational Powder Plating 
(HIVIPP) technique (E_PLATE project). Irradiation runs were performed at the ARRONAX facility by using 
stacked-foils targets and low-intensity pro- ton beams. Gamma-spectrometry measurements were performed 
up to 5 days after the End of Bombardment (EOB), in order to follow the decay of all the radionuclides of 
interest (47Sc, 46Sc, 44Sc, 44mSc, 43Sc, 48Sc, 48V, 43K, 48Cr, 49Cr, 51Cr). Cross section calculations were carried out by 
considering the reference monitor reactions proposed by the IAEA Nuclear Data section. Experimental values 
were compared with data in literature and with theoretical estimations obtained by using different nuclear 
codes: Fluka, Talys and Empire. In addition to this, a radiochemical procedure aimed at the Sc/Ti separation 
was developed in collaboration with the University of Ferrara, by using the Solid Phase Extraction 
chromatography (tests performed with cold material). 
We successfully measured the natV(p,x)47Sc and 48Ti(p,x)47Sc cross sections and the co-production of 
contaminant radionuclides (i.e. 46Sc). Results, compared with previous data and theoretical estimations, are 
shown in this work. Experimental runs with 49Ti and 50Ti targets are scheduled in 2019; considering the high-
cost of the enriched materials used, the energy ranges of major interest were identified by comparing the 
predictions of the different nuclear codes. 
Results of this study will indicate the best nuclear reaction and the optimal irradiation conditions to produce 
47Sc by using proton beams, avoiding the co-production of contaminant radionuclides, especially 46Sc. Further 
work is needed to establish a reliable 47Sc production based on particle accelerators. 
 
ISTR–2019 
 
118 
 
S13. Radiopharmacy installations 
ISTR–2019 
 
119 
 
How to set up a medium size 99mTc generator facility: IAEA experience 
Author: Adriano Duatti 
Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121 Ferrara, Italy 
Corresponding author: dta@unife.it 
The transportable 99Mo/99mTc generator is still the major global source of 99mTc, one of the most widely used 
diagnostic radionuclides. According to many Pharmacopoeias (e.g., FDA, PhEur, PhInt), this generator is 
classified as a medicinal product and not as a medical device. The reason for this choice originates from the 
fact that the eluate withdrawn from the generator contains the pertechnetate anion, [99mTc][TcO4], which in 
turn can be used, under this chemical form, as diagnostic agent for assessing thyroid’s function. Because of 
this classification, the production of a 99Mo/99mTc generator should be accomplished strictly following the 
principles of Good Manufacturing Practice (GMP) elaborated to produce injectable drugs. It should be noted 
that GMP rules only dictate that, to ensure the quality of the final product always complies with the standards 
usually described in Pharmacopoeia’s monographs, the most efficient approach is to design and build up a 
robust production process that must be fully traceable and reproducible. GMP principles provide a guidance 
for rationally designing such a process and establishing a GMP production facility, but the adopted technical 
solutions can vary depending on the local conditions and, therefore, should be tailored to each specific 
situation. Usually, a rigorous and rational approach, supported by technological advancements as well as a 
correctly designed quality management system, would suffice to delineate the most appropriate solutions. In 
this short overview, the key steps involved in the production of a 99Mo/99mTc generator and a few possible 
layouts for setting up a medium-size GMP facility are presented and discussed. 
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Design and successful operation of SPECT hospital radiopharmacy  
Author: Vijay Kumar  
Sydney Medical School, University of Sydney, Australia  
Corresponding author:  vijay.kumar@health.nsw.gov.au 
Essential elements of Radiopharmacy SPECT laboratory should address the following aspects: selecting 
appropriate staff and training, provide adequate facilities and infrastructure, develop SOPs (Standard 
operating procedures), properly documented purchase of materials, labelling procedures, standard quality 
control and quality assurance measures, waste management and systematic documentation. 
The ultimate objective of the professional SPECT hospital Radiopharmacy is to provide “Best Patient Care”. All 
operations should be carried out under the supervision of the nuclear physician in charge and a 
radiopharmacist/radiochemist will be responsible for the setting up of the suitable quality control and quality 
assurance programme. There is a large diversity of diagnostic & therapeutic NM procedures in an ever-
changing field. Increasing levels of competence & knowledge are required to maintain high quality practice. 
At an international level standardization and harmonization is difficult due to diverse practice environment. 
Therefore, IAEA developed “operational guidance on hospital radiopharmacy: a safe and effective approach”. 
The publication is not intended to over-ride local guidance or provide comprehensive advice on all aspects of 
radiopharmacy practice. There are different levels of operations in Radiopharmacy and were classified into 3 
levels. Operational level 1a-Rady to use approved products. Dispensing radiopharmaceuticals purchased in 
their final form from centralised radiopharmacy. This includes unit doses required no compounding but 
preferably it is dispensed within a Laminar flow cabinet. The cabinet is an essential equipment, as it protects 
the product from the operator. Operation at level 1b involves dispensing radioiodine (I-131) and other ready 
to use radiopharmaceuticals for radionuclide therapy. Handling of beta-emitting volatile radioisotopes should 
be performed within a “Fume cupboard” as it protects the operator from volatile radiation (eg. I-131). 
Operation at level 2a involves preparation of radiopharmaceuticals from approved reagent kits and 
radionuclide, e.g. 99mTc. The procedures should be performed within clean room equipped with Isolators with 
built-in space for preparation, dispensing, and dose-calibrator. The level-2b involves radiolabelling of 
autologous blood cells. This operation requires specialised training on the methodology and infection control. 
Operation at level-3 mainly involves in-house compounding of radiopharmaceuticals from ingredients and 3b 
is on Synthesis of PET radiopharmaceuticals and long-lived PET generators. It is beyond the scope of this 
abstract to cover details on these operations. 
New chapter on radiopharmaceuticals (International Pharmacopeia) is developed by IAEA, which gives 
detailed information on methods of analysis, sterility and pyrogen testing, monographs and networking with 
manufacturers, drug regulators and reference centres. 
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Cyclotron and PET radiopharmacy installation: experience in setting up a commercial centre 
Author: M.R.A. Pillai  
Molecular Cyclotrons, Puthuvype, Ernakulam, Kerala 682 508      
Corresponding author: pillai.m.r.a@gmail.com 
Molecular Cyclotrons is a private PET radiopharmaceuticals manufacturing and distribution facility operating 
in Kerala, a southern state of India with a population of 35 million.  The facility is built as part of a hospital 
which will specialize in cancer care with focus on targeted radionuclide therapy. The Cyclotron-PET 
radiopharmaceuticals production facility is licensed by the Atomic Energy Regulatory Board and is in 
commercial operation since 2017.   
Prior to the commissioning of this facility there were only 2 PET-CT operating in the state of Kerala and the 
radiopharmaceuticals were brought by air freight. Thanks to the local production of PET radiopharmaceuticals 
the number of PET-CT in Kerala has increased to 15 or 0.4 PET-CT per million inhabitants. The state also has 
one of the three PET-MRIs available in India.  
The Cyclotron Centre is planned as per the IAEA TRS 471: Cyclotron Produced radionuclides: Guidance for 
setting up a new facility. The facility is compliant with EU good manufacturing practices and is GMP certified. 
The cyclotron is a self shielded Siemens Eclipse HP machine with 11 MeV proton beam and dual target having 
2 x 60 A beam current. The hot cells were procured from Von Gahlen. It consists of a twin Class C hot cell 
with 100 mm lead shielding, another twin Class C hot cell with 75 mm shielding, a Class A dispensing hot cell 
with 75 mm lead shielding and a bio-safety cabinet. A comprehensive radiation monitoring system supplied 
by Rotem Industries Ltd is installed in the Cyclotron Centre.  This is an online system with possibility of retrieval 
of data as and when needed.  
Three synthesis modules are installed of which the Siemens Explora FDG 4 can do four consecutive batches on 
FDG in a row without opening the hot cell. There are two Neptis Mosaic LC modules which are capable of 
making several F-18 radiopharmaceuticals using fluoride chemistry. During synthesis, the air from the hot cell 
is collected in delay-decay tanks which are located in the cyclotron vault. The quality control laboratory is 
equipped with GC, TLC and Endosafe equipment for estimation of chemical, radiochemical and pharmaceutical 
purity.  The finished products are packed in Type A lead and tungsten packages and transported by road.  
The Cyclotron Centre is supervised by the centre manager, who is a qualified radiochemist and an independent 
AERB approved Radiation Safety Officer.  Other operating personnel include M.Sc medical physicists (2), M.Sc 
Chemists (3) and a pharmacist. Cyclotron operation is done during night and packages are despatched at 
different lots with the last batch leaving the Centre prior to 7 in the morning. About 850 batches of FDG are 
produced thus far and there was no quality failure in any of the batches. FDOPA, FLT, FET, F-choline and 
FPSMA-1007 are the other radiopharmaceuticals prepared regularly in the Centre. The centre is catering to 15 
nuclear medicine departments and FDG is also exported to Sri Lanka.  
The model developed at Molecular Cyclotrons is an ideal commercial centre and can be readily adapted by 
new comers entering the fascinating field of PET radiopharmaceuticals production.    
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How to set up a PET radiopharmaceutical facility IAEA experiences 
Author: Uday Bhonsle 
 Director of Radiopharmacy, Gulf International Cancer Center, Al Bahia, Abu Dhabi, UAE. 
Corresponding author: udaybhonsle@gmail.com 
Nuclear Medicine Imaging plays a significant role in diagnosis and management of cancer as well as many 
other diseases. Diagnostic imaging depends on injection of a radiopharmaceutical followed by a scanning using 
either SPECT CT or PET CT system depending on the organ and disease under investigation. The 
radiopharmaceutical distribution, accumulation within the body provides much needed information regarding 
diagnosis of the disease or management of the disease. The SPECT-CT or PET-CT scanners are based on physical 
principles of radiation detection and image formations. Therefore, the diagnostic accuracy of the procedure 
depends on the quality of radiopharmaceuticals.  Radiopharmaceuticals are unique pharmaceutical products 
due to their short shelf life. Certain aspects of quality of a radiopharmaceutical cannot be assessed due to the 
short life of the product therefore the quality of the radiopharmaceutical products needs to be built in the 
design of radiopharmaceutical production and use processes. The IAEA, professional organizations and 
regulators have published detailed guidelines for setting up radiopharmaceutical production facilities. 
However, mainly due to the lack of specific project management experience, many IAEA member states, 
particularly belonging to the lower and middle income group, find it difficult to implement the guidance that 
is currently available due to lack of detailed project implementation plan. This presentation will explain with 
examples different steps that need to be taken to ensure timely completion of radiopharmaceutical 
production facility that is compliant with both pharmaceutical and radiation protection regulations.  
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An effort to develop? diagnostic and therapeutic nuclear medicine practice at Fukushima Medical 
University using two medical cyclotrons 
Author: Kohshin Washiyama  
Co-author(s):  Miho Aoki; Taiki Joho; Naoyuki Ukon; Ken-ichi Nishijima; Kazuhiro Takahashi; Songji Zhao; 
Noboru Oriuchi 
Advanced Clinical Research Center, Fukushima Medical University 
Corresponding author: kwashi@fmu.ac.jp 
The Advanced Research Clinical Center (ACRC) was established at Fukushima Medical University in June 2016 
as a symbol of rehabilitation of the disaster held in 2011. Radioisotope production using two cyclotrons and 
equipment for producing labelling compounds have been introduced, providing medical services generated 
from them to Fukushima citizens and re-activating Fukushima. The center has the mission to advertise our 
current status of the recovery process through the activity of our clinical R&D and application. 
The ACRC has installed two cyclotrons created by Sumitomo Heavy Industries, Ltd. Two types of cyclotrons can 
manufacture various types of radionuclides for diagnosis and treatment. There are five laboratories for making 
radiopharmaceuticals, some of which are cGMP grade. One PET/CT and one PET/MRI are installed for daily 
diagnosis. A nine-bed section has been set up in the treatment ward to perform radionuclide therapy which 
requiring hospitalization (i.e. thyroid cancer treatment with 131I). The maximum dose approved in a bed is 37 
GBq (1 Ci). 
The compact cyclotron MP-20S-V is used for producing positron emitting radionuclides such as 11C, 13N, 15O, 
18F for diagnosis. Among these nuclides, 18F is routinely manufactured and labelled as 18F-FDG for cancer 
screening of patients. This cyclotron can also be used for research, and so far, it has been producing 64Cu, 89Zr, 
124I, which is promising for radioimmunoscintigraphy. On the other hand, the cyclotron MP-30 is an accelerator 
newly developed by Sumitomo as a new type of cyclotron capable of accelerating alpha particles. The MP-30 
can accelerate proton, deuteron, and alpha particles, and is mainly used for research and development to 
make novel radiopharmaceuticals. So far, 65Zn, 99mTc, 68Ge, 177Lu, and 211At radioisotopes have been 
manufactured. Among them, 211At has been focusing on research at our facilities especially because of the 
growing interest in targeted alpha therapy globally. Last year, we made 34 runs of 211At production via 
209Bi(a,2n)211At nuclear reaction and the sum amount of produced radioactivity reached 13.8 GBq. Most of 
them have been used for our research and development, and some have been transported to other facilities 
for chemical experiments and preclinical studies under collaboration. 
The activity of our facility has just begun. We will contribute to patients in Fukushima and nearby areas through 
daily screening with radiopharmaceuticals for diagnosis. And we aim to be one of the global R&D and 
application centres for cancer treatment through the development of new alpha and beta emitting 
radiopharmaceuticals. 
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The medical isotope browser 
Author: Arjan Koning 
Co-Author: Marco Verpelli 
Nuclear Data Section, IAEA, Vienna, Austria 
Corresponding author: A.Koning@iaea.org 
A new web tool has been developed which allows to directly predict the production yield of a medical isotope 
on the basis of user input. The first version is restricted to isotopes produced by charged-particle accelerators. 
The user can specify the characteristics of the accelerator, such as the projectile (proton, deuteron, triton, 
Helium-3 or alpha particle), current in mA, the incident and exit energy, and specify the target material and 
the desired produced radioisotope. After a simple mouse click the required isotopic yield as a function of 
irradiation and cooling time, as well as a complete description of all the produced impurities is obtained, 
virtually instantaneous. 
The medical isotope browser is based on 4 essential ingredients, which will be discussed in some detail: 
• A web-based Graphical User Interface 
• An efficient solution of the production and depletion equations 
• A radioactive decay data library 
• A complete cross section library 
A live demonstration of the Medical Isotope Browser will be given for some important examples as Tc-99m, 
Ac-225 and Ga-68. 
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The IAEA's research reactor database (RRDB) 
Author: Nuno Pessoa 
Physics Section, IAEA, Vienna, Austria 
Corresponding author: N.Pessoa-Barradas@iaea.org 
The IAEA's research reactor database (RRDB) is an authoritative database containing technical information on 
over 800 research reactors, including critical and sub-critical assemblies in 67 countries. The information in 
the database, provided by facility focal points nominated through official channels, also includes utilization 
and administrative information. The presentation will focus on the information provided by the RRDB on 
production of medical radioisotopes with research reactors worldwide. 
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Introduction to new IAEA database “cyclotrons used for radionuclide production” 
Author: Amir R Jalilian1 
Co-author(s):  Mohammad Haji-Saeid2, David Schlyer3, Aliz Simon1, Joao Osso Jr.1 
1Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Austria 
2Consultant, Vienna, Austria 
3Scientist Emeritus at Brookhaven National Laboratory, Upton New York. USA.  
Corresponding author: A.Jalilian@iaea.org 
The number of cyclotrons has expanded in the last decade due to advances in medical imaging applications 
leading to increased radiopharmaceutical demand worldwide. With the development of sophisticated 
molecular imaging techniques (PET, SPECT, PET/CT and PET/MRI); introduction of user friendly compact 
medical cyclotrons from manufacturer companies has become possible. On the other hand, in many Member 
States, several PET radiopharmaceuticals are eligible for reimbursement by government or insurance 
companies.  
An online interactive directory of cyclotrons that are used for radionuclide production in Member States is 
launched recently and contains information supplied to the IAEA. This directory was prepared through 
information collected by reports from the major manufacturers and information taken from previous 
directories.  Best efforts were made to include only those cyclotrons in current operation or under testing, but 
this was not always possible and therefore, there may exist entries in the database which are no longer valid, 
or not yet associated with an institution. These entries need to be updated. 
The directory includes a significant number of the cyclotrons world-wide that are used, at least in part, for 
radionuclide production. Some institutions reported that older cyclotrons had been shut down and replaced 
with newer cyclotrons (In an effort to keep the database as up-to-date as possible, please follow the 
instructions on the website to update details regarding your new or existing facility). 
The database is organized alphabetically by Member State and by city but can be downloaded and sorted in 
any manner desired. There are individual entries for each cyclotron even for institutions having more than one 
cyclotron. The contact person and email address were entered where available. Again, every effort was made 
to update this list, but some of the people listed have changed positions and so may no longer be associated 
with an institution. 
There are more than 1300 entries for cyclotrons operating in Member States of the IAEA. This is an increase 
of more than 40% over those reported in the 2013 cyclotron directory. The increase has been in the number 
of cyclotrons in developed countries, but even more so in the developing countries. Large concentrations of 
cyclotrons for radionuclide production are in the United States of America, Japan and Germany. The largest 
number of cyclotrons for a single country is in the United States of America. However, taken collectively there 
are more cyclotrons located in the Far East including China and Japan that are used for medical radionuclide 
production. Please visit the following website for your overview: 
https://nucleus.iaea.org/sites/accelerators/Pages/Cyclotron.aspx 
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Development and performance of a radiopharmacy platform certification, EANM experience 
 Author: Philip H. Elsinga 
University Medical Center Groningen, University of Groningen, The Netherlands 
Corresponding author: p.h.elsinga@umcg.nl 
EANM organizes radiopharmacy courses within the Framework of ESMIT (European School of Molecular 
Imaging and Therapy). Besides several e-Teaching modules designated as a level 1 activity, ESMIT organizes 
training on level 2 and level 3. 
Regarding level 2, the EANM Radiopharmacy committee has established a European Postgraduate 
Specialization Certificate in Radiopharmacy. This certificate is available to anyone who completes a defined 
program of education and a two-year period of practical experience in the field. The program addresses 
chemists, pharmacists and other natural scientists working in the small-batch production or quality control of 
radiopharmaceuticals. The program is coordinated by members of Radiopharmacy Education Board in 
collaboration with ETH Zurich Switzerland. The program consists of 3 blocks of 2 weeks and includes Module 
1: Pharmacy and Legislation; Module 2: Radiopharmaceutical Chemistry and Module 3: Radiopharmacology 
and Clinical Radiopharmacy. 
This certificate is valid for a duration of 5 years. For the (re)certification process each certificate holder is asked 
to upload documents to the EANM Area on the EANM-website. Each document will be reviewed by the 
Radiopharmacy Education Board and if accepted, 5 points will be received per document. The recertification 
obligation has been started start Jan 1st 2019. Candidates who apply for the first time will receive the 
certificate as soon as they have all the documents needed and they fulfill all the requirements. Applicants who 
ask for a recertification of the existing certificate have to wait until the old certificate has expired before a new 
one will be issued. This counts also when the total of 20 points have been reached before the expiry date. A 
new certificate will then be issued – valid for another 5 years. 
Regarding level 3, the EANM Radiopharmacy committee organizes an interactive high-end course on GMP. 
The course focuses from the basics and fundamentals of Good Manufacturing Practice (GMP) through User 
Requirement Specification (URS), Validation, Deviations and Facility Planning. Moreover, Radiation Safety, the 
question how to build up and manage a quality risk management system will be covered in the course. 
Additionally it explains the increasing regulatory demands from laboratory work to clinical trials, going from 
laboratory notes to an Investigational Medicines Product Dossier (IMPD). The target audience includes 
Radiochemists and Radiopharmacists with the interest to increase the understanding of GMP and the 
consequences of different GMP related activities (e.g. persons who have attended the EANM Radiopharmacy 
Courses) but as well Pharmacists who wants to gain a better understanding for GMP in the context of 
Radiopharmaceuticals. 
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Education and qualification of radiopharmacists in Latin America 
Author: Ana Rey Ríos 
Corresponding author: arey@fq.edu.uy 
Radiopharmacy is an area with increasing development and technological complexity. According to WHO´s 
official documents (WHO Annex 2, Report 48 -TRS 986 and Annex 3 Report37 - TRS 908) the production of 
radiopharmaceuticals requires the supervision of qualified personnel with postgraduate training and 
appropriate experience in their function. Although most countries in Latin America have adopted these 
documents in their legislation the real situation is highly heterogeneous. Almost all countries have clear 
regulations regarding radioprotection. Many countries require a pharmacist for centralized and industrial 
radiopharmacies. However, specific qualification in radiopharmacy is not clearly specified in the national 
regulations and the adequate educational offer is very restricted. In Radiopharmacies operational level 1 or 2 
(according to IAEA´s Operational guidance on Hospital Radiopharmacy) technicians are frequently in charge 
without proper qualification or supervision of a Radiopharmacist. 
The overall situation regarding regulations on educational requirements for radiopharmacy is as follows: 
Argentina, Bolivia, Chile, Cuba, Ecuador, México, Paraguay, Perú and Uruguay have no legal requirements for 
radiopharmacies at operational level 1 and 2.  On the other hand Colombia, Costa Rica and Brazil require a 
responsible pharmacist in all types of radiopharmacies and also some kind of postgraduate specific education 
in radiopharmacy as well as continuous education of all personnel. 
The educational offer is also very heterogeneous in Latin America: only Brazil and Uruguay have specific pre- 
and postgraduate university options in radiopharmacy. Countries like Argentina, Mexico and Cuba have some 
elective pre-graduate courses or postgraduate in specific courses on nuclear techniques, while the rest of the 
countries have no educational offers at all, and professionals are trained either abroad or in the working place. 
Brazil offers postgraduate courses (480 hours or more) depending from which universities mostly in Sao Paolo. 
Uruguay offers since 2016 a postgraduate diploma of specialization in radiopharmacy having 300 hours of 
theoretical and practical lessons and 300 hours of supervised professional practice both in conventional and 
PET radiopharmacy. This programme is available not only for pharmacists but also for other professionals 
(chemists, biochemists) and for professionals coming from other countries due to the flexibility and 
personalized curricula. 
In conclusion, the educational offer in radiopharmacy in the region is insufficient and should be drastically 
incremented in the near future to fulfil international recommendations. Regional networking with support 
from IAEA is the way to achieve the internationally accepted standards. 
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Master’s degree in radiopharmaceutical sciences: step forward to enhance regional capacities in 
nuclear medicine in Africa 
Author: Naoual Bentaleb  
Department of Radiopharmaceuticals Production, National Centre for Nuclear Energy, Sciences and 
Technologies (CNESTEN) Rabat, Morocco. 
Corresponding author: naoualbentaleb@yahoo.fr//bentaleb@cnesten.org.ma 
Nuclear medicine is a multidisciplinary specialty in which medicine, physics and radiopharmacy are involved. 
The preparation of high-quality radiopharmaceuticals is the base for a high-quality nuclear medicine 
examination. Radiopharmaceutical science is a rapidly expanding field and there is strong demand for qualified 
professionals. To address the gap in human resources, and to enhance national and regional capabilities in 
nuclear medicine in Africa, a master’s degree in Radiopharmaceutical Sciences was developed in Morocco by 
CNESTEN in collaboration with the Faculty of Medicine and Pharmacy of Rabat and the INSTN- France with the 
support of the IAEA and AFRA. 
The master’s degree developed attempts to address the shortage of suitably trained radiopharmacists and 
professional radiopharmaceutical scientists in Morocco and French-speaking African countries by providing 
the knowledge and skills required in the field of diagnostic and therapeutic radiopharmaceuticals. 
In the framework of the AFRA project RAF6054 relating to Strengthening and Improving Radiopharmacy 
Services, several meetings were organized to prepare the Curriculum of the master’s project which was 
initiated in 2018. These meetings were attended by representatives of the IAEA, CNESTEN, the Faculty of 
Medicine and Pharmacy of Rabat and the INSTN- France to ensure that the program is in accordance with IAEA 
standards and reviewed for their technical and scientific integrity. After the accreditation of the program by 
the Ministry of Higher Education of Morocco, the courses were open for pharmacists, chemists, biochemists 
and biologists and were started officially in October 2019. The most theoretical courses will be done at the 
faculty of medicine and pharmacy of Rabat and also in CNESTEN. For practical sessions, CNESTEN’s 
radiopharmaceuticals production facilities as well nuclear medicine hospital facilities in Rabat and Casablanca 
will be used. The two industrial PET facilities would be also supportive to ensure practical training.  
The duration of the program entitled "Radiopharmaceutical Sciences” is two years. Each academic year 
consists of two semesters. The course is made up of 18 required modules and a research project on any aspect 
of Radiopharmacy. The modules are covering the fundamentals of development, preparation, testing and 
stability of radiopharmaceutical preparations, radiolabelled drug synthesis, scientific and regulatory issues in 
radiopharmacy, as well as providing a solid foundation in medical applications of radiopharmaceuticals. 
Radiopharmaceutical science and nuclear medicine are expanding fields and there is strong demand for 
qualified professionals in Africa. Education of radiopharmacists and professional radiopharmaceutical 
scientists is necessary at the University level to allow nuclear medicine and molecular imaging in Africa to 
reach its potential regarding their benefits and usefulness in the management of cancer and other diseases.  
The development of master’s degree in radiopharmaceutical sciences in Morocco is a big step forward to 
enhance regional capacities in nuclear medicine in Africa. 
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Developing, testing and installing e-learning system for radiopharmacy as a tool to harmonize 
education in a developing country 
Author: Emilija Janevik-Ivanovska 
Faculty of Medical Sciences, Goce delve University Stip, North Macedonia 
Corresponding author: emilija.janevik@ugd.edu.mk 
The main goal of our work is to create e-learning platform for master students (pharmacist, chemist, biologist 
physicist, physician and other with academic postgraduate diploma) and post graduate degree (PGD) for 
technologists working in the field of radiopharmacy and nuclear medicine. 
Basic education in radiopharmacy is an essential component of the scientific and technical background of a 
radiopharmacist and the inescapable route by which quality assurance in radiopharmacy can be implemented. 
The purpose of this study was to evaluate e-learning as a method to improve worldwide education in 
radiopharmacy and increase the awareness about concepts pertaining the quality of radiopharmaceuticals. 
To establish an e-learning platform designed as an innovative learning apparatus that, working alongside 
conventional teaching methods, integrates education in all aspects of radiopharmacy into the curricula being 
offered by universities at existing education and training institutions is the next step forward to the global 
recognition of the unified standards. 
In this study, a few lines of analysis for developing a suitable e-learning platform in radiopharmacy were as 
follows: 
• Course flexibility to improve access and personalization by students, 
• Rigorous definition of basic concepts and methods according to international standards, 
• Significantly decrease costs for education in radiopharmacy, 
• Enable fast practical implementation of theoretical concepts through virtual laboratory, 
• Building up a worldwide available, virtual repository of learning resources in radiopharmacy. 
Findings: 
⎯ Each module is designed as a “basic unit of knowledge”, comprising a group of minimum competencies 
and knowledge about a specific subject and used independently or in combination with other modules 
or training resources; 
⎯ Students can select the module and the time that best suits his/her professional needs for accessing 
the materials; 
⎯ Diversity and interactions between different educational contexts are exploited to increase 
harmonization and integration. 
Practical implications: two categories of practical implications important for implementation of the successful 
sustainable system of quality assurance could be envisaged as follows. 
Infrastructural: 
⎯ A new hardware infrastructure dedicated to radiopharmacy, 
⎯ Novel and upgradable e-learning solutions for education in radiopharmacy, Database and soft material 
repository: 
• Basic concepts, definitions, theoretical models and analytical methods, Virtual training in 
radiopharmacy practice, 
• Quality standards and quality assurance, 
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• Translational tools to adapt the e-learning platform to various educational systems. 
Originality and value: the present work is the first analysis to assess the feasibility of a global e-learning 
platform for education in radiopharmacy. It is expected that this approach would contribute to (a) overcome 
local differences in the interpretation of radiopharmacy practice and standards, (b) to spread worldwide 
knowledge in radiopharmacy, (c) to help harmonization of regulatory systems through education and (d) to 
implement good standard for quality assurance system. 
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The World Nuclear University’s WNU’s 7 approaches to enhance professional performance 
Author: Patricia Wieland 
Co-author(s):  Sarah Cullen, Silke Klassen 
World Nuclear University, London, UK 
Corresponding author: pat.ita.w@hotmail.com 
Building the next generation of experts in nuclear energy and the applications of nuclear science and 
technology is not an easy task. Identifying potential leaders in an expanding nuclear industry is even more 
challenging. The World Nuclear University (WNU) addresses these challenges by engaging educational 
institutions, nuclear industries, international organizations, professional associations and nuclear 
professionals of all ages in an ever expanding long lasting educational global network. WNU develops 
leadership and communication skills with dynamic methods in a unique international environment.  It provides 
the ‘big picture’ necessary to work in the nuclear sector at any level and promotes up do date and tacit specific 
knowledge transfer. 
WNU has contributed to the development of human resources in the nuclear area since its creation in 2003, 
in a relevant way. It has attracted participants to pursue careers in the nuclear area, has motivated many to 
gain more visibility in their field of expertise, engage with their peers, and to pursue more formal leadership 
roles.  
This paper describes the approaches WNU uses to enhance professional performance from selection of 
participants to long term evaluation, in a continuous improvement process. 
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Track: Production of PET- and SPECT-based diagnostic, therapeutic, and theranostic 
radiopharmaceuticals  
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Tc-99m octreotide in neuroendocrine tumours: a different radiotracer from traditional 111In: our 
experience 
Author: Mariela Agolti 
Co-author(s): Camila Aruga; Lucrecia Solari 
Centro Medicina Nuclear Clinica Modelo, Parana, Argentina 
Corresponding author: marielsmednuc@hotmail.com 
Tumours deriving from cell types expressing somatostatin receptors may be imaged by somatostatin receptor 
scintigraphy.  The most common radiotracer to bind octreotide is 111In, which is not produced in our country, 
as well as in other Latin American countries. Its cost is very high, its half-life is very long, and its availability is 
rare. We have started labelling Octreotide with Tc-99m, which is a more available and cheaper, and its short 
half-life let us work more easily. The basic mechanism is the union to receptors SST 2 and 5, is conserved. We 
have studied 27 cases during 4 years with this method, and the objective of this work is to share the results of 
our experience. We had cases of carcinoid small bowel tumour, ileocecal carcinoid tumour, stage IV 
paranglioma, Meckel type carcinoid tumour, pulmonary carcinoid tumour and septal appendectomy, carcinoid 
tumour of the cecum and terminal ileum, insular and trabecular carcinoid ovarian tumour and thymoma. 
We analysed 27 cases during January 2014 until March 2019 with Tc-99m Octreotide. The dose administered 
was 30 mCi, three hours after the injection, we made whole body images, SPECT the thorax and abdomen. 
After 20 hours we performed a second round of images with a single-headed GE Gamma Camera. Of the 27 
cases studied, we ruled out 5 cases because we could not do the correct follow- up. We divided the results 
into 18 positives and 4 negatives for the studies of neuroendocrine tumours. We correlated our results with 
the biopsy, when possible (21 studied cases) and the clinical follow-up of 5 cases (especially in the negative 
studies for active neuroendocrine tumours). 
Results showed that out of the 4-negative scintigraphy, 2 were negative at the close of this study. Out of the 
18 positive cases, 18 were confirmed by biopsy and follow-up, where 1 patient died of this disease or it’ s 
complications. These results show 18 true positives, and 2 true negatives, with a method that shows a 
sensitivity of 94.5% and a specificity of 100%. 
In conclusion, Tc-99m Octreotide appears to be cheaper, more available, and with less radiation dose for 
patients. It was performed during a day and more easily performed (with low energy and high-resolution 
collimator) as an alternative to 111In octreotide scintigraphy. With a very good sensitivity and specificity. 
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Preparation and preclinical evaluation of 64Cu-Nota-Anti Muc1 as a radioimmunoconjugate for 
diagnosis of Muc1+ breast cancer by pet 
Author: Behrouz Alirezapour1 
Co-author(s): Saeed Rajabifar1; Miad Hashemizadeh2; Ehsan Maadi2; Javad Mohamadnejad3 
1Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, ISLAMIC 
REPUBLIC OF IRAN 
2Pars Isotope Company, Tehran, ISLAMIC REPUBLIC OF IRAN 
3Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, 
Tehran, ISLAMIC REPUBLIC OF IRAN 
Corresponding author: balirezapour@aeoi.org.ir 
Radioimmunoscintigraphy (RIS) has attracted considerable clinical applications in tumour detection. 
Underglycosylated MUC1 antigen is one of the early hallmarks of tumour genesis and is overexpressed in more 
than 80% of breast cancers. PR81 is a new murine anti-MUC1 monoclonal antibody (mAb). In this study, as the 
first step, we have developed an efficient indirect labelling method of PR81 with 64Cu (T1/2 = 12.8 h, β+ = 
17%, β− = 39%, EC = 43%) through using NOTA (p- SCN-Bn-NOTA) bi-functional chelator and performed 
preliminary biodistribution studies in mouse bearing breast adenocarcinoma. 
PR81 was conjugated with NOTA (Macrocyclics B-605), the average number of the chelator conjugated per 
mAb was calculated and total concentration was determined by spectrophotometrically. NOTA–antiMUC1 was 
labelled with 64Cu then Radiochemical purity and immunoreactivity, internalization study by MCF7 cell line 
and serum stability of 64Cu–NOTA– anti MUC1 were determined. The biodistribution studies and 
radioimmunoscintigraphy were performed in female BALB/c mouse bearing breast carcinoma tumour (64Cu–
NOTA–antiMUC1 i.v., 100 μl, 20±5 μg mAb, 6, 12, 24 and 48 h). 
64Cu–NOTA–anti MUC1 was prepared (RCP >98% ± 0.4, specific activity 5.2 ± 1.2 μCi/μg). Conjugation reaction 
of chelator (50 molar excess ratio) to antibody resulted in a product with the average number of chelators 
attached to a mAb (c/a) of 4.1 ± 0.5. Labelling yield with 64Cu in 400µg concentration of bioconjugate was 
96.5% ± 2.1. Immunoreaction of 64Cu–NOTA– anti MUC1 complex towards MUC1 antigen was determined by 
RIA and the complex showed high immunoreactivity towards MUC1. In vitro and in vivo stability of 
radioimmunoconjugate was investigated respectively in PBS and blood serum by RTLC method. In vitro 
stability showed more than 94% ± 1.26 in the PBS and 81% ± 2.62 in the serum over 24 hours. The 
Immunoreactivity of the radiolabelled PR81 towards MCF7 cell line was done by using Lindmo assay protocol. 
Under these conditions, the immunoreactivity of the radioimmunoconjugate was found to be 0.82. The 
biodistribution of 64Cu–NOTA– anti MUC1 complex in the mice with normal and breast tumour at 6, 12, 24 and 
48 h after intravenous administration, expressed as percentage of injected dose per gram of tissue (%ID/g). 
Biodistribution and imaging studies at 24 h and 48 h post-injection revealed the specific localization of 
complexity at the site of tumours. 
64Cu–NOTA– anti MUC1 is a potential compound for molecular imaging of PET for diagnosis and follow up of 
MUC1 expression in oncology. 
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In house preparation and biodistribution of 64Cu-ATSM, 64Cu- PTSM and 64Cu-DOTATATE for 
theranostic application 
Author: Thaer Assaad  
Co-author(s): Abdul. H Al Rayyes; Mahmoud Al-Ktaifani 
AECS, SYRIAN ARAB REPUBLIC  
Corresponding author: thassaad@aec.org.sy 
In this work the radiolabelling and biodistribution of 64Cu-ATSM, 64Cu-PTSM and 64Cu-DOTATATE were carried 
out. A routine production method of no-carrier-added 64CuCl2 was performed through the nuclear reaction 
68Zn(p,αn) 64Cu from high current solid target. By using suitable proton energy, the amount of 67Cu had been 
neglected the end of synthesis which constitutes about 1%. High quality ATSM, PTSM and DOTA-TATE were 
synthesized in our laboratory and then characterized by NMR, FTIR spectroscopies and MS spectrometer. All 
compounds were successfully labelled with 64Cu and the radiolabelling yields of the labelled compounds were 
greater than 98%. Biodistribution of 64Cu- DOTATATE were performed at 0.5, 1 and 1.5 hours. Whereas the 
biodistribution of 64Cu-ATSM and 64Cu-PTSM were carried out at 1, 2 and 3 hours. The results show that 64Cu-
DOTATATE, 64Cu- ATSM and 64Cu-PTSM are rapidly and efficiently cleared from the blood.  Only less than 1% 
of the injected activity/g remains in blood pool. Normal 64Cu-DOTATATE biodistribution in kidneys increase 
and stabilize at 10% of the injected dose per gram at one-hour post injection. Whereas stabilize at 2.5 % of 
injected dose per gram in the liver healthy cells. 64Cu-ATSM shows a lower uptake in the myocardium than 
64Cu-PTSM. 
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Trends and perspectives in prostate-specific membrane antigen based radiopharmaceuticals in 
Mexico: the experience of the National University 
Author: Miguel A. Avila Rodriguez 
National Autonomous University of Mexico 
Corresponding author: avilarod@uwalumni.com 
The Positron Emission Tomography (PET) Center of the National Autonomous University of Mexico (UNAM) is 
a state-of-the-art molecular imaging facility. It was the first PET center in Mexico and nowadays it continues 
at the forefront in this field in the country. The cyclotron radiopharmacy facility of this centre produces a broad 
palette of radiopharmaceuticals for PET-based molecular imaging applications in oncology, neurology, and 
cardiology, maintaining for almost two decades the forefront of innovation in the field of PET imaging in 
Mexico. In 2014 we introduced in the country the use of 68Ga-labelled prostate-specific membrane antigen 
(PSMA) and given its high demand, and the exponential rise in the cost of the 68Ge/68Ga generators, it was 
recently decided to move to 18F-labelled PSMA. Currently, a research project is under way to evaluate the 
clinical use of 64Cu-labelled PSMA, a better imaging option when considering theranostic applications. The aim 
of this work is to highlight the versatility and possibilities to prepare PSMA binding agents labelled with 
different radionuclides with high yields and radiochemical purity (RCP), suitable for routine clinical 
applications. 
The preparation of 68Ga-PSMA-11 (68Ga-PSMA) was performed in an iQS module (ITG GmbH) using a generator 
of the same brand. Briefly, an aliquot of 100 µl containing 12.5 µg of PSMA-11 (ABX GmbH) was diluted with 
900 µl of 0.25 M NaOAc, mixed with 4 ml of 68GaCl3 (0.05 M HCl), and incubated for 10 min at room 
temperature. Purification was made by SPE using a Sep-Pak C18 cartridge. 18F-PSMA-1007 (18F-PSMA) was 
synthetized in a cassette-based automated synthesizer (Trasis GmbH). Briefly, the aqueous 18F-trapped on an 
ion-exchange cartridge is eluted with an ethanolic solution of tetrabutylammonium bicarbonate and 
evaporated to dryness.  The trimethylammonium PSMA-1007 precursor is added to the residue and labelled 
by nucleophilic substitution to yield the crude 18F-PSMA, which is then purified by SPE. For the preparation of 
64Cu-NOTA-Benzoil-NCS-HYNIC-iPSMA (64Cu-iPSMA), the iPSMA-conjugate was synthetized at the National 
Laboratory of Research and Development of Radiopharmaceuticals (LANIDER), and labelled with 64CuCl2 
produced via the 64Ni(p,n)64Cu nuclear reaction, using a labelling kit approach.  
The non-decay-corrected yields for 68Ga-PSMA and 18F-PSMA were 70±10% (n=10) and 40±5% (n=3), 
respectively, obtaining in both cases a RCP≥98%. The labelling yield of 64Cu-iPSMA was almost quantitative 
with a RCP≥97% (n=5), without the need of purification. 
Over the past few years PSMA-PET has become the gold standard method for the diagnosis of prostate cancer 
and it is especially useful to evaluate recurrent disease with low PSA levels. The introduction of 18F-PSMA will 
mitigate the “ups and downs” in the availability of 68Ga-PSMA because of the radioactive decay of generators, 
while 64Cu-iPSMA will be of great value to obtain late images that better suit theranostic approaches using 
PSMA binding agents. 
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Membrane interacting peptides as Positron Emission Tomography (PET) based infection imaging 
probes 
Author: Jyotsna Bhatt Mitra1  
Co-author(s): Archana Mukherjee1; Kumar Mukesh1; Dash Ashutosh1 
1Bhabha Atomic Research Centre, India 
Corresponding author: jyob59@gmail.com 
Ubiquicidin (UBI) or ribosomal protein S30 (RS30) is a result of post-translational processing of a 133-amino-
acid fusion protein Fau, consisting of an N-terminal 74-amino-acid polypeptide FUBI and the C-terminal 59 
amino acid RS30 polypeptide also known as Ubiquicidin. Fragments derived from the RS30/ubiquicidin are 
known to detect bacteria in-situ. UBI (29-41) has been labelled with 99mTc as well as 68Ga and 18F in order to 
develop single photon emission computed tomography (SPECT) agent and positron emission tomography 
(PET) based infection imaging agents respectively. A smaller fragment UBI (31-38) is also reported to show 
uptake in infectious foci. We set out to compare the potential of radiolabelled UBI (29-41) and UBI (31-38) 
fragments as PET based infection imaging probes with the aim of improving the sensitivity of detection. 
To facilitate 68Ga labelling, 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) conjugated 
peptide fragments UBI (29-41) and UBI (31-38) were utilized in the current study. Interaction of peptide 
conjugates was studied with bacterial as well as mammalian membranes models using isothermal titration 
calorimetry (ITC) and circular dichroism (CD). These peptide conjugates were labelled with 68Ga in order to 
develop PET based infection imaging agent and tested for radiochemical purity (RCP), serum stability and in-
vitro association with bacteria.  Bio-distribution of the 68Ga labelled peptides was carried out in mice bearing 
infection to understand the pharmacokinetics of these agents. 
Both peptides selectively interacted with bacterial membrane model (anionic) and not with mammalian 
(neutral) membrane models. UBI (29-41) interacted more strongly with bacterial membrane model as 
compared to the octapeptide UBI (31-38). Stronger interaction of UBI (29-41) with bacterial membrane model 
could be explained by greater propensity to form helix in a “membrane like environment”. Both peptide 
conjugates could be labelled with 68Ga, with high RCP. 68Ga labelled peptide conjugates were found to be 
comparable in terms of in-vitro association with bacteria and biodistribution in mice bearing infection. 
In conclusion, our results indicate that NODAGA-UBI (29-41) was superior to NODAGA-UBI (31-38) with respect 
to binding bacterial membranes. 
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99mTc(N)(DASD)(pnpn)]+ (DASD=1,4-dioxa-8-azaspiro[4,5]decandithiocarba 
pnpn=bisphosphinoamine) for myocardial imaging 
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99mTcN-DBODC5 ([DBODC = bis(N-ethoxyethyl)-dithiocarbamate; 5 = bis(dimethoxypropylphosphinoethyl)- 
ethoxyethylamine]) is the lead candidate of a series of heteroleptic monocationic proposed compounds, for 
their favourable biodistribution profile, as myocardial perfusion imaging agent (MPIA). Phase I clinical studies 
clearly showed that its clinical properties were comparable to those of the commercially available agents. 
Therefore, direct modification of 99mTcN-DBODC(5) to increase its pharmacokinetic profile, by obtaining an 
ideal myocardial imaging without interference from the adjacent organ activities, would be desirable. This 
work describes the synthesis, characterization and the biological evaluation of four new cationic 99mTc-nitrido 
complexes, of general formula [99mTc(N)(DASD)(PNPn)]+(DASD=1,4-dioxa-8-azaspiro[4,5]decan 
dithiocarbamate; PNPn=bisphosphinoamine), abbreviated to 99mTcN-DASD(n), proposed as improved MPIAs. 
99mTcN-complexes were synthetized by a two-step reaction. The chemical nature of the compounds was 
determined by carrier-added experiments supported by radio/UV-HPLC and LC-MS analyses. Mechanistic 
studies were performed in-cellulo by using drug sensitive human cancer cell lines and the corresponding drug 
resistant sublines and in-vivo. Biodistribution studies were performed in rats and compared with the 
distribution profiles of 99mTcN-DBODC(5) and 99mTc-Sestamibi. The in-vitro and in-vivo metabolisms of the best 
compounds were evaluated by chromatographic methods. 
99mTcN-DASD(n) compounds were obtained in high yield. Biological studies revealed that the complexes have 
a fast high initial and persistent heart uptake with rapid clearance from non-target tissues. Among the tested 
compounds 99mTcN-DASD(5) and 99mTcN-DASD(7) showed improved heart uptake with respect to the gold 
standard, with a rapid liver washout and superior heart-to-liver ratio. Cellular and in-vivo studies 
demonstrated that the compounds are membrane potential responsive and are avidly transported by Pgp-
MRP1. Metabolism studies evidenced a remarkable in-vivo stability of these agents. 
99mTcN-DASD(5) and 99mTcN-DASD(7) are promising MPIAs. The rapid pharmacokinetic profiles might shorten 
the duration of imaging protocols below 30 min allowing the early acquisition of images with high quality. In 
oncological field, the advantage of the in-vivo pharmacokinetic profile can also be applied to tumour imaging. 
  
ISTR–2019 
 
143 
 
Clinical indications and labelling procedures influencing in vitro stability and early myocardial 
uptake of 99mTc-tetrofosmin 
Author: Salah Eddine Bouyoucef1 
Co-author(s):  Amel Fellah2; Amel Taïbi2 
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Corresponding author: as.taibi@yahoo.fr, salaedine@yahoo.fr, benbetka.amel@yahoo.com 
99mTc tetrofosmin is a lipophilic cationic agent (diphosphine group) used for imaging myocardial perfusion 
during stress and at rest. The myocardial uptake of [99mTc] tetrofosmin appears to occur by a passive diffusion 
process. However, the uptake and retention curve models of 99mTc tetrofosmin by myocardial tissue are not 
well established. Particularly early images for myocardial perfusion imaging and stability of [99mTc] tetrofosmin 
are not well defined. 15 preparations of [99mTc] tetrofosmin and 40 patients have been used to study the 
different parameters that are part of the process of labelling in order to study the stability of [99mTc] 
tetrofosmin and its early uptake at 5 minutes by myocardial muscle. The studied parameters were the pH, 
temperature of storage, time of agitation and the way of intravenous injection. Radiochromatography was 
performed at different times during 6 hours and early myocardial uptake was estimated by the ratio 
heart/mediastinum uptake. Early results confirm that constant agitation and storage temperature are 
influencing the in vitro stability of [99mTc] tetrofosmin meanwhile clinical indications and the PH of the injected 
solution of [99mTc] tetrofosmin are influencing the early uptake of [99mTc] tetrofosmin by the myocardium. 
  
ISTR–2019 
 
144 
 
Development, characterisation and in vivo evaluation of two 68Ga- labelled NPY analogues as 
potential tracers for breast cancer imaging 
Author: María Elena Cardoso Moreno1  
Co-Authors1: Kevin Zirbesegger; Leticia Fernández; Eduardo Savio; Mariella Teran Gretter; Ana Maria Rey 
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Receptor targeting with radiolabelled peptides has gained attention in nuclear medicine since these are over-
expressed in many proliferative processes. In particular, researchers found that Neuropeptide Y (NPY) type 1 
receptor is over-expressed in 90% of breast carcinomas. 
The aim of the present study was to develop and characterise two 68Ga-labelled NPY analogues with potential 
application in breast cancer imaging. Two peptides were used (L1, L2), both having the active sequence (Tyr-
Arg-Leu-Arg-BPA-Nle-Pro-Asn-Ile-OH), NOTA as a chelator and a molecule of lysine as a spacer. 
The amino acid sequences of both peptides are identical but L2 has an acetyl group (–COCH3) in the amino 
residue of the spacer (L1: H-Lys(NOTA)-Tyr-Arg-Leu-Arg-BPA-Nle-Pro-Asn-Ile-OH) (L2: Ac-Lys(NOTA)-Tyr-Arg-
Leu-Arg-BPA-Nle-Pro-Asn-Ile-OH). 
Each peptide (100 µg, 5.85x10-5 mmol) was incubated with [68Ga]GaCl3 (60-100MBq,0.2 mL), at pH 4.5 and 
95ºC for 10 minutes. Physicochemical characterisation included: radiochemical purity (RCP) assessed by RP-
HPLC, lipophilicity (through partition coefficient between octanol and phosphate buffer pH 7.4), plasmatic 
protein binding (PPB) by size exclusion. Stability in plasma and in labelling milieu was assessed up to 2 hours. 
Challenge with 100 molar excess of diethylenetriaminepentacetic acid (DTPA) was performed by HPLC. 
Biological behaviour was evaluated in accordance to the University Ethics Committee regulations, in female 
nude mice bearing MCF7 cancer xenograft induced with 1x106 cells injected subcutaneously into the right 
hind leg. Tumour was allowed to grow 4 weeks up to an average mass of (0.07+0.02)g. Biodistribution was 
determined one hour post injection of each tracer. 
Both complexes were obtained with RCP higher than 95% and were stable in plasma and in reaction milieu. 
Log P values were (68Ga-L1=- 3.2+0.1) and (68Ga-L2 =-2.6+0.1). Protein binding values were (31.7+0.4) % for 
68Ga-L1 and (20.1+0.3)% for 68Ga-L2. Challenge with DTPA, in both cases showed high stability and no trans-
chelation of the gallium for up to 2 hours. 
Both complexes showed low blood and muscle uptake and high renal excretion, 68Ga-L2 higher uptake in liver 
and kidneys compared to 68Ga-L1. The target/non target ratio expressed as % of injected dose/gram) was 
(3.5+0.4)% for 68Ga-L1 and (4.7+0.4)% for 68Ga-L2. 
Labelling strategy was adequate for obtaining both complexes with high RCP and remarkable in vivo stability. 
Even though both complexes showed similar behaviour, 68Ga-L2 was less hydrophilic and had lower PPB value 
compared with 68Ga-L1, probably due to the addition of the acetyl group to the amino group of the spacer. 
Biodistribution studies showed that renal elimination is the main route of excretion in both cases. Although 
tumour uptake is moderate favourable T/nT ratio encourages performing further studies in cell lines in order 
to conclude about the potentiality of both tracers as promising radiopharmaceutical for breast cancer imaging. 
Acknowledgements: ANII (POS_NAC_2016_1_130455), Pedeciba-Química. 
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 89Zr is one of the emergent isotopes due to the favourable PET imaging characteristics (β+max 0.395 MeV; 
22.7%) and half-life (T½78.4h) ideals to label antibodies. Monoclonal antibodies (MAbs) are the most approved 
biopharmaceutical in the word with a multiple and selective target. The immune PET can facilitate the approval 
for new MAbs and can help on patient selection. Due to needs of a robust production, purification and labelling 
procedure, it should be optimized on automatic modules in order to minimize the operator dosimetry and 
increase the reproducibility. 
The aim of this work is based on an easy modification of automatic, cassette base, and commercial module in 
order to dissolve and purify the 89Zr, in both formulations currently used from sputtered target. The single use 
cassette reduces the possibility to accumulate metal impurities in the purification step due to missing 
mandatory cleaning steps on synthesis modules, based on fixed tubes technology. 
An Eckert&Ziegler cassette base module were used to set up an automatic dissolution and purification 
procedure. The Sputtered 89Y targets were bombarded on TR-19 cyclotron at 12.5 MeV without degrader at 
different current 20-60 µA for a variable time 30-240 minutes. The coins were transferred on dedicated coated 
hot cells and finally inserted on a EZAG module in order to dissolve and purify the [89Zr]/[89Y] material in a 
single use cassette. A 2 N HCl solution was used to dissolve the target material, the solution was transfer to ZR 
resin (Triskem) and recovered on vial in oxalate or chloride form. 
Ten sputtered targets were processed after bombardment and final impurities profile were evaluated by γ-
spectrometry and by ICP-MS. 
In conclusion, what we described on this work is one of the possible ways to optimize the 89Zr production 
starting from 89Y sputtered target, with a simple and single use cassette recovery process based on EZAG 
module to minimize the impurities. 
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Over the past years, many different PET agents have been developed to investigate on prostate cancer (PC) to 
make the non-invasive approach a reality, in order to replace the biopsy and the related complications. The 
PC is the most common cancer that affect the male population. Due to the high incidence of this pathology, is 
mandatory to investigate on a fluorine-18 tracer that gives the possibility to overcome the gallium-68 tracers’ 
limitations. 
During the last year we have optimize a [18F]FPSMA1007 synthesis HPLC free on Ge FASTLab® module and 
related HPLC control. The aim of this study is to show the results of the routine productions in terms of yield 
and quality control by evaluation of two elution solutions (TBAHCO3/ACN or K222/ACN/K2CO3) and two HPLC 
methods. The reference one, based on Eclipseplus C-18 and a new one based on Ascentis express Peptide Es 
C-18 column. 
The synthesis method is based on one step synthesis using a new precursor commercialized by ABX and is 
tuned on Ge FASTLab® synthesizer. All the reagents are included on a single use cassette. The 18F was trapped 
on QMA and eluted with a mixture of TBAHCO3/ACN or K222/ACN/K2CO3. After drying at 125℃ on synthesis 
reactor, the dissolved ABX precursor in DMSO was added to proceed with the nucleophilic [18F]-Fluorination. 
The reaction mixture was heated up at 95℃ for 10 min the reaction step, then the mixture was cooled at 35℃ 
to start the purification step followed by formulation. The total process takes place on 37 minutes. 
HPLC analysis was performed on an Agilent 1260 Infinity HPLC equipped with an Agilent 1260 UV detector and 
a Raytest gamma-ray detector, controlled with OpenLAB. The analysis was performed on a 4,6x100 Eclipse 
Plus C18 3,5μm (Agilent) in isocratic conditions using CH3CN and 0.1 % TFA (70/30 run time 15 min) flow 0.8 
ml/min and on 4,6x150 Ascentis express Peptide Es C-18 2,7um flow 1.3 ml/min in gradient methods using 
CH3CN and a solution of dihydrogen phosphate and phosphoric acid. 
Two different elution solutions were used to compare the final process yields, at the same time, high activity 
runs were performed, in different inlet activity range, to evaluate the yield and product stability in final 
formulation. For stability study a range of 1-2.5 GBq/ml radioactive concentration was evaluated at room and 
at 40℃ for up to 12h. According to the final product formula specifications, the synthesis yield was stable in a 
range 35-55 % at the inlet activity range (55-185 GBq) with a very high Am (800-3500 GBq/µmol) at EOS. 
The radiochemical purity for all the runs were always higher than 95%. The chemical HPLC profile shows 
differences in separation for the FPSMA1007, OHPSMA1007 HPSMA1007 and reaction precursor that make a 
difference in the chemical purity evaluation. 
All the performed synthesis by using the K222 elution solution shows slightly lower yield compared to TBA. At 
the same time only the HPLC methods based on Ascentics column allow to have a right chemical purity 
evaluation due to more efficient peak resolutions. 
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Limited access to high specific activity Lu-177 in India and its cost provides necessary impetus for the present 
work on the development of Lu-177-DOTA-Rituximab by using low specific activity Lu-177. Based on the 
advantageous/favourable nuclear properties of Lu-177 over the I-131, the development of Lu-177-DOTA-
Rituximab was obviously pertinent. Towards this we attempted to optimize the radiolabelling of Lu-177-DOTA-
Rituximab using low specific activity (<15 mCi/µg) and carrier added Lu-177-Chloride. The physicochemical, 
biological quality control parameters, in vitro stability, immunoreactivity and cell binding studies were carried 
out in Daudi cell-lines. In vivo biodistribution studies were also carried out in suitable animal models. 
Lu-177-Chloride was produced at our research reactor. Rituximab(10mg/mL) pre-concentrated from 500µL to 
100µL using 30kDa MW cut-off filtration device at 5000rpm for 22minutes. Coupling of rituximab (5mg/100µL, 
34.75nM) with p-NCS-benzyl-DOTA (240µg/24µL, 347.56nM) carried out at 1:10 molar ratio incubating at 
37degC for 22hr. The conjugated reaction mixture purified using preconditioned PD-10. The DOTA-benzyl-
Rituximab eluted from PD-10 using 0.2M sodium-acetate buffer(pH~5.5) and its concentration was estimated 
by Bradford’s assay at 570nm. Prior to radiolabelling, pH of Lu-177-Chloride (285-300mCi in 250-275µL) 
adjusted to 6.5-7.0 using 0.2M sodium-acetate solution. Lu-177-Acetate incubated with 124µL of DOTA-
benzyl-Rituximab at 37degC for 80 minutes. After incubation the radiolabelled reaction mixture was purified 
using PD10 (pre-conditioned with 0.2M sodium-acetate solution). In-vitro stability of the Lu-177-DOTA-
Rituximab was ascertained by adding ascorbic acid (40mg/0.5mL of 0.2M sodium-acetate solution). The RCP 
was evaluated using TLC-SG {(0.1M sodium-citrate buffer(pH-5.0)}and HPLC (size-exclusion column, 0.05M 
phosphate- buffer, pH~6.8). Gel-clot BET-assay and sterility test were performed. 
Human Leukemia cell-line Daudi expressing CD20, used for in-vitro evaluation, grown in IMDM with 10%FBS 
at 37C. In-vitro cell-binding studies performed by incubating Daudi cells in 1mL of internalization buffer 
(IMDM, 0.2%BSA) containing radioligand (~5pmol peptide) for 15, 30, 60 & 120 minutes and washed with PBS. 
Non-specific internalization assessed by addition of cold rituximab (5nmol). For membrane receptor binding 
assay, cells homogenates were incubated at above time points. Biodistribution studies carried out in Daudi 
cell-lines xenograft tumour bearing nude mice at 6h, 24h, 48h & 72h intervals and quantified by γ-
spectrometer. 
Using Lu-177 of low specific activity (< 15 mCi/µg), 60-65mCi of Lu-177-DOTA-Rituximab (single patient-dose) 
was prepared using ~300mCi of Lu-177-Chloride. Lu-177-DOTA-Rituximab was found to be clear, colourless, 
pH between 5.5-6.0 and RAC between 8-10 mCi/mL. The RCP of Lu-177-DOTA- Rituximab estimated by TLC 
was >98% with retention-factor 0.00-0.10. RCP derived by HPLC was >95% with retention-time of labelled 
product between 14.5–15.5minutes. EL <6EU/mL, radiopharmaceutical was sterile. In-vitro and serum stability 
of the product indicated stability up to 96hr upon storage at -20C with stabilizer. 
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Lu-177-DOTA-Rituximab showed rapid binding in Daudi cells (25%), reaching a plateau after 30 - 60 minutes. 
In biodistribution study, radioactivity decreased from most organs after 24h post-injection. High uptake and 
long-term retention of radioactivity found in tumour model which corroborates with scintigraphy studies. 
Single patient dose of Lu-177-DOTA-Rituximab could be produced in optimum yield using 12-15 mCi/µg Lu-
177. The product compares well with the preparation documented using NCA Lu-177. Further studies towards 
clinical translation of this promising radiopharmaceutical in patient are underway. 
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Meta-iodobenzylguanidine (MIBG) radioiodinated with 123I, and 131I is one of the most important 
radiopharmaceuticals used in nuclear medicine. It is used for diagnosis and treatment of pheochromacytoma 
and neuroblastoma, imaging of adrenal medulla, and for studying heart sympathetic nerves. Almost described 
methods of synthesis of cold meta-iodobenzylguanidine hemisulfate are performed in accordance to Wieland 
and al procedure (1980), by condensation for 4 hours of meta-iodobenzylamine hydrochloride with Cyanamid 
into an oil bath heated at 100℃. This method seems to be long and difficult to implement for routine 
production. 
The objective of this study was to develop an efficient and rapid method for preparing MIBG. Various 
experiments in order to reduce the time of the synthesis were carried out by heating in an oven a mixture of 
meta-iodobenzylamine Hydrochloride and cyanamide at 120℃ during several times. The second step was 
done according to Wieland’s method. We have also studied the effect of the reaction time on the yield of 
meta-iodobenzylguanidine bicarbonate. 
Physicals and chemicals properties of synthetized MIBG was evaluated by the determination of melting point, 
UV-Visible spectrophotometry, spectroscopy IR and HPLC. 
Results showed high purity of synthesized molecule with yields similar to those obtained by Wieland and al 
(70%) and purity over 98 % after 30 min of reaction at 120℃. The HPLC analysis of MIBG gives a good retention 
time. 
A procedure for radioiodinated of cold m-iodobenzylguanidine with iodine-125 has been developed in our 
laboratory. Freeze-dried kits prepared from MIBG (synthesized and reference), ascorbic acid and copper 
nitrate were reconstituted in deaerated distilled water and labelled with 9-18 MBq of sodium iodide (NaI-125). 
The vials were heated in an oil bath at 100 °C for 20 minutes. 
The labelled MIBG kit presents a very high radiochemical purity and a high labelling efficiency.  
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Currently sentinel lymph node (SLN) dissection is an important procedure alongside to the tumour removal 
surgery especially for breast cancer. In general, SLN can be localised with blue dye or radiocolloid. In nuclear 
medicine, several types of radiocolloid have been utilised such as 99mTc sulfur colloid, 99mTc nanocolloid 
including 99mTc dextran. One of the critical factors that influence the detection is the particle size of the 
radiocolloid because kinetic of the lymphatic system is strongly dependent on the size of colloid. The 
appropriated size should be less than 100 nm. Regarding costs of the commercial radiocolloid, the in-house 
radiocolloid has been required. Then, aims of this study were to develop and characterise the in-house 
radiocolloid kit for SLN detection.  
The in-house dextran kit was developed in a kit form which was contained dextran and reducing agent. Then 
0.5 mL of the solution was dispensed into the evacuated vials and stored at -20oC until use. Approximately 3, 
5 and 10 mCi Na99mTcO4 was labelled with the dextran kit in triplicate before the radiochemical purity (RP) was 
determined at 15 min, 3 h and 6 h post radiolabelling by instant thin layer chromatography (ITLC). The ITLC-
silica gel and methyl ethyl ketone was used as a stationary and mobile phase, respectively. The size of the 99mTc 
dextran was evaluated by using transmission electron microscope. To examine the shelf life, 3 frozen dextran 
kits were labelled with Na99mTcO4 5 mCi at 1, 3, 6 and 12 months after kit production and analysed for the RP. 
SLN detection using 99mTc dextran in breast cancer patients was retrospectively enrolled and compared with 
the blue dye technique. 
The radiochemical purity of 3, 5 and 10 mCi 99mTc dextran were not altered after radiolabelling for 15 min, 3 h 
and 6 h which were greater than 98%. The transmission electron microscope result showed the non-uniformity 
of aggregation to form colloid with the diameter range of 15 nm to 40 nm offering the advantage for SLN 
detection. At the different storage times of 1, 3, 6 and 12 months, the RP results were 97.58 ± 0.33, 97.79 ± 
0.52, 97.88 ± 0.33 and 98.09 ± 0.43, respectively. The concordance between blue dye and 99mTc dextran to 
detect SLN was comparable.  
The in-house dextran kit showed a greater radiochemical purity than 98% over 6 hours post radiolabelling with 
the Na99mTcO4 activity up to 10 mCi. The optimum particle size was revealed. Its shelf life was up to 12 months. 
SLN detected by in-house radiocolloid was comparable to that of blue dye in breast cancer patients. Therefore, 
low cost in-house kit could be used in the routine service for sentinel lymph node detection. 
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Neuromedin N is a hexapeptide that shares the 4 amino acid Pro-Tyr-Ile-Leu homology with neurotensin and 
exhibits neurotensin-like effects in malignant glioma cells. Neuromedin B is a bombesin like peptide which 
specifically binds to BN receptors widely expressed in central nervous systems and in peripheral tissue and 
organs. This study was aimed to select and characterize the most effective Neuromedin peptide to target 
glioblastoma U87MG cancer cells. 
DOTA-Neuromedin N and B were labelled with 68Ga obtained from a 68Ge/68Ga generator, in order to quantify 
their ability to bind to their specific receptors expressed on glioblastoma U87MG cancer cells. The selective 
binding of peptides was characterized and their binding capacity towards NT receptors and BN receptors 
previously reported on U87MG cell line was tested. The influence of synthesis parameters like reaction time, 
evaporation time and pH upon overall process indicators and quality parameters of the final product were 
studied. The synthesis method has been translated to an automated synthesis module, which lead to a 
shortening of the process time, consistent high yields (>85%) and radiochemical purity greater than 90% for 
both radiotracers. The stability of the radiolabelled peptides was assessed up to 4h post-synthesis. 
Comparative preclinical in vitro assay of the cellular uptake–retention curves on U87MG cancer cells was 
performed in order to determine the time from incubation and peptide concentration at which the receptors 
are saturated, and to evaluate the retention profile over time. Specific binding of both peptides was 
characterized by selectively antagonized receptors blocking with SR 142948/48692 and NTRC 824 antagonists 
for neurotensin receptors and PD 176252/ML18 for bombesin receptors respectively. The results showed over 
60% retention of 68Ga-DOTA-Neuromedin B stable up to 80 minutes from incubation and more than 50% 
retention for 68Ga-DOTA-Neuromedin N. The preliminary in vivo investigations (biodistribution and PET 
imaging) using both 68Ga-DOTA-Neuromedin B and 68Ga-DOTA-Neuromedin N on glioblastoma bearing mice, 
at 30 min and 60 minutes post-injection, have shown promising results for glioma malignant tissues imaging. 
Acknowledgements: this work was supported by a grant of the Romanian Ministry of Research and Innovation 
UEFISCDI project number 64PCCDI/2018. 
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Prostate cancer is the second most prevalent cancer worldwide. 177Lu-PSMA-617 has emerged as a useful 
therapeutic modality in the management of metastatic castration-resistant prostate cancer. The present work 
describes a ready-to-use 177Lu-PSMA-617 injectable formulation of the produced therapeutic 
radiopharmaceutical by using medium specific activity 177Lu (> 15 Ci/mg) and evaluated for its integrity and 
performance three days post its preparation. 
The radiolabelling procedure was optimised typically for 10.0 GBq dose; by heating 177LuCl3 (corresponding 
0.1-0.2 mL; Sp. Act. > 555 GBq/mg) with commercially available (CMR, Russia) or indigenously synthesized 
PSMA-617 peptide (2.0-2.5 equiv.) in sodium acetate buffer (pH 5.0; 0.6 mL) containing sodium ascorbate (2 
mg) at 95℃ for 15-20 min. The crude radiolabelled product was then passed through Sep-Pak C18 purification 
assembly to yield the final product in ethanol which was diluted with 0.1 M sodium acetate buffer containing 
2% sodium ascorbate to reduce the final ethanolic content below 10%. The diluted radiopharmaceutical was 
then sterilized by membrane filtration and dispensed as a single patient dose (7.4 GBq) with activity calibration 
of 2 days. The preparation was then stored at -20℃ and shipped under dry ice conditions. 
Peptide to metal ratio and pH of the reaction mixture are key factors responsible to achieve high radiolabelling 
yields (> 95%) and hence recoveries of the radiolabelled product post C18 purification. Out of 15 batches, only 
one batch, recovery yield observed was less than 95%. The labelled product, at a radiochemical concentration 
of the range of 740 ±74 MBq/mL (0.1 M sodium acetate buffer with 2% sodium ascorbate) was found to be 
stable for 9 days when stored at -20℃. Ten clinical studies were carried out in diseased patients with activities 
in the range of 5.55-7.40 GBq by using ready-to-use formulation. 1- 3 days post its formulation, it showed an 
affinity towards the lesions with symptomatic relief to the patients. 
A new ‘ready-to-use’ 177Lu-PSMA-617 formulation has been developed and validated for its end-use up to 
three days post its formulation. Clinical effectiveness studies showed a positive response in a limited number 
of diseased patients. 
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68Ga-DOTA peptides, somatostatin analogs, are used for neuroendocrine tumours diagnosis. Commercial kits 
of 68Ga-DOTATATE are available for this indication with an expansive supply. The aim of this study is to evaluate 
the impact of a switch from commercial kits to a hospital production of 68Ga-DOTATOC. 
To synthetize this radiopharmaceutical in our laboratory, a quality dossier has to be submitted to the local 
authority, Swissmedic. In this dossier, we must describe the synthesis and quality control (QC) methods and 
validate them on three batches. Synthesis was done with Mini AiO® synthesis module (TRASIS, Belgium). For 
each batch, all QC required by European Pharmacopeia (8th edition) were performed. Moreover, an additional 
filter integrity test was done with Mini AiO® to assess the sterility of the synthesis process. Then, the synthesis 
of 68Ga-DOTATOC was compared to 68Ga-DOTATATE kits in regard to costs and time of production. 
On validation batches, activity yields were 84.4% ± 6.31%. All QC parameters were in conformity with the limits 
prescribed by the pharmacopeia monography. Calculated radiochemical purity was 99.36% ± 0.15% and 
residual ethanol measured was 7.77% ± 0.83%. Microbiological analyses (sterility and endotoxin) showed that 
the entire synthesis process allows sterility conditions. Furthermore, filter integrity test was successful for all 
batches. 
Synthesis module is in a hotcell with a microbiological class A with a regular microbiological monitoring. 
Sedimentation plate and filter integrity test are also performed before pharmaceutical release. Based on these 
parameters, sterility and endotoxin analyses will be performed only on validation batches and every 6 months. 
On one hand, synthesis and QC control of 68Ga-DOTATOC are longer than 68Ga-DOTATATE kits respectively 60 
minutes vs 30 minutes and 130 minutes vs 15 minutes. Indeed, more QC are needed for 68Ga-DOTATOC (HPLC, 
GC) whereas only PRC determination by TLC and pH measurement are required for 68Ga-DOTATATE kits. Thus, 
additional human resources and materials are necessary for hospital production. 
But, on the other hand products for 68Ga-DOTATOC synthesis are cheaper than 68Ga-DOTATATE kits. Based on 
a number of 130 synthesis per year scheduled by the nuclear medicine department, hospital production allows 
to obtain human resources and an important saving for the institution. 
68Ga-DOTATOC is conveniently prepared in sterile conditions by using Mini AiO® synthesis module with high 
radiochemical purity (> 99.3%) and enough final activity for 2-3 patients in a single batch. The advantageous 
costs saving compared to the commercial kits available in Switzerland prompt to extend this work to other 
68Ga radiotracers. 
Moreover, radioprotection benefits of automatized synthesis vs manual preparation of commercial kits could 
be assessed in a future study. 
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There are usually no complaints and symptoms in the early-stage of cancer where the patient is not aware of 
the presence cancer in their body. The spread of cancer cells could be prevented if known earlier. One of the 
early methods of cancer detection which is currently being developed is a technique in nuclear medicine by 
using radiopharmaceuticals. A radiopharmaceutical has two components: a radionuclide and a 
pharmaceutical. Technetium-99m has a half-life of 6 hours and a pure gamma ray transmitter (140 KeV) for 
diagnosis. Mangosteen is isolated from the pericarp of Garcinia mangostana L which is a widely developed 
anticancer activity. α-mangosteen, and γ-mangosteen compounds have anti-cancer effects in cancer cell 
proliferation disorders; so α, γ-Mangosteen is expected to be a carrier that will bind technetium-99m to cancer 
cells. This study has aimed to determine optimal labelling conditions α, γ-mangosteen with technetium-99m 
radionuclides. Determination of pH conditions, the number of reducers, the number of ligands used, and the 
variation of incubation time is essential to produce optimal labels. We labelled α, γ-mangosteen with 
technetium-99m by using a directed method. The result showed that the optimum condition for 99mTc-
mangosteen were 500 μg mangosteen, 20 μg SnCl2.2H2O, 20 µL tween 80 (0,1%), pH 8 and 5 minutes 
incubation time at room temperature. 99mTc-mangosteen has a radiochemical purity of 99.41 ± 0.04% with 
stability for 3 hours which has fulfilled the requirements (more than 90%). Based on the results of 99mTc- 
mangosteen compounds above are expected to be used for early detection of cancer. 
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68Ga-prostate-specific membrane antigen (PSMA) radioligand diagnostic is a novel diagnostic option in 
patients with metastatic prostate cancer. The aim of this work was to standardize an efficient automated 
synthesis method for radiolabelling radiopharmaceutical-grade 68Ga-PSMA for PET/CT diagnosis of prostate 
cancer. 
We employed PSMA-HBED-CC (PSMAHBED) peptide manufactured according to GMP requirements (purity 
>96%) obtained from ABX (Advanced Biochemical Compounds) and 1850 MBq ITG 68Ge/68Ga generator 
consisting of organic-matrix column metal free. Sodium acetate, ascorbic acid, NaCl, HCl Ultrapur and EtOH 
was obtained from Merck. 
Automated synthesis module “Taddeo” from COMECER was installed in a shielded Hot cell and used for 
radiolabelling. The 68Ga solution was eluted from the generator with 7mL of 0.1M HCl at a flow rate of 
2.5mL/min and transferred to a PS-H+ column and eluted with 5M NaCl (1.8mL). The total 68Ga activity 
(1400MBq) were transferred directly into the reaction vessel containing 5µg PSMA-HBED-CC peptide, 
dissolved in 1mL of Acetate buffer 1.0M with pH 4 and Ascorbic acid 10µL, heated to 92oC per 8 min. To process 
the radiolabelling product Strata-X-tubes pre-conditioned (Phenomenex) were used. The 68Ga-PSMA-HBED-CC 
was retained and unreacted 68Ga passed through into a waste vial. The Strata-X-tubes were then washed with 
5mL of pure water and the 68Ga-PSMA HBED-CC was recovered with 1.2mL EtOH/Water (1:1) followed by 10 
mL of 0.9% saline. Finally, the product was sterile-filtered under aseptic conditions through 0.22µm membrane 
filter (Milex-GV, Millipore) and the activity was measured in a Capintec-CRC-15R dose calibrator. 
The radiochemical purity and identity of the 68Ga-PSMA solution was assessed by RP-HPLC equipped with a UV 
and ɤ detector. A Lichospher-100 column C-18 (25mm x 4.6mm, 5µm) was used as a stationary phase. The 
mobile phase was as follows: 0-0.5min: 95%B; 0.5-10min: a linear gradient 80% A, flow rate 2ml/min (6). 
Retention times were 1.5- 2.0 min for free 68Ga (III) and 4.9- 5.1 the themodynamically more stable 
diastereomer (RR), 5.2- 5.4 the thermodynamically less stable. 
An indicator strip was used for the pH analysis of the 68Ga-PSMA dose and the Bacterial endotoxin content was 
analysed using an Endosafe R system (LAL test), the values limit was <175/IU/ml. The sterile filter integrity test 
of the 68Ga-PSMA solution was performed with a limit value >50psi 68Ge-contamination was detected and 
quantified using a gamma counter (at full open window and at a 1min measurement time) retaining the 
preparation for at least 48h to allow 68Ga to decay to a level allowing the detection of the impurities. The total 
radioactivity due to 68Ge must not be >0.001% referred to the original activity. 
Radionuclidic identity and purity tests were performed by gamma-ray spectrometry and the principal gamma 
peaks analysed, energies of 511Kev and 1077Kev were only allowed. The physical half-life was measured 3 
times using a Capintec-CRC-15R Radioisotope Dose Calibrator. The half-life must be 62-74min. 
Sterility test was performed by an external laboratory, according to the current US-pharmacopoeia.  
The synthesis of 68Ga-PSMA-HBED-CC parameters were optimized as described previously with 75% +/- 5% 
decay corrected radiochemical yield. The production of 68Ga-PSMA-HBED-CC was within 28 min+/-1. Over the 
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study period we made 52 synthesis of 68Ga-PSMA-HBED-CC. The radiochemical purity was >99.7% as two 
diastereomers, with pH range 5.5-7.0. The 68Ge impurities was found to be <0.0010% in the radiolabelled 
compounds. All samples passed the bacterial endotoxin test at values <10IU/mL and the sterility test. The 
residual solvent of the final product was ethanol in less than 10%. Up to date we have injected 45 patients. 
We have shown that it is possible to perform an automated synthesis to 68Ga-PSMA-HBED-CC using an 
automated synthesis module “Taddeo” from COMECER ensuring a quality and high radiochemical yields and 
radiochemical purity > 99.7%. 
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By this time acyclic and macrocyclic ligands with picolinate moieties became very attractive for binding of 
Pb2+, Bi3+, REE3+ and Cu2+. As soon as linear and cyclic ligands are already used in radiopharmaceuticals and 
characterized by different benefits and drawbacks, we decided to evaluate both types with the same set of 
picolinic arms. Here we present our first results on complexation of cations with new ligands possessing 
picolinate arms L1-L4. 
All ligands were characterized by using NMR-spectroscopy, elemental analysis and potentiometric titration. 
For complex stability study with Bi3+, Cu2+ and Pb2+ potentiometric titration and competitive extraction 
technique with radioactive tracer were used. Labelling experiments with radioisotopes of 61,64Cu and 207Bi were 
performed for leading compounds. Dissociative stability of formed complexes in presence of biologically 
relevant cations as well as re-chelation of radionuclides by serum proteins were studied. Control of labelling 
efficiency and dissociation of complexes was carried out by thin layer chromatography and protein 
precipitation accompanied by gamma-spectrometry. 
Obtained results show lower protonation constants of macrocyclic ligands obviously because of the presence 
of carbamide groups. However, complexation constants with Cu2+ and Bi3+ for L4 reach quite high values 
logK=14.6 and 19.6 respectively. Leading complexes with Cu2+ and Bi3+ possess logK=18.7 and 27.7 for L3. 
The latter characterized by the largest number of donor atoms and absence of amide groups in contrast to L4 
demonstrates the most promising complexation ability. Conditions for effective labelling of L3 by 61,64Cu and 
207Bi were determined and synthesized complexes were challenged with excess of Ca2+, Fe3+, Zn2+, stable 
Cu2+ and serum proteins. It was shown that for >95% radiolabelling yield of L3 and L4 by 207Bi is achieved at 
c(L)=0.4 mM and 1mM and by 61,64Cu at c(L)=0.2 mM for both ligands. BiL3 and BiL4 in presence of serum 
proteins have shown slow trans-chelation up to 40% in 1 hour and to 50-60% in 16 hours. It should be noted 
that acyclic ligand L3 releases cation much faster and it could be the sequence of well-known tendency of 
linear ligands to form kinetically unstable complexes. After summarizing all obtained results, we can conclude 
that novel picolinate-containing ligands form complexes almost immediately at room temperature and formed 
complexes demonstrate stability in vitro. 
Acknowledgement: this work was supported by Russian Foundation for Basic Research project №18-33-20152. 
  
ISTR–2019 
 
158 
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Because of its beta-negative (negatron) and beta-positive (positron) particle emissions, 64Cu is useful for PET 
imaging and therapy 1. 99mTc-HYNIC-iPSMA has demonstrated high ability to target tumours over-expressing 
the prostate specific membrane antigen (PSMA) useful for SPECT imaging. One critical aspect of this molecule 
is the presence of the HYNIC group acting as an additional lipophilic location for the coupling to the 
hydrophobic structure of the PSMA enzyme. Taking the advantage of HYNIC-iPSMA to detect prostate 
tumours, in this research we added NOTA to the molecule to obtain a new 64Cu radiopharmaceutical with 
theranostic potential. 
The objective was to synthesize and characterize biochemically 64Cu-DOTA-HYNIC-iPSMA as well as to evaluate 
in mice its potential as a PET imaging agent for PSMA-positive tumours. 
The p-SCN-Bn-NOTA (Macrocyclics, USA) was conjugated to the HYNIC-iPSMA ligand (molar ratio 0.95:1) by 
dissolving the compounds in 0.1 mL of 0.2M NaHCO3 (pH 9.5) and incubated at 37℃ for 1 h. After reaction, the 
sample was diluted to 50 mL using injectable grade water. The solution was filtered by membrane (0.22µm) 
and fractionated in sterile vials (2 mL and 100 µg of the conjugate per vial). Finally, samples were lyophilized 
and analysed by HPLC. The lyophilized vials containing NOTA-HYNIC-iPSMA (purity of 95%) were reconstituted 
with 1 mL of acetate buffer (1M, pH 5.0) plus 0.5 mL of 64CuCl2 (pH 4) and incubated at 95℃ for 10 min. The in 
vitro evaluation of the obtained radiopharmaceutical was carried out in human serum (stability) and in human 
prostate LNCaP cancer cells (cancer cell uptake). For PET images a lung in LNCaP micro-metastases model in 
athymic mice was used. 
HPLC analyses of NOTA-HYNIC-iPSMA showed a high yield of the reaction (99%). Only 5% of HYNIC-iPSMA 
remained as a chemical impurity. Radio-HPLC analysis showed the formation of 64Cu NOTA-HYNIC-iPSMA with 
a radiochemical purity of >98%. In vitro studies demonstrated high stability in human serum and a LNCaP cell 
uptake of 8.3±1.6 % (of the total activity) at 1 h. PET images showed a clear visualization of LNCaP metastases. 
64Cu NOTA-HYNIC-iPSMA obtained from kit formulations showed high in vitro an in vivo stability in human 
serum and specific uptake in LNCaP cells with potential as a new theranostic radiopharmaceutical. 
Acknowledgment: This study was supported by the Mexican National Council of Science and Technology 
(“Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos CONACyT”). 
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Among all alpha particle emitters, only a few nuclides are of considerable interest for alpha-
radioimmunotherapy because of their properties, such as half-live, high cytotoxicity and short path length. 
One of the most important issues, which affects the wider use of alpha-radioimmunotherapy in nuclear 
medicine, is the availability and price of the radionuclides. At-211 is produced by alpha irradiation at high-
energy cyclotrons, which are available only in a few scientific centers in the world. Resources of Ac-225 and 
Bi-213 radioisotope are quite small. On the contrary to Ac-225, Ra-223 (T1/2=11.4d) is already easily 
(commercially) available. Ra-223 is easily obtained from the Ac-227/Ra-223 generator. 
Unfortunately, Ra-223 as a member of Alkaline Earth metals, forms very weak complexes. Therefore, there is 
a lack of chelators which can effectively bind Ra-223, retain its daughter radionuclides and be coupled to 
targeting vectors. We propose to use barium ferrite (BaFe12O19) nanoparticles as multifunctional carriers for 
Ra-223 radionuclide for alpha-radioimmunotherapy and magnetic hyperthermia. 
Barium ferrite nanoparticles labelled with Ra-223 were synthesized with a hydrothermal synthesis method in 
the autoclave. The reaction mixture of FeCl3, BaCl2 and 223RaCl2 was alkalized with NaOH solution. Next, the 
reaction mixture was stirred in autoclave at 210oC for 6 h. Obtained radioactive, magnetic [Ra-223] BaFe12O19 
nanoparticles were washed with distilled water and hydrochloric acid (1 mM HCl). Yield of labelling was about 
70% (for 100kBq Ra-223). Stability of the obtained radioactive nanoparticles was tested in various biological 
solutions: 1 mM PBS, 0.9% NaCl and in human blood serum. It is confirmed that Ra-223 was highly retained 
inside nanoparticles in every tested solution. Only about 25% of Pb-211 (decay product of Ra-223) was 
released to the solution. Obtained magnetic BaFe12O19 nanoparticles were characterized by transmission 
emission microscopy and dynamic light scattering.  The diameter of synthesized nanoparticles was about 15-
30 mn and the determined saturation magnetization of obtained nanoparticles in room temperature was 
about 42 emu/g. 
In order to synthesize a radiobioconjugate having affinity to HER2 receptors, the monoclonal antibody 
trastuzumab was conjugated to the obtained barium ferrite nanoparticles. Firstly, the surface of barium ferrite 
nanoparticles was modified with 3-phosphonopropionic acid linker, and then, the monoclonal antibodies were 
coupled to the barium ferrite nanoparticles using the carbodiimide chemistry. 
Synthesized bioconjugate was characterized by thermogravimetric analysis, dynamic light scattering and was 
tested for stability in biological fluids. The obtained [Ra-223]BaFe12O19-CEPA-trastuzumab radiobioconjugate 
almost quantitatively retains Ra-223 and the majority of the daughter products. Radiobioconjugate has high 
receptor affinity towards HER2 receptors expressing on ovarian cancer cells and exhibits high cytotoxic effect 
in vitro (SKOV-3 cell line). 
Acknowledgement: this work was supported by National Science Centre of Poland (Grant OPUS 
2016/21/B/ST4/02133). 
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There is an increasing preference of PET-CT over SPECT for evaluation of metastasis as the former is able to 
identify more lesions thanks to the higher resolution. Bisphosphonate ligands conjugated to chelates and 
labelled with 68Ga are good choice as radiopharmaceuticals for PET-CT imaging in patients suffering from 
metastatic cancer. We present the comparison of 68Ga-NOTA-Bisphosphonate (NOTA-BP) with 99mTc-MDP in 
34 patients suffering from different types of cancer. 
68Ga-NOTA-BP was prepared by adding 4 ml of 68Ga (555- 925 MBq) in 0.01 M HCl to 50 µg of NOTA-BP 
dissolved in 1 ml of 0.25 M sodium acetate buffer and heating at 95℃ for 10 minutes. The product is passed 
through a 0.22 micron Millipore filter and radiochemical purity was estimated by TLC in 0.1 M trisodium citrate 
buffer. 
Thirty four patients suspected to be suffering from metastatic bone cancer were administered with 68Ga-
NOTA-BP (185-260 MBq) in saline. Imaging was done one-hour post injection in a Siemens Biograph PET-CT 
machine. A low dose CT from head to toe was acquired prior to PET. PET images were done in 2 min per bed. 
99mTc-MDP image was acquired in a GE SPECT-CT camera post 3-hour injection of ~740 MBq of activity. A visual 
comparison of the PET-CT and SPECT images were done. 
Direct comparison was performed between both the scans which were interpreted by a nuclear medicine 
physician and a detailed analysis was done qualitatively regarding the number of lesions and quality of the 
images. The number of lesions detected by 68Ga-NOTA-BP PET-CT was significantly higher when compared to 
the 99mTc-MDP bone scan.  Tracer accumulation was seen both in lytic lesions as well as in sclerotic lesions 
with latter being higher. The uptake of 99mTc-MDP was less in lytic lesions, making them difficult to identify. 
The 2D planar acquisition gathered less information and decreased the specificity especially in suspicious 
vertebral and rib lesions, which required SPECT-CT acquisition and further clarification. This process made it 
more time consuming and tedious, whereas 68Ga-NOTA-BP PET-CT obviated the need for it. The image quality 
of PET-CT was far more superior compared to the planar bone scan. The low dose diagnostic CT for anatomical 
correlation and attenuation correction that was performed increased the specificity of the study. Better lesion 
characterization and overall lesion detection was noted in the 68Ga-NOTA-BP scan. Patients could be imaged 
within 50 to 60 minutes after injection significantly lower than Tc bone scan proving to be more pleasant to 
the patient. 
In conclusion, PET-CT imaging using 68Ga-NOTA-BP is superior to 99mTc-MDP for evaluation of metastatic bone 
cancer. PET-CT identified significantly a greater number of lesions as compared to 99mTc-MDP. Routine clinical 
use of 68Ga based tracers for bone imaging will help in enhancing the utility of 68Ge/68Ga generator.  
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This study illustrates our attempt to integrate radioimaging modality via incorporating radio Cu-64 on to 
luminescent Cu nanoclusters synthesized by using BSA (Bovine Serum Albumin) and HSA (human serum 
albumin). The Cu-64 [Cu nanoclusters] are further conjugated with Erlotinib, a EGFR receptive drug to attribute 
targeting ability to the tracer cluster towards pancreatic cancer cells. In addition, the radioactive copper 
moiety Cu-64 is a dual edged sword by virtue of being a positron as well as an electron emitter (deliver a 
selective cytotoxic dose of beta radiation) there by acting as theranostic agent. Cu nanocluster enveloped by 
BSA circumvents the challenges created by trans chelation and detachment of Cu-64. The affinity of the probe 
on the targets was assessed in in vitro studies with PAN C 1 cell lines. The developed integrated imaging dual 
modality is expected to improve intraoperative assessments of pancreatic tumour demarcation. Cu-64 PET 
probes can be employed for preoperative assessment of pancreatic cancer lesions. PET probes coupled with 
luminescent copper nanoclusters can be employed for enhanced visual imaging modalities which are quite 
requisite for accurate delineating cancer lesions in the emerging era of robotic surgery. 
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Neuro-inflammatory processes are known to underlie the mechanism of neuronal damage and play a key role 
in the neurodegenerative disease progression. The cyclooxygenase 2 (COX-2) enzyme is one of the most 
studied neuroinflammatory biomarkers and an attractive target for PET imaging. Neolignan 4’-O-
methylhonokiol (MH) isolated from Magnolia officinalis, has high anti-inflammatory activity and selectively 
inhibits the expression of COX-2 with IC50=0.062 μM, as was recently shown by Kim H.S. et.al., 2015. Here we 
report the synthesis of novel labelled MH derivatives ([11C]MPbP and [18F]FEtPbP) and their preliminary 
evaluation on the lipopolysaccha- ride (LPS)-induced neuroinflammation rat model. 
The MH derivatives [11C]MPbP (4’-[11C]methoxy-5-propyl-1,1’-biphenyl-2-ol) and [18F] FEtPbP (4’-(2-
[18F]fluoroethoxy)-2-hydroxy-5-propyl-1,1’-biphenyl) were obtained by 11C-methylation and 
18F-fluoroethylation of the precursor with Boc-protecting group using synthons [11C]CH3I and [18F] FCH2CH2Br, 
respectively. After HCl hydrolysis of intermediates the crude reaction mixtures were purified by semi-
preparative HPLC. Neuroinflammation in rats was induced by an intraperitoneal injection of LPS from E.coli (2 
mg/kg) before 24 h the administration of [11C]MPbP, [18F]FЕtPbP, celecoxib or placebo into the tail vein (0.1-
0.2 mCi/0.5 ml of phosphate buffer pH 7.4, containing ethanol (5-7%, v/v)). Сelecoxib, а well-known non-
steroid anti-inflammatory drug and a selective inhibitor of COX 2 was used as a reference. Ex vivo radioligand 
biodistribution was performed by direct radiometry of organs and tissues samples. The uptake of radioactivity 
was determined by the dose administered per gram of tissue (% ID/g). 
 [11C]MPbP and [18F]FЕtPbP were obtained in decay-corrected isolated radiochemical yields 20 and 35 % based 
on the activity of the corresponding alkylating agent. The biodistribution data showed that the observed 
uptake in the brain of neuroinflammatory rats was 4 times higher than it was in intact animals. In addition, it 
was shown that [11C]MPbP оr [18F]FЕtPbP increased uptake occurred in the parts of rat brain where COX-2 
expression was observed (pons&medulla). 
A decrease in the radiotracer uptake by 2-3 times in these regions with the celecoxib pre-treatment may serve 
as evidence of this hypothesis. Synthesis of [11C]MPbP and [18F]FEtPbP, labelled MH analogues has been 
developed. On the rat neuroinflammation model, it has been shown that these radiotracers have the potential 
for PET imaging of neuroinflammation. 
Acknowledgement: this study was funded by RFBR according to the research project 17-04-02119 A. 
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Gallium-68 (68Ga, T1/2 = 68 min) has attracted increasing interest in recent years due to the expanding clinical 
applications of 68Ga-based radiopharmaceuticals. With this increased demand, there is a need for improving 
the 68Ga production capacity. The aims of this study are to enhance the production yield of 68Ga using pressed 
targets and the purification of 68Ga by using an automated cassette-based purification process. We also 
compare the chemical, radiochemical and biological properties of -cyclotron and generator- derived 68Ga for 
common nuclear imaging procedures. 
Using a digital hydraulic press, the targets were prepared using enriched 68Zn powder and were mounted on 
custom-made target supports. 68Ga was produced using 19 MeV and 24 MeV cyclotrons, recovered by 
chemical dissolution and purified by chromatography with two cation exchange resins. The radiotracers were 
then formulated the usual way as [68Ga]-DOTA-TATE and [68Ga]-PSMA-617. The PET images and distribution 
patterns of the cyclotron and 68Ge/68Ga generator produced 68Ga radiopharmaceuticals were compared in 
healthy rats and mice. 
Up to 140 GBq of 68Ga was produced following 90 min irradiation. The overall recovery yield of 68GaCl3 was 
89% with an EMA of 77 ± 5 GBq/µmol at EOB. The outcome was a radiochemical yield >95% of [68Ga]-DOTA-
TATE and [68Ga]-PSMA-617. Cyclotron and generator produced 68Ga radiopharmaceuticals were shown to be 
radioisotopically, chemically and biologically equivalent, giving matching images and identical kinetic and 
biodistribution patterns in animals. 
Overall, these results show that irradiation of 68Zn-pressed target is a very effective process. The cassette-
based purification-process developed is rapid, simple, efficient and leads to high radiochemical yield and EMA 
of 68GaCl3. Medical cyclotron can produce European Pharmacopeia compliant 68Ga radiopharmaceuticals that 
can be used as substitute of generator derived 68Ga. 
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Trastuzumab (Herceptin®), a humanized monoclonal antibody, is an approved agent used for 
immunotherapeutic treatment of metastatic breast cancer as it targets HER2 (human epidermal growth 
receptors 2) receptors over-expressed in such cancer cells. Therefore, radiolabelled Trastuzumab is expected 
to have significant potential as a radioimmunotherapeutic agent for the treatment of cancer breast patients 
over-expressing HER2 receptors. The aim of the present study is to standardize the formulation protocol of 
177Lu-Trastuzumab and scale-up the preparation for administration in patients. 
Trastuzumab was conjugated with a suitable bi-functional chelating agent (BFCA) namely, p-NCS-benzyl-DOTA 
by incubating Trastuzumab (5 mg, 35 nmol) and p-NCS-benzyl-DOTA (190 μg, 350 nmol) in sodium carbonate 
buffer (pH=9.5, 0.2 M) at 37 ℃ for 17 h. Post-incubation, the reaction mixture was purified using Amicon ultra-
centrifugal units (MW cut off 10kDa) using NaOAc buffer (pH=5.0, 0.2 M). Determination of average number 
of p-NCS-benzyl-DOTA molecules attached per antibody moiety was carried out by UV-Vis spectrophotometry 
as well as by mass spectrometry using the MALDI-TOF technique. 177Lu-Trastuzumab complex was prepared 
by incubating the purified Trastuzumab-BFCA conjugate (2 mg, 13 nmol) with 177LuCl3 [150 μL, 80 mCi (2.96 
GBq)] at 37 ℃ for 90 min at pH ~5.5. Percentage radiolabelling yield (%RCY) of the radiolabelled formulation 
was determined by paper chromatography (PC) using 0.1M sodium citrate solution as the mobile phase and 
high performance liquid chromatography (HPLC) using 0.05 M phosphate buffer with 0.05% sodium azide as 
the mobile phase. The radiolabelled preparation was purified by PD10 desalting columns using 0.2 M NaOAc 
buffer as the eluting solvent. The stability of the purified 177Lu-Trastuzumab complex was determined till 4 
days post-preparation by incubating the complex in phosphate buffered saline (PBS) at room temperature and 
carrying out the quality control analyses following the procedures mentioned above at various time intervals. 
The purified 177Lu- Trastuzumab formulation was administered in 08 cancer breast patients [~5 mCi (185 MBq) 
in each patient] for studying preliminary pharmacokinetics and biological distribution of the agent. 
An average of 7.5±1.2 p-NCS-benzyl-DOTA molecules were found to be attached per Trastuzumab moiety. 
HPLC studies showed that the 177Lu-Trastuzumab conjugate could be prepared with a %RCY of 75.78±3.56 (Rt 
= 15.5 min and 21.5 min for 177Lu-Trastuzumab and free 177LuCl3, respectively), which was subsequently 
improved to >95 by purification through PD10 column (with average recovery of 72.8±1.2%). In-vitro stability 
studies showed that the %RCY of 177Lu-Trastuzumab decreased to 84.15±1.57 after 4 days of storage at room 
temperature in PBS. Clinical studies in cancer breast patients revealed the accumulation of the radiolabelled 
antibody at breast cancer lesions with slow but gradual clearance of activity from blood and other non-target 
organs. An in-house procedure for the formulation of patient dose of 177Lu-Trastuzumab was optimized. 
Preliminary clinical imaging studies revealed the retention of affinity of Trastuzumab towards the disease after 
functional modifications and radiolabelling procedures. 
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The NK-1 receptor and its endogenous agonist Substance P (SP) is a system that have been connected with 
many physiological processes like angiogenesis, wound healing and activation of inflammation state 
mediator’s synthesis. Moreover, the overexpression of NK-1 receptor is observed on certain types of cancer 
cells especially glioma, astrocytoma, melanoma, neuroblastoma and some types of lymphomas. This makes 
NK-1 receptor a potential target for cancer diagnosis and anti-tumour agents’ therapy. Presently there are 
some known glioblastoma treatment trials with labelled derivatives of SP but none of them is effective enough. 
High affinity to NK-1 receptor exert also antagonists of this receptor. SPANTIDE I [D-Arg1,D-Trp7,9, Leu-11]SP 
is a SP-analogue peptide antagonist designed with higher in vivo stability than natural SP (half-life of 2-3 
minutes in human blood).  There are also reports that inhibition action on NK-1 receptor can be correlated 
with antitumour activity of the inhibitor. That is why our goal is to synthetize novel radioconjugates based on 
peptide antagonist SPANTIDE I and evaluate their affinity and toxicity against glioma cancer cell lines. 
In the course of this research we have synthesized two types of conjugates consisting of DOTA chelator and 
full peptide SPANTIDE I (1-11) or shorten peptide SPANTIDE I (5-11). Afterwards, we have obtained desired 
radioconjugates by labelling with Ga-68 or Lu-177 and performed an assessment of physicochemical 
parameters like lipophilicity and stability in human serum. Later, prepared radioconjugates have been 
evaluated on in vitro assay with chosen NK-1 overexpressed cell lines to determine their affinity to the receptor 
after structural modification. In the next step cytotoxicity assay has been performed. 
We have successfully obtained high specific activity in all four radioconjugates: shorten SPANTIDE I (5-11)-
DOTA and full SPANTIDE I (1-11) - (DOTA)2 labelled with Ga-68 or Lu-177. Presence of two DOTA chelators in 
full SPANTIDE I radioconjugates affects significantly on lower radioconjugates logP parameter in comparison 
with shorten SPANTIDE I (5-11) radioconjugates with one chelator. All four radioconjugates show full stability 
in human serum for more than 4 times of applied isotope half-life. In vitro assays confirm maintenance of 
receptor affinity of obtained radioconjugates on glioma cell line. 
In conclusion, obtained radioconjugates fulfil many crucial aspects for the potential radiopharmaceuticals 
strictly required from the clinical application point of view. Gallium labelled radioconjugates may show a 
usefulness in diagnosis of NK-1 receptor overexpression and lutetium labelled SPANTIDE I peptides may 
complement the therapeutic application by similar in vivo action in theranostic idea of designed 
radioconjugates. Application concept of peptide NK-1 receptor antagonists may be a helpful reference in 
further development of tumour treatment solutions. 
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This study aimed to synthesize and characterize N-(2,4,6-trimethylphenylcarbamoylmethyl)iminodiacetic acid 
(TMIDA) and then radiolabel it with technetium-99m by direct technique using sodium didithionite as reducing 
agent. The labelling parameters including TMIDA concentration, sodium didithionite concentration, pH of the 
reaction mixture, reaction temperature and reaction time were optimized. 
The synthesis N-(2,4,6-trimethylphenylcarbamoylmethyl)iminodiacetic acid (TMIDA) was prepared in two 
steps. The first one involves the synthesis of ω-chloro-2,4,6-trimethylacetanilide and the second step involves 
the synthesis of TMIDA by reaction of ω-chloro-2,4,6-trimethylacetanilide (10 mmol) and iminodiacetic acid 
(10 mmol) in 50% aqueous ethanol was refluxed for 5 h at 85℃ and adjusted to pH 11-12 with 10% NaOH 
every hour. The mixture was cooled to room temperature and the ethanol was removed using rotary 
evaporated.  The mixture was extracted three times with diethyl ether. The aqueous layer was then adjusted 
to pH 2-3 with HCl and the precipitate was formed on cooling. The precipitate was filtered off, dried and 
recrystallized with ethanol to give TMIDA (Yield: 23.5 % and Mp: 218-221 ℃). 
In the labelling procedure study TMIDA was labelled with technetium-99m by the direct technique using 
sodium dithionite (Na2S2O4) as a reducing agent as shown in scheme 2. To 100 μl of freshly eluted 99mTcO4- 
(400 MBq), the required concentration of solid sodium dithionite was added directly with continuous stirring 
followed by immediate addition of the required TMIDA concentration, which dissolved in 0.1 M NaOH. The pH 
of the preparation was adjusted followed by incubation at room temperature at a specific reaction time. 
TMIDA concentration, Na2S2O4 concentration pH, reaction time and temperature were studied as factors 
affecting labelling efficiency. Each factor studying experiment was repeated three times. 
Synthesis of N-(2,4,6-trimethylphenylcarbamoylmethyl)iminodiacetic acid (TMIDA). Synthesis of TMIDA was 
accomplished according to the reaction sequence in two steps. The first one involves the reaction between 
2,4,6-trimethylaniline derivative and chloroacetyl chloride to give ω-chloro-2,4,6-trimethylacetanilide. The 
second step involves condensation reaction between ω-chloro-2,4,6-trimethylacetanilide and iminodiacetic 
acid at alkaline pH in ethanol for 5 h to give TMIDA. 
The synthesized compound, TMIDA, was confirmed by IR, mass and 1H-NMR spectra. Factors affecting the 
percent radiochemical yield of 99mTc–TMIDA complex: 
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Biodistribution of 99mTc–TMIDA complex 
In conclusion, TMIDA can be synthesized and radiolabelled using an easy and cheap method, considering the 
biodistribution data results, 99mTc-TMIDA can be used as a hepatobiliary imaging agent for an evaluation of the 
functional status of the hepatocytes and the patency of the biliary duct. 
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Sigma receptors were initially described to be a subtype of opioid receptor, but later due to its unique 
characteristics it has been postulated as a distinguished receptor system. It is divided into Sigma 1 and Sigma 
2 subtypes. Sigma receptors are well known for their over-expression in high density, in different types of 
tumours as in those of breast, melanoma, non-small-cell lung carcinoma, prostate, glioma and tumour of 
neural origin.  Literature study shows that piperidine or piperazine moiety is an important pharmacophore 
showing binding affinity with the sigma receptors overexpressed on specific tumours. The present effort is 
directed towards the radiosynthesis of [18F]fluoroethylated analogue of 1-Acetyl-4(4-Hydroxyphenyl) 
piperazine and evaluation of its potential as a tumour marker.  
18F-fluoride production and radiosynthesis were performed using GE PETtrace cyclotron and GE TRACERlab 
module (Configured for 2-[18F]FDG production) respectively. [18F] radiofluorination was carried out using dry 
[18F] tetrabutylammonium fluoride. The radiosynthesis was carried out by a one-pot, two-step process. In the 
first step, [18F]fluoroethyl tosylate was synthesized by fluorination of ethylene ditosylate. In the second step, 
[18F]fluoroethyl tosylate was tagged with piperazine analogue to form [18F]fluoroethylated-piperazine 
analogue. The reaction mixture was purified using neutral alumina and Light C18 cartridges. The final product 
was eluted from the column with 10% ethanol. In-vitro cell uptake study was done by using melanoma cell line 
(B16F10). Bio-distribution in tumour xenograft model was carried out in C57BL6 mice with melanoma. Towards 
this B16F10 cell line (5x105 cells per mice) were injected in C57BL/6 mice. After 15 days the size of tumour 
was found to be 0.75-1 cm3. The size was considered to be sufficient for carrying out the studies. [18F] activity 
of 200 μCi per mice was injected through tail vein. Mice were sacrificed at 30, 60, and 120, min post injection 
for biodistribution studies. The same mice which was used for bio-distribution after 120 min pi was used for 
imaging using PET-CT camera at 60 min pi. 
As a result, the reaction conditions were optimized in order to obtain maximum yield of the radiolabelled 
product. The purity of the product was evaluated using Radio-TLC and radio-HPLC analysis and found to be 
more than 99%. A bed volume of 4 g neutral alumina and two Light C18 cartridges were found to be sufficient 
for efficient purification. A non-decay corrected radiochemical yield of 30% (n=4) was obtained with the 
reaction time of 60 min. In-vitro cell binding study shows good uptake in B16F10 cell line. Biodistribution study 
shows the compound to have good in-vivo stability and a significant tumour uptake till two hours. 
Tumour/blood ratio was found to increase with time. Hepatic and renal clearance pattern was observed at 
120min pi. 
In conclusion, [18F]fluoroethylated piperazine analogue was successfully synthesized and purified, with a 
radiochemical purity of 99%. The radiotracer showed enough in-vivo stability. Biodistribution studies shows 
significant tumour uptake. Further uptake studies with different tumour xenograft models are underway. 
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The radiosynthesis of 2-[18F]fluoro-2-deoxy-D-glucose [18F]FDG is a routine automated process at the 
University Institute for Positron Emission Tomography, Skopje, which is performed by using an  IBA Synthera 
V2 synthesis module. [18F]FDG is synthesized by nucleophilic fluorination followed by base-catalysed 
hydrolysis. The purification of the final product is accomplished by passing the hydrolysed reaction mixture 
through purification cartridges (strong cation exchange column, aluminium oxide column and C-18 bonded 
silica column). The objective of our study is to define whether there is a correlation between the production 
yield and the activity retained during synthesis. 
The analysis include 63 batches of [18F]FDG performed on the same module. The IFP cassettes and reagents 
kits were from the same manufacturer (ABX). In all the syntheses were used Waters 
Sep-Pak cartridges (QMA, Alumina B, C18) and SPure SCX cartridge. The radiochemical purity was determined 
by thin layer chromatography using Raytest miniGITA TLC scanner. The radioactivity retained on the cartridges, 
reaction vessels, v-vials, tube connections and [18O]H2O recovery vials, was measured using Biodex Atomlab 
500 Dose Calibrator. 
The results of the radiochemical purity show that the [18F]FDG content is more than 99% of the total 
radioactivity in all of the batches. To interpret the results of the measured retained activity, we made five 
subgroups of the batches, depending on the yield (decay-corrected): less than 50%, 50-55%, 55-60%, 60-65%, 
more than 65%. One-way analysis of variance shows that there is no statistically significant correlation 
between the yield variability and the activity retained on the C18, QMA, SCX cartridges, tubes, reaction vessel, 
v-vial and recovery vial (p>0.05, for all seven correlations). The regression analysis of the activity retained on 
the alumina cartridge indicates negative linear regression (Fig.1). 
 
Figure 1: Regression analysis of the retained activity and the yield 
A conclusion is made that in our automated [18F]FDG synthesis process, there is statistically significant 
correlation only between the [18F]FDG yield and the amount of radioactivity retained on the alumina cartridge, 
which adsorbs the unreacted [18F] fluoride. 
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Radiopharmaceuticals for positron emission tomography (PET) bearing electron rich [18F]fluorinated arenes 
are still in limited use as the direct introduction of [18F]fluoride via commonly used SNAr is not suitable. 
Recently, several transition metal-mediated labelling strategies have been introduced to address this problem. 
Among them, radiofluorination of pinacol esters of arylboronic acids (ArylBPin) mediated by copper triflate 
complex with pyridine (Tredwell at al., 2014) is one of the more promising synthetic avenues under 
development. This new methodology allows to facilitate access to clinically relevant radiotracers, 18F-ring 
fluorinated aromatic amino acids, drug-like molecules and others. However, implementation of the copper-
mediated fluorination in automated synthesizers remain a challenging task. Several studies indicated that the 
choice of phase-transfer catalyst (PTC) and corresponding base used for the generation of reactive [18F]fluoride 
species has a profound impact on the 18F-fluorination fluorination of base-sensitive ArylBP in precursors. Here 
we introduce a new 18F-processing protocol using tetrabutylammonium triflate (TBAOTf) as a neutral PTC and 
its application in the preparation of 6-[18F]fluoro-L-DOPA via copper-mediated fluorination of commercially 
available ArylBPin precursor. 
Radiolabelling precursor, 3,4-OMOM-6-(BPin)DOPA(Boc2)-OtBu, was kindly provided by ABX, Germany. 
Aqueous [18F]fluoride was loaded onto QMA carb SepPak cartidge (46 mg) from the male side, the cartridge 
was rinsed by 1.5 mL of i-PrOH and dried with helium. 18F was eluted in the opposite direction using a solution 
of 12.5 µmol of TBAOTf in 0.6 mL i-PrOH directly to a solution of 5 µmol of Cu(OTf)2Py4, 8 µmol of labelling 
precursor in 0.3 mL DMA. The mixture was heated in a sealed vial at 110℃ for 15 minutes under air. After 
intermediate purification (two C18 SepPak cartridges in a series) and acid hydrolysis the crude 6-[18F]fluoro-
L-DOPA was purified by HPLC: RP-Amide, Supelco, 250 x 10 mm, NaOAc 10 mM + AcOH 50 mM + 0,1 g/l 
ascorbic acid; flow 4 ml/min; Rt 9 min. 
Results showed: first, developed 18F-processing protocol allowed to eliminate conventional azeotropic drying 
step and to facilitate automation. The use of TBAOTf as a PTC provides a high 18F elution efficiency (up to 90%) 
and a radiochemical conversion of 83±6 (n=7) as determined by radioTLC. The desired tracer was obtained in 
a RCY of 20% (non-optimized, corrected for decay), radiochemical purity > 97% and enantiomeric purity > 98% 
within 80 min synthesis time. Notably, the suggested procedure employed reduced amounts of expensive 
precursor (8 µmol) and Cu-catalyst (8 µmol). Work is now in progress to optimize hydrolysis and purification 
conditions to increase isolated radiochemical yield. 
In conclusion, the suggested novel 18F-processing protocol enables the simple and efficient production of 6-
[18F]fluoro-LDOPA from commercially available ArylBPin precursor avoiding time consuming solvent 
evaporation steps. This method can be further extended for the preparation of other 18F-ring fluorinated 
amino acids. 
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PET-CT imaging using flourine-18 radiopharmaceuticals more specifically [18F]FDG is an integral part of cancer 
management. Fluorine-18 is produced by bombarding 18O enriched water with high energy proton beam. The 
quality of 18O water and its enrichment ratio are very important to ensure higher yields. However, there are a 
number of other factors that influence the production of 18F ions such as energy of cyclotron beam, beam 
current, volume of target and irradiation time. In a cyclotron which is routinely used for commercial 
production, the above factors are varied depending on the production needs. Hence, it is very difficult to do a 
direct comparison of the quality of different enriched water used. We have done a retrospective analysis of 
18O enriched water supplied by two different vendors, the results are presented below. 
These studies were done in a 11 MeV Siemens Eclipse HP self-shielded medical cyclotron. The cyclotron system 
has dual beam providing 11 MeV having beam current up to 60 µA in each beam line. Negative hydrogen ion 
(H-) is accelerated in quasi-spiral orbits and converted to proton beam by using extracting foil and impinged 
to water targets filled with 18O enriched water to produce 18F-ions by the nuclear reaction, 18O(p, n)18F. The 
cyclotron has two tantalum water targets having 2.6 ml capacity fitted for each beam line. 
Oxygen-18 enriched water supplied by two vendors were, ABX advanced biochemical compounds, Germany 
and Taiyo Nippon Sanso Corporation, Japan were used in these studies. While the beam current was kept 
constant at 60 µA irradiations were done for different timings, 120,150, 165 and 180 min. The amount of 
radioactivity produced was transferred to Capintec CRC-55t PET dose calibrator for measurement. 
The fluorine-18 activity formed was found to be different with the two different supplies of enriched 18O water 
and as expected the 98% enriched water gave about 300 mCi higher activity as compared to 97% enriched 
water when irradiated for 120 min at 60 µA. The results were consistent at 150,165 and 180 minutes of 
irradiation, the average yield enhanced up to 5% in each target. Due to high demand of the 18F 
radiopharmaceuticals, the higher the quantity of fluoride-18 produced, the economy of production improves 
with higher enriched water. 
It is important to evaluate each, and every input used in a commercial site used for the preparation of F-18 
radiopharmaceuticals. A judicious selection of enriched water from different vendors will help in achieving 
higher production yields, thereby improving the economy of operation of the machine. 
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Peptide receptor radionuclide theranostics is a targeted approach for imaging and therapy of cancers. In this 
purview, a number of peptide-based derivatives such as octreotide analogues, are in clinical use utilizing 
68Ga/177Lu radionuclidic pair. The octreotide peptide such as 3-Tyr-Octreotate (TATE) used for peptide receptor 
targeting is an agonist peptide which enters the tumour cell via somatostatin receptor mediated transport 
across the cell membrane. However, rapid elimination of the radiopharmaceutical from blood limits the uptake 
of the radiopharmaceutical in the tumours. To effect improved target uptake, there is an interest to explore 
the performance of radiolabelled TATE functionalized gold nanoparticles, as the later are known to have higher 
blood residence period. Surface modified gold nanoparticles are known to enter living cells and are an 
excellent candidate for utilization in biomedicines, mainly in cancers and carcinomas. The objective of the 
present work is to functionalize gold nanoparticles with TATE peptide along with DOTA chelator so as to 
radiolabel them with 68Ga/ 177Lu radionuclides and evaluate them for their theranostic potential. 
Commercially available DOTA-TATE was directly used to functionalize Gold nanoparticles. Briefly, DOTA-TATE 
(0.7 mM, 0.5 mL) solution in water was added and mixed with a solution of HAuCl4 (1mM) in TWEEN 80 (1mM). 
The resulting solution was then reduced rapidly with ice-cold NaBH4 (0.5 M, 1mL) to obtain the required ‘TATE 
along with DOTA functionalized gold nanoparticles. The obtained gold nanoconjugates were purified by 
dialysis, characterized and then used for labelling studies. The labelling protocol involved direct addition of 
purified gold nanoparticles to 68GaCl3/177LuCl3 activity (185 MBq) in 0.1M acetate buffer (pH 4-5), and the 
resulting reaction mixture was heated at 60℃ for 15-30 min to yield the radiolabelled TATE functionalized gold 
nanoparticles. 
TATE having a disulphide linkage is expected to have affinity towards Au surface under reducing conditions. 
Such a formation was observed in the present experimental conditions and gold nanoparticles in wine red 
colour were obtained. The nanocolloidal solution using UV/Vis Spectroscopy gave a prominent peak at 512nm, 
thus confirming the nanocolloidal nature of the particle synthesized with size in the range 10-20 nm. The 
radiolabelling yield as determined by paper chromatography in 0.5M citrate buffer [Rf free MCl3 (M=68Ga/ 
177Lu) =0.8-1.0; TATE functionalized Au-nanoparticle = 0-0.2] was observed to be >90% for both the 
radiometals. In vitro experiments in AR42J cell lines are underway to evaluate the potential of the 
functionalized gold nanoparticles in comparison with the DOTA-TATE metal complexes in clinical use. 
Water dispersible Gold NPs functionalized with TATE peptide along with DOTA chelator has been successfully 
synthesized. These have been successfully labelled with radiometals in reasonable yields. Further cell 
experiments are underway to evaluate the efficacy of the labelled Au nanoparticles. 
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Renaissance of 68Ga-labelled peptides has given a new dimension to theranostic imaging of neuroendocrine 
tumours and prostate cancer. The outstanding success of 68Ga-labelled agents in the last decade is primarily 
due to the availability of reliable, long-lived 68Ge/68Ga generators, extensive automation, development of new 
macrocyclic linker based 68Ga chemistry, and a huge amount of clinical data in a short time. 
Somatostatin receptors are over-expressed in neuroendocrine tumours such as pituitary adenoma, 
neuroblastoma and small cell lung carcinoma etc. These tumours are diagnosed with 68Ga-DOTA-TATE and are 
effectively treated with 177Lu-DOTA-TATE. The huge success in the management of neuroendocrine tumours 
led to rapid development in theranostic approach for prostate cancer management, as there was no specific 
diagnostic or treatment tool available prior to this agent. Urologists, endocrinologists and oncologists were 
very excited, and they passed on the benefits to the patients, the ultimate winners. 
Availability of ionic 68Ga from the 68Ge/68Ga generator is the key to the recent developments. Equally important 
is the development of macrocyclic linkers such as DOTA, NOTA etc. The ability of these linkers enabled the 
scientists to radiolabel a large number of ligands for clinical applications. The most extensively used agents 
are 68Ga-DOTA-TATE for neuroendocrine tumours, and 68Ga-PSMA for prostate cancer. The bifunctional 
chelators such as DOTA and NOTA were shown to bind 68Ga and 177Lu with equal efficiency and offered kinetic 
stability and thermodynamic stability, which is the under-pinning success for theranostic developments in the 
last decade. 
New approaches are developed for therapy, which include combined PRRT (with other treatment modalities) 
such as chemotherapy (capecitabine, doxorubicin), kinase inhibitors (sunitinib, sorafenib), intraoperative use 
of probes after PRRT with 177Lu and applications. Alpha emitters (eg. 225Ac, 213Bi, and 223Ra) were shown to be 
highly effective. Frank Roesch’s group has shown that bisphosphonates were good theranostic agents to 
deliver beta radiation to the bones and soft-tissues to augment therapeutic efficacy. 
Recent developments in “theranostic approach” are the best thing to happen in nuclear medicine in the past 
decade. They have created extensive enthusiasm around the world to apply this technology for the benefit of 
the patients. 
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Published methods for radiolabelling of ubiquicidin (UBI) 29-41 to date describe manual processes. Manual 
labelling of 1,4,7-triazacyclononane-1,4,7-triacetic acid ubiquicidin (NOTA-UBI) with Gallium-68 (Ga-68) has 
several disadvantages, including unnecessary radiation exposure to operators, and difficulty to meet Good 
Manufacturing Practice (GMP) requirements. The aim of this study was to develop an automated synthesis 
method for the labelling of Ga-68 NOTA-UBI. 
Ga-68 activity was eluted from an iThemba Labs Ge-68/Ga-68-generator using 0.6 M HCl. This approach of 
developing an automated method first duplicated the manual method developed by Ebenhan et al. (2014) 
using the generator, eluant and consumables available at our PET Centre, followed by adaptations of the 
radiosynthesis to suit the automated module. Radiolabelling yield and radio- chemical purity were determined 
after each labelling experiment to compare the efficiency of each method and changes to the protocols. 
Ga-68 NOTA-UBI was labelled using the following three generator eluate preparations: the Ge- 68/Ga-68 
generator was eluted using fractional elution and 1.5 M 4-(2-hydroxyethyl) piperazine-1- ethanesulfonic acid 
(HEPES) was added as a buffering agent (method 1); fractional generator elution was done and 1.0 M sodium 
acetate solution was added as a buffering agent (method 2); and a cationic exchange-based pre-purification 
step was utilized to clean-up the full-scale generator eluate from any possible metal impurities and combined 
with 1.0 M sodium acetate solution as buffering agent (method 3). The pH of all labelling mixtures was adjusted 
to range between 3.5 – 4.0. Following radiolabelling, a C18-cartridge based separation of Ga-68 NOTA-UBI was 
performed to free the labelled product from impurities including colloidal Ga-68. This step was performed on 
all methods. Regardless of the methods applied, Ga-68 NOTA-UBI stability and further tests were performed 
after each radiosynthesis to justify the product validity for human administration. 
NOTA-UBI was successfully labelled (n = 23) with Ga-68 using automated procedures for fractional elution and 
cationic pre-purification and sodium acetate as buffer. The best percentage of labelling efficiency (78.9 ± 3.6, 
n = 7) was obtained using the cationic pre-purification method. The average radiochemical purity for the 
cationic pre-purification method was 99.0 ± 1.7 (n = 7). When method 1 was used, the HEPES content in the 
final labelled product exceeded the limit prescribed in the European Pharmacopoeia which limited further use 
of HEPES buffer in these labelling methods. Stability and validation studies performed on the Ga-68 NOTA-UBI 
indicated that both, the fractional elution and cationic purification methods comply with specifications for 
batch release of radiopharmaceuticals intended for human use. 
An automated synthesis protocol using a Scintomics GRP Module has been successfully developed and tested 
for robustness and repeatability. Both fractional elution and cationic purification automated methods using 
sodium acetate as a buffer can be utilised for the routine synthesis of Ga-68 NOTA-UBI under GMP conditions, 
demonstrating high radiochemical yield and purity. An automated cationic pre-purification method using 
sodium acetate resulted in the best labelling efficiency. HEPES as a buffer was however found not suitable for 
routine labelling of Ga-68 NOTA-UBI. 
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According to the World Health Organisation (WHO) tuberculosis (TB) is one of the top 10 causes of death 
worldwide. It was also reported in the world in 2017 that 10 million people fell ill with TB and 1.6 million died 
from the disease. TB is an infection caused by the bacterium Mycobacterium tuberculosis.  TB usually attacks 
lungs, but it can also spread to other organs; this TB is commonly called extrapulmonary TB. This type of TB is 
relatively difficult to be detected by conventional methods, therefore a proper and specific method is needed. 
The Center for Radioisotope and Radiopharmaceutical Technology (CRRT) at the National Nuclear Energy 
Agency of Indonesia (BATAN) has been developing single-vial ethambutol radiopharmaceutical kits which can 
be used to detect this type of TB. The single-vial ethambutol kit is an improved form of the previous developed 
two-vial ethambutol kits. 
Lyophilized ethambutol kits were aseptically prepared in the clean room and consisted of ethambutol, 
SnCl2.2H2O, mannitol and sodium pyrophosphate. Lyophilization of ethambutol kits was performed by using 
a freeze dryer with freezing step, primary drying and secondary drying for 42 hours, 3 hours and 3.5 hours 
respectively. Evaluation of single-vial ethambutol kit included clarity, pH, radiochemical purity, sterility and 
endotoxin. Radiochemical purity, sterility and endotoxin tests were performed using thin layer 
chromatography, direct inoculation and Tachypleus Amebo- cyte Lysate (TAL) respectively. Radiolabelling of 
ethambutol with technetium-99m was prepared by incubating the kit erials dissolved in 1.5 mL of Tc-99m at 
room temperature for 10 minutes. 
Freeze-dried and sterile ethambutol kit has been prepared. Each ethambutol kit vial comprised a lyophilized 
mixture of 3.5 mg ethambutol, 1 mg SnCl2.2H2O, 5 mg mannitol and 17.5 mg sodium pyrophosphate. 
Radiolabelling of single-vial ethambutol was carried out by using 1.48 GBq of Tc-99m to result in a clear 99mTc-
ethambutol complex with radiochemical purity of above 85% and pH 9. Endotoxin test which was performed 
by using TAL, gave a concentration of Lysate < 0.25 EU/mL. The sterile lyophilized single-vial ethambutol kits, 
radiolabelled with Tc-99m, have been clinically tested for diagnosis of extrapulmonary TB in adults as well as 
children patients at the Hasan Sadikin Hospital, Bandung, Indonesia. The results showed that 99mTc-ethambutol 
can be used as a safe, effective and non-invasive alternative modality for diagnosis of extrapulmonary TB. 
In conclusion, freeze-dried ethambutol kit, a sterile product, has been developed and suitable for diagnosis of 
extrapulmonary tuberculosis. 
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Target-specific radiopharmaceuticals are becoming increasingly utilized in the management of cancer because 
they provide the unique tool for target-specific delivery of radionuclides to the diseased tissues. The 
encouraging results observed in the radioimmunotherapy of hematologic tumours have not yet been 
translated to solid tumours. The investigation of new radionuclides, new molecular constructs and better 
targeting strategies to prevent or overcome host toxicities will translate to progress in the therapy of solid 
tumours. For tumours associated antigens like EGFR, molecules that are overexpressed in tumours but are 
also expressed in normal tissues, monoclonal antibodies with intermediate affinity might have preferential 
uptake in target tissues overexpressing target antigen, while might decrease toxicity in normal tissue. In this 
work the preparation and preclinical evaluation of radioconjugates based on Nimotuzumab monoclonal 
antibodies with intermediate affinity and selected trivalent radiometals are described. 
Nimotuzumab is radiolabelled with selected trivalent radiometals using bifunctional chelators. The cell-binding 
characteristics and toxicity of the radioimmunoconjugates was assessed using radioimmunoassay in cultured 
cell lines. Tumour targeting properties of Nimotuzumab labelled with 177Lu, 90Y and 188Re were evaluated in 
mice bearing human carcinomas xenografts with varying EGFR expression levels. 
The radiolabelling procedures yielded a high and reproducible radiometal complexation suitable for the 
practical preparation of radiopharmaceuticals.  Radioconjugates with high radiochemical purity and specific 
activity without significant loss in the targeting function were obtained. Radioimmunoconjugates showed 
higher cell growth inhibition in cultured cell lines (overexpressing EGFR  or HER2) than unmodified monoclonal 
antibodies. Optimized preparation of Nimotuzumab labelled with n.c.a. 177Lu showed high stability in vivo. 
177Lu-Nimotuzumab showed high specific tumour uptake accompanied by low uptake in normal tissues in mice 
bearing EGFR-overexpressing human epidermoid (A431) tumour xenografts. Preparation of 
radioimmunocojugate with 90Y and its preclinical evaluation is also described. The results using 188Re in a 
Phase I clinical trial are also included in the present investigation. 
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The chemokine-4 receptor (CXCR4) is overexpressed in more than 23 types of human cancers that metastasize 
to distant organs. In the progression of breast cancer and its metastases, the overexpression of CXCR4 has 
been demonstrated in 90% of triple-negative breast cancer tumours. 
To prepare and evaluate the in vitro and in vivo ability of 68Ga-CXCR4-L and 177Lu-CXCR4-L ligands to target 
the CXCR4 protein in glioblastoma and triple-negative breast cancer cells. 
68Ga labelling was performed by adding 1 M acetate buffer (pH 4.0) and gallium-68 chloride obtained from a 
68Ge/68Ga generator (ITG, Germany) to a lyophilized formulation containing the cyclo(D-Tyr-D-
[NMe]Orn(HYNIC-DOTA)-Arg-NaI-Gly) ligand [DOTA-CXCR4-L] followed by incubation at 95℃ for 10 min. For 
177Lu labelling, 1 M acetate buffer (pH 5.0) and lutetium-177 chloride (ITG, Germany) were added to a 
lyophilized vial containing the DOTA-CXCR4-L following by incubation at 95℃ for 30 min. The radiochemical 
purity was evaluated by reversed-phase HPLC and ITLC-SG analyses.  Stability studies in human serum were 
performed by size-exclusion HPLC. In vitro and in vivo cell uptake was tested using human breast cancer cells 
(triple-negative DU-4475) and human glioblastoma cells (U87MG) with blocked and non-blocked receptors. 
Images were obtained in athymic mice with induced DU 4475 or U87MG pulmonary micrometastasis by using 
a micro- SPECT/PET/CT system. 
68Ga-DOTA-CXCR4-L and 177Lu-DOTA-CXCR4-L obtained with radiochemical purities of 95% and 99%, 
respectively, showed high stability in human serum and specific in vitro and in vivo recognition in glioblastoma 
and triple-negative breast cancer cells. Using pulmonary micrometastasis DU-447 and U87MG models, a clear 
uptake of both radiopharmaceuticals was observed. 
The results obtained in this study warrant further preclinical studies to evaluate therapeutic efficacy of 177Lu-
DOTA-CXCR4-L, as well as dosimetry and clinical studies to determine the specificity and sensitivity of 68Ga-
DOTA-CXCR4-L to target the chemokine-4 receptor in different kind of tumours. Acknowledgment 
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99mTc-labelled hexamethylpropylene amine oxime (HMPAO) is used in cerebral perfusion scintigraphy. The 
manufacturer recommends its utilization within 30 minutes after preparation. Each reconstituted vial allows 
us to perform 2 scintigraphy scans. However, some circumstances (preparation of patient, duration of 
acquisition per patient, availability of the γ-camera), make the use of the 99mTc-labelled HMPAO within 30 
minutes hard to reach. 
Our aim is to study the stability of this product beyond the period of recommended use by the manufacturer. 
We used Ceretec® as a cold kit and a fresh eluate of 99mTc (Ultratechnekow® generator). 
The preparation was carried out under the direct control of the radiopharmacist, respecting the 
manufacturer’s instructions. The control of Radiochemical Purity (RCP) was made by thin layer 
chromatography (TLC) from the 30th minute of reconstitution. 
We used a silica plate (Macherey-Nagel®) as stationary phase and two types of solvents (methylethyl keton, 
sodium chloride 0.9%) as a mobile phase in order to separate respectively: free 99mTc ([TcO]_4^-) and reduced-
99mTc associated with a secondary complex 99mTc-HMPAO ([TcO]_2+CII). The TLC plates were read by γ-camera 
(Ecam®). 
We carried out quality controls on several HMPAO preparations at times: t0=30 min; t1=60 min; t2=90 min. 
At t0, the average of the RCP was 86.5% (average of the impurities [TcO]_4^-=4% [TcO]_2+CII=11%). For t1, 
there was an increase in the percentage of the mixture ([TcO]_2+CII) from 11% to 16.5%, resulting in a 
decrease in the average of the RCP (82%). 
After 90 min, the RCP further decreased to an average of 76% ([TcO]_4^-= 4.5%, [TcO]_2+CII= 19.5%). 
According to the manufacturer’s recommendations, the preparation of 99mTc-HMPAO can only be used if the 
RCP ≥ 80%. 
In conclusion, the stability study showed that the 99mTc HMPAO is stable beyond 30 min up to 60 min after 
preparation. Thus, the product is stable for 60 min allowing flexibility of usage. Further tests are needed to 
validate these results. 
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The goal of this study is to develop a novel brain receptor imaging agent. This study reports the synthesis, 
characterization and the biological evaluation of 1-((2-methoxyphenyl) quickly (radiolabelling time <5 min.), in 
90% yield. The 99mTc-complex, characterized piperazine)ferrocenecarboxamide labelled with technetium-99m 
(99mTc-MP). The 99mTc-MP was obtained by HPLC (20 to 50% ACN of 0 at 5 min then 50% ACN of 5 at 17 min to 
finally with 50 at 20% ACN of 17 at 20 min). It was stable, neutral and lipophilic enough to cross the blood-
brain barrier which was confirmed by octanol/water partition coefficient (LogP = 1.82). In vivo biodistribution 
indicated that this complex had exceptional brain uptake (2.47% ID/g at 5 min and 0.75% ID/g at 60 min). The 
distribution of the activity at 15 minutes post-injection in various rat brain regions showed a higher 
accumulation in the hippocampus area. After blocking with 8-hydroxy-2-(dipropylamino) tetralin, the uptake 
of hippocampus was decreased significantly from 0.87% ID/g to 0.21% ID/g at 15 min p.i., while the cerebellum 
had no significant decrease. 
The new 99mTc-cyclopentadienyltricarbonyl technetium complex reported here showed promising biological 
results, making it an interesting starting point for the development of a new 99mTc complex as brain receptor 
imaging agent. 
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18F-Tetrafluoroborate (18F-TFB) is a radiotracer, promising iodide analog for PET imaging of thyroid cancer and 
sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to 
standardize y characterize a new radiosynthesis method of 18F[TFB] in facilities with little infrastructure. 
18F was produced in a cyclotron via the 18O(p,n)18F reaction with 18 MeV protons and then delivered to the hot 
cell and trapped in a QMA and plus accell CM cartridges. The cartridge was rinsed with 10 mL of water and 
dried with nitrogen for 3 minutes. After this step, the QMA was eluted with 1.2 mL of NaCl 0.9 % ([18F]-NaF 
740-1850 MBq) in the reactor where it contains 100uL of NaBF4 dissolved in water (10ug) were mixed. The 
mixture was left to react at 120℃ for 20 minutes venting the reactor every 5 minutes. 
The crude 18F-TFB product was purified by SPE using a Sep-Pak Alumina Light and plus cartridge and washed 
with 1 mL of water. Then, it was diluted with 5 ml of isotonic sterile saline and filtered through a hydrophilic 
0.22 μm Millex. Radiochemical purity was determined by TLC using SG strips as a stationary phase methanol 
as a mobile phase. TLC-strips were analysed by autoradiography.  
Results: Labelling and formulating took about 30 minutes, where the radiochemical purity of 18F[TFB] was 
higher than 98%. The radiochemical yield of 18F-TFB was 31.0% ± 0.7% (n=10) uncorrected in a synthesis time 
of 20 min (Fig 1). The final product 18F-TFB was analysed for radiochemical purity by both radio-TLC (MeOH, 
Rf=0.23 for fluoride, 1.04 for 18F-TFB) and anion chromatography HPLC with a radioactivity detector (retention 
times, 3.7 min for 18F-fluoride, 7.8 min for 18F-TFB). 
Based on the results of radiochemical purity and quality control, we can determine that this method is possible 
to adapt in facilities where there is little equipment infrastructure. A solid-phase supported synthesis of 18F-
TFB was developed via [18F]-NaF. With the optimized condition, the radiochemical yield of 18F-TFB was 31.0% 
± 0.7% (n=10) uncorrected in a synthesis time of 20 minutes. 
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68Ga-Labelled peptides have become relevant for diagnostic imaging because of their favorable 
pharmacokinetics and their usefulness as radiotracer of PET. Gastrin-releasing peptide receptor (GRPR), also 
known as bombesin (BBN) receptor subtype II, is a member of the G protein- couple receptor family of BBN 
receptors, its expression has been reported in various cancer types, including prostate cancer, breast cancer, 
colorectal cancer, pancreatic cancer, glioma, lung cancer and gastrointestinal stromal cancer. Therefore, GRPR 
became an interesting target for receptor mediated tumour imaging and treatment. The aim of this research 
was to evaluate the biodistribution and radiation dosimetry of 68Ga-Lys1, Lys3-DOTA-BBN (1,14) based on 
whole body (WB) PET imaging in healthy human subjects. 
Twelve healthy volunteers were included and underwent WB PET/CT (from the apex through the feet) at 5 
time points (1, 10, 30, 60, 90 minutes) after intravenous injection of the tracer (190 ±28 MBq). Subjects did 
not void the bladder until the entire series of images was completed. Images were analyzed using Syngo.via 
VB10B software by drawing volume of interest in source-organs to determine radiotracer uptake. 
OLINDA/EXAM software was used to estimate human radiation doses using the reference adult model. 
The dosimetry results indicate that the critical organ is the Pancreas, and urinary bladder, where the absorbed 
doses reached 206.5±35.7,210±57.1, 120±20.9, 390.23±61.6 µGy/MBq, the (women and men, respectively) 
and the effective doses were estimated as 73.2±6.0, 49.8±7.3 µGy/MBq 
In conclusion, 68Ga-DOTA-BBN is rapidly cleared from the body by urinary excretion. The mean effective dose 
(all subjects, men and women) for a typical injected activity of 185 MBq is on the order of 4 mSv, which is a 
like other 68Ga-labelled radiopharmaceuticals. 
ISTR–2019 
 
182 
 
Technetium-99m labelled Human immunoglobulin G polyclonal antibody – different approach for 
better results 
Author: Aschalew Alemu Marie1  
Co-author(s):  Yohannes Jorge Lagebo1; Paulina Apostolova2; Toni Tripunoski3; Emilija Janevik Ivanovska2 
  1Addis Ababa University, Ethiopia  
 2Faculty of Medical Sciences, Goce Delcev University Stip 
 3University Ss Cyril and Methodiuous, Skopje 
Corresponding author: aschuradio@yahoo.com 
The aim of the study was to compare the radiochemical purity of 99mTc-human immunoglobulin G using direct 
and indirect methods of labelling. 
Radiopharmaceuticals used for infection and inflammation imaging have significant use for good patient 
management outcomes especially in developing African countries. Several radiopharmaceuticals have been 
used for the diagnosis of infection and inflammation disorder.  Even though none of them is ideal, each one 
has its own strengths and weaknesses. Human immunoglobulin G as a ligand labelled with technetium-99m 
radionuclide that provides an important characteristic since there is commercially introduced injectable form 
of human immunoglobulin (IgG). It is suitable for intravenous administration for the treatment of 
immunodeficiency syndrome, and the availability of technetium-99m radionuclide has the ideal radiation 
characteristics for diagnostic imaging from the Mo- 99/Tc-99m generator. 
Human immunoglobulin G polyclonal antibody can be labelled with technetium using direct and indirect 
method. Direct method of labelling uses a weak ligand to facilitate the labelling process. Sodium 
pyrophosphate and sodium glucoheptone are the most commonly used weak ligands. Indirect labelling uses 
HYNIC that can serve us a bifunctional agent that can bind both the antibody and the radionuclide. 
We compared the labelling efficiency including radiochemical purity of directly labelled and indirectly labelled 
human immunoglobulin G polyclonal antibody for infection and inflammation disorder imaging and we found 
out that direct labelling method provide better labelling efficiency than indirect labelling method. In addition, 
it was realized that there is no difference in the labelling efficiency to use sodium pyrophosphate and sodium 
glucoheptonate as a weak ligand. 
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The widest possible range of available molecular targets and their vectors is a crucial key for targeted diagnosis 
and cancer therapy problems.  The present work is concerned with a vector: the peptidomimetic inhibitor, the 
molecular target of which is neuropilin-1 (NRP-1). NRP-1 is a receptor for the vascular endothelial growth 
factor-165 (VEGF165), playing an important role in pathological angiogenesis and in tumour development and 
progression. It has been observed that NRP-1 overexpression is associated with tumour aggressiveness in 
several types of cancers. The demonstrated involvement of VEGF165/NRP-1 complex in pathological 
angiogenesis has catalysed interest in searching for inhibitors of such interaction to combat angiogenesis 
dependent diseases. It was shown before that a heptapeptide Ala-Thr-Trp-Leu-Pro-Pro-Arg (A7R) is a good 
inhibitor of the VEGF165/NRP-1 interaction. 
The work involved the labelling of the Lys-(hArg)-Dab-(Ahx-DOTA)-Pro-Arg peptide (working name KM1) and 
preliminary physicochemical studies of obtained radiobioconjugate. KM1 is an analog of the A7R peptide what 
is stronger inhibitor of VEGF165/NRP-1 complex than A7R. 
Peptide KM1 was synthesized in the Peptides Laboratory of the University of Warsaw using the SPPS method 
on Wang resin using the Fmoc strategy. The labelling was performed with 68Ga (95℃, 10 min) and the obtained 
radiobioconjugate was purified by HPLC (semi-preparative Jupiter® Proteo column). Lipophilicity (logP value) 
was determined in a standard biological system (PBS solution and n-octanol) and the stability of the compound 
was tested in human serum. 
The labelling yield was about 72%. The determined logP value equal to -4.16 ± 0,02 indicates that 68Ga-DOTA-
KM1 radiobioconjugate is a strongly hydrophilic compound. Stability studies in human serum showed that 
about 85% of the radiobioconjugate remains in the free form in the serum solution (about 15% is combined 
with the protein present in the serum). 
The present studies are the first step on the new VEGF/NRP-1 radioisotopically labelled peptidomimetic 
inhibitors for cancer diagnostics and therapy. In the next steps, the syntheses of new peptidomimetics are 
planned as well as the using of a long-lived isotope, e.g. 177Lu or a 43,44Sc/47Sc theragnostic pair. 
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Development of the universal radiopharmaceutical kit, which would contain the active ingredient, i.e. PSMA-
11 (nazwę chemiczną tutaj), and excipients allowing its efficient radiolabelling with 68Ga eluate regardless the 
type of 68Ge/68Ga generator used, remains a challenge. The aim of the study was to determine the critical 
quality parameters of our earlier developed kit for 68Ga labelling of PSMA-11 and the investigation of 
limitations in the radiolabelling conditions. 
The study was performed using sterile and endotoxin free dry kits, which have been developed in our lab, each 
containing 20 µg of PSMA-11 and 60 mg of sodium acetate. To investigate the labelling conditions (pH, 
radioactivity, volume) the kits were labelled with 68Ga eluted from different 68Ge/68Ga generators 
(manufactured by ITG, Eckert & Ziegler and IRE) in volumes ranging from 1 to 5 ml and radioactivity from 200 
MBq up to 1.2 GBq. The labelling yield and radiochemical purity were checked by HPLC (Kinetex C18 150mm; 
A: 0.1%TFA/H2O, B: 0.1%TFA/CAN, 5-50% B in 10 min) and TLC (ITLC SG; 10% NH4OAc/MeOH 50/50 v/v). In 
the second part of study the influence of potential metallic impurities originating in the 68Ge/68Ga generator 
eluate or other reagents were tested by spiking the labelling mixture with the Zn(II), Cu(II), Fe(III), Al(III), Ti(IV), 
Ge(IV) and Sn(IV) ions. The formation of the PSMA-11 metal complexes was confirmed by HPLC-MS. The 
stability of the kits was studied in lowered temperature (2-8℃), room temperature (25℃) and in transport 
conditions (at 35℃ for two weeks). In the stability study, the main parameters controlled were the 
radiochemical purity of the labelled PSMA-11 and the radiolabelling yield after using low and high volumes of 
the eluate. 
It was observed that 20 µg of PSMA-11 in the kit is enough to obtain high radiolabelling yield (>99%) even if 
high radioactivity of 68Ga eluate (> 1GBq) was used. Also, the varying volume of the radiolabelling does not 
affect the radiochemical yield. The most critical parameter of labelling is the pH, which should be maintained 
< 5. In the pH range of 4.5-5.0 the labelling yields were >98% or between 95 and 98%, depending on the batch, 
and the type of 68Ge/68Ga generator. These differences in the labelling yields could be attributed to the 
presence of metallic impurities in the eluates. The collected stability data indicated that manufactured kits are 
very stable during storage at 25℃ as well as at elevated temperature (up to 35℃). 
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The symptomatic treatment of skeletal pain due to metastases is complex. Especially in patients with multiple 
skeletal lesions and osteoblastic lesions on skeletal scintigraphy, systemic radiotherapy with radionuclides 
linked to a bone-seeking agent is preferred because of its efficacy, low cost, and comparatively low toxicity. 
Various radiopharmaceuticals are available for this radiotherapy including 32P, 89Sr, and 186Re labelled 
hydroxyethylidene diphosphonate and 153Sm and 177Lu labelled ethylene diamine tetramethylene 
phosphonate (EDTMP). Because of its use in many Nuclear Medicine protocols including peptide radionuclide 
therapy and radioimmunotherapy, the clinical experience is higher with 177Lu. Therefore, 177Lu-EDTMP is the 
most preferred among these radio- pharmaceuticals. However, in contrast to other peptide radionuclide 
therapy agents (177Lu-PSMA, 177Lu-DOTATATE, 177Lu-DOTANOC) there is no standard and optimized method for 
the synthesis process in routine practice, and clinics use their own manual methods. The aim of this study was 
to develop the automated 177Lu-EDTMP synthesis for routine use. 
The study was conducted in 3 main groups: 1) to determine and optimize the synthesis conditions of EDTMP 
and 177Lu to be complexed in maximum ratio 2) Development of automated standardized production method 
by transferring manually determined synthesis parameters to automatic synthesis device (ML-Eazy and 
Pharmtracer, EZAG GmBH, Germany) 3). Development of the radiochemical purity analysis of method 177Lu-
EDTMP. 
Determined synthesis conditions were: EDTMP: 40 mg, 177Lu: 10-100 mCi, buffer: NaHCO3 (1M), time15-30 
min, temperature: 80 C° 
Synthesis parameters: 
1. Pre-heating of reaction vial at 50 ℃ (60 sec) 
2. Transfer of 177Lu to reaction vial by elution with radiolabelling solution (90 sec) 
3. Radiolabelling at 80 ℃ (1500 sec) 
4. Cooling with 4 mL saline 
5. Transfer by passing through Sep Pak CM cartridge 
6. Filtration from 0.22 μm filter 
Developed analysing method parameters were: Device: Shimadzu LC-20A 
Column: C-18 perfectbond ODS-H 5μm (100x4 mm) 
Mobile phase: A: water:ethanole (90:10); B: water:TFA (100:0.1) 
Elution: Gradient 100% A (0-5min), 100% B (5-5.30min), 100% B (5.30-16 min), 100 % A (16-20min) Sample 
chromatogram was presented. 
In this study, the method for automated synthesis of 177Lu-EDTMP with PharmTracer and ML-Eazy synthesis 
modules was developed. Repeatable production of this agent in pharmaceutical grade can be achieved in 
hospital setting. 
 
ISTR–2019 
 
186 
 
Preparation, characterization and in-vitro studies of [68Ga]NODAGA- Pamidronic acid for PET 
bone imaging 
Author: Zarif Naim Mohd Ashhar1;  
Co-author(s): Nor Azah Yusof1; Wan Hamirul Bahrin Wan Kamal2; Hishar Hassan1; Hazlina Ahmad Hassali2; 
Fathinul Fikri Ahmad Saad1; Siti Mariam Mohd Nor1 
1University Putra Malaysia & National Cancer Institute, Putrajaya, Malaysia 
2Malaysian Nuclear Agency 
Corresponding author: azahy@upm.edu.my, zarifnaim@gmail.com 
For years, bisphosphonates (BP) were known for their role in reducing the risk of skeletal related event in 
patients with bone metastases by accumulating and inhibiting the osteoclastic activity. Hence, since the 
emergence of germanium-68/gallium-68 generator for positron emission tomography (PET) imaging, 
developments in gallium-68 labelled BP for bone imaging have been looked into. Through the conjugation of 
a stable bifunctional chelator to a BP namely 2,2′-(7-(1-carboxy- 4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-
1,4,7-triazonane-1,4-diyl)diacetic acid (NODAGA) and Pamidronic acid, this research aims to study the 
preparation, characterization, and in-vitro studies of [68Ga]NODAGA-Pamidronic acid ([68Ga]NODPAM) for PET 
bone imaging. 
NODAGA was conjugated to Pamidronic acid via NHS ester strategy. The conjugated precursor was 
characterized using tandem mass spectrometry (MS/MS) and purified using high performance liquid 
chromatography (HPLC). The conjugated NODAGA-Pamidronic acid was radiolabelled with gallium-68 in 
acetate buffer forming [68Ga]NODPAM complex. The percentage radiochemical purity (%RCP) was assessed 
using radio-thin layer chromatography scanner (stationary phase: TLC-SG 60; mobile phase: acetonitrile:0.4M 
Phosphate (7:3)). The human plasma stability was studied 0.5 hourly for 2.5 hours. The bone binding assay of 
[68Ga]NODPAM was performed using synthetic hydroxyapatite (HA) and was compared with [99mTc]MDP. To 
visualize the retention of [68Ga]NODPAM on bone, a preliminary PET image of fresh bone incubated in 
[68Ga]NODPAM was performed. 
The MS/MS analysis of conjugated NODAGA-Pamidronic acid produced expected mass-to-charge ratio 
(calculated [M-H]- m/z: 591, obtained [M-H]- m/z: 591). Based on the fragments produced, the structure of 
NODAGA-Pamidronic acid was confirmed ([M-H-H2O]- m/z: 573, [M-H-H2O-HPO2]- m/z: 509). The %RCP of 
radiolabelled [68Ga]NODPAM was above 90% within 15 minutes at pH 4-4.5. The [68Ga]NODPAM proves to be 
stable in human plasma throughout the study. The in-vitro percentage HA bone binding assay performed 
showed significant difference between [68Ga]NODPAM 82.25%±1.72% and [99mTc]MDP of 53.21%±0.28% (p-
value <0.05). The superiority of [68Ga]NODPAM in bone binding assay may be due to its indirect chelation 
([68Ga]-chelate-BP) effect as compared to direct chelation ([99mTc]-BP) which may hinder its affinity of BP 
towards HA. Preliminary assessment using animal PET proves good bone uptake. 
 [68Ga]NODPAM was prepared and characterized accordingly and the in vitro bone binding assay was assessed. 
From previous studies, radiolabelled gallium-68 bisphosphonates showed convincing animal biodistribution 
results. Though the data obtained may not reflect overall clinical potential, preliminary data suggests that 
further [68Ga]NODPAM experiments on animal model, especially to determine the biodistribution and bone-
to-blood ratio, must be performed in order to prove its clinical indication. 
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6-[18F]Fluoro-L-DOPA, ([18F]FDOPA) or simply FDOPA is a radiopharmaceutical used for targeting dopamine 
receptors by using positron emission tomography. FDOPA is useful for different diagnosis of Parkinson’s 
disease and other degenerative disorders of the central nervous system. FDOPA PET is also useful for the 
detection and staging of endocrine and brain tumours. FDOPA is conventionally produced via electrophilic 
substitution by using fluorine-18 prepared by irradiating neon gas using deuteron beam. However, results in 
the production of low specific activity tracer. Nucleophilic substitution reaction using fluoride has been 
developed for the synthesis of FDOPA which results in the production of high specific activity tracer. Cassette 
based synthesis in automated module using novel precursors are now commercially available. Considering the 
high demand for FDOPA, we are routinely carrying out the production of FDOPA under GMP. The results are 
presented in this paper. 
No carrier added 18F was produced by 11 MeV Siemens HP cyclotron. Production of FDOPA was carried out 
using NEPTIS automated synthesizer procured from Neptis, which Belgium installed in a clean room with class 
B area. Radioactivity measurements were done using a capintec dose calibrator. Oxygen-18 enriched water 
and FDOPA cassettes, including all chemicals were procured from ABX, Germany. The precursor (S)–N-Trityl–
5–formyl-4-methoxy-methylene-2-nitro-phenylalanine tert-butyl ester is used in the cassette in addition to all 
other chemicals and purification cartridges. TLC was performed using AR2000 TLC scanner procured from 
Erkect and Ziegler. The mobile phase used for TLC is glacial acetic acid and methanol (9:1). Residual solvents 
were analysed by Agilent Gas chromatography. 
The FDOPA was prepared in a four-step synthesis in a Neptis synthesizer. Followed by the steps of nucleophilic 
fluorination, oxidation of intermediates and hydrolysis, FDOPA was trapped on HR-P cartridge and eluted with 
phosphate buffer, passed through a C-18 and Oasis Wax cartridges to remove non-polar and solid impurities. 
The product is collected in a 30 mL vial connected to a 0.22µm millipore filter. The above series of purification 
avoids the need for HPLC purification. The total duration of FDOPA production was 90 minutes. The 
radiochemical yields of FODPA (n=18) are 6 ± 1.2% (decay uncorrected) and 10.5 ± 2.2% (decay corrected).  
The radiochemical purity was always >94 % and 97.2±1.6 % (n=18) and was retained > 92% up to 7 hours. 
FDOPA was used in multiple nuclear medicine departments for PET-CT and PET-MR studies. The images were 
found to be highly useful for clinical evaluation of patients suffering from neurological disorders as well as for 
neuroendocrine tumours. 
Consistent production of FDOPA was achieved using a cassette based nucleophilic synthesis in a Neptis 
automated synthesizer under GMP conditions. Even though the final decay uncorrected yields were low (~6%), 
the product was found to be clinically useful for PET-CT and PET-MR studies. 
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Radiopharmaceuticals targeting the enzyme, PSMA over expressed in prostate and other cancers are now 
widely used in nuclear medicine. 68Ga-PSMA-11 has become a widely accepted tracer for imaging prostate 
cancer. The nuclear medicine centres which do not have access to 68Ge/68Ga generator are interested in using 
18F tracers for imaging prostate cancer. PSMA-1007 is a ligand having molecular structure similar to PSMA-617, 
which is widely used for 177Lu/225Ac therapy of prostate cancer. We describe here the production of [18F]PSMA-
1007 using Neptis Syntheziser and a commercially available cassette. 
No carrier added 18F was produced in a 11 MeV Siemens HP cyclotron. Production of [18F]PSMA-1007 was 
carried out using NEPTIS mosaic RS automated synthesizer procured from Neptis, Belgium, installed in clean 
room with class B area. Radioactivity measurements were done using Capintec dose calibrator. Oxygen-18 
enriched water and [18F]-PSMA cassettes that include all chemicals were procured from ABX, Germany. The 
precursor PSMA-1007 was used in the production, which was supplied along with cassette by ABX. TLC was 
performed using AR2000 TLC scanner procured from Eckert and Ziegler. The mobile phase used for TLC is 
Acetonitrile and Water 60/40 (V/V). Residual solvents were analysed by agilent gas chromatography. Clinical 
studies were done in patients referred to the nuclear medicine department for PET imaging of prostate cancer. 
The [18F]PSMA-1007 was prepared in two step synthesis. Followed by labelling, [18F]PSMA-1007 was trapped 
on a preconditioned C-18 cartridge and eluted with 30% ethanol and passed through Chromafix PS-H+ 
cartridge. The final product was collected through a 0.22 µ Millipore filter connected to a 30 mL vial. The total 
duration of [18F]PSMA-1007 production was 45 minutes. The radiochemical yields of [18F]-PSMA-1007 are 28 
± 8% (decay uncorrected, end of the synthesis) and 38 ± 10% (decay corrected to start of the synthesis). The 
radiochemical purity was always >98 %. [18F]PSMA-1007 was used in multiple nuclear medicine departments. 
PET-CT images are acquired 2 hour post injection of 200-300 MBq of the radiopharmaceutical in prostate 
cancer patients. The images were reconstructed with standard software and evaluated by nuclear medicine 
physicians. PET-CT images were comparable to [68Ga]PSMA-11. Compared to 68Ga-PSMA-11 images, some 
differences in physiological uptake sites of the tracer were noted with [18F]PSMA-1007 images; eg. the 
consistent tracer uptake in gall bladder owing to the hepatobiliary route of excretion of [18F]PSMA-1007. 
However, the reporting nuclear medicine physicians appreciated the image quality of [18F]PSMA-1007 images 
and judged the image quality of [18F]PSMA-1007 images at par with 68Ga-PSMA-11 for imaging prostate cancer. 
 [18F]PSMA-1007 was prepared in higher yields and in Curie quantities using a cassette based nucleophilic 
synthesis in a Neptis automated synthesizer under GMP conditions. The synthesis yields were sufficient to 
deliver the activity to multiple nuclear medicine centres. [18F]PSMA-1007 is a tracer that can be routinely 
prepared in a cyclotron and distributed to NM centres for assessment of prostate cancer. 
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cartridge purification by Sep Pak® Plus ALOX N 
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The utility of [18F]Fluoroestradiol ([18F]FES), a fluorinated steroidal tracer for determining the tissue estrogen 
receptor level of breast cancer patients is clinically proven. This radiotracer is thus used in prior prediction of 
the response of antiestrogen therapy of primary, recurrent or metastatic breast cancer. A fully-automated, 
high-yield synthesis procedure is the key requirement for its availability in large scale, ensuring its wide-spread 
clinical use. 
The radiosynthesis of [18F]FES is carried out starting from MMSE (3-methoxymethyl-16α, 17β-epiestriol- O-
cyclic sulfone) precursor. The low yield of [18F]FES obtained from this precursor is attributed to difficulties in 
the hydrolysis and purification steps after the first step radiofluoriation. 
Herein, we report an improved fully automated and optimized radiosynthesis procedure of 18F-16-α- 
Fluoroestradiol ([18F]FES) from MMSE precursor, involving hydrolysis with 2N HCl and subsequent purification 
using SepPak® Plus ALOX-N cartridge. The method is reliable, with considerably improved yield of the product 
with acceptable radiochemical purity. 
18F produced in the medical cyclotron [18O (p, n) 18F] was trapped in perfectly conditioned and dried QMA 
cartridge and TBA18F was eluted by 0.6 ml 75mM TBAHCO3. 1.2 ml dry acetonitrile was added followed by 
azeotropic distillation for obtaining extra dry TBA18F. MMSE precursor (2mg/0.8 ml dry MeCN) was added and 
radiofluorination was carried out at 120˚C for 15 minutes. Hydrolysis of the radiofluorinated MMSE precursor 
was carried out at 115˚C for 12 min using 0.7 ml of HCl (2N). The reaction mixture was cooled and around 2ml 
of pharmacopeia grade ethanol was added into the reaction vessel, under stirring condition. The reaction 
mixture was then passed through a stand of four perfectly conditioned SepPak® Plus ALOX-N cartridges 
discarding the eluent and subsequently dried by-passing helium. Finally, [18F]FES was eluted with 12 ml of 15% 
ethanol containing water in the product vial. 1.5 ml of 10% NaCl and 0.5 ml of 1(M) NaH2PO4 were added at 
the beginning of the synthesis in order to maintain acceptable pH and isotonicity of the product. 
[18F]FES was then dispensed through 0.2µ filter into sterile and bacterial endotoxin free vials. Including its 
physical properties, radiochemical purity was ascertained by radio-TLC. The product formation is confirmed 
by comparison of its TLC with that of the authenticated reference standard [19F]FES. 
The non-decay corrected radiochemical yield was found to be ~ (35±5) % (n = 3) within 60±2 mins. The 
radiochemical purity (> 95 %) was confirmed by radio-TLC using freshly prepared 95/5 MeOH/NH3 solvent. 
While [18F]FES has Rf of 0.7, free [18F]F- exhibits Rf of 0.01 and that of the radiofluorinated MMSE precursor is 
around 0.15. The radiochemical purity of [18F]FES was confirmed by comparing with the authenticated 
reference standard [19F]FES. [18F]FES obtained was clear, colourless and free of any suspended particle, with 
pH ~ 6. 
In conclusion, [18F]FES has been successfully synthesized and purified in good yield using the fluorination 
module in the medical cyclotron under optimized condition which is identical in principle with GE 
TRACERLABFX-FDG. 
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Overexpression of COX-2 receptors is observed in a variety of tumours. Therefore, development of suitable 
18F-labelled PET radiotracers of selective COX-2 inhibitors is an attractive option to target selective and specific 
inhibitors of COX-2. The binding free energy [G(-KCal/mole)] of Ac- etaminophen and F-18 labelled derivative 
of Acetaminophen has been calculated by using AUTODOCK 4.2 and crosschecked using www.swissdock.ch 
against the PDB code 3LN1 and has been found to be comparable in both cases. This encouraging result 
provides the necessary impetus towards the development of F-18 labelled derivative of Acetaminophen based 
on its property of selective COX-2 inhibition in designing PET radiopharmaceutical for tumour imaging. 
Herein, we report the fully automated radiosynthesis of the novel F-18 Fluoroethylated paracetamol by direct 
radio-fluoroethylation of paracetamol and subsequent purification with SEP-PAK® cartridge purification. The 
evaluation of the PET radiotracer has been carried out by PET/CT imaging, bio-distribution in mice tumour 
model and histopathological studies. 
The fully automated radiosynthesis of 18F-Fluoroethylated paracetamol using general purpose synthesis 
module which, in principle, is similar to GE TRACERlab FXFDG, has been carried out in three steps: (i) 
Radiosynthesis of the fluoroethylating agent, [18F]Fluoroethyl tosylate (ii) Coupling of [18F]Fluoroethyl tosylate 
with paracetamol in DMSO solvent and (iii) purification by SPE using Sep Pak® Plus ALOX N cartridges. 
Pharmacokinetic studies were evaluated by PET/CT imaging study in healthy rabbit at two different time 
points. Biodistribution study was carried out in nude mice bearing tumour (MDA-MB-231). COX-2 
overexpression in tumours was confirmed by histopathological studies. 
The non-decay corrected radiochemical yield is around (25±3) % (n = 3) within 60±2 mins (total synthesis time). 
The radiochemical purity is >95 % as confirmed by radio-TLC and radio-HPLC coupled with UV (λ=276 nm). 
Biodistribution study demonstrated significant tumour accumulation and retention over a period of two hours 
post injection. COX-2 overexpression in tumour was confirmed by histopathological studies using mouse anti-
COX2 antibody. One-hour post injection PET/CT imaging study in healthy rabbit showed very fast clearance 
from liver and blood, however, with high accumulation of the tracer in highly proliferating regions like bone 
marrow and sub-mandibular jaws. The thick leg joints showed significant uptake which can be attributed to 
age related inflammation in aged rabbit and the well-known fact that COX-2 is overexpressed in inflammation. 
Both the kidneys as well as urinary bladder showed very high tracer accumulation indicating clearance via 
renal route. 
The PET/CT image of two-hours post injection showed complete blood clearance with elimination via renal 
route, however with bone marrow accumulation. No bone uptake other than the thick joints was observed 
throughout the period of PET/CT study confirming in vivo stability of the tracer. Thick joint uptake can be 
attributed to age-related inflammation of the aged rabbit and the well-known fact that COX-2 is overexpressed 
in inflammation. 
F-18 labelled Paracetamol has successfully been designed, developed and evaluated as a PET tracer for tumour 
imaging agent based on COX-2 overexpression in a variety of tumours. 
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Neuro-endocrine tumours (NETs) are ranked among uncommon tumours but owing to their multicentric 
origin, often pose a clinical challenge for their diagnosis and treatment. In developing countries like Pakistan, 
where PET based tumour’s somatostatin receptor (SSR) imaging are limited, Tc-99m is the key imaging tool for 
diagnosis, management and assessment of therapy response.  
The aim is for two HYNIC-TATE radiopharmaceuticals (RP-1 & RP-2) of different origin, methods of labelling 
and excipient as RP-1(a single vial) while RP-2 (two vial-(HYNIC Conjugate + co-ligand) were used to compare 
their in-vitro quality and clinical diagnostic efficacy in histopathologically known NETs and others for the 
imaging of SSR avidity, evaluated for utilization in PRRT therapy. The clinical sensitivity, specificity, positive 
(PPV) and negative predictive values (NPV) of SSR scintigraphy were calculated and compared. 
The used methods included freshly eluted sodium pertechnetate for radiolabelling. The radiochemical purity 
was checked as per specifications and injected to 75 patients (43 Male, 32 Female: Age: 87-22) of known 
primary and secondary neuro-endocrine tumours (known histopathology and prognostic markers i.e. 
synaptophysin, chromogranin and Ki-67 Index). Their Tc-99m-OCT scans were correlated with histopathology, 
CT and/or MRI reports. 
It was found that RP-1 average radiolabelling efficiency was 96.4±0.2% as complex, 2.4±0.2% as hydrolysed 
and 2.6±0.3% free pertechnetate, while in RP-2 was 98.3 ±0.5% labelled, 1.82±0.4 % hydrolysed and 0.9±0.1% 
as free pertechnetate. Out of 75 in 39 patients, where imaging was performed with RP-1, 23 were found to be 
true positive, 7 as true negative (T/P), while 9 as false negative (F/N), with sensitivity, specificity, and PPV, NPV 
of 71.87%, 100%, 100% and 43.75%. While in 36 scans screened with RP-2, 22 were T/P, 6 as T/N, 8 as F/N, 
with 75.8%, 100%, 100% and 50% sensitivity, specificity, PPV and NPV. For assessment of lesion site specificity, 
14 patients with hepatic lesions were imaged with RP-1, showing 71.4% T/P, 21.4 % T/N, while with RP-2, 
81.8% as T/P, 18.18% as T/N. Similarly, in NET of lung, both had 100% T/P result. 1 patient of 
pheocromocytoma was conducted with RP-2 and was found to be T/P. 1 Patient of papillary urothelial 
carcinoma found as T/P with both radiopharmaceuticals and 1 patient of small cell NET-Gall Bladder, where 
baseline scan and post chemotherapy scan with time interval of 6 months, showed progression in disease. 
In conclusion, the SSR scintigraphy of NET with RP-2 as compared to RP-1 had better labelling efficiency with 
more sensitivity but equal specificity, having similar positive and negative predictive values. Both can be used 
for staging and follow-up assessment of patients. Developing countries where accessibility of PET-CT and 
gallium derived diagnosis is not very feasible, gamma camera for scintigraphy augmented by SPECT-CT can 
enhance the diagnostic accuracy and assessment of treatment response via these radiopharmaceuticals. 
Keeping this in view, in future the study can be performed by enhancing the number of patients imaged by 
SPECT-CT and thus further assessing the diagnostic capabilities of these kits. 
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The physicochemical properties of drug loaded nanoparticles in physiological system are important 
determinants for their in vivo distribution and drug delivery efficiency. Stability of nanoparticles in blood 
serum remains a significant challenge for successful delivery to target tissue. Analysis of intra-biliary infusion 
of nanoparticles within two-compartmental pharmacokinetic modelling revealed efficient retention in the 
liver and minimal leakage from the liver to the blood stream. Our aim was to demonstrate the utility of gamma 
camera as an effective non-invasive imaging modality for the biodistribution of docetaxel loaded liposomal 
chitosan nanoparticles. 
Folic acid thiolated chitosan was synthesized via EDAC coupling at pH-5.0 and purified by a dialyzing 
membrane. NPs were partially oxidized 1h with stirring at room temperature, tween 80 was added to make 
an emulsion. Folic acid was grafted to TCS. The docetaxel was loaded as a cross linkage using TPP (1%) solution 
in 500ml DCM, the weighed number of lyophilized liposomes were suspended in 1mg/ml solution of FA-TCS 
and stirred for 4 hours for proper coating through electrostatic interaction between liposomes and FA-TCS. 
The coated liposomes were separated through ultracentrifugation. The Docetaxel loaded liposomal 
Thioglycolated chitosan were characterized for hydrodynamic diameter and surface zeta potential and their 
Surface morphology was studied with electron microscope (FEI Nova NanoSEM 450). The encapsulation 
efficiency was calculated by ACN: MeOH: buffer and quantified by HPLC-PDA. The in-vivo pharmacodynamic 
study was prepared with docetaxel loaded liposomal thioglycolated chitosan (FORM-A) with freshly eluted Tc-
99m and docetaxel labelled alone with Tc-99m. Then, it was loaded afterwards on liposomal thioglycolated 
chitosan (FORM-B), by an optimized protocol to retain their favourable physicochemical properties. 
Radiolabelling efficiency was measured by TLC-SG and methanol using BIOSCAN-TLC scanner coupled with 
PMT detector. The radiolabelled nanoparticle complexes (avg. dose = 58±10MBq) were orally given to the 
animal model. Planer and static gamma images were acquired at the interval of 30 minutes, 1, 2, 3, 4, 24 and 
36 hours for the localization of drug absorption and delivery site. The docetaxel drug absorption rate was 
quantified by HPLC. 
The drug loaded liposome was successfully coated with FA-TCS, confirmed by change in zeta potential. 
Encapsulation efficiency indicated that liposomal formulations showed higher value above 70% as compared 
to chitosan-TGA. The radiolabelling efficiency of both formulations measured by TLC was 99.2%. Gamma 
camera acquisition quantified as activity versus time curve indicated that the form A was localized in gut after 
2 hours of administration, and HPLC quantification confirmed that 63% of the drug was absorbed at 2 hours 
of administration. Form–B images showed that 68.2% of the drug was localized in the lungs, 23.2 % in liver 
and 8.6% was excreted through kidney. Confirmation by HPLC quantification indicated slow release of drug till 
36 hours.  
The use of gamma imaging can help to locate the specific site of absorption of nanoparticles and drug release 
while HPLC helps to quantify accurate assessment of drug release in general body circulation. 
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There are a large number of advanced stage breast cancer, prostate cancer and lung cancer patients suffering 
from severe bone pain due to the metastases of the disease. The conventional therapy which includes oral 
analgesics and localised external radiotherapy has been associated with various unwanted side effects. 
Targeted radiotherapy using radiolabelled bisphosphanate complexes are known to be the most effective 
agent. These compounds bind avidly to the bone and the radiation emitted from the radionuclides can 
substantially reduce the formation of bone tumour. Zoledronic acid (ZOL), a bisphosphonate agent, is currently 
being widely used in clinical as osteoclast bone resorption inhibitor. ZOL has proven to be an effective agent 
to prevent the manifestation/occurrence of skeletal-related complications in patient with bone metastases. 
The aim of this study was to develop ZOL-Samarium-153 as a potential radiotherapy agent. The 153Sm-ZOL 
complexes were assessed for its radiolabelling efficiency, in vitro stability, and bone uptake visualized by whole 
body scintigraphic images using Sprague Dawley rats. 
Production of 153Sm was performed using 152Sm(n,gamma)153Sm reaction at TRIGA PUSPATI reactor located at 
Agensi Nuklear Malaysia. Enriched 152Sm (purity>98%) was used to produce Sm-153. ITLC-SC strips were used 
for radiochemical purity studies. Radiochromatography were performed by using BIOSCAN scanner, 
connected with NaI(Tl) detector. Scintigraphic images of the whole body were acquired using T-Quest gamma 
camera integrated with the NuQuestTM software to produce 2D whole body image. The rat was placed on a 
flat hard surface with both legs spread out and all legs fixed with surgical tape, then an aliquot of 0.2-0.3 ml 
containing 18.5-37MBq of 153Sm-ZOL was injected intravenously via the tail vein. Ketamine/xylene were used 
as anaesthesia for the rats before recording the scintigraphy images. All others activity measurements were 
made with Na(I) gamma counter. 
The labelling yield was found to be greater than 99.1+0.07. 153Sm-ZOL moves with solvent front with Rf value 
of 0.89+0.01, while free samarium-153 remained at the point of origin. Biodistribution and localization of free 
Samarium-153 cation solution and 153Sm-ZOL were studied using Sprague Dawley rats as animal model. It was 
observed that for 153Sm cation, the biodistribution was mainly accumulated in the liver, as expected. The 
uptake of 153Sm-ZOL in rat’s bone was visualized after accumulation of injected 153Sm-ZOL. Our preliminary 
study showed that free 153Sm-ZOL was excreted via the kidney. The tracer was clearly visible in bone at 2d, 4d 
and 7d post administration and the uptake in bone increased with time and accumulated in the bone as 
expected for bone avid radiopharmaceuticals. 
Radiolabelling of 153Sm-ZOL was successful with radiochemical purity (>99%). The complex also exhibited 
significant stability in room temperature for up to 24h in vitro. Scintigraphy imaging in rats shows high uptake 
of complex in skeleton up to 7 days, the duration of studies. The biodistribution results of 153Sm-ZOL 
demonstrated that this tracer has great potential to be a new candidate for clinical applications for bone pain 
palliation therapy. 
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Rhodamine (Rh) is a lipophilic cation, same as 99mTc-MIBI that specifically accumulates in the myocardium. In 
an attempt to formulate a PET-based cardiac agent with enhanced targeting efficiency, we linked Rh to 
angiotensin II (Ang II), an 8 amino acid peptide that has been known to play an important role in cardiovascular 
function. Here we evaluate the 68Ga labelled Rh-Ang II conjugate for its potential as a cardiac imaging agent. 
Rh-Lys(DOTA)-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-CONH2 was prepared conveniently by solid-phase peptide 
synthesis according to Fmoc/HBTU chemistry. Rh-NHS ester was coupled to the peptide through the amino 
group of Lys residue and radiolabelled with 68Ga via DOTA chelator. Metabolic stability of the radiotracer was 
determined in human plasma and in vivo biodistribution and pharmacokinetics was conducted on Balb/c mice 
and Sprague Dawley rats. 
Results showed that The Rh-Ang II conjugate was radiolabelled efficiently with 68Ga (>75%) as determined by 
radio-HPLC analysis and showed sufficient metabolic stability in human plasma. In mice, the radiotracer 
displayed efficient clearance from the blood and excreted from the body mainly through the renal route with 
some elimination by the hepatobiliary system. The radiotracer uptake in the heart was found to be 1.85±0.59% 
ID/g as early as 30 min post-injection. The accumulation in other major organs including liver, lungs, stomach, 
intestines and kidneys was below 8% ID/g. A high uptake by these organs may interfere with the efficient 
visualization of the heart. In case of rats, the radiotracer showed better pharmacokinetic characteristics, with 
low uptake of radioactivity in the major body organs/tissues (<4.0% ID/g). The uptake of 68Ga-Rh-Ang II in the 
heart, 1.91±0.65% ID/g, was higher than the uptake found in the blood and muscle resulting in good heart-to-
blood and heart-to-muscle ratios. Additionally, the radiotracer exhibited cardiac extraction values comparable 
to 99mTc-MIBI in rat hearts. 
These results suggest that the combination of two biomolecules is an attractive approach to enhance targeting 
efficiency and for rapid and efficient diagnostic imaging of heart. Further studies are in progress to determine 
the full potential of this cardiac imaging agent. 
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The convenient synthesis of metal chelating agents couple with tumour targeting peptides is needed to 
accelerate the research and clinical translation in molecular imaging. DOTA has been one of the most widely 
used macrocyclic ligands for the development of new metal based imaging and therapeutic agents, owing to 
its ability to form stable and inert complexes under physiological conditions making these 
radiopharmaceuticals useful for imaging and therapy. DOTA-tris-t-butyl ester is commercially available, but it 
is expensive and contain impurities of both the dialkylated and tetra-alkylated cyclen. There is a need to 
explore new methods for preparation of DOTA-tri-tert-butyl ester, which are less expensive and provide a high 
purity DOTA product.  The aim of this study was to develop a convenient and cost-effective synthetic approach 
for the preparation of DOTA peptides directly on solid support for tumour imaging and therapy. 
The tumour targeting peptide (i.e. bombesin 7-14) was synthesized by Fmoc-based solid- phase peptide 
synthesis. For coupling with DOTA, bromoacetic acid after activation with HOBt/DIC was coupled to free amino 
group of peptide resin. This was followed by the monoalkylation of bromoacetylated peptide resin with cyclen 
(tetraazacyclododecane). The cyclen peptide was then alkylated with tertbutylbromoacetate to afford the 
desired DOTA peptide. Additionally, the same peptide was prepared from commercially available tris-tert-
butyl-DOTA for comparison. These peptides after labelling with 68Ga were evaluated for their ability to bind 
bombesin receptors over-expressed on human breast and prostate cancer cells. In vivo tumour targeting was 
examined in nude mice implanted with MDA-MB-231 xenografts. 
The identity and purity of DOTA peptides was confirmed by mass spectrometry and HPLC. The peptides 
radiolabelled efficiently with 68Ga (˃90%) and exhibited high binding affinity to BN positive MDA-MB-231 and 
PC3 cancer cell lines (kd=<20 nM). In nude mice with MDA-MB-231 xenografts, 68Ga-labelled peptides 
displayed efficient clearance from the blood and uptake/retention in all the major organs was found to be low 
to moderate (below 5%ID/g). The accumulation in the BN positive tumours was ~2% ID/g at 1 h p.i., with good 
tumour to blood and muscle ratios. The main route of excretion was renal pathway. Both peptides displayed 
comparable in vitro and in vivo behaviour.  
In conclusion, we have described the preparation and in vitro and in vivo activity of two DOTA coupled 
peptides. The synthesized peptides hold good tumour affinity and tumour targeting potential. This successful 
and economical synthetic strategy can be applied to the facile synthesis of various tumour targeting peptides 
which ultimately can be translated into clinical settings. 
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Due to favourable characteristics in in-vivo applications, high specificity and long half-life of 18F (109.8 min), 
the O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) has become an important tool for molecular imaging of cerebral 
tumours.  In our previous studies we presented a convenient synthesis of [18F]FET via direct nucleophilic 
fluorination of a chiral NiII complex of an alkylated (S)-tyrosine Schiff base, Ni-(S)-BPB-(S)-Tyr-OCH2-CH2OTs (I) 
in the presence of K2.2.2 and K2CO3. After acidic hydrolysis, [18F]FET was purified using reverse phase and 
strong cation exchange cartridges. Tfhe process was automated on the Scintomics Hotboxone synthesis 
module. However, when transferring this procedure to TRACERlab FX N Pro, commonly used 18F radiolabelling 
platform, we observed two radiolabelled by-products that were not amendable to SPE purification procedure. 
Their formation may be a consequence of reaction vessel design (high volume/surface vs small amount of 
reaction mixture) and possible over-heating during vacuum drying of 18F-fluoride complex. As the construction 
of the heating block was amendable to modification, we have focused on improving fluorination process, 
substituting the K2.2.2/K2CO3 mixture with an alternate PTC- tetrabutylammonium tosylate (TBAOTs). The SPE 
purification protocol was also adjusted to better suite TRACERlab FX N Pro. 
Aqueous [18F]fluoride solution (1.3 ml) was loaded on Waters QMA carbonate Plus light Sep-Pak cartridge (46 
mg). The cartridge was rinsed with 5 ml of MeOH and dried using gas flow; the [18F]Fluoride was eluted with 
700 µl of MeOH with 4 mg of TBAOTs. After solvent removal 4 mg of I in 700 µl of MeCN was added, and 
reaction mixture heated to 80oC for 7 min. After acidic hydrolysis (0.5M HCl, 110oC, 5 min) the reaction mixture 
was diluted with 11 ml of water and 2.5 ml of 0.1M NaOH. Resulting basic solution (pH 9) was passed through 
small filtration column and three tC18 Light cartridges connected sequentially. [18F]FET was eluted with 10 ml 
of sodium acetate solution (5 mM, pH 4) containing 3% of EtOH and further purified by passing through CM 
Plus cation exchange cartridge to removal any residual nickel. 
As a result, replacement of K2.2.2/K2CO3 with TBAOTs allowed us to substantially increase radiochemical 
conversion (RCC > 85%, radioTLC). Formation of radiolabelled by-products discussed earlier was not observed 
using gradient HPLC analysis. [18F]FET was obtained with radiochemical purity >99% and enantiomeric purity 
of 94-95%. Decay corrected radiochemical yield was 50%, synthesis time ca. 35 min. 
In conclusion, using non-aqueous solution of TBAOTs as an inert PTC allowed for substantial increase of 
fluorination efficiency while avoiding formation of radiolabelled by-products. The radioactivity loss on the 
inner surfaces, which is critical for the reaction vessel on the TRACERlab FX N Pro, was minimized. The 
proposed synthesis methodology appears to be well-suited to transfer to other automated synthesizers for 
nucleophilic synthesis of 18F-labelled radiotracers. 
Acknowledgments: this research supported by RFBR grant 18-29-01015-mk. 
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16α-[18F]-fluoroestradiol ([18F]FES) is used for estrogen receptors imaging in breast cancer diagnosis and follow 
up. Although reported methods use similar labelling procedures, optimal hydrolysis and purification conditions 
may be different according to the used module. No data referring SYNTHRA RNplus Research Module were 
found in the literature. 
The aim of the present study was the optimization of the automatic synthesis of [18F]FES using the SYNTHRA 
RNplus Research platform. 
Synthesis of ([18F]FES) was achieved by reaction of 1 mg of 3-O-methoxy-methyl- 16β-epiestriol-O-cyclic 
sulfone in 1 ml of anhydrous acetonitrile with 37 GBq of [18F]F at 100℃ for 10 min. The product was hydrolysed 
at 100℃ for 12 minusing different conditions: 1) 1.0N HCl, 2) 2.0N HCl in acetonitrile: water (3.0 ml, 9:1 v/v) 
and 3) 0.5N H2SO4 in ethanol: water (3.0 ml, 9:1 v/v). Purification was performed by HPLC using a C18 column 
(VP250/10 SynthraReeperbahn, 5 μm) flow rate: 2.0 ml/min, λ=280 nm, using either a) Ethanol: water 50:50 
or b) Water: Etanol: Acetonitrile (50:25:25) as mobile phases. The peak was either diluted with 0.9% NaCl (a) 
or with 50ml of water and purified with a Sep-Pak C18 Plus-Light cartridge (b). 
The radiochemical purity (RCP) was determined by HPLC using a Phenosphere column (ODS 80 A, 250x4.6 mm, 
5 μm), flow 1.5 ml/min. and a gradient of acetonitrile in water (acetonitrile 10% to 90% from 0 to 10 min) and 
λ=280 nm. 
Results show that the module contain a reduced volume reactor (7 mL, conical shape) to perform the labelling 
and a standard reactor for the hydrolysis. 
Synthesis of ([18F]FES) was developed by a standard procedure and the labelling yield (aprox. 25%) was similar 
to the reported data. 
Hydrolysis and purification are critical steps and different conditions were assayed in order to optimize the 
RCP of the product. Hydrolysis can be performed either using HCl or H2SO4. The use of H2SO4 led to the 
formation of less impurities and consequently was selected for further experiments. Purification was 
developed by preparative HPLC. The selection of ethanol as the only organic solvent offers the advantage of 
the simplicity of the final conditioning. However, this condition led to poor RCP (<90%). The use of a mixture 
of ethanol and acetonitrile, on the other hand, required an additional step of solid phase extraction but 
rendered a RCP of approximately 100%.  
In all the syntheses, the pH was in the range of 5.0-6.0, the residual Kryptofix® was below the limit and the 
residual solvents (acetone, acetonitrile and ethanol) met the specifications. 
In conclusion, the synthesis of [18F]FES was optimized in a SYNTHRA RNplus research platform. The best 
hydrolysis condition was the use of 0.5N H2SO4 in ethanol: water (3.0 ml, 9:1 v/v) and the purification by HPLC 
using Water: Etanol: Acetonitrile (50:25:25) as mobile phase followed by solid phase extraction to remove 
acetonitrile. 
Acknowledgments: ANII (POS_FCE_2018_1_1007787).  
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Radioimmunotherapy of non-Hodgkin lymphomas with anti-CD20 monoclonal antibodies (Mabs) labelled with 
b-emitter radionuclides has resulted promising. The aim of this work was to establish a method for the 
labelling Cuban chimeric anti-CD20 MAb CIMABior with 90Y. 
The influence of 3 BCA (NHS-DOTA, p-SCN-CHX-A”-DTPA and p-SCN-Bn- DOTA) was studied. Conjugation 
reaction was performed in bicarbonate buffer 0.1mol/L pH=8.5-9.0 at room temperature, varying molar ratio 
Mab:BCA and incubation times. After conjugation, the antibody was purified by gel filtration and by 
ultrafiltration through Amicon 30 kDa and changing to ammonium acetate buffer 0.1mol/L pH=6.0-6.5. 
Labelling reactions were performed at room temperature and 42 ºC, when DTPA and DOTA derivatives were 
employed, respectively. A challenging assay against 300-fold molar excess of EDTA was used to assess the 
stability of radioconjugates. Immunoreactivity was assayed by flow cytometry. To assess the in vivo behaviour 
of 90Y- CIMABior, 9 male healthy rats received 50 µg of the Mab (37 MBq, 0.2 mL) through marginal vein of the 
tail. Blood samples were drawn, and organs collected up to 72 h. 
Results showed that depending on the BCA and the molar ratio Mab:BCA, the number of chelating groups 
bound to the antibody varied in the range from 2 to 13. The same way, the labelling yield also depended on 
the employed BCA and the number of the chelating groups in the IgG molecule. The conjugates with p-SCN-
CHX-A”-DTPA and p-SCN-Bn-DOTA showed the best results of labelling efficiency (>95%). 
Radioimmunoconjugate CIMABior-Bn-DOTA-90Y showed the highest stability (>90% after 96 h). The affinity of 
Mab CIMABior for the antigen CD20 was affected by the increasing of the molar excess of BCA in the 
conjugation reaction. Besides, the affinity for the antigen was significantly lower in case of NHS-DOTA, with 
regard to the other two immunoconjugates. Immunoreactive fraction of CIMABior-Bn-DOTA-90Y was (95.27 ± 
6.21) %. Labelled Mab showed a satisfactory in vivo stability. The main target organ was the spleen (1.2-2.0 
%ID/g). Product had an elimination pathway through kidneys and liver. PK study showed a monoexponential 
with a T1/2 = 7.0 ± 3.1 h. 
In conclusions, according with the outcomes of the present work, a methodology for the satisfactory labelling 
of anti-CD20 monoclonal antibody was established. Radioimmunoconjugate CIMABior- Bn-DOTA-90Y showed 
the most adequate initial characteristics to be used in the future for the radioimmunotherapy of NHL. 
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When radiopharmaceuticals are procured, it is tempting to select based on the cost of the product. In the case 
of Lutetium-177 for radiopharmaceutical therapy, this may have considerable practical consequences. The 
radionuclide can be produced using a direct (NCA Lu-177) or an indirect method (CA Lu-177), yielding products 
with different specific activities and different levels of contamination with Lu-177m, which has a half-life of 
160 days. We asked ourselves what the implications for waste management would be if we switched from 
NCA to CA Lu-177. 
Data from 73 Lu-177 therapy doses prepared and dispensed in our hospital were reviewed. Doses were 
individually prepared, starting with approximately 7.4 GBq Lu-177. The activity of waste from the 
radiosynthesis procedure (production waste, P) and from dispensing and administration of the patient dose 
(dispensing waste, D) were calculated. These values were used to estimate potential levels of Lu-177m in 
waste. 
Waste P contained an average of 885 ± 336 MBq and waste D 183 ± 106 MBq Lu-177. Assuming that 0.05 kBq 
Lu-177m is present per 1 MBq CA Lu-177 (Bakker et al, 2006), the waste contents of the longer-living isotope 
would be 44 kBq and 9 kBq respectively (Table 1). 
In South Africa, radioactive substances with activities less than 100 Bq/g and total activity less than 4 kBq can 
be disposed as normal waste. On the day of synthesis and administration, all our production waste would have 
exceeded the 4 kBq limit, while only 10 lots of dispensing waste would fall below that level. In our worst-case 
scenario, even if a facility were to receive a ready-to-use Lu-177 radiopharmaceutical containing Lu-177m, 
waste from dispensing may have to be stored almost 2 years before disposal. 
In this study we only considered waste and we excluded patient excreta. For radiosynthesis and therapy, other 
aspects of the radionuclide, like the effect of low specific activity, should also be carefully considered. 
In conclusion, the decision regarding Lu-177 procurement should not be based on cost only. If long-living 
contaminants are likely in a radiopharmaceutical product, waste management and storage facilities will be an 
important consideration. 
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Many radiolabelled PET tracers, which can specifically bind to 5HT1A receptors, have been developed for in 
vivo imaging of 5HT1A receptors in living brain with positron emission tomography. However, due to the high 
cost of cyclotron-produced radionuclides such as 18F, 11C and a lack of availability in most nuclear medicine 
departments (very short half-life), these tracers have limited use in clinical practice. Up to the present 
technetium-99m is still the most widely used radionuclide in diagnostic nuclear medicine by virtue of its ready 
availability, low cost and optimal radiation properties (t 1/2= 6 h, 89% photon yield of 140 keV). 
The development of 99mTc cyclopentadienyltricarbonylpiperidine derivatives, in which Tc+1 is coordinated to 
cyclopentadienide (C5H5-) and three carbonyl groups, have been reported. These complexes have shown high 
uptake in the brain of rats and rabbits, as well as high affinity to the 5HT1A receptors in rats 20 min after i.v. 
administration. 
In order to better understand the structure/biodistribution relationship of piperidine derivatives and to 
improve brain retention, two new substituted piperidine derivatives were synthesized, radiolabelled and 
evaluated by biodistribution studies in the rat brains. As Ref. we used a previously published complex. This 
complex has showed a high affinity to the hippocampus rich in 5HT1A receptors but a rapid wash out from the 
brain. 
Methodology: three piperidylferrocencarboxylats were synthesized by reaction of the piperidine alcohol with 
ferrocenecarbonyl chloride to give the corresponding esters (1, 2 and 3.) 
Radiochemical synthesis is carried out in a microwave according to the following scheme: we replaced the 
Wenzel method which suffers from inadequate conditions (high temperature and long reaction time) by a 
microwave method. This new method allowed us to achieve a higher yield (90%) for a very short time of 2 min 
and allowed us to avoid heating at 150 °C. 
Biodistribution studies: in order to increase the brain uptake of tricarbonyl complexes, substituted piperidinol 
were used for the synthesis of complex 2a and 3a. Both substituted cyclopentadienyl 
Piperidine can cross easily the blood brain barrier. However, the in vivo studies in rats showed a lower uptake 
of complex 3a carrying a butyl group in position 4 as compared to previously published data for the reference 
compound (complex 4a). On the other hand, the complex 2a carrying a methyl group in position 4 has shown 
the highest brain uptake. 
With the increase of the carbon chain in position 4 a camouflage of the functional group that interacts with 
the receptors could explain the decrease of the retention 
In conclusion, labelled complexes in the presence of a sterically hindered ester do not affect the time of brain 
retention. 
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Trastuzumab is a monoclonal antibody for treatment of HER2 positive breast cancer. Immunoconjugate of this 
antibody labelled with lutetium-177 and yttrium-90 has been investigated as potential radiopharmaceutical 
for radioimmunotherapy. In our study, the labelling was done via DOTA, DTPA and 1B4M-DTPA as a chelator 
in a molar ratio of 1:20. 
Several techniques have been used to characterize the stability and retained immunoreactivity of the antibody 
in the formulated immunoconjugates. A protein integrity and purity were accessed by Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE). Vibrational (infrared and Raman) spectroscopy provided 
molecular structure information and was found convenient for verification of possible changes in the 
secondary structure. The number of chelating groups per one trastuzumab molecule was obtained by MALDI-
TOF-MS. After conjugation, the freeze-drying process was performed to obtain stable immunoconjugates for 
further labelling. Quality control and stability were examined by ITLC using a three different mobile phases 
(0.9% saline solution, 0.4 M methanol:sodium acetate (1:1) and 0.1M acetic buffer). 
The same intensity of the fragments (25 kDa for light chain and 50 kDa for heavy chain) of lyophilized 
immunoconjugates and pure trastuzumab indicated that there is no degradation of the antibody. The presence 
of characteristic amide bands in infrared spectra (amide I (1700-1600 cm-1), amide II (1480-1575 cm-1) and 
amide III bands (1255-1244 cm-1) and Raman spectra (amide I band at ~1670 cm-1 and amide III band at 1230-
1300 cm-1) have also indicated that all samples have retained native secondary structure. An average of 3.92 
p-SCN-Bn-DTPA, 3.69 p-SCN-Bn-DOTA and 4.43 1B4M-DTPA groups could be randomly conjugated to an 
antibody molecule, which represent promising result for successful labelling. 
After labelling with 177Lu and 90Y (specific activity of 200 µCi/mL), radiochemical purity and stability studies 
were performed using ITLC method in 0.9% NaCl and 0.4 M methanol:sodium acetate (1:1) as an appropriate 
mobile phase. The stability studies after 72 h have revealed that 177Lu labelled trastuzumab is more stable 
(<10% of the released 177Lu) than 90Y-labelled one (<25% of released 90Y). 
In conclusion, our study shows successful formulation of stable radioimmunoconjugates which makes this 
proposed freeze-dried kit as a potential radiopharmaceutical in vivo investigations. 
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Developing novel agents for tumour diagnosis and therapy is relevant in the attempt to improve prognosis and 
to increase patient survival. The target of this study is the synthesis of a new phthalimide derivative and 
radiolabel with one of the most important therapeutic radioisotopes; iodine-131 is to be investigated as a 
novel therapeutic agent for cancer. 
Synthesis of biologically active novel phthalimide derivative containing pyrimidine moiety, N-(6-(2-
hydroxyphenyl)-2-mercaptopyrimidin-4-yl)phthalimide (HSPMPTH), in two steps from the intermediate 
chalcone by the claisen-schimidt condensation of N-acetylphthalimide with salicaldhyde, and then chalcone 
undergo a subsequent cyclization reaction with thiourea. The synthesized compounds were characterized by 
IR, mass and 1H-NMR spectra. New synthesized phthalimide derivative was radiolabelled with iodine-131 by 
direct electrophilic substitution reaction using chloramine-T as an oxidizing agent. The radiochemical yield was 
determined by using different chromatographic techniques (HPLC, paper chromatography and paper 
electrophoresis). Factors affecting labelling yields were optimized and a biological evaluation in solid tumour 
bearing mice was studied in detail. 
The synthesized phthalimide derivative was prepared in excellent yield (about 86 %) and its structure was 
confirmed by IR, mass and 1H-NMR spectra. The radioiodination study of HSPMPTH showed high 
radiochemical yield of 95.20 ± 1.30 and good in vitro and in vivo stability of the 131I-HSPMPTH. Biodistribution 
study for radioiodinated HSPMPTH in solid tumour bearing mice showed high solid tumour uptake and T/NT 
ratio (8.45 ± 0.08 at 30 min. post- injection) compared with many new tracers which have been developed in 
recent years. 
In conclusion, 131I-HSPMPTH accumulated specifically in the solid tumour with high T/NT ratio suggesting that 
this tracer could be considered as a potential lead for its development as a new therapeutic agent for cancer. 
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Theranostic concept was coined first by John Funkhouser in the last two decades utilizing the combination of 
a high specific drug that targets diagnostic and therapeutic tools for a specific disease. As a part of personalized 
medicine, theranostics was practically established in oncology as well as applied to nuclear medicine by 
labelled gamma emitter diagnostic imaging agent before initiating treatment of labelled beta emitter targeted 
therapeutic drug. Currently, theranostic applications are used in neuroendocrine tumour (NET) and prostate 
cancer which have been investigated in many countries around the world. Especially in European countries, 
where thousands of combinations of 68Ga and 177Lu-labelled PRRT (Peptide Receptor Radionuclide Therapy) 
together with PSMA (Prostate-Specific Membrane Antigen) have been successfully used in clinics. We aim to 
establish theranostic radiopharmaceuticals in clinically routine use in our facility. 
Four theranostic radiopharmaceuticals of 68Ga-PSMA, 177Lu-PSMA, 68Ga-HADOTATATE and 177Lu-HADOTATATE 
were manually labelled under sterile techniques. Briefly, PSMA and HADOTATATE ligands were added with 
acetate buffer 1.5 ml before mixing to 68Ge/68Ga generator eluted 68GaCl3 4 ml, then heated at 100oC, 15 
minutes. After cool down to room temperature, 68Ga-PSMA, 68Ga-HADOTATATE were purified via C-18 column, 
filtrated through 22 µ membrane filter. In the other hands, PSMA and HADOTATATE ligands were added with 
ascorbic buffer 1.5 ml before mixing to commercially available non-carrier added Lutetium-177, then heated 
at 100oC, 15 minutes. After cool down to room temperature, 177Lu-PSMA, 177Lu-HADOTATATE were filtrated 
through 22 µ membrane filter. All theranostic radiopharmaceuticals were subjected to quality control process 
before injection to patients. 177Lu-DOTATATE was co-infused with amino acid solution for renal protection. 
Post-treatment SPECT scan time for the patients who were injected with 177Lu- PSMA, 177Lu-HADOTATATE, 
were 0, 1, 4, 14, 48 hrs, respectively. Absorbed dose in kidneys was determined following the MIRD method. 
From February 2018 to February 2019, we performed 68Ga-PSMA 35 doses, 68Ga-HADOTATATE 7 doses, 177Lu-
PSMA 13 does and 177Lu-HADOTATATE 5 doses. No nephrotoxicity of 177Lu-HADOTATATE and 177Lu-PSMA was 
found in all cases of our patients according to joint IAEA, EANM and SNMMI protocol guidance. 
The first proof-of-concept theranostic in Thailand has been successfully established in King Chulalongkorn 
Memorial Hospital without nephrotoxicity. In very near future, two new theranostic radiopharmaceuticals, 
225Ac-HADOTATATE and 225Ac-PSMA, will be introduced to provide better effective result and enhance our 
patients’ benefit. 
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HER 2 is a transmembrane protein expressed in a variety of tissues involved in cell development, proliferation 
and differentiation.  Amplification of HER2 gene leads to over expression of HER2 receptors and uncontrolled 
growth. HER2 expression is associated with aggressiveness of tumours. The anti HER2 monoclonal antibody, 
Trastuzumab (145 kDa), binds to domain IV of HER2 receptor and inhibits the tumour growth. The fragment 
of trastuzumab bearing antigen binding site, Fab (45 kDa), is explored for imaging HER2 expression in breast 
cancer patients. 
The Trastuzumab Fab was generated with papain digestion and conjugated with a bifunctional chelating agent 
NOTA. The NOTA conjugated Ga-68 trastuzumab Fab was separated and was radiolabelled with freshly eluted 
Ga-68 from Ge-68/Ga-68. Radiolabelled Ga-68 NOTA- Ga-68 trastuzumab Fab (Ga-68 trastuzumab Fab) was 
separated using PD-10 column and passed through 0.22 μm filter for sterility. The radiochemical purity of Ga-
68 Fab was assessed by paper chromatography using sodium-citrate (pH-5.5) as mobile phase, apyrogenicity 
with PTS and sterility in culture broth for 7 days. The patients (n=7) with immunohistochemistry (IHC) proven 
HER 2 expressing breast cancer (n=7) and HER 2 negative (n=2) were recruited. The F-18 FDG PET/CT was done 
in all patients. After obtaining permission from the Institute and informed written consent forms from 
patients, Ga-68 trastuzumab Fab (3-5 mCi) was injected and PET/CT was acquired after 1.5, 3.0 hour. Scans 
were analysed by two nuclear medicine physicians and compared with 18F- FDG findings. 
The Fab region of trastuzumab is responsible for binding with HER2 ligand binding domain. Fab was generated 
by papain digestion and separated by desalting (P-10 column). The NOTA conjugation was standardized at 4℃ 
from 22 to 24 hours incubation time and average 1.5 NOTA molecules per Fab (MALDI-TOF) were conjugated 
at 25:1 molar ratio of NOTA:Fab. The labelling efficiency of Ga-68 trastuzumab Fab was more than 50% and 
after purification, the radiochemical purity was >95%. The Ga-68 trastuzumab Fab was found sterile and 
pyrogenic. Ga-68 trastuzumab Fab MIP PET image showed high blood pool activity at 1.5 h, which was 
decreased at 3h.  However, high kidney and bladder activity demonstrated clearance by the renal route. The 
uptake at primary and metastatic lesions was visualized at 1.5 h and increased at 3 h, in terms of SUV max, in 
all HER2 expressing patients. However, no uptake was observed in HER 2 negative patients. The liver uptake 
was noted in all patients. The lesions detected on Ga-68 trastuzumab Fab PET/CT were comparable with F-18 
FDG PET/CT. To the best of our knowledge this is the first human study using Ga-68-Fab. 
In conclusion, the Ga-68 Fab has been formulated and demonstrated to be potential for targeting HER2 
positive lesions. In the future, this imaging could be utilized to demonstrate the pattern of HER2 receptor 
throughout the body before and after trastuzumab and trastuzumab radioimmunotherapy therapy. 
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Recently, the (E)-2-(2-(2-(2- [18F]-fluoroethoxy)ethoxy)ethoxy)-5-(4-methylaminostyryl) pyridine) (a.k.a. [18F]-
florbetapir) was developed in our laboratory as a radiotracer to detect β amyloid deposition in the brain using 
PET scan assisting for diagnosis of Alzheimer’s disease. In this research, we aimed to compare the production 
yield of [18F]-florbetapir obtained from the newly adapted synthesizing materials with an optimized method 
and that of the original method. 
 [18F]-florbetapir was produced at Siriraj Cyclotron Centre using HM-20S cyclotron with CFN-MPS200 module 
(Sumitomo, Tokyo, Japan). The activated fluoride (18F) was combined to AV-105 precursor by substituting the 
tosylate leaving group in a fluorination step. Then, 1N hydrochloric acid was added and pH-adjusted with 1N 
sodium hydroxide to remove the boxylic protecting group with deprotection process or hydrolysis. During 
synthesizing steps, in the original method (Method A) we used FLT cassette (Sumitomo, Tokyo, Japan) with 
installed silicone tubes. In the new method (Method B), we replaced all original tubes in FLT cassette with 
PharMed® BPT tube (Saint-Gobain, Akron Ohio, United States), which was further sent for sterilization at local 
central sterile supply department (CSSD) before use. Following purification via HPLC semi-preparative, the 
products from both methods were neutralized with 0.5% sodium ascorbate/water (non-diluted in method A 
and diluted 1:8 in method B), purified with Sep-Pak tC18 reverse phase column, eluted into the vial containing 
normal saline and filtrated with 0.22 µm Millex GV filter. 
The quality control of [18F]-florbetapir was done by standard methods for the determination of basic 
characteristics of radiopharmaceuticals including appearance, acid-base range, radiochemical purity, residual 
solvent, pyrogenicity, half-life, chemical impurities, sterility, nuclidic purity and assay of ascorbic acid. The 
remaining radioactivity inside the tubes, overall yield, specific activity, radiochemical purity and other physical 
properties from both methods were compared. 
The remaining radioactivity inside the tubes of method B was 3.23±1.4 (n =4), which was 32.57% decreased 
from 9.93±1.52% remaining radioactivity in the tubes of method A (n = 3). The recovery rate from tC18 after 
neutralization with 0.5% sodium ascorbate/water (Method B) was 94.72±6.00%, which was higher than 
76.71±4.58% from method A. 
The overall yield, specific activity and radiochemical purity of [18F]-florbetapir produced by method B were 
21.4±0.2% (not decay corrected), 5.24±2.25 TBq/mmol and 96.1±3.2%, respectively, which were higher than 
5.7±1.50%, 1.26±0.28 TBq/mmol and 95.84±0.80% obtained from method A. Other physical properties 
including appearance, acid-base range, half-life, residual solvents (acetonitrile and DMSO), total chemical 
impurities, assays of ethanol and assays of sodium ascorbate, and bacterial endotoxins of [18F]florbetapir 
produced by both methods were within standard criteria. 
We successfully improved [18F]florbetapir production by optimizing a new type of tubing cassette material to 
use with the automated synthesizer and minor adjustment of neutralization method. This new method 
provides higher production yield and higher radiochemical purity as compared to our previous method. In 
addition, this applied cassette is able to reduce production cost, easy to operate and suitable for Siriraj 
Cyclotron facility. 
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The use of 18F-FDG for PET/CT imaging is relatively new in Oman with only two centres, Sultan Qaboos 
University Hospital (SQUH) and Royal Hospital. At the onset, 18F- FDG was imported from Dubai which is about 
an hour. flight from Muscat, however, in 2015, a cyclotron was installed at the Royal Hospital, which now 
supplies both centres. To ensure patients and staff safety, as well as good image quality, a continuous and 
rigorous quality control (QC) of 18F-FDG is necessary. 
The aim of this study is to highlight the potential value of continuous surveillance of the quality of ready to 
use 18F-FDG, to share our initial experience in this area, and finally to highlight the importance of a radio-
pharmacist in a nuclear medicine department. 
A review of the quality control release form for each new batch of 18F-FDG which includes, radionuclide and 
radiochemical identity, radiochemical purity, chemical purity, pH, sterility, and bacterial endotoxin level as 
well as patient preparation before 18F-FDG injection, and any patient complaints after injection and image 
quality. 
We receive 18F-FDG only after all the tests are passed, patient injection and release after scan is always after 
all QC has been completed, however, there may be challenges associated with using 18F-FDG in our institution 
without a qualified radio pharmacist. These will be presented at the conference. 
In conclusion, a continuous and rigorous quality control of 18F-FDG by the qualified persons is important for 
patients and staff safety, as well as good image quality. This study highlights the critical role and the 
importance of an in-house radio pharmacist in a NM department. 
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Design, synthesis and evaluation of a family of 99mTc estradiol derivatives for breast cancer 
imaging 
Author: Maria Emilia Tejeria  
Co-author(s): Javier Giglio; Ana Rey 
Área Radioquímica, Facultad de Química, Universidad de la República (UdelaR), Montevideo, Uruguay. 
Corresponding author: etejeria@fq.edu.uy 
With the objective to develop a potential radiopharmaceutical for estrogen receptors imaging we present the 
design of a family of 99mTc complexes derived from estradiol, using different oxidation states of the metal and 
chelating units and studying their influence on the overall properties of the resulting products. Ligands were 
synthesized starting from ethinylestradiol, derivatizing the triple bond to incorporate different donor atoms 
to coordinate the 99mTc. 
The selected labelling strategies were the formation of a Tc (I) tricarbonyl complex (C1) with an N,N,O donor 
atom set, a Tc (V) nitride symmetric complex (C2) with two units of estradiol and dithiocarbamate as bidentade 
chelator and a Tc (III) 4 + 1 complex (C3) using a ligand bearing an isonitrile moiety and an NS3 tridentate 
coligand. Characterization stability studies, lipophilicity, protein binding, in vitro cell binding and in vivo overall 
biodistribution. 
Results show that synthesis of the ligands was successful in all cases, although the difficulty level is remarkably 
different. The selected labelling strategies rendered the desired 99mTc complexes with high radiochemical 
purity. However, HPLC purification was required for C3. 
All complexes showed high stability in labelling milieu and in human serum for at least 3 hours. Lipophilicity 
expressed as log P (partition coefficient between octanol and phosphate buffer 0.1M, pH = 7.4) was 1.3 ± 0.1 
for C1, 0.8 ± 0.1 for C2 and 0.48 ± 0.06 for C3. C3 exhibited the lowest lipophilicity which agrees with the 
bibliography which indicates that the preparation of Tc(III) 4+1 complexes could be a good strategy to reduce 
the overall lipophilicity . 
A moderate protein binding in comparison to ethynilestradiol (98%) was observed in all the three cases with 
values of 33 ± 11%, 41 ± 9% and 46 ± 6, respectively. 
Binding to MCF7cells was 2.0 ± 0.2%, 6.8 ± 0.9% and 3,33 ± 0,12% respectively, while tritiated estradiol 
(Estradiol [6.7-3H (N)]) exhibited a binding of 6.6±1.4%. C2, a symmetric Tc(V)-nitrido complex bearing two 
units of the pharmacophore has the highest binding. Our findings are in agreement with reports that indicate 
the positive effect of dimerization or multimerization in receptor binding. Biodistribution in normal rats for C1 
and C2 showed low blood activity (0.70 ± 0.26% and 5.13 ± 2.49% at 2 hours, respectively). However, liver 
uptake was very high for C1 (40.8 ± 2.4%) and moderate for C2, (13.0 ± 1.3%). Excretion occurred mainly 
through the hepatobiliary system with only a minor fraction excreted in the urine. C2 has the properties in 
vitro and in vivo properties. In vivo studies for C3 are being performed. 
In conclusion, influence of the chelating system in the physicochemical and biological properties of Tc-labelled 
in biomolecules is clearly demonstrated by our experimental results. Consequently, the design of the suitable 
chelator is crucial in obtaining the biological stability and pharmacokinetics desired for a radiopharmaceutical. 
Acknowledgments: ANII (FCE_1_2017_1_136416), CAP, PEDECIBA-Química, Bayer Schering Pharma AG, Hans-
Jürgen Pietzsch. 
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Prostate specific membrane antigen (PSMA) is a type II membrane protein which is widely expressed on the 
surface of prostate cancer cells.  One of the functions of PSMA is to be receptor mediating the ligand 
internalization. This feature of PSMA is employed in the diagnostic and therapeutic procedures that use PSMA 
as an antigen target. 
Over the years, small molecules with high affinity for PSMA have been developed and labelled with positron 
emitters (e.g. 68Ga, 18F, 11C, 64Cu, or 86Y). One of these radiolabelled ligands, [68Ga] PSMA-11, is the most 
frequently used tracer for PET imaging of the prostate cancer. PSMA-11 has a strong binding affinity for the 
PSMA protein and is effectively internalized in the prostate cancer cells. 
The aim of this work is to test a new approach to the labelling of the PSMA-11 ligand with 68Ga eluted from 
the Galli Eo generator (IRE Elit) in slightly alkali milieu. 
The 68Ga-eluate was loaded to the Oasis MCX cartridge. The cartridge was activated before use and thoroughly 
washed with water after the loading 68Ga. The radionuclide 68Ga was eluted from the cartridge with 0.1M 
NaHCO3 (pH = 8.5). The precursor PSMA-11 was mixed directly with the eluate. Activities were determined 
using an ionizing chamber, pH was measured for all samples that were further analysed by LC-MS and HPLC 
systems. 
A total of 18 experiments of labelling PSMA-11 with 68Ga were performed. In these experiments, altogether 
34 samples of PSMA-11 were labelled and subjected to radiochemical purity test. All the samples were 
compared with the standard for [68Ga]PSMA-11. In more than 20 samples radiochemical yields (RCY) exceeded 
90 % and in only 5 samples the RCY dropped below 50 %. 
Table 1 shows average values of pH, activity, retention times (RT) and radiochemical yields (RCY) with standard 
deviations (STDEV) for samples of 68Ga-labelled PSMA-11 in 0.1M NaHCO3. 
 
Tab. 1. Results for labelling of PSMA-11 – average values of pH, activity, retention times (RT) and RCY with 
standard deviations (STDEV) 
In conclusion, a new method of labelling PSMA-11 ligand with 68Ga in 0.1M NaHCO3 (pH = 8.5) using Oasis MCX 
cartridges was developed and tested. The results demonstrated that the method is straightforward, rapid (the 
whole process of labelling takes 10–15 min) and reproducible. 
  
ISTR–2019 
 
209 
 
Influence of 99mTc-chelation at N-terminal and/or C-terminal on receptor binding affinity of NGR 
peptides 
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Corresponding author: vkusum@barc.gov.in 
The NGR peptide has high affinity towards aminopeptidase receptors (APN or CD13 receptors) upregulated in 
tumour angiogenic blood vessels as well as in melanoma, ovarian, prostate, lung, and breast tumours. This 
study aimed at determining the influence of modification of NGR peptide at either N- or C-terminal on the 
receptor binding affinity. Tridentate ligand scaffolds were introduced at N- or C-terminal of NGR peptide via 
click chemistry for radiolabelling with 99mTc(CO)3-precursor. In vitro and in vivo evaluation of N- and C-terminal 
radiometalated peptides was performed to determine the effect on receptor binding affinity. 
The N- and C-terminal azide-functionalized NGR peptides, K(N3)c(CNGRC)G-CONH2 (1a) and c(CNGRC)K(N3)G-
CONH2 (2a) were synthesized manually by standard Fmoc solid phase peptide synthesis protocol.  For N-
terminal modification CNGRCG sequence was first assembled on the solid phase followed by coupling of Fmoc-
Lys(N3)-OH at the N-terminus. The C-terminal modification of NGR peptide was performed by loading Fmoc-
Gly-OH as the first amino acid on the solid phase followed by Fmoc-Lys(N3)-OH. Further CNGRC sequence was 
assembled and disulphide bridge was formed by cyclization of cysteine sulphides. Subsequent to cleavage 
from the solid phase and purification by semi-preparative HPLC, the azide peptides were subjected to click 
reaction with propargyl glycine in solution phase to synthesize peptide constructs K(Pra-Tz)c(CNGRC)G- CONH2 
(1b) and c(CNGRC)K(Tz-Pra)G-CONH2 (2b) respectively, containing a tridentate chelating unit for radiolabelling 
with [99mTc(CO)3]+ core. Peptide constructs were characterized by mass spectroscopy. The radiotracers, 
99mTc(CO)3-K(Pra-Tz)c(CNGRC)G-CONH2 (1c) & 99mTc(CO)3-c(CNGRC)K(Tz-Pra)G-CONH2 (2c) were analysed by 
HPLC and evaluated for in vitro receptor affinity in murine melanoma B16F10 cells and in vivo pharmacokinetic 
behaviour  was  determined  in  C57BL/6  mice bearing melanoma tumour. 
The N- and C-terminal azide-NGR peptides (1a and 2a) synthesized manually by solid phase peptide synthesis 
were obtained in an overall yield of 27% and 31% respectively; with >98% purity. Radiometalation of peptide 
constructs 1b and 2b resulted in formation of neutral 99mTc(CO)3-NGR complexes, 1c and 2c respectively with 
>95% radiochemical purity. The C- terminal modified peptide exhibited higher binding affinity towards B16F10 
cells in comparison to N-terminal modified peptide (IC50 values 1b: 136 @ 2.3 nM; 2b: 65 @ 1.7 nM). The C-
terminal con- struct 2c exhibited higher uptake in murine melanoma B16F10 cells during in vitro studies. In 
vivo tumour uptake of 2c was higher than of N-terminal modified peptide construct 1c at 2 h p.i. (2.4 @ 0.5 vs 
1.9 @ 0.3% ID/g respectively). Blocking studies carried out by co-injection of cNGR peptide led to ~50% 
reduction in the tumour uptake at 2 h p.i. suggesting receptor-mediated uptake of radiotracers. Both the 
radiotracers exhibited rapid urinary excretion and cleared from all the major organs (heart, lungs, spleen, 
stomach and blood) at 4 h p.i. (<1% ID/g). 
The N- and C-terminal modified peptide constructs could be radiometalated with 99mTc(CO)3 core in good 
radiochemical yield (>95%). However, higher in vitro cell uptake and in vivo tumour uptake was observed for 
the C-terminal construct illustrating the preferred conjugation of drugs, dyes, radiometals etc. at C-terminus 
of NGR peptide. 
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Preparation of small batches of custom ordered 131I capsules in hospitals and institutes is often done manually. 
Operators could be exposed to a significant level of radiation exposure doses during manual preparation of 
capsules with high activities of 131I. There are few commercial solutions for automatic capsule filling, but those 
devices are very expensive. We developed a simple and affordable automatic system for this purpose. The 
goal of this publication is to present and shortly describe the function of our system. The system consists of 
PC controlled device which is dedicated to precise dosage of 131I solution and filling of capsules with different 
amount of radioiodine activities. The whole device is located into a dedicated chamber, shielded by lead bricks. 
It is known that the solution volume in microliters closely correlates with the activity in mCi, which is a basic 
principle of our system. The first step in the whole process is filling of the known volume of 131I solution into 
the syringe. The next step is filling-out the needed volume (i.e. activity) in the capsule and closing it with 
appropriate cap. The third step includes measuring 131I activity in the capsule (dose calibrator) and printing its 
value on the self-adhesive label. The final step is to transport the capsule to a lead container. The whole 
process is automated, controlled by PC, which is equipped by an appropriate software. The advantage of this 
system is that it is suitable for custom ordered capsules because every produced capsule can be of desirable 
activity and calibration date. The list of capsules with their activities and calibration dates can be easily 
uploaded to the system as an Excel file. Our system reduces the unnecessary radiation exposure of personnel 
and also prevents errors caused by subjective or objective reasons, which are often the case during manual 
capsules filling. 
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Breast cancer (BC) is the most common invasive cancer diagnosed in women worldwide. The estrogen receptor 
(ER) is a well-established biomarker for prognosis and guiding treatment of patients, and it is a good target for 
molecular imaging and radionuclide therapy.  The objective of this study was to improve the theranostic value 
of previously studied 111In-labelled ER-targeting moieties (e.g. estradiol derivatives/LXXLL-based peptides) by 
enhancing the delivery of the radionuclide into BC cells’ nucleus in close proximity to DNA. To achieve this 
goal, we have explored an approach that combines into a single 111In-hybrid compound two different biological 
targeting moieties for dual targeting of BC cells. Hybrid compounds containing an ER ligand conjugated to a 
DOTA derivative functionalized with a nuclear-targeting moiety (DNA-intercalating agent, AO, or a peptidic 
nuclear localizing sequence, NLS) were synthesized. The bifunctional compounds were radiolabelled with the 
Auger electron emitter Indium-111 that has simultaneous emissions of gamma radiation aiming the selected 
delivery into ER plus breast cancer cells. 
Synthesis of a DOTA- based pre-chelator that could allow double vectorization with two different molecular 
entities was achieved by following an orthogonal strategy. The versatility of this chelator to prepare 
radiolabelled hybrid compounds was demonstrated by the synthesis of three different conjugates containing 
an ER-binding molecule and a nuclear-targeting agent. Radiolabelling with 111In was performed at 95ºC, pH=5 
acetate buffer. Radiochemical purity and in vitro stability of the radiolabelled compound was evaluated with 
HPLC. Cellular uptake of 111In conjugates were assessed in MCF-7 (ER+) and MDA-MB-231 (ER-) human BC cells. 
The subcellular localization, in particular the internalization into the cell nucleus was also evaluated. The ability 
of 111In-compounds to induce DNA damage in-vitro was tested by incubation with double-stranded plasmid 
DNA for 140 hours. The biodistribution was assessed in female mice with MCF-7 xenografts. 
The synthesis of dual-conjugates comprising an ER-targeting and a nucleus targeting moieties was successfully 
achieved by following an orthogonal strategy. The In-/111In- complexes of the hybrid conjugates were 
successfully prepared and the radiolabelled conjugates demonstrated high stability. The prepared dual-
targeting radiolabelled probes [111In]ER3AO, [111In]E2NLS and [111In]E2AO demonstrated high nuclear 
internalization (higher than 50%) in MCF-7 cells, proving the efficacy of the applied nuclear-targeting 
approaches. Moreover, [111In]ER3AO demonstrated ability to cause direct damage in DNA. Preliminary 
biodistribution studies of [111In]ER3AO in tumour-bearing mice were also encouraging since high in-vivo 
stability, fast blood clearance from blood and uptake in the ER-rich organs and in the tumour, as well as high 
target tissue/ non-target tissue radioactivity ratios were obtained. 
A straightforward and versatile synthetic approach was used for the synthesis of bifunctional radioconjugates 
bearing two different molecular entities. The favourable biological results of the 111In conjugates in cellular 
and animal models represent promising properties for the development of radiopharmaceuticals for Auger 
therapy. 
Acknowledgments: F. Vultos thanks FCT for PhD grant (SFRH/BD/84509/2012). The work was supported by 
UID/Multi/04349/2013. 
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Cancer is one of the leading causes of death in the world, including Indonesia. By 2030, it is estimated that 
cancer sufferers reach 26 million people and 17 million dies from cancer, with a faster increase in developing 
countries. The application of nuclear techniques in nuclear medicine plays an important role in diagnosing 
cancer, measuring therapy responses, and identify an optimal therapy. PSTNT - BATAN has contributed to the 
development of diagnostic kits, one of which is 99mTc-Glutathione. By utilizing these diagnostic kits, there is a 
tendency to increase the risk of drug interactions consumed by cancer patients with diagnostic kits that can 
lead to misinterpretation of data. This study aims to investigate the possible alteration in the pharmacokinetics 
profiles and biodistribution of 99mTc-Glutathione when given in combination with cancer drugs in Balb/C strain 
mice (Mus musculus). The study was divided into four groups of normal and model animals test. Each group is 
differentiated by treatment, i.e. control (I), animals test with doxorubicin treatment (II), 5-fluorouracil (III), and 
methotrexate (IV). Each drug is intravenously, after 5 minutes it is injected with 99mTc-Glutathione 
intravenously. Furthermore, the pharmacokinetics and biodistribution studies were carried out. Study of 
pharmacokinetics and biodistribution interaction showed that the administration of cancer drugs before 
administration of 99mTc-Glutathione reduces the elimination half-life and target / non-target organ ratio 
significantly. The target / non-target ratio of 99mTc-Glutathione (control) and 99mTc-Glutathione that combined 
with cancer drugs doxorubicin, 5-fluorouracil, and methotrexate in normal mices are:7.01, 1.47, 1.43, and 5.61 
respectively. Whereas, the target / non-target ratio of 99mTc-Glutathione (control) and 99mTc-Glutathione that 
combined with cancer drugs doxorubicin, 5-fluorouracil, and methotrexate in cancer model mices are: 2.94, 
1.33, 0.42, and 2.11 respectively. The results can certainly cause misinterpretation of diagnosis data. 
Therefore, the phenomenon of drugs and radiopharmaceutical interactions must be considered by clinicians 
in nuclear medicine.                                                
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Cancer is a major health problem and it is estimated that more than 10 million new cases of cancer diagnosed 
worldwide with more than 4 million deaths, annually. Chemotherapy is still the primary choice in cancer 
modality that uses chemotherapeutic drugs to eradicate and inhibit the growth of cancer cells. This treatment 
has excellent reliability and is effective to kill cancer cells, but its cost is high. Therefore, patients tend to seek 
alternative treatment such as consuming traditional herbal medicine. Abundant presence of flavonoid in 
natural products used as traditional herbal medicines that have an interesting bioactivities need to be studied. 
Quercetin (3,3′,4′,5,7- pentahydroxyl-flavone) is a flavonoid compound found in many fruits and vegetables 
that have antioxidant activity. As an antioxidant compound, quercetin will protect the body from free radical 
that can increase the risk of disease. However, as a traditional herbal medicine, its effectiveness is not yet 
been fully established due to the lack of scientific information. Many in-vitro studies have proven the 
effectiveness of quercetin as an anticancer compound, but the data from in-vivo study is still limited. In recent 
years, several radioisotopes have been utilized for biodistribution studies of biologically important natural 
products because nuclear medicine techniques provide some advantages over conventionally used methods 
in term of detection sensitivity and availability. This study was conducted as a preliminary study to understand 
the biodistribution pattern of 99mTc-quercetin on normal balb/c mice. In vivo data from this study would 
provide meaningful biological and pharmacological information of 99mTc-quercetin for understanding its 
effectiveness as for development of quercetin as anticancer agent. 
99mTc-quercetin was prepared by addition of 30 µl (1 mg/ 1 mL) of solution SnCl2. 2H2O into a glass vial 
containing 320 µL quercetin solution (0,5 mg/320 µL) and 200 µL 0.2 M phosphate buffer pH 7.5. pH of the 
mixture was adjusted to 7.5 by addition of NaOH 0,1 N and final volume of the mixture was carried out into 
600 µL by addition of bidistilled water. Thereafter, 400µL (± 0,5 mCi) of freshly eluted 99mTcO4 was added into 
the vial and incubated within 5 minutes in room temperature. 
Radiochemical yield of 99mTc-quercetin was determined by using a thin layer chromatography using TLC-SG 
F254 strips with two solvent systems to distinguish and quantify the amounts of radioactive contaminants 
(free 99mTcO4, 99mTcO2). Chromatography system of TLC-SG F254 / acetone was used to separate impurities of 
99mTcO2, while TLC-SG F254/NaCl 0.9 % was used to separate free 99mTcO4. Radioactivity on chromatograms 
strips was measured using TLC-scanner (AR-2000, BIOSCAN). 
Animal studies were conducted in accordance with our institutional guidelines and were approved by the 
Ethics Committee for Care and Use of Experimental Animal - National Nuclear Energy Agency. Biodistribution 
studies were performed by intravenous administration of a 0.1 mL 99mTc-quercetin (2.6 μCi/100 μL) to 5-week-
balb/C mice (BIOFARMA). Groups of three mice were used for the experiments. Organs of interest were 
removed, weighed, and the radioactivity was determined with an automatic-well γ counter (2470 Wizard, 
PERKIN ELMER) at 15 minutes, 1, 3, and 24 h post-injection. Urine and faeces were collected for 24 h post 
injection, and the radioactivity counts were determined. 
Labelling efficiency of the 99mTc-quercetin was assessed by thin layer paper chromatography. In TLC-SG F254 
using saline as the solvent, free 99mTc moved with the solvent front, while 99mTc-quercetin and 99mTcO2 
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remained at the spotting point. 99mTcO2 was determined by using TLC-SG F254 / acetone as the mobile phase 
where the 99mTcO2 at the point of spotting while free 99mTc and 99mTc-quercetin moved with the solvent front. 
The radiochromatogram of 99mTc-rutin was presented. 99mTc-quercetin had labelling efficiency > 90 % and can 
be used to carry out in vivo test. 
Biodistribution study in normal mice showed that the radioactivity levels in the stomach were below 1%ID up 
to 24 h post-injection, indicating that 99mTc-quercetin was stable in vivo. The uptake of 99mTc-quercetin in 
kidney in 15 minutes was 6.13±1.05 %ID/g and remain 3.31±0.29 %ID/g at 24 hour post injection. After 15 
minutes, 1 hour, 3 hour and 24 hour post injection the radioactivity levels on the blood was 3.39±0.21 %ID/g, 
1.81±0.54 %ID/g 1.59±0.30 %ID/g and 0.46±0.07 %ID/g respectively. These results suggested that 99mTc-
quercetin had fast rate of plasma clearance after administration. The biodistribution study of 99mTc-quercetin 
also demonstrated that high radioactivity accumulation was found in the liver at all post injection time points, 
indicating that 99mTc-quercetin was lipophilic compound. Moreover, the radioactivity was observed in the 
intestine for 15 minutes, 1 hour, and 3 hours that is 1.63±1.96 %ID/g, 1.53±0.33 %ID/g, and 1.44±0.53 %ID/g.  
Then, the uptake value was decreased after 24 hours to 0.54±0.20 %ID/g. This study also showed that 99mTc-
quercetin was excreted through urinary and faecal excretion. These results in the current study demonstrated 
that intravenously injected of 99mTc-quercetin was metabolized in the liver and moved to intestine via the bile 
duct.  
This study gave preliminary biodistribution data of 99mTc-quercetin in normal mice. Further studies on target 
accumulation of 99mTc-quercetin in animal model with cancer would provide a good basis for developing 
radiolabelled flavonoid as radiotracer to understand the mechanisms of quercetin as anticancer. 
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Currently, theranostics for both imaging and concomitant chemoradiotherapy is widely used in the treatment 
of cancerous patients. In this regard, defining the optimal timing between Pt-drugs injection and radiation 
delivery to the patients is an important issue. Recent advances in the field of nuclear medicine can potentially 
solve this problem by selective delivery of Pt-based compounds labelled with a positron/Auger-emitting 
radionuclide to cancer cells. In this study, we designed and validated for the first time a 64Cu-NOTA terpyridine 
platinum conjugate as a novel Pt-based positron/Auger emitting agent targeting G-quadruplexes DNA 
structure. This project is aimed to demonstrate that such theranostic agent could give rise to a synergistic 
effect with a greater selectivity toward cancer cells. 
The in-vitro cytotoxic and synergistic effects of the conjugate were assessed by Presto-blue assay. The cellular 
uptake, internalization and efflux of 64Cu-NOTA terpyridine platinum conjugate was measured for colorectal 
cancer cell (HCT116) as well as a normal fibroblast cell line (GM05757) at 24, 48 and 72 h after initial incubation 
time. 
As a result, natCu-conjugate showed 3.4, 1.7 and 2.3 times higher cytotoxicity against HCT116 cells relative to 
GM05757 fibroblast normal cells. However, natCu-conjugate exhibited 9.6, 11.5, 14.1 folds lower cytotoxic 
effects on HCT116 cells than cisplatin at 24, 48 and 72 h, respectively. The internalization of 64Cu-conjugate 
in HCT116 cells increased from 15 min (0.04±0.021%) to 24h (18.7±2.8%) and followed by a plateau at 48h 
(18.6±1.5%), post-administration. The percentages of internalization were significantly higher in HCT116 
cancer cells as compared to GM05757 normal cells at 24h, 48h and 72h post-administration (Pvalue<0.001), 
which is associated with higher cytotoxicity of the conjugate toward HCT116 cells. More importantly, the efflux 
profile of HCT116 cells showed that a considerable amount of 64Cu-conjugate was retained throughout the 
time course from 15 min (100±7 %) to 72h (48±6%). Additionally, there was a little percentage of the conjugate 
(<1%) internalized at 4 ℃ and all time points, indicating that passive uptake of the compound is not primarily 
responsible for internalization. A synergistic (radiosensitizing) effect was measured for the 64Cu-conjugate (5 
and 8MBq) at low concentrations (<100µM). Conversely, cell viability (%) started to increase steadily exhibiting 
an infra-additive (radioprotective) effect at the highest concentration (500µM) on the HCT116 cells. 
These results support the potential use of 64Cu-labelled terpyridine platinum conjugate as a novel theranostic 
agent to diagnose and treat cancers. 
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Creation of the first public PET unit at Sahloul hospital in Sousse, Tunisia 
Author:  Najla Ayachi1  
Co-author: Asma Toumi2; Anis Majoul2; Kaouthar Chatt2 
1Ministère de la santé 
2Hopital Sahloul 
Corresponding author: ayachinajla@gmail.com  
The International Atomic Energy Agency has established programs and cooperation with developing countries 
to promote applications in nuclear medicine. 
The objective of this work is to report the progress of the first public PET unit in Tunisia and to raise the 
difficulties encountered in launching its operation. 
The PET unit has been designed in compliance with the regulations in force regarding radiation protection and 
manipulation of injectable drugs. 
It includes a "hot" zone formed by a room designed for the PET- CT camera, a control room with lead glass, an 
interpretation room for exams, a hot laboratory or radiopharmacy, an injection room divided into three 
individual boxes and a room for the storage of radioactive waste until decay. 
The "cold" zone includes the space reserved for the reception and registration of patients, a waiting room for 
non-injected patients and offices. 
The local of radiopharmacy is intended to hold, prepare and control radiopharmaceuticals. It is classified in 
controlled atmosphere zone (class D) and includes a ventilated hot cell in depression, adapted to the handling 
of the high energies thus respecting the recommendations of the good practices of preparation. 
The creation of the unit is subject to an authorization regime. 
The PET unit is ready to receive the PET- CT Camera but the reception has not yet taken place. This delay is 
mainly due to the heavy administrative tasks. Indeed, the complexity of the procedures is causing a delay in 
the start of the activity. 
PET- CT activity, in the public sector in Tunisia, will see soon the light of day. However, the willingness of the 
various parties involved is necessary to speed up the start of this activity. A revision of the procedures is also 
desirable in order to reduce the time of reception of the next two public units. 
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A new compact high power e-beam accelerator for radiotherapeutic production: a first evaluation 
Author: Samy Bertrand  
Co-Author: Jeremy Brison; Jean-Michel Geets; Cristiana Gameiro 
IBA, Belgium  
Corresponding author: samy.bertrand@iba-group.com 
Recent developments in the theranostics field have put actinium-225 (225Ac) under the spotlight. Its historical 
supply from 229Th generators will rapidly be limited (yearly supply of 1-2 Ci), which has led to the development 
of other viable alternatives. Production of radiotherapeutics such as 225Ac, 67Cu and 47Sc from photoreaction 
with gamma beams have already been demonstrated. This production route is relatively safe when compared 
to proton irradiation and results in good purity of the final product. However, the low intrinsic reaction yield 
is a showstopper, especially when combined with the low power of the most available electron accelerators. 
This paper will present a new high-power industrial electron accelerator capable of producing several curies 
of 225Ac from photoreaction on 226Ra. 
The Rhodotron® TT300 is a well-known electron accelerator for industrial applications. The new high energy 
version (Rhodotron® TT300 HE) with high current and continuous beam capacity can therefore be used for 
efficient radiotherapeutics production. 
Based on theoretical models and on experiments, a production of 0.0093 µCi / (h.mg of 226Ra.µA) EOS (end of 
synthesis) of 225Ac can be extracted after 18 days of decay. 
Several parameters can be adjusted to increase its production capacity (electron energy, mean current, 
quantity of 226Ra irradiated, and geometry) 
The estimated yield is of 147.85µCi of 225Ra/(h.mg of 226Ra) or 65µCi of 225Ac/(h.mg of 226Ra). Considering an 
irradiation of 150h of 1g of 226Ra, one could weekly produce up to 9.7Ci of 225Ac after 18 days of decay. In this 
approach, the target capsule containing large quantities of radium is totally decoupled from the accelerator 
and beam line vacuum and can be designed to avoid radium release. 
The following technical challenges are under evaluation: converter electron-gamma, target container, target 
cooling, and shielding. 
Extrapolation from experiments on 225Ac production shows that the Rhodotron® TT300 HE could provide 
sufficient levels of production to respond to the increasing demand of 225Ac. The challenges to integrate such 
an accelerator in a radioisotope production line have been highlighted. Appropriate design of the facility could 
allow to produce other therapeutic isotopes such as 67Cu and 47Sc using the same photonuclear route. 
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Optimized non-conventional radioisotopes production with industrial mid-energy cyclotron 
Author: Samy Bertrand1  
Co-author(s):  Benoit Nactergal1; Jean-Michel Geets1; Eric Kral1; Sebastien de Neuter1; Jozef Comor2; 
Francisco Alves3 
1 IBA 
2 Elex Commerce 
3 Coimbra University 
Corresponding author: samy.bertrand@iba-group.com 
While F-18 is still one of the most used radionuclides in PET procedures, other metallic non-conventional 
radioisotopes, such as copper-64, zirconium-89, scandium-44 and undeniably gallium- 68 are gaining interest. 
The production of these radioisotopes usually requires more sophisticated infrastructure and their intrinsically 
low reaction yields often limit the levels of activity produced. This paper presents the solutions developed in 
order to increase the production rates and facilitate production processes of non-conventional radioisotopes 
in an industrial mid-energy cyclotron, while preserving its compactness and simplicity. A proton only optimized 
cyclotron with fixed energy has been designed using the well-known internal ion source, negative ions 
acceleration (H-) and stripping extraction 1. 
Custom energy: some novel radioisotopes require lower energy in order to limit the co-production of 
impurities. As an alternative to degrade foils, the industrial cyclotron proposes one or two exit ports that can 
be operated at lower fixed energy (typically between 13 MeV and 15 MeV). This feature helps to overcome 
the beam current limitation of the degrader foils and allows to safely increase the current in the target. 
High current: the cyclotron has been designed to improve performance of ion sources, beam transmission and 
beam extraction. This state-of-the-art cyclotron is able to produce and sustain over an extended lifetime a 
total beam current of up to 300 μA. 
High power solid target: solid target low reaction yields often requires increasing the target current in order 
to reach higher production capacity. A high-power solid target station has been designed to match the 
performance of the optimized cyclotron (i.e. maximum current acceptance for 64Ni targets up to 300 μA 
without energy degrader). It can accommodate various target materials to produce 64Cu, 89Zr, 123/124I. Suitable 
chemistry system for separation and purification are also available. 
68Ga Liquid target technology: many recent developments in the production of radiometals with liquid targets 
have been published. Production rates and purity levels reached for 68Ga showed that this technology is a 
perfect viable alternative to the 68Ge/68Ga generators. The same process philosophy was successfully applied 
in the production of 64Cu and 61Cu. 
In conclusion, the selection of a production mode for a given radioisotope will require the careful assessment 
of the pro’s and con’s of each process and the production capacity that they offer. 
Results: The custom energy feature has been successfully tested in a factory. Two beam exit ports (out of a 
total of 8) can be modified to accommodate lower proton energy on target for more effective non- 
conventional radioisotope production. The high current 300 μA cyclotron was fully installed, commissioned, 
and accepted in 2017. The liquid target technology has now proven records and it benefits from an increasing 
popularity. In conclusion, combining the cyclotron, its dedicated features, the different target technologies 
and the chemistry solutions, a whole range of possibilities are given to easily produce non-conventional 
radioisotopes. These integrated attractive solutions can be implemented in a PET radiopharmacy without 
compromising the large-scale production of conventional PET radioisotopes. 
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Research and development initiatives on radiopharmaceutical production in the Philippines 
Author: Adelina Bulos  
Co-author(s):  Rommel Mascarinas; Ivy Angelica Nunez; Joanna Michelle Chua 
 Philippine Nuclear Research Institute 
Corresponding author: admb_79@yahoo.com 
In response to the increasing demand for radioisotopes and radiopharmaceuticals in nuclear medicine sector 
in the Philippines, the Philippine Nuclear Research Institute (PNRI) initiated the establishment of a Tc-99m 
generator production facility. Technetium-99m or Tc-99m is still the most commonly used radioisotope for 
diagnosis and imaging of various organs and determining physiological functions. 
The Tc-99m generator production facility was established at the Philippine Nuclear Research Institute (PNRI) 
through the assistance of the Department of Science and Technology (DOST) and of the International Atomic 
Energy Agency (IAEA). The facility aims to make locally available the Tc- 99m generator for medical applications 
as well as for research initiatives for radiopharmaceutical applications. The facility is envisioned to meet the 
country’s requirements for all the major medical radioisotopes, starting with the local production of Tc-99m 
and the most commonly used Tc-99m radiopharmaceuticals. At present, all radioisotope supplies in the 
country are sourced overseas at prices that vary accordingly. 
With the establishment of the PNRI’s laboratories, we now have a GMP-grade Tc-99m generator facility 
capable of producing 50 Tc-99m generators per batch. Instead of Tc-99m being imported, it will be the parent 
Mo-99 that will be transferred to PNRI facility from Mo-99 processing facilities overseas, contained in 
specialized transport containers, and via airfreight arrangements so it can be processed locally to make Tc-
99m generators. But, to make Tc-99m radiopharmaceuticals, the other non-radioactive components also 
needed to be sourced from abroad. Thus, it has become imperative to also locally produce the non-radioactive 
components or the kits. 
The PNRI is currently vigorously conducting research and development activities for producing locally the most 
common Tc-99m radiopharmaceuticals such as MDP, DTPA and sesta-MIBI, initially. Through the IAEA TC 
program, the Institute was also able to establish a clean room facility for aseptic manufacturing of these kits. 
This poster presentation describes the PNRI Mo-99/Tc-99m generator production facility, its technical 
specifications, generator process flow and radiation safety measures. The benefits, opportunities, challenges, 
and issues related to its establishment and operation will also be presented. Furthermore, the 
radiopharmaceutical kit facility will also be described and the different on-going research initiatives and 
activities including capacity building on radiopharmaceutical production technology will be discussed. 
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A comparative study of passive air sampling in different radiopharmacies 
Author: Fany Pricile Ekoume1 
Co-author(s): Hendrikus Boersma2; Sietske M. Rubow3 
1Yaoundé General Hospital, Cameroon  
2University Medical Centre Groningen, The Netherlands 
3Stellenbosch University, South Africa 
Corresponding author: ekoumefanypricile@gmail.com 
Assessing air quality in areas where radiopharmaceuticals are prepared and dispensed should be a routine to 
ensure product safety. Passive microbiological sampling is a relatively simple and affordable method for 
evaluation of air quality. This study compared air sampling results from two African radiopharmacies (noted 
as “Y” in Cameroon and “T” in South-Africa) and one European radiopharmacy, “G” in the Netherlands. 
Tryptic soy agar settle plates were opened for 2 to 4 hours at predetermined locations in sites where 
radiopharmaceuticals were produced, either during work or while work stations were not used (“rest”). After 
exposure, the plates were incubated at 30 to 35℃ for 72 hours and the number of colonies forming units (CFU) 
per exposure hour was determined. Based on the GMP grade of the sampling location and the corresponding 
recommended action limits, the percentage of settle plate results exceeding limits were recorded. We 
compared data from “Y” to “T” data and routinely collected samples from “G” (Fischer’s exact test with P<0.05 
considered significant). 
456 samples at rest and 198 samples during work were collected in 6 different sampling sites over a 6-month 
period at radiopharmacy “Y”. At “T”, 184 samples were collected during work versus 87 at rest during a 12-
month sampling period. “G” provided results of 315 samples collected over one year during work. 
Table 1: Colony counts exceeding relevant limit 
  “Y” “T” “G” 
Site Limits Rest Work Rest Work Work 
Area where RP are prepared < 1 35* # 39%* # 7% 8% 3% 
Other Class A area < 1 8% 16% 0% 20% 10% 
Open Bench (class C) 50 14%* # 15%* # 0% 3% 0% 
Floor (class D) 100 43%* 45%* - - 0% 
* differs significantly from “G”                       # differs significantly from “T” 
Results for all sampling sites at radiopharmacies “Y” differed significantly from those at “G”. The highest 
number of CFU/h in the Tc-99m radiopharmaceutical preparing cabinets were 58 at “Y”, 6 at “T” and 1 at “G”. 
The results reflect the facility design and practice. Radiopharmacy “Y” does not have clean rooms. The closed 
cabinet used for radiopharmaceutical preparations runs without maintenance or filter replacement. 
Radiopharmacy “T” has a dedicated shielded laminar air flow cabinet with a regular maintenance programme. 
The room is however not a designed clean room. Radiopharmacy “G” is a GMP certified site. 
Despite recent improvements in staff training and cleaning procedures at “Y”, further steps are required. “T” 
should also investigate means to improve air quality in the radiopharmacy. 
Conclusion: Compared to “G,” both “T” and “Y” radiopharmacies need some improvement in the air quality of 
their respective units to reach GMP compliant performance levels. More corrective actions are needed at “Y” 
for reducing the risk of microbial contamination of radiopharmaceuticals. 
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Studying and assessment of clean area for Tc-99m production in radioisotope production facility 
Author: Hesham Elkhatib 
 Egyptan Atomic Energy Authority 
Corresponding author: heskhatib1966@yahoo.com 
Clean rooms nowadays have high technology solutions with very high demands on the air cleanliness level.  
Not only particulate matter but also airborne molecular contaminants (AMC) are addressed in more and more 
applications. Therefore, it is important to estimate the level of air cleanliness in the cases of new production 
of, or reconstruction of a clean room. Radioisotopes production facility (RPF) is a facility that needs clean room 
to produce technetium (Tc-99m) for medical purposes. The air cleanliness level in a clean room is dependent 
on the quality of the air supply, contamination sources, design of the ventilation system as well as strict 
procedures to sterilize available surfaces on the area and commitment to follow precautions in the area. Three 
classes are available in production area, A, C and D according to ISO 14644-1. Measurements are also taken to 
verify the particle counts in areas of technetium loading as well as prediction of these counts by a computer 
program, which predicts the particles and necessary time required to achieve the standard particle counts. 
Biological tests also are conducted to control and assess sterility of the area to assure cleanliness and validity 
for medical radioisotope production. High efficiency particulate air filters with class H14 are dedicated for the 
clean area and equipped with pressure drop manometers to decide its replacement in case of blockage. The 
prediction results are verified by measurements. 
This program estimates the cleanliness class in clean rooms or in other spaces (offices, etc.) using different 
types of air filters. Depending on the number of people, the activity in the room, the ventilation system and 
the filter selection the clean room class is calculated. 
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Survey on arduous challenges and possible tracks of heightening the radiopharmacy and nuclear 
medicine services in Africa 
Author: Yohannes Jorge Lagebo 
Co-author: Aschalew Alemu Marie 
1 Addis Ababa University, Ethiopia 
Corresponding author: jorgelagebo@yahoo.com 
Radiopharmacy is the backbone of the nuclear medicine services. Without radiopharmaceuticals, it would be 
impossible to imagine services for nuclear medicine patients. Strengthening the radiopharmacy services within 
an institution, country or in a region, implicitly means strengthening the corresponding nuclear medicine 
patient services. These services have meaningfully advanced in several continental regions of the globe in the 
last two to three decades. Unfortunately, this contemporary global developmental momentum in 
radiopharmacy and nuclear medicine is yet to be attained generally in Africa. This global scientific and 
technological advancements in radiopharmacy and nuclear medicine have in turn brought undeniably 
remarkable contributions to other diversified disciplines of clinical medicine, by enhancing their roles in 
effective diagnosis and management of various debilitating diseases including cancer. The objective of this 
survey is to identify some of the possible reasons attributing to the comparative backwardness of the 
radiopharmacy and nuclear medicine services being rendered in many African countries. Based on the findings, 
there is an emphasis to give relevant recommendations to change the existing professional status quo in 
radiopharmacy and nuclear medicine patient services, such as in African countries. Unlike most countries in 
the other continental regions of the globe, there are several African countries where there have not even been 
initiated radiopharmacy units and nuclear medicine patient services. The started services in some of the 
countries are not satisfactory and not in pace with the accepted scope and standard level of patient services. 
The survey was conducted through literature review, questionnaire, review of countries reports, one to one 
interview administered to professionals and via critical personal observations of experienced professionals. 
The results of the survey findings will be discussed thoroughly, and the possible service heightening 
recommendations will be forwarded. The survey showed that the practicality of radiopharmacy and the 
associated nuclear medicine patient services are unacceptably low in Africa, and several African countries are 
not yet to start these services for the benefit of patients in their respective countries. 
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Parametrical study for iodine plate out theoretical model in fission radioisotope production plant 
ventilation pipes 
Author: María Cecilia Maneiro  
Co-author: Alexis Maître; Fabiana Molli; Hernán Meier; Ricardo Rey; Sandra Matzkin 
 INVAP S.E., Argentina  
Corresponding author: mmaneiro@invap.com.ar 
The radioisotope production plants aim to select, extract, purify and condition fission product radioisotopes 
for medical use. 99Mo and 131I are the radioisotopes that are the most widely worldwide produced by fission 
in nuclear research reactors by irradiation plates made of Al-U. After irradiation, the plates, which contain 
99Mo and 131I, are transferred to the radioisotope production plant for separation, conditioning, quality control 
and dispatch of radioisotopes and radiopharmaceuticals products. Some of these stages take place in an 
enclosed shielded place called “Hot Cell”. Radioactive gases as iodine and noble gas are emitted in the 
enclosure. Radioactive iodine can be deposited on the inner side of ventilation pipes. This phenomenon is 
called plate out. 
This work studies variations in many parameters in order to determine which ones have the most impact on 
shield thickness to minimize the dose rate to workers. When the plate out in ventilation pipes is estimated, a 
transport calculation is done to determine the shield needed to protect the workers. 
The dose rate to an operator during hot cell operation depends on many parameters as: 
• Neutron flux 
• Decay time 
• Emission of radioactive iodine 
• Decay time process system 
• Diameter and length of ventilation pipes 
• Air velocity in the ventilation pipes 
• Iodine molecular forms 
• Shield thickness 
For each parameter, a deviation from a base case, based on INVAP experience, is proposed. The iodine plate 
out in the exhaust ducts is calculated and the lead thickness needs to have a dose rate inferior to 0.1mSv/h 
that is calculated with MICROSHIELD®. The following results were obtained related to the shielding thickness:  
⎯ Parameter Result 
⎯ Initial Inventory Limited impact  
⎯ Length duct Limited impact  
⎯ Airflow Limited impact 
⎯ Iodine Emission Significant impact 
⎯ Decay time Negligible 
⎯ Chemical form Significant Impact in Fraction of I2 
This work shows that the parameters that have the most significant impact on the thickness of the shield 
needed to protect the plant personnel from the gamma radiation coming from radioactive iodine deposited 
in the exhaust ducts of the hot cells of a radioisotope production plant by fission are: 
• The fraction of iodine emitted during the process, and 
• The chemical form of the iodine released 
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An overview of commercial nuclear pharmacy in the US-safely delivering 35,000 patient-ready 
radiopharmaceuticals doses each day 
Author: Jeffrey Norenberg  
 University of New Mexico, USA 
Corresponding author: norenberg@nanp.net 
This presentation will describe the current pharmacy practice model for commercial nuclear pharmacies which 
safely deliver over 35,000 patient-ready radiopharmaceuticals to hospitals and clinics throughout the US. 
These short-lived drugs enable over 10 million nuclear medicine procedures each year in the US. 
The first commercial nuclear pharmacy was established in 1972 at the University of New Mexico by Dr. Richard 
Keesee, a true pioneer who recognized the need for standardization and uniformity of radiotracers used for 
nuclear medicine imaging. Applying pharmacy principles together with resource consolidation and just-in-time 
inventory management, is how commercial nuclear pharmacy was born. 
Today, nuclear pharmacies embrace the highest standards of quality and professionalism to ensure that 
patients have access to safe and effective radiopharmaceuticals for diagnostic imaging and therapy. Founded 
in 1984, the National Association of Nuclear Pharmacies (NANP) is a non-profit industry association of over 
four hundred nuclear pharmacies, comprising most nuclear pharmacies in the United States. The membership 
of the NANP includes chain, independent, and academic/institutional nuclear pharmacies. NANP also has 
Associate Members, who are companies primarily involved in manufacturing or operating support in nuclear 
pharmacy. NANP serves its members in three main areas: business issues, legislation and regulation, and 
education. 
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Saskatchewan centre for cyclotron sciences: a new multi-user research and production facility 
Author: D Schick-Martin; Jacqueline Cawthray  
Co-author: J MacKenzie; D Frattinger; L Matei 
Saskatchewan Centre for Cyclotron Sciences, Saskatoon, Canada 
Corresponding author: d.schickm@fedorukcentre.ca 
The Saskatchewan Centre for Cyclotron Sciences (SCCS), located at the University of Saskatchewan, in 
Saskatoon, Canada, is a multi-user radioisotope and radiopharmaceutical production and research facility 
operated by the Sylvia Fedoruk Canadian Centre for Nuclear Innovation (Fedoruk Centre). The SCCS supports 
an interdisciplinary program to develop and produce radioisotopes, radioprobes and radiopharmaceuticals for 
use across the life sciences including medical, veterinary and agriculture. The facility is outfitted with recently 
renovated state-of-the-art cGMP production clean rooms, QC laboratories, packaging rooms, and research hot 
labs, facilitating innovative radiopharmaceutical research and development. The recently renovated 
Innovation Wing serves as a world-class multi-user research facility equipped with a pre-clinical imaging suite, 
animal housing and support capabilities, radiopharmaceutical development, radiochemistry, analytical and 
tissue culture laboratories, and the PhytoSuite - a nuclear imaging suite dedicated to plants and soils including 
a molecular imaging system for plants, based on PET technology. 
The paper will provide a perspective of the renovation process and lessons learned regarding the project 
requirements to address the needs of different types of users. 
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Development of radiopharmaceutical production in Bangladesh 
Author: Momtaz Fatima Waheed 
Bangladesh Atomic Energy Commission 
Corresponding author: momtaz_waheed@yahoo.com 
The production of radioisotopes for medical diagnosis and treatment are the important activities of 
Bangladesh Atomic Energy Commission (BAEC). Tc-99m generator is in regular production line, which is 
extensively used in 15 Nuclear Medicine Centres of the BAEC and all other private & government run nuclear 
medicine departments of the country. RIPD has installed a cGMP compliant facility in May 2005 with the 
technical cooperation of IAEA (BGD2010). This plant can produce 50 generators per batch by processing 
maximum 30Ci of fission Mo-99. Since 2005 BAEC has fulfilled the entire demand of the country for Tc-99m 
generator by using imported Molybdenum-99.  Iodine-131 is currently imported to treat patients. The 
Radioisotope Production Division (RIPD) of BAEC has established an ISO certified clean room facility to produce 
Tc-99m cold kits to meet the country’s demand. BAEC is trying to establish a Lu-177 production plant. The 
country’s only cyclotron is run by a private hospital. The second cyclotron is going to be installed under BAEC 
very soon. Two SPECT/Computerized Tomography (CT) and two Positron Emission tomography (PET)/CT 
scanners have been installed. A linear accelerator has been installed to treat cancer patients. In therapeutic 
related services, beta ray therapy is now given by Strontium-90 for pterygium treatment at different centres.  
A new research reactor (20 MW) dedicated for medical radioisotope production is planning to be installed. 
BAEC is trying to serve the patients of the country to achieve a healthy life and to substitute import of 
radioisotopes and radiopharmaceuticals by homegrown production. 
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Education/Awareness-2 
Author: Boima Darju 
Ministry of Education Liberia 
Corresponding author: bdarju2013@gmail.com 
Education, including e-learning certification and training methodologies for professionals involved in 
radiopharmacy can establish a good foundation and create several opportunities in this important field. 
Education and awareness are very cardinal in the area of radiopharmacy. This field is quite essential in the 
area of improving human health as it provides a valuable diagnostic information It is important to adequately 
capacitate professionals to be able to cope with major challengers in the coming decade, where new concepts 
will be developed in dealing with new trends of humans illness, like in the case of Ebola, a pressing illness in 
Africa. This virus infects the reproductive organ of male and female in macaques, so human could be similarly 
infected in this manner. 
The IAEA should organize a periodic training for young radiopharmacy professionals, empowering 
universities/institutions in under privilege countries through scholarships to encourage more young students 
in the field and to create a workable system and collective efforts in awareness for all. Through radiopharmacy, 
professionals will adequately be informed, grape new visions about the growing challenges and put into place 
a resilient solution mechanism. 
Institutions will be empowered, and many young students will grow their interest in the field. In conclusion, a 
good level of education for these professionals will positively correlate a breakthrough and new discovery in 
the interest of the global population in health advancement. Followed by an in-depth multi-dimensional 
analysis of credible research activities.  
  
ISTR–2019 
 
231 
 
Relevance of the study of radiopharmacy at San Francisco Xavier University 
Author: Elizabeth Huanca  
Universidad SFXCH, Bolivia 
Corresponding author: ehuancasardinas@hotmail.com 
The objective of the present work was to evaluate the pertinence of maintaining the subject of radiopharmacy 
in the curriculum of the chemical pharmaceutical career in the Faculty of Pharmaceutical and Biochemical 
Sciences at the Universidad Mayor Real and Pontificia de San Francisco Xavier de Chuquisaca. A questionnaire 
was applied to graduates of this career who performed their rotatory internship at the Institute of Nuclear 
Medicine. The results reflect that: 100% needed knowledge about the management of radioactive material; 
100% consider that for their training it is necessary to study the subject of radiopharmacy; 100% indicate that 
the presence of the pharmaceutical chemists are fundamental in the laboratory of radiopharmacy; and 60% 
indicate that they have a low level of management of laboratory material and biosecurity techniques. Hence, 
it is necessary to develop professional criteria through practices throughout the training in the Race, 
considering that from the fourth-year students have a real vision of what will be their professional work, and 
also bearing in mind that the formation of the pharmaceutical chemist must respond to science and 
technology. In conclusion, since the subject of radiopharmacy does not count in the curriculum, the graduated 
students from the faculty do not have sufficient knowledge in the matter; therefore, the inclusion of said 
matter is important. 
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Development of nuclear pharmacy training module in Malaysia 
Author: Noratikah Mat Ail 
Co-author(s): Suharzelim Abu Bakar; Zaitulhusna Md Safee 
Corresponding author: atikah2257@gmail.com 
Clear, transparent and updated guidelines are the driving force for improving the quality of services provided 
by medical institutions in the Ministry of Health Malaysia (MOH) to prioritize the interests of the patient for 
appropriate and optimal diagnosis and therapy. Human capacity building is crucial for optimizing human 
resources to meet the vision and mission in delivering excellent Nuclear Pharmacy Services. Credentialing of a 
nuclear pharmacist through a structured training course is obligatory to ensure the individual pharmacist 
qualifies and is competent before he/she is capable to manage and use the controlled radioactive drugs or 
radiopharmaceuticals. 
Nuclear Pharmacy Training Module (NPTM) was developed by the Pharmacy Services Programme, MOH to 
provide standardization of nuclear pharmacists training and to encourage Good Radiopharmacy Practices 
when preparing radiopharmaceuticals. 
The training module consists of two parts; Hospital Nuclear Pharmacy practice and PET Manufacturing 
Practice. It also covers the radioactive relevant legislation in complying with the requirements under local 
Atomic Energy Licensing Regulations (Basic Radiation Safety Protection 2010) which requires the employer 
and nuclear medicine facilities to provide training, retraining and updating the skills and knowledge of their 
personnel. 
This module is divided into two components, didactic (Section 1) and experiential (Section 2) for the training 
programs in Part A: Hospital Nuclear Pharmacy and Part B: PET Manufacturing Nuclear Pharmacy. The didactic 
component involves 66 hours of lectures given by selected speakers such as nuclear medicine 
consultants/physicians, physicists, and nuclear pharmacists while the experiential component provides the 
trainees with hands-on experience in handling radiopharmaceuticals. This component requires to be 
completed while working in a nuclear pharmacy for 12 weeks and with the assistance of a senior qualified 
nuclear pharmacist serving as a preceptor. Preceptors are responsible to evaluate the trainees. Each part (Part 
A and Part B) consists of four (4) components: tutorial, examination, experiential and soft skills. Trainees will 
be assessed on exercise questions, which carry 20% of total marks. Trainees are required to achieve at least 
50% from written examination and 80% in the experiential component.  Any trainee who fails to pass the 
minimum requirement in the written examination will need to sit for a viva examination to evaluate his/her 
knowledge and skills. Certification is awarded to a trainee who has successfully completed the program and 
demonstrated their knowledge and competency by examination. 
In conclusion, thirty individuals have successfully completed the NPTM over the past nine years with the 
improvement in productivity and adherence to quality standards. The development of individual skills allows 
them to undertake a greater variety of work which not only focuses on the technical handling of 
radiopharmaceuticals but also gets them to be involved in the clinical team. 
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One of the key aspects of Good Manufacturing Practices is the education and training of personnel. According 
to WHO´s official documents the production of pharmaceutical products requires enough qualified personnel 
to perform all necessary tasks. In the specific case of radiopharmaceuticals, technical staff should have a 
postgraduate training or technical training as well as an appropriate experience in their function. However, 
radiopharmacy education at university level is not accessible in most Latin-American countries and 
professionals in this area continue to be trained in the working place without sufficient theoretical 
background. 
In this context a new postgraduate Diploma in Radiopharmacy offered by the Faculty of Chemistry in Uruguay 
has started in 2016, with the objective to offer specific education to professionals working in the field. The 
programme is open to professionals with a university degree in Chemistry, Pharmacy or Biochemistry, both 
from Uruguay and other countries. The syllabus include: i) 300 hours of lessons (theoretical and practical) and 
300 hours of a supervised professional practice in conventional Radiopharmacy (at the Nuclear Medicine 
Centre in the University hospital) and PET (at the Uruguayan Centre for Molecular Imaging. The Diploma can 
be obtained in one year. The curricula include basic topics of nuclear physics, radiation detection, radiation 
biology and radioprotection, as well as updated information on labelling chemistry, clinical application of 
radiopharmaceuticals, GMP, regulations and guidelines and research and developments in the area. The 
candidates can also select complementary courses according to their background between a wide range of 
options including analytical, inorganic or organic chemistry, microbiology, pharmaceutical technology or 
clinical assays. 
Flexibility is a key feature of our Diploma. The recognition of the previous education and working experience 
of the candidates and the option of performing the professional practice in an accredited Radiopharmacy in 
their own country offer the possibility to shorten the curricular time and reduce the cost. 
The Diploma has until now four graduates from Colombia (1), Costa Rica (2) and Uruguay (1). We also have 4 
other students from Uruguay who will finish by December 2019.The profile of our graduates and students is 
very different. Some of them have been working in the area before but needed to increase their knowledge 
to adjust to the increasing requirements of the regulations or to catch up with the new developments. Others 
are completely new in the field and either have working proposals in Radiopharmacy or are interested in 
opening the possibility to work in the area in the near future. 
According to the opinion of our students “the Diploma has a broad range of topics, solid professionals with 
deep knowledge in the field and very good didactic materials”. “The Diploma offered an enlightening 
experience that lead to the achievement of new professional goals” 
However, the implementation of the Diploma is still in an initial phase and further modifications and 
improvement will be introduced to better suit the necessities of the professionals of Radiopharmacy in Latin 
America. 
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Accelerators of Ural Federal University as a base for student education and stuff training 
Author: Oleg Riabukhin 
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The Ural Federal University (UrFU) is one of the largest higher educational institutions in Russia bringing 
together fundamental education and innovative approach towards the challenges of modern times. As a part 
of UrFU, the Institute of Physics and Technology (IPT) has more than 55 years’ experience in acceleration 
technique exploitation (R&D mostly) and education of students in a field of Nuclear Physics and Technologies 
including questions of nuclear reactors, isotopes production, dosimetry and radiation detection. From 2015 
the IPT was equipped by new accelerators: 18-24 MeV TR-24 proton cyclotron and 10 MeV E-beam LINAC. On 
the basis of these installations, centres of nuclear medicine (for radiopharmaceutical production and 
implementation) and radiation sterilization (for radiation processing) were organized. Taking into account 
IPT’s background in the field of radiation application and education, install equipment was the objective of the 
Education and Training Center (ETC). 
For organizing ETC, it is planned: 
⎯ To employ teachers’ staff from Experimental Physics and Radiochemistry departments, Nuclear 
Medicine and Radiation Sterilization Centers, Medical University with experience in international 
collaboration in the fields of accelerator operation, radiation interaction with matter, dosimetry, 
radiation detection, isotopes and radiopharmaceutical production, and using radiopharmaceuticals; 
⎯ To attract specialists in the quality control and assurance (QC/QA) procedures in the field of radiation 
technologies; 
⎯ To elaborate educational and training programs including theoretical and practical exercises on topics 
of radiation processing of materials and radiopharmaceutical production and implementation; 
⎯ To obtain an international experience through participating in Regional Training Courses of IAEA TC 
projects on subjects related with nuclear physics and radiation technologies. 
As a result of our activity in ETC organizing at the present day we have elaborated international training course 
programs on the subject of “Multipurpose Irradiation Centre as a Component of Centre of Nuclear Science and 
Technology” supported by the State Corporation Rosatom. It aims to train foreign participants, inside this 
country training course program on the subject of “Radiation sterilization at E-beam facility” for Russian 
participants. 
On the operating base of radiation sterilization center, numbered IAEA RER1017 and RER1019, the regional 
training course “Dosimetry at E-beam and Gamma- Facility” was carried out in 2017 and 2019. The staff of ETC 
regularly takes part in IAEA meetings, workshops and training courses in RER 1019, RER 9149 and plans to take 
part in RER 1020 related with radiation technologies, radiation safety and radiotracers. The nuclear medicine 
center will be commissioned during 2019 and will start radiopharmaceutical production. 
The IPT of Ural Federal University is in the beginning phase of developing an education and training center on 
the base of proton and electron accelerators and it has all the premises to become an international 
multifunctional center of education and training. 
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Radiopharmacy is a branch of nuclear medicine (NM), which was started in Sudan in 1962 at RICK (Khartoum), 
1995 at NCI, Wad Medani. Later, Shendi came to the picture as a third public centre. Now there are 6 NM 
centres, 3 out of them are public and 3 are private. The public ones are located in Khartoum (capital of Sudan), 
Wad Medani (NCI is ~196 km south Khartoum) and Shendi (~200km north Khartoum). There are two more 
centres are coming up, one in Marawe (north Sudan) and the other is in Alobaid (west Sudan). 
Instruments available, functions and size: all the centres are equipped with SPECT gamma cameras, dose 
calibrators. The functions and size of radiopharmacy units in Sudan are different from one to another. In RICK, 
there are an oncology department, NM department, and medical laboratories for general investigations. In 
NCI there are 6 departments on oncology, NM, radiology, medical physics, laboratories and blood bank, and 
molecular biology. In Shendi there are oncology and NM departments. 
The 99Mo-99mTc generators come from Monrol – Turkey twice a month through (national medical supply fund 
– NMSF). Performed investigations include but are not limited to bone scan, hepatobiliary, thyroid, renal 
studies, and perfusion lung scan. In RICK, in addition to the above, the cardiology gated blood pool scan has 
been carried out. In NCI, we performed 99mTc-PYP hot spot scans, parathyroid scan using 99mTc-MIBI. 
Training received: thanks goes to the IAEA for providing the man power with fellowships, scientific visits and 
training courses, as well as equipment and experts. 
Challenges: there are challenges facing the radiopharmacy practices in Sudan: high cost for running and 
maintaining radiopharmacy services, and brain drain of trained radiopharmacists. They go to other countries 
with better infrastructure in radiopharmacy and better payment; with high salaries and incentives, leading to 
the survival of workers abroad. Other challenges also include lack of funding and high cost of equipment and 
radiopharmaceuticals, lack of understanding of radiopharmacy and NM by health administrators. Careful 
management of resources and information drives have helped to sustain the radiopharmacy and NM service 
despite economic problems in the country. Still there is a severe shortage of trained staff in NM and 
radiopharmacy in Sudan. 
The pharmaceutical requirements of good radiopharmacy practice (e.g. suitable facilities for sterile 
preparations) in most radiopharmaceuticals laboratories still need further improvements (public and private). 
Training and education needed: Any procedure in radiopharmacy laboratories should be done in the right way 
to maintain the sterility and pyrogenicity. Therefore, radiopharmacy professionals should have adequate 
training in all aspects of sterile preparation, quality control, radiation safety and radiochemistry to ensure that 
they are competent to handle radioactive materials and that can take responsibility for their level of practice. 
Impact evaluation of IAEA assistance: Standards of radiopharmacy practice have been improved to some 
degree with continuous training by holding the previous training courses and hoping they will continue 
through upcoming projects. We hope continuation of these training courses for radiopharmacists, both 
hospital based as well as regulators. Exposure of technologists for external training has had effective impact. 
Risk towards the patients has been decreasing, and there is an increased awareness of radiopharmacy. The 
improvement in documentation of training and procedures will improve safety and efficacy of 
radiopharmaceuticals to the benefit of patients and staff safety. 
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African countries are at various levels in radiopharmacy practice.  Cyclotrons are only available in few 
countries. Other countries have technetium based radiopharmacy practice. Staff hired to work in the 
institutions that have nuclear medicine practice may not necessarily have the requisite qualifications and 
competencies of radiopharmacy practice. The IAEA through the AFRA projects has funded some short courses 
for radiopharmacy for various African participants working in radiopharmacy. However, participants from 
different countries have different needs depending on their background degree and their current and future 
levels of radiopharmacy practice. Thus, it is important to have the bassline data on competencies in 
radiopharmacy so as to design radiopharmacy courses that would suit the varied participants from Africa. 
There was a survey on radiopharmacy competencies. A data collection form was used to collect the required 
data and to be sent out to radiopharmacy practitioners working in several countries in Africa. The received 
data was analysed. 
20 Participants from 10 African countries responded. The practice involved research in radiopharmacy (30%), 
procurement and supply chain of radiopharmaceuticals (16.7%), PET radiopharmaceuticals production (8.3%), 
technetium based radiopharmaceutical preparations (40%), dispensing of radiopharmaceuticals including 
radio iodine (60%), blood cell labelling (8.3%) and quality assurance and quality control (16.7%). Note that 
participants were involved in more than one practice area.  
The participants were mostly Bachelor of Pharmacy graduates (80%) and 20% had additional MSc in 
radiopharmacy. Less than 10% had other degree qualifications such as a Bachelor of Science in radiography or 
biology. For the Bpharm graduates, 60% did not have any additional radiopharmacy training.  30% of these 
had done some short courses in radiopharmacy. None had done any online course in radiopharmacy. The short 
courses done in radiopharmacy had provided competencies in the following areas: quality control procedures, 
fluorodeoxyglucose preparation, preparation of technetium-based radiopharmaceuticals, health worker 
safety, and radiation risk assessment and radiation dose calculation. 
Based on the current practice, participants mentioned the following areas where there are skills gaps and 
would require further training: dose calculations, peptide and protein PET radiopharmaceutical production, 
blood cell labelling, radiation protection, GMP in radiopharmacy, quality control for radiopharmaceuticals and 
safe handling of iodine 131. 
In conclusion, African countries are at various levels of radiopharmacy practice with only limited number of 
cyclotrons (in South Africa, Morocco, Egypt and Kenya). Most of other countries are only involved in 
technetium based radiopharmaceutical preparations and dispensing of iodine. Fewer still do blood cell 
labelling. It is important to set standards on the qualifications for practice of radiopharmacy. It is also 
imperative to include radiopharmacy modules in the Bachelor of Pharmacy programs. Some of the knowledge 
gaps mentioned can be fulfilled by having an online course with various modules. The IAEA can focus some of 
the radiopharmacy training where there are knowledge gaps.  
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Nuclear medicine in Colombia involves a set of diagnostic and therapeutic procedures through sources of open 
radiation, consisting of radioactive isotopes, radiopharmaceuticals and radionuclides for human use, which is 
currently developed in the country in 82 licensed nuclear medicine services. 
The regulatory authorities of this subject are combined between the Ministry of Mines and Energy, in terms 
of radiological protection and by the Ministry of Health and Social Protection, regarding the health issue, 
issuing regulations according to their competence. The Ministry of Mines and Energy authorizes the entry and 
handling of radioactive material in the country, and the Ministry of Health and Social Protection regulates its 
applications in medical services. 
Therefore, in 2015, Colombia issued regulations for radiopharmacies, their products and their certification in 
Good Practices for the Preparation of Radiopharmaceuticals, issued by the National Institute for Surveillance 
of Medicines and Foods -INVIMA for a term of 5 years, in order to guarantee quality, safety and efficacy of this 
type of products, as well as their availability and access to the population. This regulation does not apply to 
Good Manufacturing Practices, clinical trials or industrial production of radiopharmaceuticals. 
This regulation defined requirements that include personnel issues, staffing, infrastructure, equipment, return 
of materials and radiopharmaceuticals, documentation, quality management system, quality control analysis, 
pharmaceutical quality water collection system, validation, preparation of radiopharmaceuticals and analysis 
(by contract, agreement and / or quality agreement), materials, distribution and transportation, processing, 
dispensing and administration of radiopharmaceuticals and pharmacovigilance. 
To date, according to information from the Ministry of Mines and Energy sent by INVIMA to this Ministry, 
there are 116 radiopharmacies in the country (hospital and centralized), of which only 6 meet the 
requirements and are certified in Good Practices for the preparation of radiopharmaceuticals. Additionally, 
there are no industrialized radiopharmacies in the country that produce radiopharmaceuticals, which means 
that all products (cold kits, generators and some radionuclides) are imported, since there is no nuclear reactor 
in the country. 
Taking into account the above, it is necessary to review, analyse and modify, if deemed appropriate, the 
requirements of the current regulation, in critical aspects that have presented problems for the 
implementation of the regulation, mainly in terms of staff availability and training, infrastructure, endowment, 
quality control, quality management system, validation, preparation, dispensing and administration of 
radiopharmaceuticals and pharmacovigilance. 
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The installation of a new platform in a radiopharmacy unit represents a challenge to adapt the labelling 
techniques with GMP requirements. It is a great opportunity to improve radiosynthetic conditions and it 
involves the introduction of new procedures into the Quality Management System of The Uruguayan Center 
of Molecular Imaging (CUDIM) Centre. 
Our purpose was to optimize the production of different 18F-radiopharmaceuticals in accordance with GMP 
quality requirements in the new automated radiosynthetic platform RN Plus Research (Synthra). 
CUDIM has recently acquired a radiosynthetic module RN Plus® Research (Synthra) to replace a TRACERlab® 
Fx FN (General Electric). The new platform enables more versatility due to the presence of two reactors and a 
major number of interconnections. The module was installed in a hot cell Comecer MIP1 LAF (air quality Class 
A). To perform the acceptance test, the following radiopharmaceuticals were synthetized: [18F]AlF- PSMA-11, 
[18F] Fallypride, [18F]FMISO. Since two reactors are available, the labelling steps were performed in the first 
one and the hydrolysis steps (if necessary) in the second one. The reaction volume for labelling of the new 
module is 7 mL, whereas the TRACERlab® Fx FN (GE) is 11 mL. Therefore, it was necessary to adjust the amount 
of the solvent in order to carry out the labelling reactions. Another advantage of the new module is the fact 
that the preparative HPLC allows to perform the purification steps using solvents gradient.  
Table 1 – Radiochemical yield obtained for each module (mean ± SD, n = 3) 
Radiochemical Yield 
(No decay corrected) 
Tracerlab FxFN 
(General Electric) 
RNplus Research 
(Synthra) 
[18F]AlF-PSMA-11 18 ± 2 % 23 ± 3 % 
[18F]Fallypride 11 ± 1 % 20 ± 5 % 
[18F]FMISO 22 ± 4 % 40 ± 5 % 
Table 1 shows a comparison of the radiochemical yield obtained in each module for the radiopharmaceuticals. 
Physicochemical and microbiological controls were performed according to quality control specifications 
established by CUDIM for the different radiotracers. Besides this, a production under clinical trial was also 
optimized in this module ([18F]-FPR-04-MZ). The quality system documentation was updated to introduce the 
procedures of the new platform. 
The introduction of a new radiosynthesis module into the radiopharmacy unit was carried out in accordance 
with the quality system of CUDIM. The new established methodologies enabled us to optimize the production 
procedures and thus increase the radiosynthetic yields. 
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In Brazil, as it has been occurring worldwide, the number of procedures using radiopharmaceuticals are 
increasing. The production and selling of short half-life radioisotopes are monopolized by the Brazilian 
Government. In 2006, a Constitutional Amendment revoked the state monopoly due to the need for the use 
of short half-life radioisotopes in nuclear medicine centres very far from government production facilities. The 
aim of this study is to describe the current status of radioisotope production and sales in Brazil and discuss 
some licensing process. Currently, there are 14 radiopharmaceuticals production facilities and 4 
radiopharmacies operating in Brazil. The type of licensing process conducted in Brazil does not take into 
account the population density of each state, with a free competition model being adopted. Because of this, 
there are a lot of equipment concentrated in the Southeast while no cyclotrons or radiopharmacy operating 
in the Northern part of the country. One of the biggest obstacles during the licensing process is the designation 
of qualified personnel in radiopharmacy or accelerator for radiopharmaceutical production as operation 
workers and radiation safety officers. Currently, there are only 17 qualified workers in these fields. Regarding 
regulatory inspection in Brazil, during the facilities licensing process two types of inspections are usually 
performed: one to monitor the radiopharmaceutical production (usually overnight) and another to verify 
records and to test security systems. The number of facilities for radiopharmaceuticals production and sales 
are increasing. However, several external factors such as the distance from the nuclear medicine centres, and 
qualified personnel have proved crucial for the economic viability of this type of facility, and a rigorous 
licensing process is necessary to ensure radiological protection. 
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Up to date, [68Ga]PSMA has been used in a clinical research context. Sales authorization for a new 
radiopharmaceutical or imaging equipment alone does not support the continuity and increase of the role of 
nuclear medicine. Each country and health system have their own set of requirements and priorities. Health 
Technology Assessments (HTA) tools could and should be considered. Mostly, to base and to help decision-
makers to spread or not any new technology in local or regional levels. Efficacy and accuracy of [68Ga]PSMA 
PET/CT in the real world could be assessed in primary and in secondary studies. Only after that any 
consideration on local or regional use and economical aspects could be applied by health systems. The present 
study discusses how HTA tools on the use of [68Ga]PSMA PET/CT can help health systems. 
Test/imaging accuracy, detectability, positivity and change of management were some of the diverse 
comparators and outputs used in primary and secondary studies using [68Ga] PSMA PET/CT, that the present 
study evaluated under HTA requirements. The selection criteria, applicability and association to the treatment 
efficacy of the comparators and outputs were assessed and discussed. 
The selection of a variable as an outcome in secondary studies can vary from the detectability of the lesion, 
(indicators of) positivity, sensitivity and specificity, change of management, etc. HTA guidelines for diagnostic 
procedures consider only accuracy as an outcome. However, costs of imaging diagnostics procedures are 
considerably high compared to other kinds of tests. Then, clinical outputs, considering effective change of 
management and consequent therapy results are necessary. Secondary studies are frequently associated with 
critical weaknesses, such as risk of bias, publication bias, true effect, and study heterogeneity. HTA requires a 
more integrative information assessment of the diagnostics and treatment. Investments and costs associated 
with change of management should be evaluated by considering patient prognosis/response and not only the 
imaging test specification. Nuclear medicine and HTA integrated goals can enlarge significantly the number of 
studies and patients to accelerate the approval procedure. 
The use of [68Ga]PSMA PET/CT, as many other procedures in nuclear medicine, still needs a broad approach 
considering HTA requirements. HTA needs to evaluate the procedure by diagnostic accuracy and the resulted 
patient treatment efficiency. While SR/ MA evaluate a procedure single outcome, multicentric and integrative 
studies, capable of collect and assess multivariate data seem to be the way to identify true effects over the 
patient prognosis. 
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Uganda has had a steadily growing cancer burden (1) and rapid population growth (2) in the last few decades. 
There has been an overall increase in the incidence of cancers in both males and females, with incidence rates 
of major cancers such as breast and prostate showing particularly marked in- creases (3.7% and 5.2% annually, 
respectively). Nuclear medicine is a key weapon in the arsenal against neoplastic diseases, among its other 
applications in medicine. There is thus to a steadily increasing demand for Radiopharmaceuticals in the country 
and thus a need for a progressive strengthening of the systems that provide assurance of their safety and 
efficacy. 
For the last few decades, the country has had one nuclear medicine facility which is under the Mulago National 
Referral Hospital in the nation’s capital - Kampala. The said nuclear medicine facility has for the past three 
years been closed as the hospital was undergoing renovations and infrastructural upgrades. The works in the 
department are near completion and the nuclear medicine practice will soon resume. 
Aga-Khan university hospital, a private hospital in Uganda has declared intentions of opening a nuclear 
medicine department and has publicly stated that a cyclotron will be installed soon among others for use in 
their nuclear medicine practice. This will raise the number of nuclear medicine facilities in Uganda to two and 
with the resumption of Mulago National Referral Nuclear Medicine Department, there will be regular import, 
possible production, hospital compounding / preparation and use radiopharmaceuticals in the country. 
The Atomic Energy Act No. 24 of 2008 mandates the Atomic Energy Council to regulate all peaceful uses of 
ionizing radiation in Uganda for the protection of people and the environment from the harmful effects of 
ionizing radiation. The National Drug Policy and Authority Act of 1993 mandated the National Drug Authority 
to regulate the import, production, sale and use of drugs within Uganda for the protection of the public from 
possible effects of substandard or low-quality drugs. 
As it is already known, radiopharmaceuticals used in nuclear medicine are a combination of both drugs and 
radioactive sources. The laws and organizations respectively mentioned above regulate the two components 
of radiopharmaceuticals independently, yet they are combined their production or import and their 
production and use considers them as one. 
There is thus the need to harmonise the legal and regulatory frameworks to implement sound interfaces 
between both regulatory systems in order to address the gaps and overlaps in the regulation radio- 
pharmaceuticals in Uganda. The paper will identify and propose fixes to the gaps and overlaps in Uganda’s 
regulatory framework for radiopharmaceuticals. 
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This study was conducted to synthesise radioactive gold nanoparticles (198AuNPs) and bimetallic gold 
nanoparticles (AuHgNPs) for application in cancer therapy. The β¯ particles emitted by 198AuNPs can be used 
for cancer therapy while AuHgNPs is a promising nanoparticle for radiosensitization effect in radiotherapy. 
Gold nanoparticles (AuNPs) in liquid form was synthesized by reducing Tetrachloroauric acid with Trisodium 
citrate (Turkevich Method), producing particles with sizes of 10, 40 and 80 nm. The neutron bombardment of 
AuNPs was carried out at TRIGA PUSPATI Reactor yielding 198AuNPs. Then, the neutron activation analysis 
(NAA) was performed on the 198AuNPs to analyse its composition. The 198AuNPs was then let to decay 
completely before the Inductively Coupled Plasma – Mass Spectrometer (ICP-MS) was being used to confirm 
the presence of mercury and gold (AuHgNPs). This study confirmed a suitable method of producing 198AuNPs 
and AuHgNPs from AuNPs synthesized by the Turkevich Method. 
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Protein-based nanoparticles have been used as vehicles to deliver radioactivity to tumour cells for external 
imaging and targeted radiotherapy, also used as drug delivery for chemotherapeutics. The development of 
these nanocarriers holds the potential to overcome some of the current problems associated with the existing 
traditional nuclear medicine agents. A nanosized vector can be administered using minimally invasive 
techniques (e.g., by intravenous or intratumour injection), penetrate across tumour vasculature and improved 
tumour uptake if compared to common labelled radiopharmaceuticals. The aim of the present work was the 
study of radiolabelling of bovine serum albumin (BSA-NPs) and papain (P-NPs) nanoparticles, synthesized by 
gamma ray irradiation, with 99mTc and characterize their in vitro and in vivo properties towards potential novel 
nanoradiopharmaceuticals. The nanoparticles were synthesized with an average diameter of 9.3 ± 1.9 and 
25.1 ± 2.9 nm, P-NPs and BSA-NPs respectively. The direct labelling of protein nanoparticles with 99mTc was 
optimized using different concentration of reducing agent SnCl2, pH and reaction time. Radiochemical 
evaluation was performed using TLC and by high performance liquid chromatography (SEC-HPLC). Ex vivo 
biodistribution studies and SPECT/CT imaging were performed in male AG129 mice and female spontaneous 
breast cancer model (MMTV-PyMT mice), respectively. Excised tumour of 4T1 xenograft model was used to 
perform autoradiography and immunohistochemistry assays. The radiolabelling reached around 95% yield, 
and the 99mTc-BSA-NPs showed stability for 24 h in all assayed conditions, while 99mTc-P-NPs presented stability 
for 6 h in human serum. Radiolabelled P-NPs were mainly identified in the spleen, lungs and featured a renal 
excretion profile. On the other hand, the 99mTc-BSA-NPs were found in the liver and spleen to a larger extent, 
undergoing hepatic excretion. Ex vivo biodistribution also showed good tumour uptake for both nanoparticles, 
and SPECT/CT images corroborated these results. The autoradiographic studies and immunohistochemistry 
assays revealed a high density of both papain and BSA nanoparticles in peripheral regions of tumour tissue 
and confirmed the efficacy of the developed nanoradioparmaceuticals for targeting breast cancer. 
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Recently, radioactive nanoparticles have attracted intense interest in medicine, both in diagnostics and 
therapy. Among various β– emitters, 198Au radionuclide exhibits very attractive properties for its application 
in targeted radionuclide therapy (t1/2 = 2.7 d, βmax = 0.96 MeV). Unfortunately, both Au+ and Au3+ cations 
do not form stable complexes and it is impossible to attach them to biomolecules, therefore an interesting 
approach would be the synthesis of gold nanoparticles (AuNPs) containing 198Au. Additionally, employing 
AuNPs allows the simultaneous use of a number of therapeutic methods, such as chemo and radiotherapy in 
one agent, which is extremely important due to the high resistance of cancer cells. To increase the efficiency 
and selectivity of the therapy as a novel targeted brachytherapy is required to apply radioactive gold 
nanoparticles for the treatment of locally-advanced neuroendocrine cancer. 
The aim of our research is to obtain a multimodal radiobioconjugate containing simultaneously a 
chemotherapeutic, radionuclide and biomolecule in a one structure. To achieve this goal, we proposed that 
the radioactive gold nanoparticles (198AuNPs) as a β- emitter and a carrier for doxorubicin (DOX) are used in 
chemotherapeutic and octreotide as guiding vectors with an affinity to SSTR2 receptors overexpressed in 
neuroendocrine tumour cells. 
Synthesis of radioactive gold nanoparticles (198AuNPs) was performed by using a radioactive 198Au precursor, 
which was obtained in 197Au(n,γ)198Au reaction in the reactor. To determine the shape, size, size distribution, 
zeta potential TEM (Transmission Electron Microscopy) and DLS (Dynamic Light Scattering) techniques were 
applied. The chromatography methods such as HPLC (High Performance Liquid Chromatography) and SEC (Size 
Exclusion Chromatography) were used to analyse the efficiency of the obtained DOX-PEG-SS-PEG-DOX, 
Octreotide-PEG-SS- PEG-Octreotide conjugates and the final product -Octreotide-PEG-197AuNPs-PEG-DOX. 
To avoid radioactivity contamination of used equipment, the analysis of physicochemical parameters of 
nanoparticles were carried out on non-radioactive 197AuNPs. The DLS and TEM measurements confirmed the 
expected average size (~5 nm) and spherical shape of the synthesized nanoparticles. The zeta potential value 
showed the high stability of 197AuNPs without a tendency to agglomeration.  The 197AuNPs were modified with 
bifunctional hydrophilic polymer polyethyleneglycol (PEG) in different molar ratios to optimize a degree of 
surface coverage. The synthesis of DOX-PEG-SS-PEG-DOX and Octreotide-PEG-SS-PEG-Octreotide conjugates 
were carried out with the use of triethylamine and DMF as a solvent. The products were successfully purified 
by HPLC using semi-preparative C18 column and finally analysed with the MS method. Bioconjugates of 
radioactive nanoparticles 198AuNPs with doxorubicin and octreotide were obtained by spontaneous 
attachment of the DOX-PEG-SS-PEG-DOX and Octreotide-PEG-SS-PEG-Octreotide compounds to the gold 
nanoparticles through the sulphide bond. 
Based on the strong affinity of sulphur to gold, the synthesized DOX-PEG-SS-PEG- DOX and Octreotide-PEG-
SS-PEG-Octreotide conjugates were attached to the 198AuNPs surface. The obtained multimodal 
radiobioconjugate Octreotide-PEG-198AuNPs-PEG-DOX containing in its structure doxorubicin, radionuclide 
and octreotide could be a promising radiopharmaceutical for the treatment of neuroendocrine tumours. 
  
ISTR–2019 
 
247 
 
Gold-198 coated superparamagnetic iron oxide nanoparticles (SPION) for cancer radiotherapy 
and magnetic hyperthermia 
Author: Michał Żuk1 
Co-author(s): Agnieszka Majkowska-Pilip2; Aleksander Bilewicz2; Magdalena Osial2; Paweł Krysiński1 
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In modern world cancer is the second cause of death after cardiovascular diseases, making it a serious threat 
to human life.  The World Health Organization estimates that every sixth deaths are due to cancer.  To 
counteract these unfavourable statistics novel methods of cancer treatment are needed.  Due to the high 
resistance for the single treatment, the synergistic approach shows great promise in cancer therapy. Especially, 
combining external radiotherapy with hyperthermia showed great promise in treating locally advanced head 
and neck cancer in comparison to radiotherapy alone. Also, a combination of hyperthermia with radiotherapy 
may be much more effective against hypoxic cancers through radiosensitization. Currently in our group, we 
propose the use of a combination of internal radionuclide therapy in combination with magnetic 
hyperthermia. 
Superparamagnetic iron oxide nanoparticles (SPIONs) which show high heating efficiency in the alternating 
magnetic fields and can be easy coated with radioactive layer of 198Au. 198Au (τ1/2=27d) is obtained by neutron 
irradiation of high purity gold in n,y reaction. As a soft energy B-emitter, 198Au could be used in radionuclide 
therapy of small tumours or tumours metastasis. 
The modified method developed by Lee et. al. was used for synthesis of 198Au coated SPIONs Briefly, SPIONs 
were synthesized through precipitation from solution containing Fe(II) and Fe(III) ions with 25% NH3 aq. After 
synthesis, nanoparticles were coated with sodium citrate as a stabilizing agent preventing against SPIONs 
agglomeration and added to boiling gold-198 solution for core-shell coating reaction which was performed 
under reflux. Finally, the product was purified by magnetic sedimentation and centrifugation and resuspended 
in deionized water. 
Preliminary results indicate that obtained SPION-198Au nanoparticles show satisfactory stability in 0,9% NaCl, 
PBS solutions and additionally in human serum. Despite the existence of the gold coating, the nanoparticles 
retain comparable magnetic properties to unmodified SPIONs. Studies on modification by attachment of the 
targeting vector and the in vitro tests are planned to be made. 
Acknowledgments: the contribution of M.T. Żuk was realized within Project No POWR.03.02.00-00-I009/17-
00 (Operational Project Knowledge Education Development 2014-2020 co-financed by European Social Fund). 
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Dosimetric model based on the distribution of PSMA targeted radiopharmaceuticals to bone 
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Targeted radiopharmaceuticals based on PSMA inhibitors (iPSMA) have been proved as suitable agents for the 
detection and treatment of advanced metastatic prostate cancer (PCa) 1. Recent clinical studies have shown 
that the therapeutic application of iPSMA labelled with 177Lu produce a decrease of more than fifty percent in 
the prostate antigen (PSA) levels, as well as a significant survival increase. However, bone metastases appear 
to respond less to treatment with 177Lu-iPSMA than visceral or lymph nodal disease. Due to their destructive 
power, alpha particle emitters have been proposed as an ideal option for targeted radiotherapy of resistant 
bone metastases. Dosimetric models are needed for a personalized alpha particle targeted radiotherapy. 
The objective is to obtain a dosimetric model based on a subcellular distribution of targeted 
radiopharmaceuticals in an animal bone metastases model generated from prostate cancer cells embedded 
in ectopic bone plaques. 
In the present study the radiation absorbed dose produced by 177Lu-iPSMA and 225Ac-iPSMA to prostate cancer 
cell nuclei was assessed by using in vivo biokinetic data obtained from experimental measurements of 
radiopharmaceutical distribution at a cellular level considering the influence of bone microenvironment. For 
this purpose, LNCaP cells embedded in ectopic bone plaques were grown in adult mice during 20 days, 
radiopharmaceuticals were administered and their biokinetics were analysed under a fluorescence 
microscope to determine the distribution of the radiopharmaceutical in the bone matrix and in the 
mesenchymal tissue. In order to calculate the absorbed dose in LNCaP cell nuclei, Monte Carlo simulation with 
the MCNPX code was used and a dosimetric model was obtained. 
Results show that 225Ac-iPSMA releases a nine hundred-fold radiation dose greater than 177Lu- iPSMA. The 
obtained dosimetric model considers these differences in order to calculate the absorbed dose in LNCaP cell 
nuclei, needed for the elimination of prostate cancer cells in a bone metastasis without damaging adjacent 
tissues (such as bone marrow). 225Ac-iPSMA has potential dosimetric and radiobiological advantages over 
177Lu-iPSMA in the treatment of bone metastases in patients with advanced prostate cancer. 
Since the biological effect of beta emissions are significantly different to that of alpha particles and due to the 
recent attention that alpha particle radiopharmaceutical therapy has been acquired for the successful 
treatment of bone lesions, the developed dosimetric model is useful for the personalized and safe application 
of 225Ac-iPSMA. 
Acknowledgment: This study was supported by the Mexican National Council of Science and Technology 
(“Laboratorios Nacionales” and CONACyT-SEP-CB-2018, A1-S-36841). 
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Abundant expression of somatostatin receptors (SSTR) in differentiated neuroendocrine tumours (NET) serve 
as a potential target for designing agents for diagnostic imaging and treatment. In this study, the theranostic 
concept has been utilized by choice of SSTR-targeting compounds, Ga-68-DOTATATE and Lu-177/Y-90 
DOTATATE towards diagnosis and treatment of NET. In-vitro and in-vivo evaluation of the efficacy of these 
NET specific diagnostic and therapeutic radiopharmaceutical pair was performed using SSTRII positive (AR42J) 
and negative (HCT116 and MCF7) cell lines. 
Y-90-DOTATATE was produced from Carrier free, clinical grade Y-90-Acetate, sourced from a two- stage Sr-
90/Y-90 generator system based on supported liquid membrane (SLM) technology. Lu-177- Chloride were 
produced in our research reactor using enriched Lutetium-177-oxide {Lu-176 (n,γ) Lu-177}. Ga-68-DOTATATE 
was synthesized using Gallium-68-Chloride obtained from Ge-68/Ga- 68 generator. The endotoxin limit was 
quantified by gel-clot BET assay and sterility test done by direct inoculation. 
Pancreatic carcinoma cell-line AR42J (expressing SSTRII), Human colon carcinoma cell-line HCT- 116 (with 
SSTRII expression) and MCF7 (with negative SSTR II expression) were used for the in vitro evaluation. The cells 
were grown in IMDM medium with 10% FBS in 5% CO2 at 37 C. In vitro cell-binding and receptor binding 
studies were performed by incubating AR42J cells and cell homogenate respectively with radioligand (~5x10–
12 mol DOTATATE) up to 120 min followed by washing with PBS. Non-specific binding was assessed by addition 
of cold DOTATATE (5x10–9 mol). The degree of receptor mediated uptake of the radio-conjugate was 
determined by biodistribution studies in tumour bearing athymic nude mice. The Lu-177/Y-90 DOTATATE 
(50μCi-100μCi/mice) was injected in xenografted mice through tail vein. Planar scintigraphy/ PETCT images 
were obtained for comparative analysis. 
Radiopharmaceuticals showed rapid cell binding (in the range of 25-40%) in AR42J cell line, reaching a plateau 
after 30 min with Ga-68, Lu-177 and Y-90-DOTATATE. Compared to AR42J, the HCT116 and MCF7 cell line 
showed 8-10% and 5-6% respectively. Yttrium showed marginally higher percentage of internalization in AR42J 
in cell line as compared to Ga-68 and Lu-177. In PET/CT imaging study, Ga-68 showed precise localization of 
tumour in nude mice xenograft. 177Lu-DOTATATE showed localization in tumour by SPECT scanning. 
Biodistribution analysis of the tumour bearing mice revealed that radioactivity in the blood and most of the 
organs decreased after 24hour post-injection. High uptake and long-term retention of radioactivity were found 
in kidney (8.01% ID/gm), and tumour (3.17% ID/gm) which is in concordance with our scintigraphy studies. 
The indigenously produced Ga-68, Lu-177 and Y-90-DOTATATE presented here is sustainably refined and 
advanced with respect to targeting large volume NET lesions. Pre-clinical evaluation of Lu-177/Y-90 DOTATATE 
theranostic pairs show optimal targeting properties for treatment of neuroendocrine cancer patients. PET/CT 
imaging using Ga-68-diagnostic counterpart provide essential information about SSTR density, which is 
relevant for treatment decisions, and selecting patients for treatment with peptide receptor radionuclide 
therapy (PRRT) with the therapeutic pairs. 
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Breast cancer is the most common cause of death from cancer overall. Breast tumours are traditionally 
classified according to their estrogen receptor status: Hormone-dependent tumours (ER+), and hormone-
independent tumours (ER-). These receptors serve as targets for endocrine therapies of these cancers. But 
they also can be used as targets for diagnostic imaging and radiotherapy. For example, antiestrogens, such as 
tamoxifen, are largely used for the treatment of women suffering of ER breast cancer. It is known that 
prolonged treatment with tamoxifen develops drug resistance. Radioimaging methods for early diagnosis are 
attractive because they simultaneously and non-invasively provide information on all tumour sites and allow 
treatment at an early stage. For radiotherapy, a non-penetrating radiation is needed. 99mTc presents very 
favourable characteristics to be used in nuclear imaging medicine. Just below technetium in the periodic table, 
rhenium has two radioactive isotopes suitable for therapeutic use: Since rhenium occurs naturally as a mixture 
of non-radioactive isotopes 185Re and 187Re, it is possible to work on the non-radioactive rhenium compounds 
first to predict the behaviour of technetium compounds. Their interest could thus be evaluated, before tackling 
the radioactive 186/188Re and 99mTc derivatives. Their ultimate use in vivo and their availability in aqueous 
solutions make it necessary to find water-stable rhenium and technetium compounds. The stable piano stool 
CpM(CO)3 core (M = Re, Tc) is one of the most promising moieties for this purpose. The preparation of 
radiopharmaceuticals should ideally allow the incorporation of the radionuclide at the final step of synthesis. 
It also requires a rapid and simple isolation and purification of the final product. Therefore, it is important to 
find a suitable stable precursor for the synthesis of rhenium and technetium compounds bearing the 
cyclopentadienyl tricarbonyl motif. We were interested in using the ferrocenyl derivatives as precursors for 
rhenium and technetium ligands of the Estrogen Receptor. Many rhenium and technetium estradiol 
derivatives have been proposed, but most of them fail to have a strong enough affinity for the estrogen 
receptor. The search for improved or more tunable radiopharmaceuticals is still currently undertaken and 
recent research has been directed to radiopharmaceuticals based on compounds containing the CpTc(CO)3 
group or Tc(CO)3core because of the high stability of these moieties. Consequently, we sought to explore this 
field, by proposing suitable ferrocenyl tamoxifen-type molecules for the double metal exchange reaction. We 
had interest in preparing several compounds and examining their potential as a radiopharmaceutical. 
Therefore, the development of such hormone receptor ligands for diagnostic imaging is a promising area of 
research. 
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The objective of this study was to evaluate the in vitro potential of the 177Lu-PSMA(inhibitor)-RGD 
radiopharmaceutical to bind PSMA and α(v)β(3) integrins overexpressed in LNCaP (lymph node metastasis-
derived) and PC3 (bone metastasis-derived) prostate cancer cell lines. 
The LNCaP (PSMA-positive) and the PC3 (α(v)β(3) integrin-positive) cells were grown in RPMI 1640 
supplemented with 10% of fetal bovine serum and 1% of antibiotics. For evaluating the cell uptake, 1x10⁵ cells 
were incubated (45 min, 37℃) with the treatments (177Lu-PSMA(inhibitor)-RGD 60 nM and their monomers as 
controls:177Lu-PSMA-617 and 177Lu-RGD, 30 nM). Then, cells were washed with glycine buffer (pH 2.8, 50 mM) 
followed by the addition of NaOH 0.3 M to determine the cell uptake and internalization fraction. For binding 
affinity, 1x10⁵/well were incubated (1h, 37℃) in the presence of a constant concentration of the 177Lu-
PSMA(inhibitor)-RGD with cold peptide at 12 different concentrations (from 0 to 5,000 nM, n=3). After washing 
the cells, the bound activity was counted in a gamma NaI(Tl) detector. The 50% inhibitory concentration (IC50) 
was estimated by fitting the competitive binding curves to the Hill function (Origin OriginLab 8.0). To 
determine IC50 for 177Lu-PSMA-617 and 177Lu-RGD the same procedure was performed. The cell viability was 
assessed with the XTT assay kit (Roche, Germany). LNCaP or PC3 cells (8x103 cells/well, 96 well plates) were 
incubated with each treatment for 4 h (~2 Bq/cell) and cell viability was evaluated in 24hours and 48hours. 
The control group represents 100% of viability with untreated cells. The cell absorbance was measured at 
λ=450 nm. The differences between the 177Lu-PSMA(inhibitor)-RGD radiopharmaceutical and their monomers 
were evaluated using Student’s t-test. 
Cell uptake studies for PC3 cells showed a statistically-significant higher uptake of 177Lu-PSMA(inhibitor)- RGD 
(3.64±0.58%) compared with 177Lu-PSMA-617 (0.32±0.08%,p<0.05), and not statistically significant when 
compared with 177Lu-RGD (3.02±0.34%,p>0.05). For LNCaP cells, there was statistically significant differences 
in the 177Lu-PSMA(inhibitor)-RGD (6.24±0.32%) compared with the 177Lu-PSMA-617 (5.35±0.16%,p<0.05) and 
177Lu-RGD (1.01±0.05%,p<0.05). The affinity of 177Lu-PSMA(inhibitor)-RGD for PSMA (5.7±1.3nM) was 1.6 times 
higher than PSMA-617 (8.9±0.9nM,p<0.05). In terms of α(v)β(3) integrins, the binding affinity of 177Lu-RGD 
was 6.2±1.2nM and 4.5±0.7nM for 177Lu-PSMA(inhibitor)-RGD, with a statistically significant difference 
between them (p<0.05). After expo- sure to 177Lu-PSMA(inhibitor)-RGD, the effect on cell viability was 2.5 
times higher in LNCaP cells (18.61%) compared with the observed viability in PC3 cells (47.07%). 
The radiotracer showed specific recognition for PSMA and α(v)β(3) integrins, and the capability to inhibit 
cancer cell proliferation with suitable affinity to be used as a radiotheranostic agent. These pre-liminary results 
warrant future preclinical studies to establish the potential of 177Lu-PSMA(inhibitor)- RGD for the treatment of 
prostate cancer. 
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Breast cancer is a very important health problem. More than 60% of breast tumours that are positive for 
estrogen receptor (ER+) are also positive for progestogen receptor (PR+), and almost 75% of these tumours 
(ER+/PR+) respond positively to endocrine therapy. However, a radiotracer directed to PR has potential 
advantages over one aimed at ER. There is a better correlation between the PR status and the response to 
hormone therapy. Additionally, a radiotracer capable of recognizing PR could be used after the initiation of 
anti-estrogenic hormone therapy, while an ER-directed one may not be useful when the ER tumour is 
saturated by the hormonal agent. 
The aim of this work was the preparation of a [99mTc]Tc labelled levonorgestrel derivative (LevOH) and its 
physicochemical and biological evaluation as a potential agent for imaging breast cancer by gamma 
scintigraphy. 
LevOH bearing functional groups to coordinate Tc through the formation of a tricarbonyl complex was 
synthesized by a 1,3-dipolar cycloaddition of Huisgen, catalysed by Cu(I) between the azide group of N-Boc-3-
azido-L-alanine and the terminal alkyne of levonorgestrel. Labelling was performed in 2 steps by involving the 
synthesis of the fac-[99mTc]Tc(CO)3(H2O)3 precursor and the subsequent substitution with LevOH. The 
physicochemical characterization included: stability in reaction milieu, in plasma, lipophilicity and plasma 
protein binding. In-vivo evaluation was performed in athymic mice with human xenograft tumours obtained 
by inoculation of MCF-7 cells (ER+, EP+) at 1, 4, 12 and 24 hours post-injection. 
 
Figure 1 
 
 
The derivatization of levonorgestrel was achieved by one of the so-called “click chemistry reactions” which are 
very specific and avoid the necessity of complicated purification and isolation processes. The ligand bears 3 
electron-donor groups that can be used for coordination of Tc through the formation of a tricarbonyl complex 
(Fig. 1). The radiolabelling was performed in the same pot that the derivatization leading to a main product, 
[99mTc]Tc(CO)3LevOH, that was isolated by HPLC, with radiochemical purity > 95%. The complex remained 
stable in the reaction milieu at least for 3 hours and in plasma for 2 hours. The Log P value was (0.67 ± 0.01), 
suitable for the passage through biological membranes. Plasma proteins binding was (85.4 ± 2.3)%,  which  is 
reasonable when taking into account that levonorgestrel is transported in plasma by the sex hormone binding 
globulin in 70%. In-vivo biodistribution was very favourable, with low blood activity (4 % at 1 hour post- inj.), 
high urinary elimination (60±2% at 24 hours) and a tumour /muscle ratio ranging from 2.8 to 6 (from 1 to 24 
hs. post-injection). 
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The physicochemical and biological evaluation of the complex [99mTc]Tc(CO)3LevOH showed a promising profile 
for a potential imaging agent of ER+/EP+ breast cancer by gamma scintigraphy. Nevertheless, further studies 
with cell lines and isolated receptors will be done in order to assess the potentiality of this approach. 
Acknowledgments: ANII FCE_1_2017_1_136416, CAP, CUDIM, CMNIM Hospital de Clínicas. 
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Prostate cancer cells show great demand of cell membrane lipids for growth and proliferation. Acetate as an 
important intermediary substrate is the main carbon source for fatty acid and lipid synthesis. The lipogenic 
phenotype of prostate cancer can be imaged, among others, with 11C-acetate PET. Cancerous cells govern the 
use of acetate for de novo lipogenesis wherein fatty acid synthase (FASN) is the rate limiting enzyme. Earlier 
studies have shown that there is a direct correlation between 11C-acetate uptake and FASN expression. 
Several clinical studies have evaluated the potential clinical role of 11C-acetate for PET imaging of prostate 
cancer. The information on the uptake and retention rates of 11C-acetate on a cellular level is, however, 
limited. Therefore, a study was performed to evaluate the in vitro kinetics of 11C-acetate in prostate cancer in 
real-time. 
In a kinetic assay, the 11C-acetate uptake and retention rates by PC3 and DU145 (low and high aggressive) cell 
lines were evaluated under the same conditions. In order to check the uptake saturation of 11C-acetate, two 
assays were performed where the uptake was monitored over time using LigandTracer White. In a blocking 
assay, two experiments were performed in parallel on PC3 cells. Another in vitro study was performed on 
DU145 and PC3 cells to compare their uptake per cell. 
The uptake was linear and proportional to the 11C-acetate concentration in solution indicating the continuous 
consumption of the latter by the cells for lipogenesis. The relative uptake rate of 11C-acetate was significantly 
(p=0.002) higher for PC3 cells than that for DU145 cells indicating that 11C-acetate is taken up in proportion to 
fatty acid synthesis. There was a significant difference (P=0.001) between the retention rates for DU145 and 
PC3 cell lines showing that PC3 has a 2 times faster anabolic metabolism than DU145. In a titration assay, it 
could be seen that 11C-acetate uptake by DU145 and PC3 cells in vitro was characterized by a steady uptake 
(figure 1). The 11C-acetate uptake was strongly reduced when excess of non-labelled acetate was added, 
indicating the specific uptake of 11C-acetate. The uptake of 11C-acetate by PC3 cells was about three times 
higher than that by DU145 cells. The 11C-acetate concentration was gradually increased by subsequently 
adding 200, 600, 1800, and 3000 kBq, respectively. 11C-acetate retention was monitored after replacement of 
the incubation solution with medium after 125 min. 
In vitro studies demonstrated higher uptake and retention (p<0.01) of 11C-acetate in the more aggressive PC3 
cells. Thus, faster kinetics of 11C-acetate might reflect the level of aggressiveness of the cancer cell lines. 
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Cerenkov radiation (CR) is the energy produced in the ultraviolet-visible region of the electromagnetic 
spectrum. It is produced when charged particles are travelling faster than the speed of light in the same 
medium. This effect produces polarization of the molecules, which relaxes by releasing energy in ultraviolet 
and/or visible radiation form. When β particles travel through tissue with energies higher than 219 keV, CR 
occurs. Spectral optical window of the tissue is from 600 nm to 1100 nm, consequently, the amount of CR 
within this range could be useful for quantitative preclinical studies from optical images. 177Lu is a radionuclide 
with a half-life of 6.71 d and a βmax emission of 0.497 MeV (78%), and it has been used successfully for 
radiopeptide therapy. Some β particles emitted by 177Lu are in relativistic limited because they travel faster 
than the speed of light in different mediums. The in vivo evaluation of 177Lu radiopharmaceuticals could be 
used in preclinical studies by CR imaging. The objective was to determine the experimental emission spectrum 
of CR-177Lu and to evaluate their transmission properties in tissue. 
Theoretical and experimental characterization of the emission and transmission spectra in tissues of the 177Lu-
CR within the Vis-NIR region (350-900 nm), were carried out by using the Frank-Tamm and relativistic theory, 
Monte Carlo simulation (MCLTmx code) and light spectroscopy. The acquisition of 177Lu-CR images of mice was 
performed by using a CCD camera. The total number of image photons/second/mm2 was quantitatively 
analysed. The total number of disintegrations and the biokinetic models in the kidneys and tumour regions 
were obtained using the image quantitative analysis. 
Results showed a good agreement between theoretical and experimental 177Lu-CR emission spectra. At 1.9 cm 
of tissue depth, there is still a signal in the spectral range. The total number of disintegrations obtained by 
177Lu-CR image analysis showed a good agreement when compared with reported ex-vivo studies of 177Lu 
(<3%). 
In conclusion, preclinical CR images demonstrated that the biokinetics of 177Lu-radiopharmaceuticals in the 
main organs of mice can potentially be acquired from CR optical images. 
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Poly-N-vinyl pyrrolidone-co-acrylic acid nanogels have been developed as nanocarrier systems. Their small size 
(80 nm), minimal toxicity, stability in serum and easiness of their surface modification (by attachment of 
targeting molecules, fluorescent probes or chelators for radiolabelling) make them interesting candidates for 
innovative drug delivery systems. The aim of the presented work was the evaluation of biological properties 
of 177Lu radiolabelled nanoparticles modified by conjugation of DOTA-bombesine. 
DOTA-bombesin-nanogels and DOTA-bombesin alone were labelled with 177LuCl3 (LutaPol) and 90YCl3 (ItraPol). 
The labelling yield was assessed by TLC (iTLC SG plates/0.2M KCl pH 2.4). Purification of radiolabelled 
preparations was conducted by size exclusion chromatography (mini PD10 columns eluted with saline) and 
ultrafiltration (amicon ultra centrifuge filters 3kDa). In vitro binding studies in AR42J cell line (rat’s pancreatic 
cancer cells) were performed to assess the biological activity. Standard procedures for assessing specific and 
non-specific binding and internalization were employed. Biodistribution was evaluated in two animal models: 
normal Wistar rats and the tumour model - female BALB/c Nude (CAnN.Cg-Foxn1nu/Crl). To grow the tumours, 
the AR42J cells (106 cells in 200 μL PBS) were inoculated on the left or right shoulder. The radiolabelled 
nanogels were administrated intravenously and intratumourally in the dose of 10 MBq/animal. The animals 
were sacrificed at different time points after injection and the radioactivity distribution was measured ex vivo 
after organ dissection. 
The radiolabelling yield of nanogels was in the range of 50-70% and after purification by size exclusion and 
ultrafiltration the radiochemical purity was more than 95%. [177Lu]-DOTA-bombesin-nanogel conjugates 
showed high affinity to the AR42J cells at the level of 8.4% of specific binding and 80% internalisation rate, 
which was comparable to that of [177Lu]- DOTA-bombesin. In vivo biodistribution in normal rats revealed that 
the liver is the critical organ with over 80% of accumulation of injected dose (%ID). Biodistribution after iv. 
injection to tumour bearing animals revealed increasing accumulation of labelled nanoconjugates in the 
tumour from 0.2% ID/g at 2 h p.i. to 2.3% ID/g at 24h p.i. and high accumulation in the liver. After 
intratumourall injection no leakage of radioactivity was observed over 48h. 
The specific membrane binding and internalization to the AR42J cells of the radiolabelled DOTA- bombesin-
nanogel was comparable to that of DOTA-bombesin which confirmed the targeting properties of the 
nanoconjugate in vitro. However, the biodistribution revealed that radiolabelled DOTA- bombesin-nanogels 
highly accumulate in the liver with rather small fraction taken up by the tumour. Further studies are needed 
to modify the size or/and surface of these nanoconjugates in order to improve the biodistribution pattern. 
Importantly, retention of [177Lu]-DOTA-bombesin-nanogel in the tumour after intratumourall administration 
confirmed its stability in vivo and indicates the potential of the particles in direct therapy of primary tumours. 
Acknowledgements: the study was performed within the International Atomic Energy Agency co-ordinated 
research project. F22064 „Nanosized Delivery Systems for Radiopharmaceuticals.” 
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Copper, as a natural bioelement in the human body, incorporated into a variety of proteins, is involved in key 
biological processes based on its redox properties. Its trafficking, accumulation and clearance are tightly 
controlled in normal health but often disturbed in disease states. These mechanisms can be exploited for both 
imaging and therapy, based on several radioisotopes of copper which are of certain medical interest. 64CuCl2 
has recently been proposed as a promising agent for cancer theranostics, based on preclinical studies. The use 
of 64CuCl2 for therapy raises important radiobiological questions, therefore this study proposes a comparative 
radiobiological evaluation of the intracellular effects induced in different tumour cells. 
An automated process for the production and purification of copper-64 produced by irradiating solid targets 
in a variable energy (14-19 MeV) cyclotron has been employed, by using a commercially available automated 
solid target system comprising modules for electrodeposition, pneumatic transfer, irradiation, dissolving and 
purification. To comparatively evaluate the biological effects, we used a panel of tumour cell lines: U87MG 
(glioblastoma), AR2J (pancreatic cancer cells), HT29 (colon adenocarcinoma), A431 (epidermoid carcinoma) 
and DU-145 (prostate cancer cells) in comparison with non-tumoural, control cell lines (monocytes ATTC). We 
performed cytogenetic and radio-cytotoxicity assays to evaluate the significant changes at cellular level 
induced by the exposure to 64CuCl2: cell viability by MTT/MTS, micronuclei testing genotoxicity and 
morphologic apoptosis and H2AX, when relevant. 
Results showed that tumour cells were found to exhibit increased 64CuCl2 uptake comparing to normal cells; 
early DNA damage, higher cytotoxicity and genotoxicity were also observed in tumour cells, with different 
intensities for different cancer cells tested. Double strain breakages were observed, which correlate with 
deficient DNA-damage repair capacity. The results contribute to elucidation of mechanisms involved, to 
quantify radiobiological effects and to sustain the use of 64CuCl2 for theranostic applications. 
Acknowledgement: this work was supported by a grant of the Romanian Ministry of Research and Innovation 
CCCDI - UEFISCDI project number 64PCCDI/2018, PNCDI III. 
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Beta emitters are widely used in treatment of various oncological diseases for a long time. Alpha emitters 
belong to new and perspective candidates for therapeutic use and some of them have been already introduced 
into clinical practise. Targeted alpha-particle therapy (TAT) is a rapidly evolving field of cancer treatment. 
Nevertheless, there are some severe issues that prevent TAT from being a leading modality in radionuclide 
therapy. The nuclear recoil effect that causes the daughter nuclei release from the original 
radiopharmaceuticals is a critical problem for alpha emitters. Moreover, targeting and proper dosimetry is still 
an issue. Therefore, we focused on the dosimetry on cellular and subcellular level with an aim to quantitatively 
and qualitatively compare the effect of alpha and beta emitters on living cells. 
For our study we used Ra-223, Sm-153 and Re-186 as a model radionuclides. All radionuclides were used in 
the range 0-8 kBq/mL. Studied cell lines were V79 (Chinese hamster lung fibroblasts), DU145 (human 
adenocarcinoma cell line) and U87 (human primary glioblastoma cell line) obtained from American Type 
Culture Collection (ATCC). All cells were cultivated in humidified atmosphere under standard culture 
conditions (37℃, 5 % CO2). Chines hamster cell line (V79) was cultivated in Dulbecco’s Modified Eagle’s 
Medium (Sigma-Aldrich, Germany) supplemented with 10% of Fetal Bovine Serum South America Origin 
(Biosera, France) and 1% of Penicillin-Streptomycin (Biosera, France)). Human adenocarcinoma cell line 
(DU145) and human glioblastoma cell line (U87) were cultivated in Eagle’s minimum essential medium (Sigma-
Aldrich, Germany) supplemented with 10% of Fetal Bovine Serum of South America Origin (Biosera, France), 1 
% of Penicillin-Streptomycin (Biosera, France)), 1 % of L-glutamine (Sigma-Aldrich, Germany), 1 % of Non-
essential amino acids (Sigma-Aldrich, Germany) and 1 % of pyruvate (Sigma-Aldrich, Germany). All cell lines 
have been cultivated in the presence of Ra-223, Sm-153 or Re-186 for 24 hours after the monolayer of the 
cells was created. After the cultivation with Ra-223, Sm-153 or Re-186, the clonogenic survival test was 
performed and survival curves for all cell lines were constructed. 
All obtained survival curves correspond to the linearly quadratic model. Sensitivity of both human carcinoma 
cell lines (adenocarcinoma and glioblastoma cell line) to treatment by all used radionuclides is higher than the 
sensitivity of the Chinese hamster pulmonary fibroblast cell line. Sensitivity of tested carcinoma or tissue cell 
lines is higher to alpha treatment than to beta treatment using the same applicated activities of alpha or beta 
emitters.  The achieved results enabled further progress in enhancing the alpha dosimetric studies. 
Acknowledgment: this work was supported by the Health Research Agency of the Czech Republic (grant No. 
NV16- 30544A). 
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The role of the specialist in radiopharmacy is important in the medical interpretation of images obtained in 
nuclear medicine studies. One of the most common problems associated with radiopharmaceuticals is an 
unexpected or altered biodistribution, which can have a significant clinical impact on dosimetry, interpretation 
of the scan and the precision of the images for diagnosis. In its most extreme manifestations, the results of 
images with altered biodistribution may compromise the usefulness and precision of nuclear medicine studies. 
The biochemical and pharmaceutical interpretation of the molecular mechanisms involved must be 
considered. 
Studies carried out will be analysed in order to consider important factors that affect the biodistribution of 
radiopharmaceuticals that can be the following main categories and include: 
⎯ Problems in preparation methods or in the formulation of radiopharmaceuticals; 
⎯ Problems caused by radiopharmaceutical administration techniques; 
⎯ Previous Medical procedures, such as biopsy puncture, surgery, radiotherapy or dialysis; 
⎯ Due to changes in biochemistry and physiopathology of the patient and also by pharmacological 
interactions. 
The altered biodistribution of 99mTc radiopharmaceuticals is generally associated with increased amounts of 
99mTc radiochemical impurities, such as 99mTcO4 free, impurities and particles, such as 99mTc colloids or reduced 
99mTc hydrolyzed species, or other radionuclides. 
Failure in the function of excretory organs and systems, such as the hepatobiliary and genitourinary systems 
can contribute to the altered biodistribution of radiopharmaceuticals. 
Incidental findings perfusion artefacts that commonly occur may have clinical significance and/or may affect 
the interpretation of the study, and should be considered and reported appropriately. 
An important factor, not always considered, is dose infiltration or contamination with antiseptics and 
aluminium during dose administration, which can cause significant artefact. 
In conclusion, new molecular radiopharmaceuticals for diagnostic or therapeutic use, should be considered, 
since pharmacological interactions should be evaluated and in the same way, the techniques of labelling and 
administration. 
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The receptor for chemokines CXCR4 is mainly expressed in cells of the central nervous and immune systems, 
hematopoietic stem cells, endothelial and epithelial cells. The ability of CXCR4 to mediate the metastasis of a 
variety of cancers has been studied because it is associated with angiogenesis, tumour progression and 
survival. Several CXCR4 antagonist peptides have been used to reduce tumour growth and angiogenesis in 
preclinical studies. Recently our group has radiolabelled a new chemokine-4 ligand (CXCR4-L) with Tc-99m for 
specific imaging of tumours with CXCR4 expression. The objective is to estimate the biokinetics and radiation 
dosimetry of 99mTc-CXCR4-L in six healthy subjects and to evaluate its ability to target CXCR4 in one patient 
with medulloblastoma. 
The radiopharmaceutical 99mTc-CXCR4-L was obtained with radiochemical purity >98% from lyophilized 
formulation. The complete body anterior and posterior gamma images from six healthy humans (three women 
and three men) were acquired at different times after radiopharmaceutical administration (20 min, 1, 2, 4, 6 
and 24 h). Images of each time frame were corrected by attenuation and scattering. The geometric mean of 
the anterior and posterior images was obtained and regions of interest (ROI) were selected (source organs). 
ROI’s time-activity curves of 99mTc-CXCR4-L were used to set the biokinetic models and estimate the total 
number of disintegrations (N) that took place in the source regions. Using OLINDA/EXM and N data the internal 
radiation doses were calculated. 
A brain SPECT/CT image was acquired in a medulloblastoma tumour 3 h after administration of 99mTc-CXCR4-
L. 
The half-life value of blood activity had one fast and two slow components of 0.81 min (T1/2α=ln2/51.01), 
12.19 min (T1/2β=ln2/3.41) and 2.03 h (T1/2γ=ln2/0.34), respectively. The equivalent doses calculated for a 
study using 740 MBq in females for brain, breast, kidneys, liver, lungs, and spleen were 0.0025 ± 0.0002, 0.2235 
± 0.0474, 0.0232 ± 0.0042, 0.1046 ± 0.0265, 0.3236 ± 0.0650 and 0.0054 ± 0.0006 mSv, correspondingly, and 
in males for brain, kidneys, liver, lungs and spleen were 0.0026 ± 0.0007, 0.0764 ± 0.0655, 0.1078 ± 0.0115, 
0.3483 ± 0.0423 and 0.0052 ± 0.0014 mSv, respectively. The average effective dose for the six subjects was 
3.91E-3 ± 3.25E-4 mSv/MBq. The 99mTc-CXCR4-L uptake in medulloblastoma of the patient was significantly 
higher in respect to the background of the lesion. 
In conclusion, the 99mTc-CXCR4-L radiation absorbed doses in source organs was comparable to those 
recommended for Tc-99m imaging studies. The radiopharmaceutical uptake in tumour of medulloblastoma in 
the brain was significantly higher than the background brain uptake, which demonstrated the ability of the 
new 99mTc-labelled CXCR4 ligand to detect tumours with CXCR4 expression. 
Acknowledgment: this study was supported by the Mexican National Council of Science and Technology 
(LANIDER, CONACyT-ININ). 
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The development of novel radiopharmaceuticals is a labour intensive, time consuming and expensive period 
similar to novel drug delivery systems. The targeting ability to the desired disease site should be evaluated for 
the assessment of the specificity of radiopharmaceuticals. Therefore, in vitro cell culture studies are becoming 
widespread all around the world due to being easy to apply, and a rapid and safe method for the development 
of novel radiopharmaceuticals. In vitro cell culture studies gained a significant role in preclinical studies 
depending on obeying the three R concepts (replacement, reduction and refinement) and animal welfare. By 
this way, unnecessary laboratory animal use in research has reduced significantly. 
Cell culture studies comprise the studies after growing under controlled conditions after removing cells from 
the tissues. Cell culture studies can be used in molecular biology as model systems, cancer research, toxicity 
tests, virology, vaccine production, monoclonal antibody production, organ and tissue production, gene 
therapy and as preclinical studies in drug development. Similar to novel drug development studies, 
radiopharmaceutical development studies benefited from cell culture studies in tumour modelling, BBB 
modelling, permeability, cytotoxicity, cell binding and uptake and targeting. 
This research comprises a series of different studies evaluating cell binding studies of novel 
radiopharmaceuticals for tumour imaging. In vitro cell culture model, property, culture conditions, and 
applications of radiopharmaceuticals were maintained, and specific cell binding and uptake of 
radiopharmaceuticals were evaluated by obtaining microscopy images, fluorospectroscopy and counting 
radioactivity in gamma counter. For this purpose, either tumour binding or BBB penetration of radiolabelled, 
active targeted liposomes were evaluated and compared with unmodified, PEGylated liposomes in different 
cell culture lines. 
According to cell culture studies, significantly higher uptake was observed with radiolabelled tumour specific 
ligand modified liposomes in cell binding and surface association of different tumour cell lines, when compared 
with unmodified conventional liposomes. Successful cell culture studies are thought to mimic in vivo 
conditions and live tissue functions more properly.  
This research gives an overview to a series of different studies performed by our group evaluating cell binding 
and cell surface association studies of novel radiopharmaceuticals for different diseases. Therefore, in vitro 
cell culture studies are essential for the development of novel radiopharmaceuticals similar to drug 
development by reducing unnecessary animal utilization, more rapidly and safer. 
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The process of drug discovery and development requires substantial resources and time. A good 
understanding of the pharmacokinetics of the existing drugs could lead to a more successful strategy. The 
application of pharmacokinetic principles is one of the tools available for optimizing drug therapy, including 
drugs whose concentration-pharmacological response relationship is well established. Leishmaniases are 
mosquito-borne infectious diseases caused by protozoan parasites of the genus Leishmania.  The mainstay of 
treatment remains pentavalent antimonial agents in the form of sodium stibogluconate (Pentostam®) or 
meglumine antimoniate (MA, Glucantime®). Despite the pharmacokinetics of pentavalent antimonials having 
been already reported, the available data are conflicting due to the different methodologies employed to 
measure antimony (Sb), the sample numbers, and the treatment schedules. In this review, we discussed the 
use of the radiolabelled compound to provide a sensitive and powerful tool to determine their 
pharmacokinetic properties. Radioisotopes of Sb were prepared to follow the biodistribution of MA and its 
liposomal formulations, also to evaluate the amount of Sb incorporated inside the liposomes. Samples of free 
MA and MA-liposomes in clean polypropylene tubes were placed together with Sb standards inside the 
aluminium container. Irradiations were carried out at a thermal neutron flux of 0.8 x 1012 n.cm-2.s-1 for 15 
minutes inside the nuclear reactor. Two Sb tracers, 122Sb and 124Sb, were produced through the reactions 
121Sb(n,γ)122Sb and 123Sb(n,γ)124Sb. Studying the biodistribution of MA is easier and faster when the drug is 
radioactive when compared to conventional analytical techniques. Because there are no antimony 
radioisotopes commercially available, irradiating the MA was the best choice for the in vivo evaluation studies.   
The advantage of this procedure is that neutron irradiation of the stable antimony isotopes present in the MA 
formulation enables the detection and quantification of total antimony, but without distinguishing between 
the pentavalent and trivalent antimony species. We also found that there was no difference in the 
antileishmanial activity in the irradiated MA compared to the non-irradiated MA in both in vitro and in vivo 
evaluations. The use of radiotracers as a tool to evaluate the biodistribution of drugs in animal models is a 
feasible approach and these results could contribute to the development of new pharmacological studies using 
drug delivery systems for leishmaniases. This work emphasizes the importance of antimony pharmacokinetic 
profile in finding better therapeutic protocols as to its dosage, administration interval, and the duration of 
therapy. The use of radiotracer has great potential for improving the efficiency in the drug development 
process. 
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Myoview™ (Tetrofosmin) is a pharmaceutical agent which needs to be radiolabelled with technetium-99m 
according to manufacturer’s guideline to become 99mTc-Tetrofosmin. It then needs to undergo a radiochemical 
purity (RCP) test to determine that the percentage RCP is within acceptable limit. This is defined according to 
WHO Pharmacopeia (≥90%), before being used for nuclear cardiology imaging. Myoview™, which is quite 
expensive in Malaysia (€950 / 5 vials), is supposed to be reconstituted with 12GBq of technetium-99m with 
final volume of 8mL (radioactivity concentration of 1.5GBq/mL) and it can be used for approximately 8 one-
day protocol patients. Using a new cardiac dedicated gamma camera (GE Discovery NM 530c), the department 
anticipates an increased number of patients and scans per day resulting the enlarged usage of Myoview™; and 
thus, an increase in operational costs. Increasing radioactivity concentration per vial may be done to cater this 
issue. 
To determine RCP percentage of 99mTc-Tetrofosmin compounded outside manufacturer’s guidelines at 
radioactivity concentration of 2.0GBq/mL, 2.5GBq/mL and 3.0GBq/mL at time 0, 4, and 8 hours post-
reconstitution with null hypothesis: RCP percentage of 99mTc-Tetrofosmin is ≥ 90% and alternative hypothesis: 
RCP percentage of 99mTc-Tetrofosmin is < 90%. 
Five batches of 99mTc-Tetrofosmin were prepared at each radioactivity concentration of 2.0GBq/mL, 
2.5GBq/mL and 3.0GBq/mL. Each batch underwent 9 RCP tests using TEC-Control™ chromatography system; 
3 tests for each sampling time at 0, 4, and 8-hour post-reconstitution. Data were analysed using one-sample 
T-Test and Repeated Measures ANOVA. 
RCP’s mean percentage of each sampling time (0hr, 4hr and 8hr): at a concentration of 2.0GBq/mL were 
94.52%, 96.24% & 95.72%; at concentration of 2.5GBq/mL were 96.15%, 95.86% & 95.21%; and at 
concentration of 3.0GBq/mL were 95.80%, 95.71% & 93.41%. A one-sample t-test was run to determine 
whether RCP percentage in samples was different as compared to the acceptable limit. RCP’s mean percentage 
of 99mTc-Tetrofosmin (95.41% ±1.86) was higher than the acceptable limit of 90%, which is statistically 
significantly higher by 5.41 (95% CI, 5.97 to 4.85), t (44) = 19.5, p < 0.0005. As there was a statistically significant 
difference between mean (p < 0.0005) and the mean is more than the acceptable limit, we can accept the null 
hypothesis and reject the alternative hypothesis. Repeated measures ANOVA was used to determine whether 
there is significant difference of RCP percentage of each radioactivity concentration at different sampling time. 
Result shows there was no statistically significant effect of sampling time (0hr, 4hr and 8hr post- 
reconstitution) on radioactivity concentration of 2.0GBq/mL, (Wilks’ Lambda = .39, F (2,3) = 2.32, p>0.05), on 
radioactivity concentration of 2.5GBq/mL (Wilks’ Lambda = .53, F (2,3) = 1.3, p > 0.05) and on radioactivity 
concentration of 3.0GBq/mL (Wilks’ Lambda = .31, F (2,3) = 3.29, p>0.05). 
The RCP percentage of 99mTc-Tetrofosmin that were compounded at a radioactivity concentration of 
2.0GBq/mL, 2.5GBq/mL and 3.0GBq/mL were acceptable regardless of sampling time. This study may be used 
to save approximately €47,500 per year of the departmental in operational costs. 
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The main aim of this study is to develop a new microbiological control method for the solution of iodine 131 
in a closed system for radiopharmacy services not equipped with a class of A Hot Cell dedicated to 
microbiological analysis according to GMP requirements. 
The method is based on the preparation of perforated petri dishes containing three culture media. The 
perforation of the Petri dishes was realized under a class A laminar flow hood using a heated metal cylindrical 
rod. A sterile magnetic stir bar was then placed in each Petri dish before closing the hole and sealing Petri 
dishes with autoclaving adhesive. 
First, the method was tested inside a class C room then inside an unclassified area by perforating the adhesive 
with a sterile syringe and injecting a volume of sterile water before the perforation was closed by a second 
sterile adhesive. Seeding was performed by moving each Petri dish on a magnet. Then the Petri dishes were 
incubated inside the Hot Cell at room temperature for yeasts and molds at 32.5 ℃ and for Total Aerobic 
Microbial and Total Coliform. A positive control (bacterial suspension) and a negative control (sterile water) 
were performed for each culture medium. Finally, the method was tested inside a class C Hot Cell for three 
production batches of sterile iodine- 131. 
Results showed that after 5 days incubation at 32,5℃ and 7 days at room temperature, The Petri dishes were 
sterile for both tests performed in class C room and for the unclassified room. The same result was obtained 
with the solution of iodine-131 in the three production batches. 
This new method has shown good efficiency to keep the sterility of culture medium during the microbiological 
analysis independently of the environmental class. It could be adopted by radiopharmacy services for the 
control of the solution of iodine-131 and other radiopharmaceuticals. This method would make it possible to 
carry out the microbiological analysis of radiopharmaceuticals quickly without waiting for the decay. 
Moreover, it allows to minimize the risk of exposure of the laboratory technicians by iodine inhalation. 
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Various diagnostic and therapeutic radiopharmaceuticals are regularly supplied for clinical use across India by 
BRIT. BRIT QA/QC monographs and Indian Pharmacopeia approve parametric release of short lived injectable 
radiopharmaceuticals as it is not feasible to complete the Sterility Test (ST) before the product is released. 
However, as a good manufacturing practice, it is mandatory that the test be commenced at the earliest. 
Conventional methodology for ST involves manual transfer of test samples - minimum four vials per batch -
into sterile growth media under aseptic conditions. This method is time-consuming, requires skilled persons 
and results in considerable radiation exposure to analyst in routine testing facilities. We describe here a simple 
vacuum-based manifold system which was designed in house, validated and tested in routine use to 
circumvent these problems. 
The vacuum-based manifold system consisted of four silicone tubings (Masterflex) connected to a vacuum 
pump and attached to sterile needles (Fig. 1). These needles were introduced into Fluid Thioglycollate Medium 
(FTM) and Soyabean Casein Digest Medium (SCD) bottles (HiMedia Laboratories). A sterile assembly containing 
a spinal needle (18G) connected to a sterile needle (23G) via silicone tubing was used.  The spinal needles were 
introduced into the sample vials such that their tip touched the base of the vials. Individual vacuum control 
for each of the four sets was done using solenoid valves placed between the media bottles and the vacuum 
trap. Switching on the vacuum and respective solenoid valve ensured withdrawal of the entire sample volume 
through the spinal needle and tubing into the media vial. Test samples were housed in slotted lead stand of 
appropriate thickness. The whole assembly was set up inside a Biosafety Cabinet (Class III). The inoculated 
media were incubated at 30-35oC and 20-25oC respectively for 14 days and examined for microbial growth by 
visual examination. 
 
Sterile saline was used to inoculate the media in the same manner and used as controls. The 
radiopharmaceuticals tested by this method included: 153Sm-EDTMP, 131I-mIBG and Na99mTcO4 eluates from 
90Mo-99mTc generators (04 batches each, RAC ~20mCi/mL (740MBq/mL) per vial). 
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Results shows that all the injectable radiopharmaceutical products tested passed the ST as indicated by 
absence of microbial growth on completion of the 14 days incubation period. 
In conclusion, the adaptation of the ST method using a vacuum manifold, besides being safe and time saving, 
provides a reliable quality control testing option for radiopharmaceuticals and decreases personal errors. This 
method can result in a significant reduction in the radiation dose received by the analyst and provides a 
feasible alternative to the conventional method. 
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Green Analytical Chemistry (GAC) is a branch of Green Chemistry based on the principles of sustainable 
development through eco-friendly analysis in laboratories. This employs techniques which replace or modify 
organic solvents, corrosive and toxic reagents, hazardous pollutants and carcinogens with safer ones, making 
it possible to reduce the amounts of reagents consumed and generated waste. 
99mTc-radiopharmaceuticals are most widely used for radionuclide imaging of various organs. 99mTc-based 
radiopharmaceuticals are produced using sodium[99mTc]pertechnetate (Na99mTcO4) and cold kits generally 
procured from commercial sources. Na99mTcO4 is eluted from 99Mo/99mTc generator systems and the quality of 
radiopharmaceuticals in turn depends on the quality of the Na99mTcO4. 
Radiopharmaceuticals are required to undergo Quality Control (QC) testing as it is important to have a product 
with acceptable QC specifications described in the Pharmacopoeias. Radiochemical purity (RCP) is a very 
important parameter which reflects the integrity and stability of radiopharmaceuticals. RCP of Na99mTcO4 is 
done by paper chromatography and should be ˃ 95%. RCP determination of Na99mTcO4 eluates from 
99Mo/99mTc generators is done by using paper chromatography (PC) followed by scanning for radioactivity 
using radiochromatogram scanner. The chromatograms are developed in any one of the solvent systems: 
1. 85% Methanol 
2. Methyl ethyl ketone (MEK) 
3. 0.9% Sodium chloride (Saline). 
 The aim of this work was to standardise an eco-friendly, alternative method for assessing RCP of Na99mTcO4 
using Double Distilled Water (DDW) as the mobile phase (MP).  
Na99mTcO4 was eluted from a 99Mo/99mTc Column (alumina) generator (BRIT). Paper chromatography of 
Na99mTcO4 was done in duplicate by ascending chromatography by using strips of Whatman No.3 (3x23cm). 
Determination of Reduced Hydrolysed Technetium (RHT) (impurity) in these eluates (06 batches) was done in 
the same manner by adding 10% SnCl2 in 0.1N HCl to the eluates and heating for 10 minutes at 100℃. The 
chromatography strips were scanned in a radiochromatogram scanner and the RCP data was computed.  
Table 1: % RCP values of Na99mTcO4  and RHT in four different solvent systems 
 
90.00%
95.00%
100.00%
Batch
No. 1
Batch
No. 2
Batch
No. 3
Batch
No. 4
Batch
No. 5
Batch
No. 6
85% Methanol
MEK
SALINE
DDW
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The percentage RCP of Na99mTcO4 & RHT (Table 1) by using the alternative procedure (DDW) is in good 
agreement with the other three standard chromatography procedures. Hence, this method can be used as an 
alternative method as it is compatible with routine nuclear medicine practices and can be easily adopted in 
hospital radiopharmacies. 
RCP determination using DDW is very convenient to use in hospital radiopharmacies as DDW is inexpensive 
and easily available. The method was standardized by us; hence, it provides an opportunity for utilizing the 
GAC techniques in the field of QC, besides offering significant ecological and economical merits. 
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Diagnostic and therapeutic injectable radiopharmaceuticals are regularly supplied by BRIT to use in Nuclear 
Medicine Centres all over India. It is mandatory to perform Bacterial Endotoxin Test (BET) before releasing 
these products. Bacterial endotoxin is the only significant pyrogen of concern in parenteral drug preparations 
due to its potency and ubiquity in nature. The adverse effects of bacterial endotoxins are dependent on dose, 
route and rate of administration. For BET based on gel-clot formation, Limulus Amoebocyte Lysate (LAL) 
reagent is commercially a viable option for routine testing. However, attention to test conditions are important 
as the method is both time and temperature sensitive. We describe here the optimisation of BET by gel clot 
method of various injectable radiopharmaceuticals based on test dilution, preparation of samples/controls, 
maintenance of test conditions and acceptance criteria. 
BET was carried out in accordance with the Indian Pharmacopeia using standard kit reagents (Charles River, 
India). It is required to calculate the Maximum Valid Dilution (MVD) for radiopharmaceutical products to 
establish the extent of dilution to avoid interfering test conditions. MVD = EL/ (EL is the Endotoxin Limit of 
injectable radiopharmaceuticals and is the sensitivity of LAL reagent used). The EL is 25 EU/mL (EU= Endotoxin 
Units) based on 7 mL being the maximum volume for the most injectable radiopharmaceuticals and the of the 
lysate used is 0.125 EU/mL. Hence, the permitted MVD works out to be 1:200. The exceptions are 177Lu-
DOTATATE and 68Ga labelled DOTATATE and PSMA, the former being unstable at higher radioactive 
concentrations and the latter formulated in a higher volume due to logistical reasons (Table 1). For the test, 
diluted samples (MVD) were incubated with LAL reagent at 37±1℃ for 60±2 minutes. At the end of the 
incubation period, the tube was inverted by 180° to detect gel–clot formation. The results were compared 
with negative and positive water control tests and product control tests. The former contained endotoxin free 
water and the latter contained the radiopharmaceutical product in the absence and presence of standard 
endotoxin, respectively. 
Table 1: MVD values of in house produced injectable radiopharmaceuticals 
 Product No. of Batches 
tested  
Volume 
(mL) 
EU/mL MVD 
1 131I-mIBG  440 7 25 200 
2 153Sm-EDTMP  395 7 25 200 
3 32P-sodium orthophosphate  223 7 25 200 
4 32P-Sm-Phosphate Colloid  47 7 25 200 
5 Na99mTcO4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                310 7 25 200
6 177Lu-EDTMP 14 7 25 200 
7 177Lu-PSMA 10 7 25 200 
8 177Lu-DOTATATE 26 12 14 120 
9 68Ga-DOTATATE 18 10 17.5 140 
10 68Ga-PSMA 34 10 17.5 140 
All the injectables, diluted as per the optimised protocols, passed the BET when tested by the gel- clot method 
thus verifying the suitability of the test protocol under actual conditions of use. The consistent results observed 
during the testing of these considerable numbers of batches proved the validity of the test. 
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In conclusion, BET testing of in-house produced injectable radiopharmaceuticals, as per the protocols 
standardised by us, has proved to be a reliable and reproducible quality control method in our experience in 
BRIT. 
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Radiopharmaceutical preparations (RP) or radiopharmaceuticals are medicinal products which, when ready 
for use, contain one or more radionuclides (radioactive isotopes) included for a medicinal purpose (diagnostic 
or therapeutic). In the nuclear medicine department, the reconstitution of a radiopharmaceutical is done by 
labelling a chemical molecule, the vector, with known pharmacokinetic and pharmacodynamics properties by 
a radionuclide, the marker. In vivo monitoring after administration of the RP is achieved usually by detecting 
the gamma radiation emitted by the radionuclide (scintigraphy). Technetium-99m (99mTc) is the most used 
radionuclide in 99% of nuclear medicine prescriptions. 99mTc is obtained by elution from “99Mo/99mTc 
radionuclide generators” delivered once or twice a week in each nuclear medicine department. This system 
allows the separation of the daughter radionuclide (99mTc) from the parent radionuclide (99Mo) fixed on a 
chromatographic column loaded with aluminium oxide (Al2O3). The amount of 99mTc recovered (Elution yield) 
depends on the efficiency of this system relative to the physicochemical interactions of the eluent (Isotonic 
Sodium chloride) with the adsorbate (99Mo/99mTc) and the stationary phase (Al2O3). 
In this study, we worked on the optimization of the “99Mo/99mTc Radionuclide Generators”. First, we 
characterized the chemistry surface of α alumina used as stationary phase according to particles sizes 
distribution, contact time and pH ranges. Therefore, we identify new quality control parameters and 
specifications for α alumina powder in order to produce homogenous batches of alumina columns and finally 
more reproducible yield generators. 
The main parameters checked were: particle size, specific surface and surface chemistry. We evaluated 
alumina’s charge density by identifying four parameters: active sites number (SN), alumina surface charge (Q), 
zero charge point (ZCP) and isoelectric point (IEP). 
Then, we studied the adsorption of molybdenum on this alumina in order to optimize the efficiency of the 
99Mo/99mTc generators. 
It emerges from this study that alumina having particle sizes distribution between 63 and 200μm offers optimal 
acid-base properties, and that the mechanism of adsorption of molybdenum on Al2O3 is by electrostatic type 
in the range of pH < 5. Between pH 5 and 7 the molybdenum is adsorbed molecularly, while it is carried out 
by ion exchange at pH higher than 7. 
The maximum adsorption level is carried out at pH 4. 
The columns filled with alpha alumina conditioned at pH=4 offer the best performance in terms of yield 
generators. 
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The molecule of [18F] -FDG decomposes over time due to different factors. Among these are the following: pH, 
temperature of storage and the phenomenon of radiolysis that intensifies when the radiopharmaceutical is 
produced in high concentrations. In the facility where this study has been carried out, concentrations of up to 
110 mCi / ml of [18F]-FDG are usually produced and a sterilization cycle is applied by autoclaving.  Under these 
conditions the degradation process of the molecule is increased. It has been documented that the control of 
pH, temperature and the use of free-radical scavengers such as ethanol are strategies that slow down this 
process. In this work, the effect of autoclaving, the activity concentration and the incorporation of ethanol 
were studied on the stability of the [18F] -FDG molecule by periodically determining the radiochemical purity 
for nine hours. These studies verified that the application of a cycle of autoclaving and a high concentration of 
activity produce a greater degradation of [18F]-FDG molecule over time. On the other hand, ethanol fulfilled 
the role of stabilizer by significantly increasing the stability of the radiopharmaceutical over time. In 
conclusion, a 0,3% of ethanol was added, and the final product was stable up to 9 hours after EOS. 
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The amino acid based radiotracers labelled with 11C or 18F are of significant importance for imaging cerebral 
tumours with PET. Both biodistribution and kinetics of L-isomers of amino acids are known to be different from 
those for D-isomers, and the L-configuration is generally preferred for brain 
tumours imaging. Therefore, the enantiomeric purity (EP) test is an important part of quality control of L-[11C-
methyl]methionine ([11C]MET), O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) and other clinically relevant PET 
radiotracers. Despite of the use of enantiomerically pure precursors, racemization may occur during 
radiolabelling process by lowering the EP. In common practice, the EP control is performed by chiral radioHPLC 
by using two types of columns: Crownpak CR(+) (Daicel) containing crown ether stationary phase or Chirobiotic 
T (Astec) with sorbent based on covalently binding glycoproteins to silica gel. Quality control (QC) analysis with 
Crownpak column required an aqueous perchloric acid, pH 1-2, as an eluent; care must be taken for the use 
of organic solvents destroying the column capacity. On the contrary, Chirobiotic column is compatible with 
any type of buffers and organic solvents facilitating its use and handling during QC routine. However, when 
transferring our QC routines from Crownpak CR(+) to Chirobiotic T, we observed some discrepancy in the 
results. Therefore, we decided to perform a systematic study of the above mentioned columns via analysis of 
the same batches of [11C]MET and [18F]FET. 
HPLC analysis was performed by using Dionex ISC-5000 system equipped with a gradient pump, Rheodyne 
type injector with a 20 μL loop, UV absorbance detector with variable wavelength connected in series with a 
radiodetector, Carrol and Ramsey Associates, CA, USA, model 105-S. The system 1 consists of Crownpak CR(+) 
column, Daicel (150x4,0 mm), eluent HClO4, pH 2 for [11C]MET and HClO4, pH 2 +10% MeOH for [18F]FET. The 
system 2 includes Chirobiotic T, Astec (250x4,6 mm), eluent 20% aqueous EtOH for [11C]MET and 0,1% TEA 
acetate, pH 4, containing 20% of EtOH, for [18F]FET. 
For both radiotracers the use of Crownpak (+) gives a lower EP value comparing with Chirobiotic T column. 
The difference in the EP value between the columns was in range of 2,4-4,0% for the same sample of the 
radiotracer. Interestingly, for both columns the five-fold dilution of the analytical sample resulted in 1.5% 
increased content of L-isomer. In addition, we analyse a series of cold methionine solutions prepared with 
different ratios of L- and D- enantiomers. We observed the overestimated value for D-isomer for Crownpak 
(+), whereas its content was underestimated by using Chirobiotic T. The deviation from the calculated 
(theoretical) value of D-isomer was from 0,67 to 1,92%. 
Our results showed that determination of the EP of amino acids radiotracers may be influenced by the type of 
chiral column and the analytical sample dilution. This study will be continued to include different amino acids. 
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Gallium-68 is a generator produced radionuclide with optimum nuclear physical characteristics which makes 
it an important isotope for positron-emission tomography. 
Radiochemical purity (RCP) is an extremely important parameter for radiopharmaceuticals (RPs) and its 
determination is a critical point of QC in routine clinical practice. Knowing the exact value of content of every 
radiochemical impurity is very important during R&D of [68Ga]Ga-RPs as well. The results of evaluation of 
[68Ga]Ga-RPs using various TLC and HPLC procedures were compared and presented previously and it was 
shown that HPLC results do not always match TLC results. In a number of cases results of HPLC analysis of 68Ga 
conjugates were performed according to 9th Ph. Eur., whoever its recommendations do not reflect the real 
unbound gallium-68 content in radiopharmaceutical preparations. This uncertainty comes from nonspecific 
sorption of unbound gallium-68 on C18 phase. The aim of this study was to fix the weakness of HPLC analysis 
procedure, since in some cases it can be difficult to replace. 
It was found that in pH range from 3 to 6, there is a significant capture of the gallium-68 ionic forms on the 
reversed phase of the HPLC column. The value of the capture also depends on the nature and concentration 
of the buffer agent in the preparation. The nature of this phenomenon is a subject of pure radiochemistry. 
New data shedding light on this effect will be presented. 
It is highly probable that the same effect can occur when analysing other metal-based RPs (such indium-111, 
lutetium-177, etc.). To date some very interesting correlations between chromatographic behaviour during 
QC of gallium-68 and zirconium-89 were found and will be presented. 
In order to avoid the capture of unbound gallium-68 on the column during HPLC analysis new procedure of 
sample processing and analysis was developed. The procedure involves usage of chelators in order to prevent 
gallium-68 sorption on the column. For this purpose, DTPA, DOTA, NOTA and HBED were evaluated. The details 
of their influence on the course of analysis will be presented. 
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Medical Molybdenum-99 (99Mo) is a fission product of uranium 235U, process in which more than 200 different 
radionuclides are produced. Strontiun-90 (90Sr) and strontium-89 (89Sr) are byproducts of this fission and their 
activity must be quantified to meet the quality standards required by the European Pharmacopoeia 9.0. Total 
radioactivity due to 90Sr and 89Sr must not exceed 6 x 10-5 per cent of the total radioactivity.   
89Sr and 90Sr decay by β emission solely and their activities can be measured by Cherenkov counting, with 
counting efficiencies of 42 % and 1 % respectively. Yttrium-90 (90Y), the daughter nuclide of 90Sr, is useful for 
the indirect measurement of the 90Sr activity by Cherenkov counting (counting efficiency 72%).  
The goal of this study is to obtain separate 89Sr and 90Sr activities by Cherenkov counting after chromatographic 
separation of Sr from Y.  
Known activities of radionuclide standards (89Sr and 90Sr) were mixed together and treated as real samples.  
Eichrom Sr® resin, 2 mL packed cartridges were used to separate the strontium mixture from yttrium prior to 
Cherenkov counting using Triathler Liquid Scintillation Counter (Hidex).   
The time of separation of the Sr mixture was recorded as the start of yttrium ingrowth and cartridges placed 
in sealed bags for use in 90Y separation following ingrowth period. After chromatographic separation, the 
elution containing Sr (10 mL) was measured for 30 minutes. One week later, Sr strip solution used for 
Cherenkov counting was transferred to the appropriate Sr resin cartridge. Time of separation of yttrium was 
recorded as stop time for yttrium ingrowth and samples were prepared for Cherenkov counting.  
Strontium nitrate (Sr(NO3)2) was used as yield tracer and measured using a Agillent 5110 ICP-OES Instrument.  
The chemical yield of Sr for the chromatographic separation was 97.2 ± 2.5 % while the Cherenkov counting 
efficiencies for 89Sr, 90Sr and 90Y were 40.5 ± 2.2 %, 0.5 ± 0.1 % and 71.5 ± 2.9 % respectively. 89Sr activity was 
calculated considering: Sr and background count rates, 89Sr and 90Y Cherenkov counting efficiency, Sr yield, 90Y 
in-growth factor, 89Sr and 90Sr decay correction.   
The difference between the activity of 89Sr standard added and Cherenkov activity of Sr measured was 7.7 ± 
4.9 %.  
90Sr activity was calculated based on 90Y Cherenkov counting, considering: 90Y and background count rates, 90Y 
Cherenkov counting efficiency, Sr and Y yields, 90Y in-growth factor and decay correction. The difference 
between the activity of 90Sr standard added and Cherenkov activity of Sr calculated was 9.4 ± 5.2 %.   
Cherenkov counting turned out to be very useful for the activity determination of 89Sr and 90Sr when both are 
present in a sample. 
  
ISTR–2019 
 
278 
 
Implementation of a quality assurance program and quality control results of 
radiopharmaceuticals 
Author: Kirill Skovorodko 
Co-author: Rūta Urbanavičiūtė  
Vilnius University Hospital Santaros Klinikos, Lithuania 
Corresponding author: kirill.skov@gmail.com 
In accordance with international guidelines and recommendations, the quality assurance (QA) program should 
cover all clinical aspects of nuclear medicine related to the smooth operation, including quality control (QC) 
of radiopharmaceuticals. In order to reduce risk of repeated studies, misinterpretation of the images and to 
protect patient from unnecessary radiation exposure due to poor quality radiopharmaceuticals, QC 
procedures should always be performed on a daily basis prior to radiopharmaceutical administration by 
appropriately trained personnel. The objective of this study was to evaluate quality control results of 
technetium (99mTc) based radiopharmaceuticals and to determine the molybdenum (99Mo) content in a 
99Mo/99mTc generator eluate. 
The data was collected from November 2017 till February 2019 in Vilnius University Hospital Santaros Klinikos 
nuclear medicine department. In this study, two methods of quality control were conducted: radionuclidic and 
radiochemical purity. For estimating radionuclidic purity of a 99Mo/99mTc generator (manufacturers: POLATOM 
POLGENTEC and GE Drytec) 99Mo breakthrough test in a pertechnetate solution of 99mTc was done.  99Mo 
assayed was measured with Veenstra VDC- 405 radionuclide activity calibrator. The dose calibrator QA and QC 
were performed routinely according to local and international recommendations including intercomparison 
measurements that performed Centre for Physical Sciences and Technology, Ionizing radiation metrology 
laboratory with secondary standard radionuclide calibrator Capintec CRC-15R. For 99mTc (99mTc-MIBI; 99mTc- 
MAA; 99mTc-MDP; 99mTc-MAG3; 99mTc-DTPA; 99mTc-DMSA) labelled radiopharmaceuticals, radiochemical purity 
Biodex Tec-Control thin-layer chromatography (TLC) system was used. The Sigma-Aldrich Chemie solvents and 
reagents were used to perform each chromatography test. All the radiopharmaceutical preparations were 
performed according to manufacturer instructions. 
99Mo breakthrough tests of radionuclidic purity (n=192) were 0.0028 ± 0.011%. According to inter- national 
guidelines and vendors recommendations the limit allowed is 0.1% for contamination by 99Mo. Radiochemical 
purity results for 99mTc-MAA was 99.11 ± 1.49% (n=14); for 99mTc-MIBI was 90.87 ± 5.01% (n=41); for 99mTC-
MDP was 98.51 ± 2.55% (n=24); for 99mTc-MAG3 was 98.11± 1.29% (n=21); for 99mTc-DTPA was 97.46 ± 2.93% 
(n=19); for 99mTc-DMSA was 95.73 ± 3.85% (n=8), respectively. For most radiopharmaceuticals, the lower limit 
of radiochemical purity is 95%. In our department, the results of QC for almost all radiopharmaceuticals were 
at the acceptance level, only for 99mTc-MIBI tests the values were slightly lower than European Pharmacopoeia 
limits (≥94%). In daily practice we use thin-layer chromatography and radionuclide activity calibrator. 
In nuclear medicine, an administration of correct radiopharmaceuticals activity to the patient is strongly 
dependent on the accuracy of the QC measurements of all equipment. It is important to have a product with 
acceptable quality control parameters in order to make the study of nuclear medicine effective and to protect 
the patient from unnecessary radiation exposure. In our daily practice we successfully implement thin-layer 
chromatography method for 99mTc labelled radiopharmaceuticals and radionuclidic purity in a 99Mo/99mTc 
generator eluate. In order to improve our QA program, in the future we need to start QC procedures with TLC-
scan systems. 
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Radionuclide generator systems continue to play a key role in providing both diagnostic and therapeutic 
radionuclides for various applications in nuclear medicine. The generators represent important in-house 
production systems that can provide daughter radioisotopes generated by parent decay on-demand without 
the need for local access to an accelerator or nuclear reactor. Cuba has not had accelerators or reactors for 
many years, so its radionuclide and radiopharmaceuticals production is based mainly on importation or local 
generators production. The present work resumes the Cuban experience in the production of radionuclide 
generators. 
As it is known, the most widely used generator for clinical applications is the 99Mo/99mTc generator system. In 
CENTIS facilities, the production of this product began in 2003 using the column chromatography method as 
a separation technology. More than 4 000 generators have been produced in different presentations (8GBq, 
20GBq, 37GBq, 55,5GBq and 74GBq) during these years. A summary of the production process parameters 
and quality control results of the last five years is reported. Based on the data, it is concluded that a stable 
production process has been established. 
On the other hand, the success in the development of therapeutic radiopharmaceuticals has driven the 
development of generators that provide therapeutic radionuclides. In 2010, Cuba received the first prototype 
of 90Sr/90Y generator based on an electrochemical separation for its evaluation and setting up as a part of a 
Technical Cooperation Project with the IAEA (Project CUB/2/015). Several parameters for the separation of 90Y 
with the required quality were evaluated and the results are reported here. In consequence, the final 
technological procedure was established and the first national authorization to produce radiopharmaceutical 
quality grade of 90Y was issued in December of 2011. 
Among many other requirements one of the main challenges for our radionuclide generators production has 
been the need to manufacture and operate under the conditions of good manufacturing practices (GMP) 
guidelines since these products represent final product or active pharmaceutical ingredients (APIs) which will 
be incorporated into radiopharmaceutical products prepared for human use. In the present work, we included 
the necessary modifications performed to our 99Mo/99mTc generators production and the conditions 
established for the production of 90Y to comply with the current GMP guidelines. 
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A mini plant has been designed and developed to obtain 99mTc from irradiated MoO3 pellets. This mini plant 
has a maximum capacity of 37 GBq and is constituted by three modules where the operations of dissolution 
of MoO3, extraction of 99mTc and evaporation of the solvent are carried out. The mini plant is completed with 
a module for the injection of the necessary chemical reagents and a module for obtaining an isotonic solution 
of 99mTc with the required activity. All the modules except for the separator and evaporator are communicated 
by Serial RS485 with a main control panel. They operate independently through a set of interconnected 
electrovalves, which are activated sequentially to execute each stage during the process of obtaining 99mTc. 
The mini plant has a vacuum pressure system necessary to carry out the transport of radioactive material 
between the various modules. It also has a SCADA system displayed on a touch screen HMI, which allows the 
control and monitoring of each stage. The implementation of the entire main control system was carried out 
in a PLC programmable logic controller and the modules under microcontrollers. 
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Technetium-99m [t1/2= 6.02h; 140.51 keV (89%)] continues to be the workhorse isotope in 
diagnostic nuclear medicine till today. Therefore, various methods of sourcing this isotope constitute 
a relevant field of research.  The methods which are exposed to produce 99Mo are 98Mo (n, g) 99Mo 
in a research reactor, 100Mo (p, x) 99Mo or 99mTc directly through 100Mo (p, 2n) 99mTc, in a 
cyclotron,100/natMo(g,n)99Mo, in a linear electron accelerator. Herein we report a new 99Mo/99mTc 
generator based on column chromatographic technique using activated charcoal in tandem with a 
small cation exchanger column and an alumina column utilizing (n,g)99Mo, to produce highly purified 
Na[99mTc]TcO4. 
Molybdenum-99 produced from irradiation of natural MoO3 through 98Mo(n,g)99Mo reaction was 
supplied as [99Mo]Na2MoO4 in 0.5 M NaOH (150 mg Mo/ml:1.11–2.22 GBq/ml), by the Radiochemical 
Section, Radiopharmaceutical Division, Bhabha Atomic Research Centre (BARC) and Board of 
Radiation & Isotope Technology (BRIT), Mumbai, India. The pH of the [99Mo]Molybdate solution was 
adjusted to pH-3 using dilute nitric acid and the solution was loaded to a preconditioned powdered 
charcoal column (500mg) with a flow rate of 1.5ml/min. The column was washed with H2O followed 
by a dilute of NaOH to remove 99Mo. The adsorbed 99mTc was then eluted from the charcoal column 
with hot H2O. The 99mTc eluate was further purified by passing the 99mTc solution through a tiny 
Dowex-50X8 column (500mg) connected in tandem with a small acidic alumina column (1g). Finally, 
highly pure sodium 99mTc-pertechnetate was recovered from acidic alumina column with 3-5 ml 
saline. The whole process flow diagram is shown in Fig. 1. The performance of the new 99Mo/99mTc 
generator based on activated charcoal column chromatography was evaluated by studying recovery 
yield of 99mTc, physicochemical qualities of 99mTc-pertechnetate and radiolabelling of 99mTc-
pertechnetate with kits like MDP, DTPA & MIBI obtained from BRIT, Mumbai, India.  
Fig. 1. Flow diagram of charcoal column chromatography based 99Mo/99mTc generator 
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It was found that the adsorption of 99mTc on charcoal column from 99Mo/99mTc solution (pH-3) was 
around 90-95% (n=5) in comparison to that of alkaline or neutral 99Mo/99mTc solution where it was 
35-60%. The average yield of recovery of 99mTc was above 80%. The quality control studies showed 
that 99mTc-pertechnetate has the following characteristics:  i) Clear solution; ii) pH:  6-7; iii) 99Mo 
breakthrough: <0.002%; iii) Mo and Al impurities: < 10 ppm; iv) RC Purity: >99% and v) RN Purity: 
>99.9%. The RC purities of 99mTc-compounds like 99mTc–MDP, 99mTc–DTPA and 99mTc-MIBI were found 
to be above 95% (n=6). 
In conclusion, an efficient technique has been developed to recover 99mTc as Na[99mTc]TcO4 
formulation in good yield and high quality from a research reactor produced (n, g)99Mo. 
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The Ge-68/Ga-68 radionuclide generator has a big perspective to become one of the most important 
sources of radionuclides for PET. Recently, available generators inorganic ion exchangers, especially 
titanium and tin oxides, are used as a stationary phase and diluted hydrochloric acid as eluent. Even 
though they provide Ga-68 in convenient chemical form, some of them do not provide it in a sufficient 
radionuclidic purity in one separation step as the Ph. Eur. limit for the mother radionuclide is 0.001%. 
This work was focused on the development of Ge-68/Ga-68 generator system based on the 
nanocomposites of cerium(IV) and zirconium(IV) in the polyacrylonitrile matrix. These perspective 
stationary phases should provide eluate in excellent quality. 
Cerium(IV), zirconium(IV) and titanium(IV) oxides and hydroxides were studied as potential active 
ion-exchanger components. All materials were characterized by X-ray powder diffraction, 
transmission and scanning electron microscopy, FT-IR and Raman spectrometry. Sorption properties 
of these materials were examined by the measurement of equilibrium distribution coefficients, Dw, 
of Ge-68 and Ga-68 in the presence of diluted hydrochloric acid (concentrations: 1 mol/l; 0.1 mol/l; 
0.01 mol/l and 0.001 mol/l). On the basis of the separation factor, α, the optimal concentration of 
hydrochloric acid was determined and two materials with the best separation factor, cerium(IV) oxide 
and zirconium(IV) hydroxide, were granulated into the polyacrylonitrile matrix. Prepared composites 
were used for the construction of two model generators with bed volume of 0.57 ml and 1.6 MBq of 
Ge-68 and 1 MBq of Ge-68 for cerium(IV) oxide and for zirconium(IV) hydroxide, respectively. Elution 
curves, yields of elution and contamination percentages were determined for both prepared model 
generators. 
Considering the separation factor, α, of Ge-68 and Ga-68 for individual acid concentrations, the 
optimal medium for separating these radionuclides is 0.1mol/l hydrochloric acid (α = 26 857 for 
cerium(IV) oxide and α = 4 949 for zirconium(IV) hydroxide). 
The model generator containing cerium(IV) oxide as stationary phase provided Ga-68 with yields over 
90 % in 1.6 ml of eluate and the contamination by Ge-68 was under 0.0004 %. Used flow rate was 
0.32 ml/min. Even after 6 months of usage, the yield did not decrease under 60 % and the 
contamination remained under 0.0002 %. These observations probably relate to the increasing 
affinity of both radionuclides to the stationary phase over time and the radiation degradation of the 
composite can also play its role. 
However, for the case of model generator based on zirconium(IV) hydroxide, the yield of Ga-68 
elution was considerably lower than in the case of cerium(IV) oxide generator under the same 
conditions of elution and also the contamination by Ge-68 exceeded the limit of 0.001 %. 
ISTR–2019 
 
285 
 
Experiments with model generators gave us some very promising results and in the upcoming study 
the separation qualities and radiation stability of cerium(IV) oxide composite has to be confirmed 
using higher activities of Ge-68. 
Acknowledgements: this work was supported by Technology Agency of The Czech Republic, grant no. 
TJ01000334 and the Health Research Agency of the Czech Republic, grant no. NV16-30544A. 
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In recent decades, great efforts have been paid for the development of radiopharmaceuticals which 
can be used for combined imaging and therapy or briefly, for radiotheragnostics. This approach of 
employing one molecular vector to render diagnosis beside targeted radiotherapy claim the parallel 
expansion in the production and separation of radioisotopes of dual purposes. One of these 
radioisotopes which received great attention, scandium-47, due to its favourable nuclear and 
chemical properties [T½ = 3.35 d, Eβ-(max.) = 600 keV, Eγ = 159 keV]. In this context, it seemed of 
interest to study the production and separation of Sc-47 and this work spotlights on the rapid and 
effective separation of no-carrier-added (NCA) Sc-47 from natural Ca targets using inorganic ion 
exchanger. 
A target of 1 gm of natural calcium carbonate was irradiated in the ETRR-2 Research Reactor, Egypt, 
at a thermal neutron flux of 1.8 x 1014 n cm-2 s-1 for 24 h. zirconium-vanadate gel was prepared 
following the method published by Roy, et al. and studied as a sorbent material for the separation of 
47Sc(III) from 47Ca(II). The Influence of HCl and HNO3 concentrations on the distribution coefficients 
of 47Sc(III) and 47Ca(II) ions was investigated by batch technique. Chromatographic column separation 
of 47Sc(III) from 47Ca(II) was carried out using the prepared zirconium vanadate gel. Finally, the 
radionuclidic and radiochemical purities of the eluted 47Sc(III) were examined. 
The results obtained from the batch adsorption studies revealed that the adsorption efficiency of 
47Sc(III) ions is strongly dependent on the initial acid concentration and high adsorption can be 
obtained at 0.001 M HCL and HNO3. Conversely, the change in acid concentration not affect the 
47Ca(II) ions adsorption. These results are in concordance with numerous studies in which the ionic 
radius of one ion is smaller than the other. This finding made us consider the possibility of 
radiochemical separation of 47Sc(III) from 47Ca(II) using zirconium vanadate gel ion exchanger packed 
column, where 47Sc(III) is substantially retained at 0.001 M HNO3 without any remarkable adsorption 
of 47Ca(II) ions. 1 M HNO3 directly eluted the retained 47Sc at a flow rate of 1 ml/min with elution yield 
of 75%. The eluted 47Sc with high radiochemical and radionuclidic purities. 
In summary, Zirconium vanadate gel is an effective material for separation of 47Sc(III) from irradiated 
Ca target with high yield and high purity and our results thus hold a great promise for the use of 
47Sc(III) in the preparation of radiopharmaceuticals for theranostics applications. 
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Mo-99 is the most widely used radionuclide in the field of nuclear medicine. 
The Mo-99 production facilities must be designed by taking into account the minimization of fission gas 
emissions, complying with the regulations in force according to the regulatory authority of each country. 
It is important to know the stages of the production process that generate the greatest amount of fission gases 
to take the necessary precautions to reduce their emissions in the facility. 
The production process of Mo-99 begins with the irradiation of uranium mini-plates in a research reactor 
originating more than 250 radioactive species among which is the Mo-99. 
The separation process of Mo-99 consists of several separation and purification stages that are carried out in 
shielded hot cells, due to the high activity contained in the irradiated plates coming from the reactor. 
One of the first steps is the dissolution of the plates in an alkaline medium and filtration. During this stage, 
large quantities of radioactive gases are released, where the most important are radioiodines and radioxenons 
accompanied by a large amount of heat generated. 
The resulting uranium precipitate is stored in the production of hot cells for months to decay. 
The removal of the heat generated by the uranium precipitate holders is very important because it is necessary 
to maintain the temperature inside the cell below 45 ° C, in order to prevent damage of the sealing gasket 
material used in the containment box. In addition, each uranium precipitate holder must be sealed in order to 
contain the fission gases. 
The present work describes the evaluation of alternatives for the heat removal in the cell whose purpose is to 
converge in the design of the ventilation of the plant to avoid the emission of these gases outside the facility. 
The radionuclide composition of the uranium precipitate contained in the filters and the power generated 
were simulated by using the NUCLEONICA® software paying attention to these fission gases and their evolution 
inside the filter holder, highlighting the importance of ensuring tightness in the filter holder in the first 8-10 
weeks. 
For the removal of the heat in the dissolution cell, two cases were studied using the computational fluid 
dynamics code (CFD) ANSYS FLUENT®; cooling of the filters with air outside the enclosure and cooling of the 
filters with ventilation air inside the enclosure. 
The input data for the simulation in FLUENT were those obtained in NUCLEONICA. 
As a conclusion, it is proposed to refrigerate the filters with forced ventilation outside the enclosure; in this 
way the refrigeration of the filters is not interrupted, keeping below the required temperature inside the 
enclosure during the 8-10 weeks for the decay of the gases nobles avoiding their emission to the ventilation 
system.  
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Fluorine-18 is one of the important positron emitting radionuclides that is used for the preparation 
of an array of diagnostic radiopharmaceuticals. Low energy (11-18 MeV) cyclotrons are used for this 
purpose in which oxygen-18 enriched water is irradiated with 11-18 MeV protons. The yield of 
production depends on several factors including beam current, beam energy and time of irradiation. 
A systematic assessment of fluorine-18 production in a newly installed 11 MeV Siemens Eclipse HP 
cyclotron is presented in this paper. 
Siemens Eclipse HP cyclotron, having a dual beam with current up to 60 µA, each beam line is used 
for the production of fluorine-18. 2.6 mL of 97% oxygen-18 enriched water where it was loaded to 
one of the tantalum targets. The loaded oxygen-18 water in the target was then pressurized using 
argon gas up to 375-385 psi. 11 MeV proton beam was extracted from negative hydrogen beam using 
a carbon extraction foil and it was directed to the tantalum target. The proton beam traversed 
through a copper hex grid, 25 µm target window (Havar foil) and the water target, respectively. The 
formed activity was measured in a dose calibrator and compared with the theoretical yield calculated 
as described below. 
Energy reduction of the proton beam in the Havar foil and in the water was calculated using Stopping 
and Range of Ions in Matter (SRIM). Stopping power and range of proton in water are calculated in 
the PSTAR programme of the National Standards and Technology (NIST). Cross-section data of 
18O(p,n)18F are referred from the IAEA EXFOR library. The total range of the proton beam in water 
was divided into smaller segments of micrometre level and the production rate of fluorine-18 was 
calculated for each segment. Integration of these segments gave the total fluorine-18 production 
rate. For more accurate approximation of the calculation, proton scattering with hydrogen nuclei was 
also considered. 
Fluorine-18 yields were calculated by two means. In the first method, yields were calculated by taking 
the standard equation accounting for the proton flux, cross section and the number of target nuclei. 
These values were significantly lower than the experimental values. In the second method, scattering 
of the protons with the hydrogen nuclei in water was also considered to calculate the theoretical 
yield of fluorine-18 formed. The yield calculated by this modified method was comparable with the 
practical yield obtained. 
Elastic scattering of proton with the hydrogen nuclei in water molecule provided a significant 
contribution to the fluorine-18 production providing better theoretical approximation that are 
comparable to the practical measurements of fluorine-18 production. Since the literature about the 
elastic scattering of proton with the hydrogen nuclei in water are only a few, this study adds as a 
proof for the p-p scattering in water. 
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In-111-Pentetreotide (OCTREOSCAN®) is a commercially available FDI approved SPECT agent for 
imaging of neuroendocrine tumours (NET). However, production of the medically important In-111 
in a medical cyclotron for formulation of In-111 Pentetreotide metallic radioisotope, using prototype 
semi-automated indigenously developed solid-target assembly, and its radiochemical separation 
from irradiated natural Cd possess is a considerable challenge. 
Towards this, we explored the possibility of producing In-111 using natural Cd targets (electroplated 
on copper discs) via Cd-111 (p, n) In-111 nuclear reactions, in the 16.5 MeV medical cyclotron. 
Column chromatography separation of In-111 from target matrix and other radionuclides formed as 
activation products were performed to obtain purified In-111-chloride. The purity of the separated 
In-111-chloride was established after radiolabelling with pentetreotide. Consistent yield of pure In- 
111-Pentetreotide provided support to the formation of In-111 of required purity. 
The present work thus envisages cost-effective and pharmaceutical grade production of In-111-
chloride in the 16.5 MeV cyclotron as a cost-effective diagnostic radiopharmaceutical for patients 
with neuro endocrine tumours. 
Natural cadmium was electrodeposited over circular copper disc (diameter: 25 mm and 2 mm thick) 
using non-cyanide bath. Electrodeposited natural cadmium target was irradiated by 15.5 MeV (after 
attenuation from havar foils) proton beam for 1h at 5µA current using indigenously developed solid 
target assembly. The irradiated disc was decayed for 24h prior separation to remove other short-
lived radioisotopes. Radiochemical separation was carried out by co-precipitation with 8M HCl and 
concentrated HBr and column-based ion exchange chromatography using acidic alumina oxide and 
Dowex-50W-X-4, 200-400 dry mesh, H+ form. RCP of purified In-111-chloride was evaluated by HLPC 
using RP18 in gradient mode (0.1%TFA in water and acetonitrile) coupled with NaI(Tl) and UV(220 
nm) at 1mL/min. Radionuclidic purity assessed by γ-spectrometry in 64K-MCA coupled with HPGe 
detector. The purified In-111-chloride (220 µCi/mL) were radiolabelled with pentetreotide using 
citrate buffer containing gentisic acid as stabilizer. RCP of In-111–Pentetreotide assessed by HPLC. 
Non-cyanide electroplating bath yielded 200µm thick electrodeposition of natural cadmium 
(diameter 15mm) on copper disc. Our route for producing In-111, using 200µm thick natural cadmium 
target offers maximum yield of 128 µCi/µAh at EOB(n=3). The radiochemical yield (RCY) of the 
purified In-111-chloride after radiochemical separation was ~45-50 %. The recorded γ spectrum of 
purified In- 111-chloride shows only two prominent characteristics peak (171 and 245 KeV) of In-111. 
The RCP of In-111-chloride derived by HPLC was >98% with retention-time between 2.40–
3.40minutes. 
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The RCP of the radiolabelled In-111-Pentetreotide(n=3) was >98% with retention-time between 30.5- 
31.5minutes. EL <6EU/mL and product were sterile. Retention of RCP on storage at -20degC, at 72h 
post-preparation was confirmed by the single radioactive peak (Rt: 31.4minutes) in HPLC 
chromatography. 
In conclusions, the quality control parameters of the produced In-111-chloride from natural Cd 
target, using indigenously developed solid-target system were validated and compared to the 
pharmacopeia standard. The radiolabelling studies of pentetreotide, yielding the product in 
acceptable RCP establishes the quality of the In-111-chloride used and adds support to its use as a 
pharmaceutical grade radiochemical. 
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Despite in the last decade a large number of papers on therapeutic radiometals (TRMs) have been 
published, a worldwide ten-year trend analysis of the scientific literature on this topic has never been 
made before. The aim of the present study is therefore to quantify and identify the global trend of 
scientific literature and emphasize the interdisciplinary nature of this research field by analysing the 
TRMs research output (2008-2018). 
The Bibliometric data search, focused on conventional (131I, 90Y, 177Lu, 188Re, 186Re, 153Sm, 89Sr, 169Er) 
and emergent (67Cu, 47Sc, 223Ra, 166Ho, 161Tb, 149Tb, 212Pb/212Bi, 225Ac, 213Bi, 211At, 117Sn) TRMs, has 
been performed on Scopus database and elaborated with Excel. The data-analysis has been 
performed in terms of years of publication and TRMs category (conventional vs emergent) in order 
to illustrate the trend of the last decade. Moreover, with the aim to underline the multidisciplinary 
character of this research field, data have been categorized in terms of Journal-Subject-Areas. Finally, 
the authors’ country provenience has been analysed with the aim to map the worldwide interest and 
investment of resources on TRMs. The 81.3% and 18.7% of the total number of publications, 12.717, 
regards conventional and emergent TRMs respectively. Among conventional, 131I, 90Y and 177Lu while, 
among emergent, 223Ra, 117Sn, 213Bi, and 225Ac resulted as the most investigated TRMs. 
The multidisciplinary character of the publications differs from conventional TRMs, where most 
contributions come from preclinical and clinical fields, to emergent TRMs. Thus, the major interest in 
their production studies makes the contribution unbalanced mainly for Physics, Engineering and 
Material Science fields. From the geographical analysis, it appears that almost half of the total 
number of works, on both conventional and emergent TRMs, have been published by European 
researchers. It is also evident the high collaboration grade between countries, characteristics in line 
with the multidisciplinary of this medical sector. Top 20 countries have also been drawn up. On the 
podium of conventional TRMs, there are USA, Germany, and China, while the USA, Germany, and the 
United Kingdom are on the podium of emergent TRMs. 
The overall conclusion is that the success of NM has been intimately linked to the availability of new 
TRMs. In recent years a particular focus on the production and application of emergent TRMs, such 
as 67Cu, 47Sc, has been encouraged by the interest in the theranostics personalized approach. 223Ra 
and 225Ac alpha emitters are also gaining attention particularly in the USA and Germany. Among 
conventional radionuclides, instead, the research on 177Lu is constantly growing. In conclusion, the 
radiopharmaceuticals field is constantly evolving thanks to the contribution of specialists coming 
from different disciplines and the collaboration between countries. 
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The goal of present investigations is the implementation and optimization of the technological process for the 
synthesis of Zr-Mo gel from the high-active Mo samples after an irradiation in the WWR-M research reactor 
Institute for Nuclear Researches NAS of Ukraine. Production of the radiopharmaceutical sodium pertechnetate 
(99mTc) by means of the portable 99Mo-99mTc generator. 
The Mo oxide (MoO3) of 10 - 20 g in the sealed quartz ampoule was used as the target material; it has been 
irradiated by the neutron flux of 5×1013 n/cm2×s in the wet channel of the WWR-M reactor. The irradiate Mo 
oxide dissolves in the sodium hydroxide solution. The zirconyl chloride solution is prepared in advance, and 
then it is sterilized. The molybdenum solution was added to the zirconyl chloride solution by drops at the 
intensive mixing with heating. The temperature of mixture was equal to 50 oC. The gel draining is considered 
completed when it is possible to see the small gel pieces (the size less than 5 mm) of yellow-green colour. For 
the disintegration of pieces (i.e. transformation to the particles with the sizes from 100 to 500 µm) the hot 
sodium chloride isotonic solution is supplied from the sterilizing module. The filtration of excess water from 
the Zr-Mo gel was performed by means of the Shotta filter with the hole size up to 40 µm. Taking into account 
the big number of factors influencing the Zr-Mo gel synthesis, we have used the results of previous 
investigations, which have been used as the input data for the development of installation for the Zr-Mo gel 
synthesis. 
The chromatography column with Zr-Mo gel (99mTc) is the Teflon tube equipped by the protruded outer 
grooves to close with rubber stoppers and the aluminium caps for the flasks. The glass wool tampon and the 
aluminium oxide for the chromatography are located in the column.  In all cases the amount of aluminium 
oxide for the cleaning of 99mTc eluate from admixtures of 99Mo and for the reaching of solution required acidity 
was equal to 2.0 g. The amount of Zr-Mo gel was in the range from 2 to 4 g. The elution of sodium 
pertechnetate 99mTc solution is carried out by means of the sterilized solution of sodium chloride 0,9 %. The 
efficiency of 99mTc elution is more than 70 %. The investigation of the elution efficiency was carried out by the 
radiometry method on the gamma-spectrometer. In all cases 99mTc was obtained by means of the portable 
generators. The 99mTc activity in the eluate was measured several days later after production. 
The remotely manipulated devise for the production of the Zr-Mo gel has been made, which will allow the 
treatment of the irradiated Molybdenum (MoO3) samples. The design of 99Mo-99mTc generator has been 
developed and constructed. 
The physical and chemical parameters of the radiopharmaceutical sodium pertechnetate (99mTc) have been 
determined by means of the inductively coupled plasma methods, the gamma-spectrometry and the 
potentiometry. The radionuclide purity of sodium pertechnetate 99mTc exceeded the value of 99.9% during 
whole time of the generator availability. The radiochemical purity of sodium pertechnetate 99mTc is 99,4 %. 
The eluate acidity of the radiopharmaceutical sodium pertechnetate 99mTc is in the range from 4.6 to 6.3.  The 
total activity of 99Mo in the prepared generators was between the range from 10 to 13 GBq for the moment 
of supply to the medical institution in dependence on the Zr-Mo gel amount, which was putted into a 
chromatography column of generator. It was determined that the parameters are complying with the 
requirements of the Terms of Reference and the European Pharmacopoeia. 
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67Cu is one of the most promising beta-emitters for cancer treatment. It is also a gamma-emitter and thus can 
be used as a theranostic radioisotope either by itself or together with positron-emitting 64Cu.  One of the most 
efficient production routes for 67Cu is photonuclear method based on the 68Zn(γ,p)67Cu reaction.  Typically, a 
30-40 MeV electron accelerator is used with Ta or W converter to generate bremsstrahlung X-rays, which 
irradiate the zinc target. However, relatively low reaction cross section (11 mb at 22 MeV) impedes obtaining 
high specific activities of the irradiated target. To improve the efficiency of the production and to increase the 
specific activity we propose a “one-stage” approach with zinc acting both as a converter and a target. 
To evaluate 67Cu production yield in the “one-stage” setup, we used the transport code PHITS (Particle and 
Heavy Ion Transport Code System). First, the spectral density of the bremsstrahlung photons flux was 
simulated; then it was convoluted with the 68Zn(γ,p)67Cu reaction cross section from the IAEA Handbook on 
Photonuclear Data. Such approach reduces the statistical uncertainty of the calculated values and eliminates 
problems concerning the simulation of (γ,p) reaction using built-in PHITS models. Spatial distribution of the 
produced 67Cu in a large zinc target was found and used to determine the optimal target dimensions to 
maximize 67Cu specific activity. The results were compared to the conventional “two-stage” approach which 
uses a 2 mm thick tungsten converter and proved to yield higher specific activity. Depending on the target 
size, absolute values for the “one-stage” approach were found to range from 1.22 to 5.28 MBq/g for natural 
zinc target assuming 1-hour irradiation with 40 MeV 1 kW beam. 
Monte Carlo simulation showed that the “one-stage” setup provides higher specific activity of the produced 
67Cu due to better utilization of the electron beam power. The drawback of this approach is high heat 
deposition into the target. Thermomechanical analysis of the system was performed to find maximum electron 
beam power the target can withstand.
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Track: Production of PET- and SPECT-based diagnostic, therapeutic and theranostic medical 
radioisotopes
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The increasing interest in the use of 68Ga for theranostic application continues to grow requiring more sources 
of this radioisotope. Nowadays, due to the high demand and limited availability of (GMP) 68Ge/68Ga generators 
there is a long waiting list limiting the access to 68Ga-radiopharmaceuticals worldwide. IBA and 
ICNAS/University of Coimbra have developed a GMP liquid target process for the production [68Ga]GaCl3.  At 
the same time, to support this initiative, the EDQM has accepted to work on a new monograph for the 
production of this isotope with a cyclotron. The first draft of this monograph (Gallium (68Ga) chloride 
(accelerator-produced) solution for radiolabelling (3109)), was published for public consultation in the end of 
2018 in Pharmaeuropa 30.4. 
In this study, we will provide the quality control methods and results for the [68Ga]Cl3 produced from a liquid 
target and we will demonstrate that the quality obtained meets all the requirements set forth in the Eur. Ph. 
draft. We will also explain how to establish the shelf-life considering the regulatory aspects. 
The process herein described is fully automated and employs commercially available systems: a dedicated 
liquid target system, where a solution enriched 68Zn is irradiated; and a Synthera® Extension module for the 
post-process step to obtain purified and ready-to-use [68Ga]Cl3 for further labelling. The whole process can be 
put in a GMP environment. The quality control methods are based on the Eur. Ph. draft and the results will be 
reported. Most of the new monograph is based on the existing Eur. Ph. Gallium (68Ga) Chloride solution for 
labelling 07/2013:2464, except for the radionuclidic purity. The major radionuclidic impurities are 67Ga and 
66Ga, mainly because of isotopic impurities in the target material and the competing (p,2n) and (p,n) reactions. 
The new Eur ph. requires radionucludic purity (RNP) of > 98% and this RNP must be guaranteed over the entire 
shelf-life of the labelled compound. Another critical requirement (for the efficiency of the labelling) is the 
metallic impurities (Fe and Zn in µg/GBq), which is also challenging since the starting target material is zinc 
solution. 
All of these parameters have been tested and validated against the current Eur. Ph. draft. Several batches have 
been produced and consistently meet the requirements with shelf-life ranging from 3-5 hours end of post 
process (GaCl3) giving enough time for the labelling on site or even the possibility of some distribution to 
nearby radio pharmacies. 
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Iodine-131, with a half-life of 8.02 days, is one of the most widely used radionuclides in medical diagnosis and 
therapy for a variety of thyroid disorders. Sodium iodide [131I] has been produced on 2018 by CNESTEN. The 
manufacturing process and the formulation of the product have yielded a high quality finished product. The 
formulation is an aqueous solution of the active substance sodium iodide [131I] containing sodium thiosulphate 
as a reducing agent to inhibit radiolytic oxidation of sodium iodide [131I] and liberation of free iodine [131I]. The 
current formulation use 0,08 ± 10%mg/mCi of sodium thiosulphate. 
The objective of the present study is to provide data on optimum quantities of sodium thiosulphate used in 
the manufacture of Sodium iodide [131I] and also to follow the impact of variation of its concentration 
throughout the period of validity of the product. 
The study was performed on three batches with two types of samples: dispensing solution (without reducing 
agent) and finished product containing sodium thiosulphate. Relating to the finished product two different 
activities, a low activity (10 mCi/ 5 ml) and a high activity (100 mCi /5 ml) were chosen. Testing was performed 
on four time points after production (J0, J+8, J+15, J+22 (expiry date)). Only pharmacopoeial methods were 
used. Identification and concentration of thiosulfate are determined by HPLC. 
Results showed that for dispensing solution, the stability indicating factor (radiochemical purity and pH) 
remained nearly constant throughout the shelf life. For finished product, Sodium thiosulphate concentration 
decreased throughout the shelf life. Specification for appearance, radioactivity, radiochemical purity and pH 
were always met. 
No significant difference was found between low (10 mCi) and high (100 mCi) activities comparing with the 
proposed specifications. The radioactive concentration remains constant throughout the shelf life. This is an 
indication that no volatile iodine is formed by oxidation of the iodide.  
The pH remains constant because the formulation contains a buffer. 
Under normal condition, a formulation without sodium thiosulphate would still render a product of the same 
high radiochemical purity. However, there is a risk that air might be introduced accidentally into the solution 
when multi-doses are withdrawn hence the need to use sodium thiosulphate as a reducing agent. 
From the results above it can be concluded that despite the drop in the concentration of sodium thiosulphate, 
no effect is observed on the other parameters throughout the shelf life. The presence of sodium thiosulphate 
throughout the shelf life is necessary as a safety precaution.  For this reason, it is proposed to maintain the 
current formulation with 0,08 ± 10%mg/mCi of sodium thiosulphate which also has demonstrated its quality 
throughout the shelf life. Higher concentration of sodium thiosulphate is not necessary. 
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Long-lived radionuclides with half-lives from 5 to 312 days are common radionuclide impurities in 18F-labelled 
radiopharmaceuticals. They are produced along with [18F]fluoride under the action of high-energy protons, 
neutron and γ-quants on target body and ion window foil during irradiation of [18O]H2O. Subsequent elution 
of the impurities to a synthesis module results in the contamination of radiopharmaceutical products, as well 
as radioactive waste accumulation. 
In the present study the isotopic composition and partition of long-lived radionuclides between recovered 
[18O]H2O, solid state extraction cartridges, as well as the final pharmaceutical preparations were studied by 
means of HPGe γ-spectrometry and liquid scintillation technique. 
It was shown that 51Cr, 52Mn, 54Mn, 56Co, 57Co, 58Co, 7Be, 57Ni are the major γ-emitting radionuclides in 
irradiated water coming from Cyclone 18/9 HC with niobium target and Havar window foil. The activities of 
65Zn, 92mNb, 95Nb, 184Re, 183Re, 95Tc and 96Tc are at least three orders of magnitude lower. Reactions for the 
formation of the named nuclides are proposed. 
Over 90% of chromium and beryllium radionuclides precipitate on QMA light cartridge, while 65- 80% of 
cobalt, 65-70% of manganese and over 92% of nickel radionuclides are removed to recovered [18O]H2O. Only 
minor percentage of cobalt, manganese, chromium and beryllium isotopes (1-7%) is eluted from QMA light 
cartridge by carbonate solution. Whereas technetium, rhenium, niobium radionuclides existing in anionic 
forms in water-acetonitrile solution in the presence of [18F]fluoride are eluted quantitatively in the reactor 
vessel. Further purification from γ-emitting long-lived radionuclides strongly depend on the synthesis scheme 
implemented. High specific activity of 3H was found in irradiated [18O]H2O resulting from side reaction 18O(p, 
T)16O. Since in production process 18F is separated from the water by ionic exchange on QMA light cartridge 
over 90% of 3H is segregated into recovered [18O]H2O. Residual tritium is washed along with 18F into reactor 
vessel and further goes to gaseous effluents during the fluoride drying step. In most 18F-labelled 
radiopharmaceuticals, except sodium fluoride, tritium activity is comparable with natural levels. 
In the present work it was shown that activities of long-lived radionuclides in 18F-labelled radiopharmaceuticals 
were much below the pharmacopeia levels. Leaching of activated Havar foil window was found to be the main 
source of γ-emitters and should be minimized in order to decrease the amount of radioactive wastes and 
overexposure of patients. Attention should be paid to the accumulation of tritium-containing liquids and 
gaseous effluents worldwide from multiple PET cyclotron radiochemistry facilities. 
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Molybdenum-99 (99Mo) is the most important isotope because its daughter isotope, technetium-99m (99mTc), 
has been the most widely used medical radioisotope for more than 50 years, accounting for > 80% of total 
nuclear diagnostics worldwide. 
The design of 99Mo production facilities must consider and not exceed the maximum limit of emissions 
required by the corresponding regulatory authority for each country where plants of this type are installed. 
For this, it is important to have knowledge of the production process and analyse which are the stages of the 
process that generate the release of a greater inventory of radioactive gases and, in this way, to be able to 
take measures to reduce the emissions of the installation. 
This work is based on the study of the different stages of the production process of 99Mo through low 
enrichment Uranium (LEU) and the analysis of those stages of the process that involve the release of 
radioactive gases into the environment in the hot cells. 
The stages of the process that are analysed are those that have controlled releases of radioactive gases and 
those stages that have uncontrolled releases and whose emissions are more difficult to be treated, which are 
product of openings in the production system of 99Mo. 
In addition, a theoretical model is presented to estimate the emissions at each stage of the process, using the 
Nucleonica software as a calculation support software, in order to obtain an analysis of emissions from hot 
cells to the ventilation system in each of the stages of 99Mo production process. These values are compared 
with those obtained during the start-up of a production plant, relating the maximum values of emissions in 
normal operation with the stages of the process associated with these releases, focusing attention on 133Xe 
and 135Xe. 
Finally, this work provides estimated values of iodine and xenon emissions in each stage of the process and 
the fractions of these gases released into the hot cell environment, providing a detail of the analysis to 
determine the stage of the process responsible for these emissions. 
The analysis showed how the release of 133Xe are products that have a significant decay time, while 135Xe 
emissions are due to equipment openings in the production process. 
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In the framework of the LARAMED program (laboratory of radionuclides of medicine) at the INFN-Legnaro 
National Laboratories (LNL), we have carried out a study of nuclear reaction calculations using different nuclear 
codes: Fluka, Talys and Empire. The calculations were directed to aid experimental investigations in finding 
efficient routes and conditions for the production of emerging theranostic radionuclides. The calculation 
involved not only cross-section evaluations but also yields, activities, isotopic and radionuclidic purities. We 
have studied in particular the cyclotron-based production of 47Sc in the framework of the experimental PASTA 
project.  This project aims to measure various production cross sections, to seek for the best irradiation 
conditions for 47Sc production. The radioisotope is also included in the CRP No. F22053 by the IAEA, together 
with 67Cu and 186Re, as emerging theranostic radionuclides. The use of 47Sc as a theranostic agent is hindered 
by the fact that there is not yet an established economical route for the production in sufficient quantities and 
purity. The goal of this theoretical study is to support the PASTA experiment in the search of efficient routes 
for the production of 47Sc. 
The study initiated by considering existing experimental production data involving proton beams. These data 
have been integrated later with the results obtained in the PASTA project at the ARRONAX facility and 
compared with theoretical estimations obtained by using different nuclear codes. Starting from the theoretical 
cross-sections we have calculated yields and activities produced, together with isotopic and radionuclidic 
purity. 
We have calculated production of the theranostic 47Sc by proton collision with targets of natTi, 48Ti, 49Ti, 50Ti 
and natV. Analysis has been performed with nuclear reaction codes Talys 1.9, Empire 3.2 and Fluka dev 2018.0. 
Considering the co-produced Sc-isotopes and their half-lives, the main contaminant is 46Sc and its production 
had to be avoided or minimized. The use of natTi and 48Ti targets appears not to be suitable for the production 
of 47Sc with high purity in the range E<100 MeV, while, with targets made of enriched 49Ti, 50Ti and natV, it was 
possible to identify energy regions suitable for the production of 47Sc with high level of purity. The selected 
regions are 25-40 MeV for the enriched 49Ti target, 10-20 MeV for the enriched 50Ti target, and 20-30 MeV for 
natV. For natV we have calculated the activity produced for given beam current and impinging energy and 
target thickness. For the specific parameters considered, we predicted significant production of 47Sc with a 
high level of purity. 
The results of this phenomenological study appear very promising and should stimulate thick target yields 
measurements in the corresponding irradiating conditions to substantiate the predictions. 
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The isomers Hg-197m/Hg-197g represent a new potential theranostic radionuclide pair. The shorter lived Hg-
197m (T½ = 23.8 h) emits a dominant 134 keV γ-line (Iγ = 33.5 %) suitable for SPECT imaging, while the ground 
state Hg-197g (T½ = 64.6 h) provides therapeutic low energy β particles with maximum energy of 523 keV. 
Moreover, the well-known chemical properties of mercury allow for rapid and efficient separation and later 
for straightforward labelling using appropriate chelators. 
The Hg-197m/Hg-197g pair production is possible either via proton-induced, or via deuteron-induced nuclear 
reactions on naturally monoisotopic gold targets. The choice of projectile and its energy allows for changing 
the isomeric ratio in the product. That is why precise knowledge of the excitation functions is highly desirable. 
Currently available data are scarce and sometimes inconsistent. 
The excitation functions were measured using the stacked foils technique on the cyclotron U-120M of the 
Czech Academy of Sciences in the energy interval of 6.4–35.3 MeV. After the irradiation, the foils were 
measured using a γ-ray spectrometer equipped with an HPGe detector in order to determine precisely the 
activity of radionuclides born in the target. Subsequently, cross-sections and their uncertainties were 
calculated. 
The measured cross-sections for the nuclear reactions Au-197(p,x)Hg-197m, Hg-197g, Hg-195m, Hg- 195g, Au-
196m, Au-196g, Au-194g in the energy range of 6.4–35.3 MeV were compared with previously published 
experimental data and with theoretical prediction of the excitation functions adopted from the nuclear 
reaction model code TALYS (library TENDL2017). Thick target yields were calculated. All activities of the 
ground-state isomers were corrected for the contribution of the metastable isomeric nuclei. Our data are 
generally in a good agreement mainly with the majority of recently published data sets. Inconsistencies were 
observed mainly in the case of Hg-197g, for the older data and sometimes with the TALYS prediction. 
We provided a detailed cross-section data for the nuclear reactions Au-197(p,x)Hg-197m, Hg-197g, Hg-195m, 
Hg-195g, Au-196m, Au-196g, Au-194g covering the energy range of 6.4–35.3 MeV. The thick target yields 
calculated from the experimental data allow for reliable prediction of the activities at the EOB and the isomeric 
ratio Hg-197m/Hg-197g as the function of energy. 
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Technetium-99m is the most widely used radionuclide for medical imaging. It is generally obtained by elution 
of commercially available 99Mo/99mTc generators. Research reactors have been the main source of 99Mo, the 
parent of 99mTc, for several decades. Due to their aging, the numerous alternative production modes of 99Mo 
or directly 99mTc were investigated. One of them is the photonuclear reaction 100Mo(g,n)99Mo with 
bremsstrahlung irradiation obtained by the use of an electron accelerator. This method offers a less-expensive 
alternative to fission-made 99Mo, but with lower yield resulting in low specific activity (LSA) of 99Mo. This 
requires efficient methods of 99mTc separation from large excess of molybdate and the application of new 
adsorbents with high capacity for Mo. The International Atomic Energy Agency initiated the Coordinated 
Research Project No. F22068 (2017-2020) on “New Ways of Producing Tc-99m and Tc-99m Generators” in 
order to promote this technology in Member States. POLATOM is participating in this project since the last 
year. The main goal of our work is to develop a practically useful separation method of pharmaceutical grade 
99mTc. 
The separation of 99mTc will be performed in so called reverse generator system. Investigation on resins 
selective for 99mTc and allowing to pass Mo through the column are under way. The experiments with AnaLig-
Tc-02 resin (IBC Advanced Technologies, Inc.) were performed to optimize 99mTc separation from molybdenum. 
The sorption yield of 99mTc on this resin as a function of NaOH concentrations was studied. We used various 
resin amounts at different flow rates. The same process using 99mTc as tracer and natural molybdenum with 
different ratios of both metals is studied in detail. The TRU resin (Triskem International) and other solid phase 
extraction systems are also tested to obtain the highest yield of 99mTc with the lowest Mo contamination. 
In conclusions we believe that this study will be a good starting point for the design of the new 99Mo/99mTc 
generator suitable to use LSA 99Mo. 
Acknowledgements: This project was supported with the funds awarded by the Ministry of Science and Higher 
Education in Poland within the agreement No. 3969/IAEA/2018/0, IAEA Research Contract No. 22652 and 
CERAD project, financed under Smart Growth Operational Programme 2014-2020, Priority IV, Measure 4.2. 
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The interest in 89Zr radioisotopes is increasing in the last years due to its half-life that allows to label 
biomolecules, such as monoclonal antibodies, for pharmacokinetic studies and clinical trials to trace slow 
biological process. Due to the availability of the target material in natural form, the 89Y(p,n)89Zr is considered 
the best nuclear reaction for the production of 89Zr in medical cyclotrons. Nowadays, the design and 
manufacturing of appropriate cyclotron solid targets for the production of large amounts of 89Zr with high 
specific activity remain a technological challenge. 
The LNL-INFN group, in the framework of the LARAMED (laboratories for radioisotopes of medical interest) 
project, has developed two methods for 89Y targets realization for the production of 89Zr. The targets have 
been tested in collaboration with IRCCS Sacro Cuore-Don Calabria Hospital in Negrar (VR). 
The first proposed method is Magnetron Sputtering (MS) deposition of yttrium material directly onto niobium 
backing (chosen due to its chemical inertness). MS is a physical vapour deposition technique that takes place 
in a vacuum by means of inert gas plasma (Ar).  The material of interest is attached to the cathode, and plasma 
is created when a difference of potential is applied between the cathode and the substrate (anode). The 
positive ions of the inert gas are accelerated towards the cathode. When the ions collide with the atoms of 
the sputtering target, the energy transfer causes the detachment of some atoms, which are then deposited 
on the substrate. Magnetron sputtering is characterized by elevated plasma utilization efficiency thanks to its 
magnetic confinement. 
The yttrium MS process parameters have been optimized in order to obtain thick (~70 µm), dense film, 
adherent to niobium backing, thanks to minimizing the intrinsic stress, which can compromise the 
performance of produced cyclotron target. 
Spark Plasma Sintering (SPS) was chosen as a second target preparation technique. SPS combines 
simultaneous application of uniaxial pressure with pulsed direct electrical current (DC) under vacuum. In this 
work, commercially available 150 µm thick yttrium foil has been bonded to niobium backing to realize the 
targets. 
In order to realize a comparison, targets obtained by both described methods, MS and SPS, were irradiated at 
12.7 MeV, increasing proton beam current in steps using TR19 cyclotron at IRCCS Sacro Cuore-Don Calabria 
Hospital in Negrar (VR). The visual inspections of the targets after irradiations and the radionuclide purity after 
the dissolution process in HCl and standard radiochemical separation procedure were taken into account. 
The comparison of the two methods, MS and SPS, from the technological point of view (target thickness, 
realization time, density, efficiency, backing material, beam current supported), has been done. 
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The targeted treatment of cancerous tumours by alpha-emitting radionuclides has shown remarkable efficacy 
in recent clinical trials. It is likely that this treatment option will ultimately be applicable to a wide range of 
cancers and other diseases, subject to the development of specific carrier molecules. Currently Ac-225 is 
mainly produced from natural ingrowth in existing stocks of Th-229. An anticipated wider application for 
radiotherapy will require many orders of magnitude of more radionuclide than can currently be produced. 
Consequently, following up on earlier experimental work at JRC, we are pursuing alternative production 
methods. In particular, the production by irradiation of Ra-226 with medium-energy protons at cyclotrons will 
be investigated. In this talk, past experience with proton irradiation of Ra-226 at JRC Karlsruhe will be 
reviewed. In addition, short- and medium-term plans for future work in this direction will be presented.  
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99mTc (T1/2=6.06 h, Eγ =140 keV (89%)) is the most used radionuclide worldwide for Single Photon Emission 
Computed Tomography scans (SPECT). It is commonly obtained from the decay of its parent nuclide 99Mo 
(T1/2=66 h), by eluting compact and transportable 99Mo/99mTc generator systems that makes it available 
directly in nuclear medicine departments. The majority of 99Mo is produced in a few ageing nuclear reactors 
around the world, using highly enriched uranium (HEU) targets. The unexpected worldwide Technetium-99m 
(t1/2=6h, Eγ=140keV) shortening occurred on the radioisotope market in 2009-2010, due to the reactor-
produced parent nuclide 99Mo production crisis. It has prompted new ideas about alternative production 
routes of this important gamma emitter radionuclide used in 85% of diagnostic nuclear medicine procedures. 
In the framework of INFN-funded (National Scientific Committees 5-CSN5, (2012-2017) research programs 
APOTEMA/TECHN-OSP, and of a Coordinated Research Project (CRP Code: F22062) promoted by the 
International Atomic Energy Agency (IAEA), we developed in collaboration with other Italian Universities and 
Research Institutions, a technology to produce GBq amount of 99mTc by the existing medical cyclotron network 
in Italy, through the (p,2n) nuclear reaction on a 100Mo enriched metal target. 
Several 100Mo metal target configurations were developed based on the prototype solid target station of a 
TEMA Sinergie assembled at the GE PETtrace (16MeV) cyclotron. Among them, the SPS (spark plasma 
sintering) technique, allowing to utilize an inert backing plate, has been chosen as the most efficient. 
A remotely controlled module for the fast and efficient extraction and purification of 99mTc from the irradiated 
100Mo enriched metallic target, by exploiting the high efficiency of the Solvent Extraction (SE) technique, has 
been developed. The automatic module assembly was based on pre modular units (Modular-Lab Standard, 
Eckert & Ziegler) and was customized by adding a handmade glass column vial (length =25 cm, ø =1cm) and a 
home-made reactor heater. Quality controls have been conducted on the final products following the 
monograph specifications. Radiolabelling and imaging studies with a clinical gamma camera, have been 
conducted as well. Finally, an efficient procedure for the recovery of expansive 100Mo was developed. 
The developed technology allowed to obtain cyclotron-produced [99mTc]TcO4 suitable for clinical application 
with a Quality Assurance (QA) process in compliance with the European Pharmacopoeia recently issued. Local 
nuclear medicine departments equipped by medical cyclotrons and our technology will be able to self-produce 
sufficient amount of 99mTc for their daily diagnostics needs. 
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Technetium-99m (99mTc) is currently available from 99Mo/99mTc generators as the β-decay product of 99Mo 
(T½=66 h). Nowadays, 99Mo is mostly obtained as a fission product in nuclear reactors by neutron-induced 
reactions on highly enriched uranium. Alternative production routes, such as direct production of 99mTc via 
100Mo(p,2n)99mTc reaction using medical cyclotrons has the potential to be both reliable and relatively cost-
effective. However, results showed that the extracted 99mTc from the proton-bombarded 100Mo-enriched 
target contains small quantities of several Tc radioisotopes (93mTc, 93Tc, 94Tc, 94mTc, 95Tc, 95mTc, 96Tc and 97mTc). 
The aim of this work was to estimate the dose increase (DI) due to the contribution of Tc radioisotopes 
generated as impurities, after the intravenous injection of four radiopharmaceuticals prepared with cyclotron-
produced 99mTc (CP-99mTc) using 99.05% 100Mo-enriched metallic targets. 
Four 99mTc radiopharmaceuticals (pertechnetate, sestamibi (MIBI), hexamethylpropylene- amine oxime 
(HMPAO) and disodium etidronate (HEDP)), were considered in this study. The biokinetic models reported by 
the International Commission on Radiological Protection (ICRP) for each radiopharmaceutical were used to 
define the main source organs and to calculate the number of disintegrations per MBq that occurred in each 
source organ (Nsource) for each Tc radioisotope present in the CP-99mTc solution. Then, target organ equivalent 
doses and effective dose were calculated for each Tc radioisotope with the OLINDA/EXM software versions 
1.1 and 2.0, using the calculated Nsource values and the adult male phantom as program inputs.  Total 
effective dose produced by all Tc isotopes impurities present in the CP-99mTc solution was calculated using the 
fraction of total activity corresponding to each radioisotope generated by the bombardment of 100Mo-enriched 
(99.05%) metallic target. Finally, the effective obtained dose was compared with the effective dose delivered 
by the generator-produced 99mTc. 
The total effective dose increases of CP-99mTc radiopharmaceuticals, calculated with both versions of the 
OLINDA software, remained within the 10% limit in all cases, from 6 up to 12 hours after end of bombardment 
(EOB). The Tc radioisotopes with the highest concentration in the CP-99mTc solution at EOB are 94mTc and 93mTc. 
However, their contribution to DI 6 hours after EOB is minimal, due to their short half-lives. 96Tc is the 
radioisotope with the largest contribution to the effective DI, followed by 95Tc and 94Tc, although their 
concentration in the CP-99mTc solution is 5 times less than 94mTc and 93mTc at the EOB. This is due to the types 
of their emissions and relatively long half-lives. 
The increase in the radiation dose caused by the other Tc radioisotopes contained in produced CP-99mTc, as 
described here, is quite low. Although the concentrations of the 94Tc and 95Tc radioisotopes in the CP-99mTc 
solution exceed the limits established by the European Pharmacopoeia, CP-99mTc radiopharmaceuticals could 
be used in routine nuclear medicine diagnostic studies if administered from 6 to 12 hours after the EOB; thus, 
maintaining the effective DI within the 10% limit. 
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The development of a CuO – wires form - reactor at laboratory scale is carried out to convert on line H2 gas 
into H2O vapour and to avoid the handling of explosive gas. The process of regeneration of CuO is also 
developed in order to reuse the reactor a large number of cycles. 
2 CuO + H2 —–> Cu2O + H2O Reaction 1 (CuO reduction or H2 conversion) 2 Cu2O + O2 —–> 4 CuO Reaction 
2 (Cu2O oxidation or CuO regeneration) 
The objective is to have a unit operation that meets the safety requirements in the management of H2 that is 
produced when the irradiated targets in a research reactor, of aluminium cladding base, are dissolved in 
alkaline solution, for the production of fission radioisotope of medical use (99Mo, 131I, 133Xe, etc.). 
2 Al + 2 NaOH + 2 H2O —–> 2 NaAlO2 + 3 H2 Reaction 3 (Irradiated target dissolution) 
If the H2 gas is not properly managed, it can reach concentrations above the lower flammability limit, and 
under favourable conditions of oxygen index and activation energy can be produced by ignition and 
consequent deflagration and/or explosion of the H2. 
The experimental tests were made in a CuO fixed-bed tubular stainless-steel reactor heated by electrical 
heaters. The CuO used is Merk catalogue 102765, p.a. grade, wire fine about 0.65 x 3 mm for elementary 
analysis, (surface: CuO, core: Cu2O, CuO: minimum 55%). The dimensions of the reactor are: 70 mm diameter 
and 300 mm length with a 3.5 kg CuO capacity. 
Conversion and regeneration experiments are carried out at different temperatures and flow rates to find the 
optimal conversion and regeneration conditions. Effect of temperature and residence time on CuO-H2 and 
Cu2O-O2 reactions are evaluated. 
The experiment is complemented by the analytical determination of Cu, Cu2O, CuO and O species, plus the 
measurement of the CuO weight variation and the produced mass of water. 
The CuO wires fixed-bed reactor preheated to 250-350 Celsius degree is a passive equipment where the H2-
CuO reaction has an efficiency exceeding 99%. The hysteresis in the regeneration stage - loss of CuO which is 
available for conversion reaction- is minimal and ensures a rate of reuse of the reactor exceeding 100 cycles. 
With each conversion / regeneration cycle a slight degradation of the CuO bed is observed due to the decrease 
of the exposed superficial area of the CuO wires due to the collapse of some of them by local heating. This is 
largely avoided by performing at the beginning of the process the pre-treatment of the CuO to reduce the CuO 
concentration from 55 to 30%. 
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The great advancement of nuclear medicine (NM) held in the last decades mainly relies in the development 
and use of a wide range of different and more effective radiopharmaceuticals. This goal has been achieved by 
combining the biological behaviour of new ligand molecules, selective for the specific tumour target, and the 
main nuclear properties of novel radioisotopes, specific for diagnostic, therapy and theranostic applications. 
The use and availability of a variety of radionuclides has experienced a great development as a result of the 
increase of technologies related to their production, even based on cyclotrons. 
At INFN-LNL a BEST 70p high performance cyclotron was installed in 2015, to be dedicated not only to the new 
frontiers of nuclear physics studies (SPES project), but also to the interdisciplinary and medical physics 
investigations, through the LARAMED project, acronym for LAboratory of RADionuclides for MEDicine. Albeit 
the facility is currently under development (installation of beam-lines, laboratories etc), since 2012 the team 
started working on the production of conventional and innovative radionuclides for NM applications. 
LARAMED activities have started with TECHN-OSP and APOTEMA projects, aimed at the direct production of 
Tc-99m with small cyclotrons already installed in hospitals. The focus is now devoted on studying new 
emerging radionuclides such as Cu-67 (COME project), Sc-47 (PASTA project) and Mn-52 (METRICS project). 
These studies have allowed the development of new techniques for producing thin solid targets by using High 
Energy Vibrational Powder Plating (HIVIPP) method (E- PLATE project) and high-power target (TERABIO 
premium-project). 
The collaboration with NM radiopharmacies holding a PET cyclotron (e.g. the Sant’Orsola Hospital in Bologna 
and the Sacro Cuore Don Calabria Hospital in Negrar), as well as with national and international research 
institutes, such as several INFN sections, the University of Ferrara, the CNR in Milan and the ARRONAX facility 
(Nantes, France), made all this effort possible. 
An up-dated overview of the on-going projects regarding different radiometals, produced by using proton 
cyclotrons, is the purpose of this poster. Results from cross-section measurements, target production, 
irradiation runs, target processing and recovery, that was carried out by the LARAMED research group will be 
presented. 
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The application of 89Zr as a diagnostic radionuclide in PET is of increasing interest, due to easy production, 
from natural 89Y target and chemical separation. Furthermore, the physical t1/2 = 3.27 days is appropriated 
for long-term metabolic investigations, such as observed in antibodies or nanomaterials. Recently we had 
studied the use of liposomes composed phosphatidylserine (PS) to delivery chemotherapeutics for cancer 
treatment, based on the property of PS to be recruited by cells, adsorbed in their surface, followed by 
endocytosis. To measure in vivo drug delivery or liposome biodistribution we decide to label liposome with 
the isotope 89Zr. Since liposomes are structures composed by a hydrophobic phospholipid bilayer, containing 
an inner and external hydrophilic core, we studied different labelling procedures. The aim was to optimize the 
production of 89Zr in our cyclotron and evaluate the conditions for radiolabelling the PS liposome. 
89Zr was produced by 89Y(p,n)89Zr nuclear reaction in a GE cyclotron PETtrace 880, using a homemade target 
built in aluminium. High purity (> 99 %) 89Y sheet (16.6x16.6x0.125 mm) was bombarded with 12.8 MeV 
protons, at a current of 10 uA, by 180 min. Activated 89Y sheet was dissolved in 6 M HCl and 89Zr was purified 
by filtration in hydroxamate column, eluted with oxalate solution (0.1 M). Liposome formulation was prepared 
dissolving 10 mg of commercial PS in chloroform/methanol (10:1) and dried under vacuum, then it was 
dissolved in saline and sonicated by 10 min. Radiolabelling was performed by three different methods: 1) 
sonicated formulation was reacted with SNC-Bn-DFO overnight followed, concentration in Amicon 10 kD and 
reaction with [89Zr(oxalate)] at 37 oC/1 h; 2) sonicated compound was incubated with 8-hydroxyquinoline 
(8HQ) at 37 oC/1h; 3) [89Zr(SNC-Bn-DFO)] was mixed in saline and used to dissolve dried PS, followed by 
sonication during 10 min. [89Zr(liposome)] purification and labelling efficiency was performed in PD-10 column 
eluted with PBS 0.1 M pH 7.4. 89Zr yield at EOB/acid digestion was 444 ± 74 MBq, and activity was recovered 
in 80-85% from hydroxamate column. The relevant formation of undesired 88Zr (t1/2 83 d; 393 keV gamma 
line) was not observed by gamma spectrometry. Radiolabelling yield was lower than 1 % for methods 1 and 2, 
and method 3 gave 53 % of labelled product. 
The conditions to produce 89Zr on a PETtrace cyclotron using a homemade target was optimized. Liposome 
radiolabelling conditions still in development, having the method 3 [89Zr(SNC-Bn-DFO)] the most promising 
results regarding radiolabelling yield. 
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Multimodality imaging is a diagnostic technique that combines morphological and functional information for 
improving the power of current imaging methods. PET or SPECT with CT are currently the most popular 
multimodal imaging technologies in this field while the combination of PET or SPECT with MRI (magnetic 
resonance imaging) is a newly-established technology. This multimodal technology usually involves the use of 
two different compounds, a contrast agent for MRI (i.e. Gadolinium-based molecules) and a radioactive tracer 
for PET/SPECT, generating a mismatch in the diagnostic information content. 
In this regard, we want to investigate the possibility and the effect of having a molecular fusion between PET 
and MRI by using a bimodal probe, a molecule able to be detected by both techniques. The same compound 
will act as a contrast and as a radioactive agent, preserving both the paramagnetic and nuclear characteristics. 
Manganese is the only transition element having paramagnetic properties suitable for MRI and two 
manganese isotopes, 52Mn and 51Mn, positron emitters that could be employed as PET tracers. 
The scope of the METRICS project (METRICS: Multimodal pET/mRi Imaging with Cyclotron-produced 52/51Mn 
iSotopes), funded by INFN (CSN5 2018–2020), aims to develop a perfect molecular matching between PET and 
MRI using paramagnetic and radioactive manganese isotopes to afford an unprecedented type of PET/MRI 
hybrid imaging and to develop the technology, target, and separation module to self-produce by cyclotron the 
51/52Mn. So far, natural chromium targets have been successfully produced and tested under a proton beam 
up to 50 µA (~ 1 kW) for thermomechanical tests, manganese paramagnetic complexes have been synthesized 
and characterized, while dosimetric studies and Cr/Mn radiochemical separation are currently under 
development. 
In this work we present the preliminary results of the METRICS project. The possible efficacy of having a real 
molecular fusion between PET and MRI by using a new bimodal probe, based on the use of manganese 
paramagnetic complexes, labelled with 51/52Mn radionuclides will be underlined. 
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The development of therapeutic radiopharmaceuticals labelled with radioisotopes emitting alpha particles 
provides additional challenges compared with beta-minus radioisotopes in terms of radiation safety but also 
with regard to the deleterious effects of high radiation fields over the labelling chemistry and shelf life because 
alpha particles deposit large amounts of energy in a highly focal manner producing a well-known deleterious 
effect mostly related to the radiolysis produced by the high LET alpha particles. 
These problems for labelling at high activities for therapeutic purpose and distribution of the radioisotope to 
locations distant from the production site for industrial applications have been the most comprehensively 
investigated for At-211, and similar difficulties probably exist with others alpha particle emitters like Ac-225. 
The radicals, ion and molecular species produced by radiolysis process might produce profound changes on 
the labelling process in several ways including producing changes in the oxidation state of the radioisotope 
(observed for At-211), degradation of the labelling precursor, or side-reactions by having a potential impact 
on labelling yields, purity of the radiopharmaceutical products or shelf life. For At-211 serious problems were 
already found for labelling at high activities but also for delivering activities. 
Given the excellent results already observed on the treatment of patients with prostate cancer with 225Ac-
PSAM-167, currently several countries are working in developing new production technology in order to 
secure the supply of Ac-225, like Argentina. Given the half-life of Ac-225 that allows supply to distant location 
the radiolysis issue might become critical for producers planning to deliver Ac-225 kilometres away from the 
production site because the radiation doses delivered by at least five alpha particles coming Ac-225 and its 
daughters, Fr-221, At-217, Bi-213 and Po-213 will make the situation potentially worst and worth to be 
studied. 
This presentation will show in detail that the level of radiation dose delivered on several scenarios for Ac-225 
and its daughters are even much higher than the ones delivered for At-211 and extremely much higher that 
with beta minus emitters like Lu-177. Due to the radiolysis, water solutions of Ac-225 will produce very high 
concentration of radicals and molecular products like hydrogen and hydrogen peroxide, producing a reaction 
media for labelling is extremely harsh. For example, delivering 50 mCi at a location distant 10 hours away will 
arrive a delivery radiation dose (Gy) into the Ac-225 solution astonishing high, 7.5 times more that for At-211 
with a concentration of H2O2 200 times higher than the prototypical concentration used for labelling PSMA-
167 (200 micrograms). This labelling environment might preclude achieving good labelling yields or even 
making impossible to avoid severe side reaction. It might require not also a systematic study about this 
potential issued but also to find new strategies for delivering activity to make possible the supply of Ac-225 to 
distant locations. 
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Cyclotron solid target realization is often crucial for radioisotope production. A set of most standard 
techniques for target preparation is often inefficient for the refractory metals, like Ti, Mo, W, Zr. In the case 
of enriched isotopes, a technique that causes minimal material losses is absolutely essential. The High Energy 
Vibrational Powder Plating (HIVIPP) method, based on the motion of material powders in an electric field, 
provides a solution to minimize losses and deposition of “problematic” refractory metals. The deposition 
process is carried out in a vacuum inside a quartz cylinder with electrodes mounted at its top and bottom. A 
high voltage (>2 kV) applied to the electrodes causes the powder motion towards the electrode of the opposite 
charge on which particles are deposited. The HIVIPP method allows preparation of targets with areal densities 
ranging from μg/cm2 up to mg/cm2, with a very high yield and of excellent thickness homogeneity, superior 
to the one obtained by conventional evaporation. 
In order to guarantee a reliable and reproducible application of the HIVIPP method for other enriched 
materials, a deep study of the process is required. The “E-PLATE: Electrostatic Powder Plating for Accelerator 
Targets” project of INFN (2018-2019) is devoted to R&D on HIVIPP technique aimed to depose optimization 
and overcoming thickness limitation (evident from previous works of I. Sugai). This is done to allow the 
preparation of the targets as for nuclear cross-section measurements (program-minimum), as for medical 
radionuclides production (program-maximum). 
The E-PLATE project includes the use of the appropriate Design of Experiment (DOE) approach, to understand 
the influence of further factors on the deposited thickness: electric field, powders size, powders oxidation 
level, the distance between electrodes. Since the cyclotron-based production of 99mTc high-efficiency 100Mo 
target deposition is of great interest, Mo powder deposition onto Cu target backing was defined as a modelling 
system for HIVIPP process study. To assure the reproducibility of the experiments, the automation of the 
deposition system was realized. In order to guarantee no additional powders oxidation, the system has been 
equipped with dedicated Ar glove-bag. The powders size is defined by sieving natMo powders with certified 
sieves in Ar atmosphere. The experiments corresponding to the DOE plan are ongoing. 
The obtained process model after statistical analysis of the experimental data of the deposit thickness (using 
both measurements: weighting of the samples and Rutherford backscattering spectrometry analysis) will be 
used to optimize the deposition parameters. 
First results showed that an HIVIPP deposition system was installed at INFN-LNL and was successfully used for 
the production of 48Ti targets (0.1-2 mg/cm2 thick) for the nuclear cross section measurements aimed to verify 
47Sc production. 
Several HIVIPP deposited natMo on copper backing targets have been tested for thermomechanical stability 
under TR19 cyclotron proton beam at “Sacro Cuore Don Calabria” Hospital. The targets withstood the heat 
powder density up to 1kW/cm2 without any visible alterations. 
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47Sc is considered as a promising beta-emitter for cancer radioimmunotherapy. Its practical application is 
hampered by the absence of a technology that could provide sufficient yield of the target isotope at a tolerant 
content of admixtures. A possible approach to settle this issue is a carrier-free 47Sc production using a soft 
technology on the basis of the 48Ti(gamma,p)47Sс reaction in the field of high-energy bremsstrahlung radiation 
of an electron accelerator. In this work, the analysis of the key factors that determine the photonuclear yield 
of 47Sc in a thick titanium production target is carried out. 
An analytical model providing the description of isotope generation in a thick target exposed to a spatially 
nonuniform flux of high-energy X-ray photons is developed. A set of main parameters of the process 
determining the total yield and distribution of activity in a target has been established. It is shown, that those 
parameters are the normalized coefficient of photonuclear conversion, the rms radius of photon flux density 
at a target, and also average annular divergence of the photon flux. The proposed approach is used for the 
optimization of geometry and activation mode of a cylindrical target from titanium. An independent study was 
conducted using a simulation technique on the basis of a GEANT4 transport code. The conditions of activation 
of targets from natural titanium in the electron energy range 30-95MeV are experimentally studied as well. 
It is established, that within the stated range of electron energy the yield of main scandium admixtures 48Sc 
and 46Sc are respectively by one and two order of values less than the yield of 47Sc.The dependence of the 47Sc 
gross and specific activity of a cylindrical target on its dimensions and electron energy has been calculated. 
In the case of a target from titanium enriched in 48Ti and activation mode (40MeV; 0.3mA), the capacity of the 
photonuclear method amounts up to 1GBq/h 47Sc at low content of by-products. 
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Scandium-44 emitting β+ particles (Eβ+= 1474 keV) with a gamma radiation component of 1157 keV is 
becoming interesting as a PET radionuclide. Due to its half-time of 3.35 h it can be complementary to 68Ga or 
18F. On the other hand, the 47Sc, an isotope with potential for radionuclide therapy, gives the possibility for 
employment of 44Sc/47Sc isotopic pair in disease diagnosis, therapy dose estimation and assessment of 
therapeutic response. Scandium-44 can be produced from 44Ca via 44Ca(p,n)44Sc nuclear reaction. The aim of 
this study was to develop a working procedure for separation of 44Sc of sufficient purity and specific activity to 
be used for medical needs. 
Calcium targets, natural and enriched (99.2%), were prepared by pressing calcium carbonate powder or 
metallic calcium dendritic chunks into pellets. Typical irradiation conditions were from 45 min to 3 h at 13 - 23 
µA of the proton beam current. After irradiation the calcium targets were dissolved in 3 M hydrochloric acid 
and 44Sc was separated from excess of calcium by precipitation of scandium hydroxide using ammonia. The 
targets were also dissolved in 11 M hydrochloric acid and 44Sc was separated by extraction chromatography 
on UTEVA resin. The 44Sc was further purified and concentrated on a cation exchange resin. Gamma 
spectrometry with a high purity germanium detector when used to determine the separation efficiency and 
radionuclide purity. 
Results showed that twenty two irradiation and separation runs were performed using both natural and 
enriched calcium targets. As result of 1hour proton activation s of 44CaCO3 pellet with 99.2% enrichment more 
than 4.8 GBq of 44Sc activity at EOB was obtained.  
The recovery yield of 44Sc in both investigated separation methods was comparable and amounted to above 
90%. The working procedures were developed and the quality of separated 44Sc solution was determined by 
labelling the bioconiugates. The chemical purity of the product was sufficient for preclinical experiments. 
In conclusion, Scandium-44 can be produced inexpensively with adequate yields and radionuclide purity via 
44Ca(p,n)44Sc nuclear reaction in medical cyclotrons. The obtained 44Sc is pure in terms of radionuclide and 
chemical purity, as shown by the results of peptides radiolabelling. 
Acknowledgements: This project was supported with the funds awarded by the National Centre for Research 
and Development in Poland within the Applied Science Program, grant no PBS3/A9/28/2015 and CERAD 
project, financed under Smart Growth Operational Programme 2014-2020, Priority IV, Measure 4.2. 
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Conjugation of nanomedicine and radiopharmacy treats a new research and technology area that is named 
nanoradiopharmacy. It has great advantages in disease diagnosis and control and subsequent therapy, due to 
the ability to develop molecular diagnostics for the early detection of disease as well as the ability to develop 
increasingly personalized and individualized treatments. Nanostructured materials attracted considerable 
attention because of their high surface area to volume ratio resulting from their nanoscale dimensions. This 
class of sorbents is expected to have a potential impact on enhancing the efficacy of radioisotope generators 
for diagnostic and therapeutic applications in nuclear medicine. Radiolabelled nanoparticles represent a novel 
class of radiopharmaceutical agents with great potential in cancer research. The radiolabelled nanoparticles 
can be used for specific tumour imaging or for effective tumour treatment by specific radiation. Various kinds 
of nanoradiopharmaceuticals, such as Tc-99m nanogels, have been industrialized and applied for disease 
diagnosis purposes. But, nanoradiopharmacy like other technologies has its own limitations that must be 
considered. 
Nanoparticles have several orders of magnitude larger than classical drugs and represent an important 
advancement in drug therapy because they can be assembled as multimolecular complexes including not only 
pharmacologically-active molecules, but also molecules for selective targeting to specific tissues. The Liver and 
spleen have important roles in nanoparticles pharmacokinetics. The spleen has a mechanism for sequestrating 
nanoparticles. A preferential accumulation in the liver and in the spleen was observed by researchers. It was 
found that unmodified nanoparticles disappear from the blood in seconds or minutes after their injection.  
Renal filtration has a significant role in this process if their size is smaller than 15 nm, whereas for nanoparticles 
larger than 40 nm, their disappearance from the blood is mainly dependent on their accumulation in cells of 
the reticuloendothelial system. This significantly reduces nanoparticle half-life and represents a major barrier 
for the implementation of their clinical use. Nanoparticle uptake is mainly operated by liver Kupffer cells, but 
splenic macrophages also have a significant role. Splenic capture can be used to selectively deliver old drugs 
to the spleen. Additionally, researchers found that spleen capture is a limiting factor in nanoparticle 
pharmacokinetics and that it has to be overridden in order to optimize its therapeutic effects. 
In most cases after injection of nanoradiopharmaceuticals, due to the pharmacokinetics role the radioactivity 
is detected in the liver and spleen. Hence, increasing the internal radiation dose in liver and spleen may initiate 
the creation of some kind of diseases for the liver and spleen. Radiation induced toxicities in non-tumourous 
liver tissues are associated with the development of numerous symptoms or have serious chronic side effects 
(Fig. 1). 
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Figure 1. In planar images of liver after injection of Technetium-99m nanocolloid. 
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